



HU000029465T2

(19) **HU**(11) Lajstromszám: **E 029 465**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: E 12 171813	(51) Int. Cl.: C07K 16/00	(2006.01)
(22) A bejelentés napja: 2006. 08. 10.	A61K 39/00	(2006.01)
(96) Az európai bejelentés bejelentési száma: EP 20060171813	A61K 393/95	(2006.01)
(97) Az európai bejelentés közzétételi adatai: EP 2573114 A1 2013. 03. 27.	C07K 16/32	(2006.01)
(97) Az európai szabadalom megadásának meghirdetési adatai: EP 2573114 B1 2016. 03. 30.	C07K 17/00	(2006.01)
	C12Q 1/68	(2006.01)
	G01N 335/74	(2006.01)
	C12N 15/00	(2006.01)
	C07K 16/44	(2006.01)
	C07K 16/28	(2006.01)
	C07H 21/04	(2006.01)

(30) Elsőbbségi adatok: 707419 P 2005. 08. 10. US	(73) Jogosult(ak): MacroGenics, Inc., Rockville, MD 20850 (US)
(72) Feltalálók(k): Stavenhagen, Jeffery, 2100 Köbenhavn (DK) GORLATOV, Sergey, Gaithersburg, MD 20877 (US) Rankin, Christopher, Cabin John, MD 20818 (US) TUAILLON, Nadine, Gettysburg, PA 17325 (US)	(74) Képvisező: Advopatent Szabadalmi és Védjegy Iroda, Budapest

(54) **Variáns fc-régiókkal rendelkező antitestek azonosítása és előállítása, valamint eljárások azok alkalmazására**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 573 114 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
30.03.2016 Bulletin 2016/13

(21) Application number: **12171813.4**

(22) Date of filing: **10.08.2006**

(51) Int Cl.:
C07K 16/00 ^(2006.01) **A61K 39/395** ^(2006.01)
C07H 21/04 ^(2006.01) **C12N 15/00** ^(2006.01)
C12Q 1/68 ^(2006.01) **C07K 17/00** ^(2006.01)
C07K 16/28 ^(2006.01) **C07K 16/32** ^(2006.01)
C07K 16/44 ^(2006.01) **G01N 33/574** ^(2006.01)
A61K 39/00 ^(2006.01)

(54) **Identification and engineering of antibodies with variant Fc regions and methods of using same**

Identifizierung und Herstellung von Antikörpern mit abweichenden Fc-Regionen und Anwendungsverfahren dafür

Identification et ingénierie d'anticorps avec régions Fc de variante et procédés d'utilisation associés

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **10.08.2005 US 707419 P**

(43) Date of publication of application:
27.03.2013 Bulletin 2013/13

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
06801146.9 / 1 919 503

(73) Proprietor: **MacroGenics, Inc.**
Rockville, MD 20850 (US)

(72) Inventors:
• **Stavenhagen, Jeffery**
2100 København (DK)
• **Gorlatov, Sergey**
Gaithersburg, MD 20877 (US)
• **Rankin, Christopher**
Cabin John, MD 20818 (US)
• **Tuaille, Nadine**
Gettysburg, PA 17325 (US)

(74) Representative: **Bizley, Richard Edward et al**
Avidity IP
Broers Building
Hauser Forum
21 J J Thomson Ave
Cambridge CB3 0FA (GB)

(56) References cited:
WO-A2-00/42072 WO-A2-2004/063351
WO-A2-2004/099249

- **SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγRI", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M009483200, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591-6604, XP002271092, ISSN: 0021-9258**
- **STAVENHAGEN JEFFREY B ET AL: "Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fc gamma receptors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US LNKD- DOI:10.1158/0008-5472.CAN-07-0696, vol. 67, no. 18, 1 September 2007 (2007-09-01), pages 8882-8890, XP002489883, ISSN: 0008-5472**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 573 114 B1

Description**1. FIELD OF THE INVENTION**

5 **[0001]** The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ R1IIIA and/or Fc γ R1IIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The mol-
 10 ecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc γ R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

2. BACKGROUND OF THE INTENTION**2.1 Fc RECEPTORS AND THEIR ROLES IN THE IMMUNE SYSTEM**

15 **[0002]** The interaction of antibody-antigen complexes with cells of the immune system results in a wide array of responses, ranging from effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phago-
 20 cytosis to immunomodulatory signals such as regulating lymphocyte proliferation and antibody secretion. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells. The diversity of cellular responses triggered by antibodies and immune complexes results from the structural heterogeneity of Fc receptors. Fc receptors share structurally related ligand binding domains which presumably mediate intracellular signaling.

25 **[0003]** The Fc receptors, members of the immunoglobulin gene superfamily of proteins, are surface glycoproteins that can bind the Fc portion of immunoglobulin molecules. Each member of the family recognizes immunoglobulins of one or more isotypes through a recognition domain on the α chain of the Fc receptor. Fc receptors are defined by their specificity for immunoglobulin subtypes. Fc receptors for IgG are referred to as Fc γ R, for IgE as Fc ϵ R, and for IgA as Fc α R. Different accessory cells bear Fc receptors for antibodies of different isotype, and the isotype of the antibody
 30 determines which accessory cells will be engaged in a given response (reviewed by Ravetch J.V. et al. 1191. Annu Rev Immunol. 9: 457-92; Gerber J.S. et al. 2001 Microbes and Infection, 3: 131-139; Billadeau D.D. et al. 2002, The Journal of Clinical Investigation, 2(109): 161-1681; Ravetch J.V. et al. 2000, Science, 290: 84-89; Ravetch J.V. et al., 2001 Annu. Rev. Immunol. 19:275-90; Ravetch J.V. 1994, Cell, 78(4): 553-60). The different Fc receptors, the cells that express them, and their isotype specificity is summarized in Table 1 (adapted from Immunobiology: The Immune System in
 35 Health and Disease, 4th ed. 1999, Elsevier Science Ltd/Garland Publishing, New York).

Fc γ Receptors

40 **[0004]** Each member of this family is an integral membrane glycoprotein, possessing extracellular domains related to a C2-set of immunoglobulin-related domains, a single membrane spanning domain and an intracytoplasmic domain of variable length. There are three known Fc γ Rs, designated Fc γ RI(CD64), Fc γ R1I(CD32), and Fc γ R1II(CD16). The three receptors are encoded by distinct genes; however, the extensive homology between the three family members suggest they arose from a common progenitor perhaps by gene duplication.

Fc γ R1I(CD32)

45 **[0005]** Fc γ R1I proteins are 40KDa integral membrane glycoproteins which bind only the complexed IgG due to a low affinity for monomeric Ig (10^6 M⁻¹). This receptor is the most widely expressed Fc γ R, present on all hematopoietic cells, including monocytes, macrophages, B cells, NK cells, neutrophils, mast cells, and platelets. Fc γ R1I has only two immu-
 50 noglobulin-like regions in its immunoglobulin binding chain and hence a much lower affinity for IgG than Fc γ RI. There are three human Fc γ R1I genes (Fc γ R1I-A, Fc γ R1I-B, Fc γ R1I-C), all of which bind IgG in aggregates or immune complexes.

[0006] Distinct differences within the cytoplasmic domains of Fc γ R1I-A and Fc γ R1I-B create two functionally heterog-
 55 enous responses to receptor ligation. The fundamental difference is that the A isoform initiates intracellular signaling leading to cell activation such as phagocytosis and respiratory burst, whereas the B isoform initiates inhibitory signals, e.g., inhibiting B-cell activation.

Signaling through Fc γ Rs

5 [0007] Both activating and inhibitory signals are transduced through the Fc γ Rs following ligation. These diametrically opposing functions result from structural differences among the different receptor isoforms. Two distinct domains within the cytoplasmic signaling domains of the receptor called immunoreceptor tyrosine based activation motifs (ITAMs) or immunoreceptor tyrosine based inhibitory motifs (ITIMs) account for the different responses. The recruitment of different cytoplasmic enzymes to these structures dictates the outcome of the Fc γ R-mediated cellular responses. ITAM-containing Fc γ R complexes include Fc γ RI, Fc γ RIIA, Fc γ RIIIA, whereas ITIM-containing complexes only include Fc γ RIIB.

10 [0008] Human neutrophils express the Fc γ RIIA gene. Fc γ RIIA clustering via immune complexes or specific antibody cross-linking serves to aggregate ITAMs along with receptor-associated kinases which facilitate ITAM phosphorylation. ITAM phosphorylation serves as a docking site for Syk kinase, activation of which results in activation of downstream substrates (e.g., PI $_3$ K). Cellular activation leads to release of proinflammatory mediators.

15 [0009] The Fc γ RIIB gene is expressed on B lymphocytes; its extracellular domain is 96% identical to Fc γ RIIA and binds IgG complexes in an indistinguishable manner. The presence of an ITIM in the cytoplasmic domain of Fc γ RIIB defines this inhibitory subclass of Fc γ R. Recently the molecular basis of this inhibition was established. When colligated along with an activating Fc γ R, the ITIM in Fc γ RIIB becomes phosphorylated and attracts the SH2 domain of the inositol polyphosphate 5'-phosphatase (SHIP), which hydrolyzes phosphoinositol messengers released as a consequence of ITAM-containing Fc γ R-mediated tyrosine kinase activation, consequently preventing the influx of intracellular Ca $^{++}$. Thus crosslinking of Fc γ RIIB dampens the activating response to Fc γ R ligation and inhibits cellular responsiveness. B cell activation, B cell proliferation and antibody secretion is thus aborted.

20 [0010] Shields et al. (2001), J. Biol. Chem. 276(9): 6591-6604, seek to determine the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, And FcRn receptors and disclose select IgG1 variants and the binding affinities thereof. WO 04/063351 A2 (MacroGenics, Inc.; Stavenhagen *et al.*) discloses molecules comprising particular variants of the Fc region, which bind Fc γ RIIIA and/or Fc γ RIIA with greater affinity relative to comparable molecules comprising the wild-type Fc region. WO 00/42072 A2 (Genentech, Inc.) discloses polypeptides comprising specific variant Fc regions and their effect on binding affinity and effector function. Stavenhagen et al. (2007), Cancer Res. 67(18):8882-8890, discloses particular Fc domains and their binding affinities to Fc receptors CD16A and CD32B. WO 04/099249 A2 (Xencor Inc.) discloses specific Fc variants, methods for their generation, and antibodies and Fc fusion proteins that include the specific variants.

30

35

40

45

50

55

TABLE 1. Receptors for the Fc Regions of Immunoglobulin Isotypes

Receptor	Fc γ RI (CD64)	Fc γ RII-A (CD32)	Fc γ RII-B2 (CD32)	Fc γ RII-B1 (CDC32)	Fc γ RIII (CD16)	Fc ϵ RI	Fc α RI (CD89)
Binding	IgG1 10 ⁸ M ⁻¹	IgG1 2 x 10 ⁶ M ⁻¹	IgG1 2 x 10 ⁶ M ⁻¹	IgG1 2 x 10 ⁶ M ⁻¹	IgG1 5 x 10 ⁵ M ⁻¹	IgE 1010 M ⁻¹	IgA1, IgA2 10 ⁷ M ⁻¹
Cell Type	Macrophages Neutrophils Eosinophils Dendritic cells	Macrophages Neutrophils Dendritic cells Platelets Langerhan cells	Macrophages Neutrophils Eosinophils	B cells Mast cells	NK cells Eosinophil Macrophages Neutrophils Mast Cells	Mast cells Eosinophil Basophils	Macrophages Neutrophils Eosinaphils
Effect of Ligation	Uptake Stimulation Activation of respiratory burst Induction of killing	Uptake Granule release	Uptake Inhibition of Stimulation	No uptake Inhibition of Stimulation	Induction of Killing	Secretion of granules	Uptake Induction of killing

2.2 DISEASES OF RELEVANCE

2.2.1 CANCER

5 **[0011]** A neoplasm, or tumor, is a neoplastic mass resulting from abnormal uncontrolled cell growth which can be benign or malignant. Benign tumors generally remain localized. Malignant tumors are collectively termed cancers. The term "malignant" generally means that the tumor can invade and destroy neighboring body structures and spread to distant sites to cause death (for review, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-122). Cancer can arise in many sites of the body and behave differently depending upon its origin.

10 Cancerous cells destroy the part of the body in which they originate and then spread to other part(s) of the body where they start new growth and cause more destruction.

[0012] More than 1.2 million Americans develop cancer each year. Cancer is the second leading cause of death in the United States and if current trends continue, cancer is expected to be the leading cause of the death by the year 2010. Lung and prostate cancer are the top cancer killers for men in the United States. Lung and breast cancer are the top cancer killers for women in the United States. One in two men in the United States will be diagnosed with cancer at some time during his lifetime. One in three women in the United States will be diagnosed with cancer at some time during her lifetime.

[0013] A cure for cancer has yet to be found. Current treatment options, such as surgery, chemotherapy and radiation treatment, are oftentimes either ineffective or present serious side effects.

20 *Cancer Therapy*

[0014] Currently, cancer therapy may involve surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient (See, for example, Stockdale, 1998, "Principles of Cancer Patient Management", in Scientific American: Medicine, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV). Recently, cancer therapy could also involve biological therapy or immunotherapy. All of these approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient. Additionally, surgery may not completely remove the neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent and although can be effective, is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of the cancer cells. Biological therapies/immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.

[0015] With respect to chemotherapy, there are a variety of chemotherapeutic agents available for treatment of cancer. A significant majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of the deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division (See, for example, Gilman *et al.*, Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Eighth Ed. (Pergamon Press, New York, 1990)). These agents, which include alkylating agents, such as nitrosourea, anti-metabolites, such as methotrexate and hydroxyurea, and other agents, such as etoposides, camptothecins, bleomycin, doxorubicin, daunorubicin, *etc.*, although not necessarily cell cycle specific, kill cells during S phase because of their effect on DNA replication. Other agents, specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest. Chemotherapy protocols generally involve administration of a combination of chemotherapeutic agents to increase the efficacy of treatment.

[0016] Despite the availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks (See, for example, Stockdale, 1998, "Principles Of Cancer Patient Management" in Scientific American Medicine, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10). Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, *etc.* Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even those agents that act by mechanisms different from the mechanisms of action of the drugs used in the specific treatment; this phenomenon is termed pleiotropic drug or multidrug resistance. Thus, because of drug resistance, many cancers prove refractory to standard chemotherapeutic treatment protocols.

[0017] There is a significant need for alternative cancer treatments, particularly for treatment of cancer that has proved refractory to standard cancer treatments, such as surgery, radiation therapy, chemotherapy, and hormonal therapy. A promising alternative is immunotherapy, in which cancer cells are specifically targeted by cancer antigen-specific antibodies. Major efforts have been directed at harnessing the specificity of the immune response, for example, hybridoma technology has enabled the development of tumor selective monoclonal antibodies (See Green M.C. *et al.*, 2000 Cancer

Treat Rev., 26: 269-286; Weiner LM, 1999 Semin Oncol. 26(suppl. 14):43-51), and in the past few years, the Food and Drug Administration has approved the first MAbs for cancer therapy: Rituxin (anti-CD20) for non-Hodgkin's Lymphoma and Herceptin [anti-(c-erb-2/HER-2)] for metastatic breast cancer (Suzanne A. Eccles, 2001, Breast Cancer Res., 3: 86-90). However, the potency of antibody effector function, e.g., to mediate antibody dependent cellular cytotoxicity ("ADCC") is an obstacle to such treatment. Methods to improve the efficacy of such immunotherapy are thus needed.

2.2.2 INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

[0018] Inflammation is a process by which the body's white blood cells and chemicals protect our bodies from infection by foreign substances, such as bacteria and viruses. It is usually characterized by pain, swelling, warmth and redness of the affected area. Chemicals known as cytokines and prostaglandins control this process, and are released in an ordered and self-limiting cascade into the blood or affected tissues. This release of chemicals increases the blood flow to the area of injury or infection, and may result in the redness and warmth. Some of the chemicals cause a leak of fluid into the tissues, resulting in swelling. This protective process may stimulate nerves and cause pain. These changes, when occurring for a limited period in the relevant area, work to the benefit of the body.

[0019] In autoimmune and/or inflammatory disorders, the immune system triggers an inflammatory response when there are no foreign substances to fight and the body's normally protective immune system causes damage to its own tissues by mistakenly attacking self. There are many different autoimmune disorders which affect the body in different ways. For example, the brain is affected in individuals with multiple sclerosis, the gut is affected in individuals with Crohn's disease, and the synovium, bone and cartilage of various joints are affected in individuals with rheumatoid arthritis. As autoimmune disorders progress destruction of one or more types of body tissues, abnormal growth of an organ, or changes in organ function may result. The autoimmune disorder may affect only one organ or tissue type or may affect multiple organs and tissues. Organs and tissues commonly affected by autoimmune disorders include red blood cells, blood vessels, connective tissues, endocrine glands (e.g., the thyroid or pancreas), muscles, joints, and skin. Examples of autoimmune disorders include, but are not limited to, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, dermatomyositis, lupus erythematosus, multiple sclerosis, autoimmune inner ear disease myasthenia gravis, Reiter's syndrome, Graves disease, autoimmune hepatitis, familial adenomatous polyposis and ulcerative colitis.

[0020] Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis are types of inflammatory arthritis. Arthritis is a general term that describes inflammation in joints. Some, but not all, types of arthritis are the result of misdirected inflammation. Besides rheumatoid arthritis, other types of arthritis associated with inflammation include the following: psoriatic arthritis, Reiter's syndrome, ankylosing spondylitis arthritis, and gouty arthritis. Rheumatoid arthritis is a type of chronic arthritis that occurs in joints on both sides of the body (such as both hands, wrists or knees). This symmetry helps distinguish rheumatoid arthritis from other types of arthritis. In addition to affecting the joints, rheumatoid arthritis may occasionally affect the skin, eyes, lungs, heart, blood or nerves.

[0021] Rheumatoid arthritis affects about 1% of the world's population and is potentially disabling. There are approximately 2.9 million incidences of rheumatoid arthritis in the United States. Two to three times more women are affected than men. The typical age that rheumatoid arthritis occurs is between 25 and 50. Juvenile rheumatoid arthritis affects 71,000 young Americans (aged eighteen and under), affecting six times as many girls as boys.

[0022] Rheumatoid arthritis is an autoimmune disorder where the body's immune system improperly identifies the synovial membranes that secrete the lubricating fluid in the joints as foreign. Inflammation results, and the cartilage and tissues in and around the joints are damaged or destroyed. In severe cases, this inflammation extends to other joint tissues and surrounding cartilage, where it may erode or destroy bone and cartilage and lead to joint deformities. The body replaces damaged tissue with scar tissue, causing the normal spaces within the joints to become narrow and the bones to fuse together. Rheumatoid arthritis creates stiffness, swelling, fatigue, anemia, weight loss, fever, and often, crippling pain. Some common symptoms of rheumatoid arthritis include joint stiffness upon awakening that lasts an hour or longer; swelling in a specific finger or wrist joints; swelling in the soft tissue around the joints; and swelling on both sides of the joint. Swelling can occur with or without pain, and can worsen progressively or remain the same for years before progressing.

[0023] The diagnosis of rheumatoid arthritis is based on a combination of factors, including: the specific location and symmetry of painful joints, the presence of joint stiffness in the morning, the presence of bumps and nodules under the skin (rheumatoid nodules), results of X-ray tests that suggest rheumatoid arthritis, and/or positive results of a blood test called the rheumatoid factor. Many, but not all, people with rheumatoid arthritis have the rheumatoid-factor antibody in their blood. The rheumatoid factor may be present in people who do not have rheumatoid arthritis. Other diseases can also cause the rheumatoid factor to be produced in the blood. That is why the diagnosis of rheumatoid arthritis is based on a combination of several factors and not just the presence of the rheumatoid factor in the blood.

[0024] The typical course of the disease is one of persistent but fluctuating joint symptoms, and after about 10 years, 90% of sufferers will show structural damage to bone and cartilage. A small percentage will have a short illness that

clears up completely, and another small percentage will have very severe disease with many joint deformities, and occasionally other manifestations of the disease. The inflammatory process causes erosion or destruction of bone and cartilage in the joints. In rheumatoid arthritis, there is an autoimmune cycle of persistent antigen presentation, T-cell stimulation, cytokine secretion, synovial cell activation, and joint destruction. The disease has a major impact on both the individual and society, causing significant pain, impaired function and disability, as well as costing millions of dollars in healthcare expenses and lost wages. (See, for example, the NIH website and the NIAID website).

[0025] Currently available therapy for arthritis focuses on reducing inflammation of the joints with anti-inflammatory or immunosuppressive medications. The first line of treatment of any arthritis is usually anti-inflammatories, such as aspirin, ibuprofen and Cox-2 inhibitors such as celecoxib and rofecoxib. "Second line drugs" include gold, methotrexate and steroids. Although these are well-established treatments for arthritis, very few patients remit on these lines of treatment alone. Recent advances in the understanding of the pathogenesis of rheumatoid arthritis have led to the use of methotrexate in combination with antibodies to cytokines or recombinant soluble receptors. For example, recombinant soluble receptors for tumor necrosis factor (TNF)- α have been used in combination with methotrexate in the treatment of arthritis. However, only about 50% of the patients treated with a combination of methotrexate and anti-TNF- α agents such as recombinant soluble receptors for TNF- α show clinically significant improvement. Many patients remain refractory despite treatment. Difficult treatment issues still remain for patients with rheumatoid arthritis. Many current treatments have a high incidence of side effects or cannot completely prevent disease progression. So far, no treatment is ideal, and there is no cure. Novel therapeutics are needed that more effectively treat rheumatoid arthritis and other autoimmune disorders.

2.2.3 INFECTIOUS DISEASES

[0026] Infectious agents that cause disease fall into five groups: viruses, bacteria, fungi, protozoa, and helminths (worms). The remarkable variety of these pathogens has caused the natural selection of two crucial features of adaptive immunity. First, the advantage of being able to recognize a wide range of different pathogens has driven the development of receptors on B and T cells of equal or greater diversity. Second, the distinct habitats and life cycles of pathogens have to be countered by a range of distinct effector mechanisms. The characteristic features of each pathogen are its mode of transmission, its mechanism of replication, its pathogenesis or the means by which it causes disease, and the response it elicits.

[0027] The record of human suffering and death caused by smallpox, cholera, typhus, dysentery, malaria, etc. establishes the eminence of the infectious diseases. Despite the outstanding successes in control afforded by improved sanitation, immunization, and antimicrobial therapy, the infectious diseases continue to be a common and significant problem of modern medicine. The most common disease of mankind, the common cold, is an infectious disease, as is the feared modern disease AIDS. Some chronic neurological diseases that were thought formerly to be degenerative diseases have proven to be infectious. There is little doubt that the future will continue to reveal the infectious diseases as major medical problems.

[0028] An enormous number of human and animal diseases result from virulent and opportunistic infections from any of the above mentioned infectious agents (see Belshe (Ed.) 1984 Textbook of Human Virology, PSG Publishing, Littleton, MA).

[0029] One category of infectious diseases are viral infections for example. Viral diseases of a wide array of tissues, including the respiratory tract, CNS, skin, genitourinary tract, eyes, ears, immune system, gastrointestinal tract, and musculoskeletal system, affect a vast number of humans of all ages (see Table 328-2 In: Wyngaarden and Smith, 1988, Cecil Textbook of Medicine, 18th Ed., W.B. Saunders Co., Philadelphia, pp.1750-1753). Although considerable effort has been invested in the design of effective anti-viral therapies, viral infections continue to threaten the lives of millions of people worldwide. In general, attempts to develop anti-viral drugs have focused on several stages of viral life cycle (See e.g., Mitsuya et al., 1991, FASEB J. 5:2369-2381, discussing HIV). However, a common drawback associated with using of many current anti-viral drugs is their deleterious side effects, such as toxicity to the host or resistance by certain viral strains.

3. SUMMARY OF THE INVENTION

[0030] Described herein is the identification of mutant human IgG1 heavy chain Fc regions, with altered affinities for Fc γ R receptors (e.g., activating Fc γ Rs, inhibitory Fc γ Rs), using a yeast display system. In vivo animal modeling and clinical experiments indicate that the Fc region plays an essential role in determining the outcome of monoclonal antibody therapy. Current approaches to optimize the Fc region function (e.g., antibody-dependent cell mediated cytotoxicity (ADCC), complement dependent cytotoxicity (CDC) activity) in therapeutic monoclonal antibodies and soluble polypeptides fused to Fc regions have focused on a limited number of single amino acid changes based on structural analysis and/or computer aided designs. Alternative approaches in engineering Fc regions have focused on the glycosylation of

the Fc region to optimize Fc region function.

Described herein is a selection of possible mutants for alteration in one or more Fc functional activities, such as but not limited to ADCC and CDC, from an unbiased library of Fc variants. The present description details methods for engineering Fc

5 regions and identification and screening of novel Fc variants outside the expected regions identified by structural studies. Expected regions as used herein refer to those regions that based on structural and/or biochemical studies are in contact with an Fc ligand.

[0031] Described herein is a discovery platform for the identification of Fc variants with improvement in one or more Fc effector function by combining cell based functional assays and combinatorial library construction with state of the art automation. The present disclosure assembles complete combinatorial libraries by saturating regions of interest within the Fc with modifications that cover all possible amino acid changes. Combinatorial libraries will be tested using a set of binding and functional assays to select mutants based on improved biological function.

[0032] The present invention relates to molecules, preferably polypeptides, and more preferably immunoglobulins (e.g., antibodies), comprising a variant Fc region, having one or more amino acid modifications (e.g., substitutions, but also including insertions or deletions) in one or more regions, which modifications alter, e.g., increase or decrease, the affinity of the variant Fc region for an Fc γ R. Specifically, said one or more amino acid modifications increases the affinity of the variant Fc region for Fc γ R1IIIA and preferably said one or more amino acid modifications increase the affinity of the variant Fc region for Fc γ R1IIA.

The present invention is based on a polypeptide comprising a variant IgG1 Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type IgG1 Fc region, such that said variant Fc region of said polypeptide binds Fc γ R1IIIA with a greater affinity, and Fc γ R1IIB with altered binding affinity; wherein said greater and altered binding affinities are relative to the binding affinities exhibited by such polypeptide to said Fc γ R_s if comprising a wild-type Fc region; and wherein said at least one amino acid modification comprises a set of substitutions selected from the group consisting of: (1) a substitution at position 243 with leucine and at position 292 with proline; (2) a substitution at position 243 with leucine, at position 292 with proline, and at position 305 with isoleucine; (3) a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; (4) a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine; and (5) a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine; wherein the positions are numbered according to the EU index as in Kabat.

In a preferred embodiment, the molecules of the invention further specifically bind Fc γ R1IIB (via the Fc region) with a lower affinity than a comparable molecule (*i.e.*, having the same amino acid sequence as the molecule of the invention except for the one or more amino acid modifications in the Fc region) comprising the wild-type Fc region binds Fc γ R1IIB. In some embodiments, the invention encompasses molecules with variant Fc regions, having one or more amino acid modifications, which modifications increase the affinity of the variant Fc region for Fc γ R1IIIA and optionally Fc γ R1IIA and enhance the affinity of the variant Fc region for Fc γ R1IIB relative to a comparable molecule with a wild type Fc region. A preferred embodiment is a variant Fc region that has enhanced affinity for Fc γ R1IIIA and Fc γ R1IIA but reduced affinity for Fc γ R1IIB relative to a comparable molecule with a wild type Fc region.

[0033] The Fc variants of the present invention may be combined with other Fc modifications, including but not limited to modifications that alter effector function. The invention encompasses combining an Fc variant of the invention with other Fc modifications to provide additive, synergistic, or novel properties in antibodies or Fc fusions. Preferably, the Fc variants of the invention enhance the phenotype of the modification with which they are combined. For example, if an Fc variant of the invention is combined with a mutant known to bind Fc γ R1IIIA with a higher affinity than a comparable molecule comprising a wild type Fc region; the combination with a mutant of the invention results in a greater fold enhancement in Fc γ R1IIIA affinity.

[0034] In one embodiment, the Fc variants of the present invention may be combined with other known Fc variants such as those disclosed in Duncan et al, 1988, Nature 332:563-564; Lund et al., 1991, J. Immunol 147:2657-2662; Lund et al, 1992, Mol Immunol 29:53-59; Alegre et al, 1994, Transplantation 57:1537-1543; Hutchins et al., 1995, Proc Natl. Acad Sci USA 92:11980-11984; Jefferis et al, 1995, Immunol Lett. 44:111-117; Lund et al., 1995, Faseb J 9:115-119; Jefferis et al, 1996, Immunol Lett 54:101-104; Lund et al, 1996, J Immunol 157:49634969; Armour et al, 1999, Eur J Immunol 29:2613-2624; Idusogie et al, 2000, J Immunol 164:41784184; Reddy et al, 2000, J Immunol 164:1925-1933; Xu et al., 2000, Cell Immunol 200:16-26; Idusogie et al, 2001, J Immunol 166:2571-2575; Shields et al., 2001, J Biol Chem 276:6591-6604; Jefferis et al, 2002, Immunol Lett 82:57-65; Presta et al., 2002, Biochem Soc Trans 30:487-490; US 5,624,821; US 5,885,573; US 6,194,551; PCT WO 00/42072; PCT WO 99/58572. In certain embodiments, the Fc variants of the present invention may be combined with one or more of the Fc variants, *i.e.*, amino acid modifications relative to a wild-type Fc region, presented in tables 5, 6, 7, and 8, *infra*.

[0035] The invention encompasses molecules that are homodimers or heterodimers of Fc regions. Heterodimers comprising Fc regions refer to molecules where the two Fc chains have the same or different sequences. In some embodiments, in the heterodimeric molecules comprising variant Fc regions, each chain has one or more different

modifications from the other chain. In other embodiments, in the heterodimeric molecules comprising variant Fc regions, one chain contains the wild-type Fc region and the other chains comprises one or more modifications. Methods of engineering heterodimeric Fc containing molecules are known in the art and encompassed within the invention.

[0036] Described herein are molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild type Fc region, which variant Fc region does not bind any Fc γ R or binds with a reduced affinity, relative to a comparable molecule comprising the wild-type Fc region, as determined by standard assays (*e.g.*, *in vitro* assays) known to one skilled in the art. In a specific embodiment, the invention encompasses molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild type Fc region, which variant Fc region only binds one Fc γ R, wherein said Fc γ R is Fc γ IIIa.

[0037] The affinities and binding properties of the molecules of the invention for an Fc γ R are initially determined using *in vitro* assays (biochemical or immunological based assays) known in the art for determining Fc-Fc γ R interactions, *i.e.*, specific binding of an Fc region to an Fc γ R including but not limited to ELISA assay, surface plasmon resonance assay, immunoprecipitation assays (See Section 5.2.1). Preferably, the binding properties of the molecules of the invention are also characterized by *in vitro* functional assays for determining one or more Fc γ R mediator effector cell functions (See Section 5.2.6). In most preferred embodiments, the molecules of the invention have similar binding properties in *in vivo* models (such as those described and disclosed herein) as those in *in vitro* based assays. However, the present invention does not exclude molecules of the invention that do not exhibit the desired phenotype in *in vitro* based assays but do exhibit the desired phenotype *in vivo*.

[0038] In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIIa with a greater affinity than a comparable molecule comprising the wild-type Fc region binds Fc γ RIIIa, provided that said variant Fc region does not solely have a substitution at any one of positions 329, 331, or 332, and do not include or are not solely substitution with any one of: alanine at any of positions 256, 290, 298, 312, 333, 334, 359, 360, 326, or 430; a lysine at position 330; a threonine at position 339; a methionine at position 320; a serine at position 326; an asparagine at position 326; an aspartic acid at position 326; a glutamic acid at position 326; a glutamine at position 334; a glutamic acid at position 334; a methionine at position 334; a histidine at position 334; a valine at position 334; or a leucine at position 334; a lysine at position 335.

[0039] In another specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIa with a greater affinity than a comparable molecule comprising the wild-type Fc region binds Fc γ RIIa, provided that the one or more amino acid modifications do not include or are not solely substitution with an alanine at any of positions 256, 290, 326, 255, 258, 267, 272, 276, 280, 283, 285, 286, 331, 337, 268, 272, or 430; an asparagine at position 268; a glutamine at position 272; a glutamine, serine, or aspartic acid at position 286; a serine at position 290; a methionine, glutamine, glutamic acid, or arginine at position 320; a glutamic acid at position 322; a serine, glutamic acid, or aspartic acid at position 326; a lysine at position 330; a glutamine at position 335; or a methionine at position 301.

[0040] In a preferred specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule has an altered affinity for an Fc γ R, provided that said variant Fc region does not have a substitution at positions that make a direct contact with Fc γ R based on crystallographic and structural analysis of Fc-Fc γ R interactions such as those disclosed by Sondermann *et al.*, (2000 *Nature*, 406: 267-273, which is incorporated herein by reference in its entirety). Examples of positions within the Fc region that make a direct contact with Fc γ R are amino acids 234-239 (hinge region), amino acids 265-269 (B/C loop), amino acids 297-299 (C'/E loop), and amino acids 327-332 (F/G) loop. In some embodiments, the molecules of the invention comprising variant Fc regions comprise modification of at least one residue that does not make a direct contact with an Fc γ R based on structural and crystallographic analysis, *e.g.*, is not within the Fc-Fc γ R binding site.

[0041] In another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with an altered affinity relative to a molecule comprising a wild-type Fc region, provided that said at least one amino acid modification do not include or are not solely a substitution at any of positions 255, 256, 258, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 300, 301, 303, 305, 307, 309, 312, 320, 322, 326, 329, 330, 332, 331, 333, 334, 335, 337, 338, 339, 340, 359, 360, 373, 376, 411b, 419, 430, 434, 435, 437, 438, 439. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with an altered affinity relative to a molecule comprising a wild-type Fc region, provided that said variant Fc region does not include or are not solely a substitution at any of positions 255, 258, 267, 269, 270, 276, 278, 280, 283, 285, 289, 292, 293, 294, 295, 296, 300, 303, 305, 307, 309, 322, 329, 332, 331, 337, 338, 340, 373, 376, 416, 419, 434, 435, 437, 438, 439 and does not have an alanine at any of positions 256, 290, 298, 312,

333, 334, 359, 360, 326, or 430; a lysine at position 330; a threonine at position 339; a methionine at position 320; a serine at position 326; an asparagine at position 326; an aspartic acid at position 326; a glutamic acid at position 326; a glutamine at position 334; a glutamic acid at position 334; a methionine at position 334; a histidine at position 334; a valine at position 334; or a leucine at position 334; a lysine at position 335 an asparagine at position 268; a glutamine at position 272; a glutamine, serine, or aspartic acid at position 286; a serine at position 290; a methionine, glutamine, glutamic acid, or arginine at position 320; a glutamic acid at position 322; a serine, glutamic acid, or aspartic acid at position 326; a lysine at position 330; a glutamine at position 335; or a methionine at position 301.

[0042] In a specific embodiment, the invention encompasses, a molecule comprising a variant Fc region, wherein said variant Fc region does not include or are not solely a substitution at any of positions 268, 269, 270, 272, 276, 278, 283, 285, 286, 289, 292, 293, 301, 303, 305, 307, 309, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 416, 419, 430, 434, 435, 437, 438 or 439 and does not have a histidine, glutamine, or tyrosine at position 280; a serine, glycine, threonine or tyrosine at position 290, a leucine or isoleucine at position 300; an asparagine at position 294, a proline at position 296; a proline, asparagine, aspartic acid, or valine at position 298; a lysine at position 295. In yet another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with a reduced affinity relative to a molecule comprising a wild-type Fc region provided that said variant Fc region does not have or are not solely have a substitution at any of positions 252, 254, 265, 268, 269, 270, 278, 289, 292, 293, 294, 295, 296, 298, 300, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438, or 439. In yet another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with an enhanced affinity relative to a molecule comprising a wild-type Fc region provided that said variant Fc region does not have or are not solely a substitution at any of positions 280, 283, 285, 286, 290, 294, 295, 298, 300, 301, 305, 307, 309, 312, 315, 331, 333, 334, 337, 340, 360, 378, 398, or 430.

[0043] In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region does not include a substitution or does not solely have a substitution at any of positions 330, 243, 247, 298, 241, 240, 244, 263, 262, 235, 269, or 328 and does not have a leucine at position 243, an asparagine at position 298, a leucine at position 241, and isoleucine or an alanine at position 240, a histidine at position 244, a valine at position 330, or an isoleucine at position 328.

[0044] In a specific embodiment, molecules of the invention comprise a variant Fc region having one or more amino acid modifications (e.g., substitutions), which modifications increase the affinity of the variant Fc region for Fc γ RIIIA and/or Fc γ RIIA by at least 2-fold, relative to a comparable molecule comprising a wild-type Fc region. In certain embodiments, molecules of the invention comprise a variant Fc region having one or more amino acid modifications (e.g., substitutions), which modifications increase the affinity of the variant Fc region for Fc γ RIIIA and/or Fc γ RIIA by greater than 2-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 8-fold, or at least 10-fold relative to a comparable molecule comprising a wild-type Fc region. In other embodiments of the invention, molecules of the invention comprising a variant Fc region specifically bind Fc γ RIIIA and/or Fc γ RIIA with at least 65%, at least 75%, at least 85%, at least 95%, at least 100%, at least 150%, at least 200% greater affinity relative to a molecule comprising a wild-type Fc region. Such measurements are preferably in vitro assays.

[0045] The invention encompasses molecules with altered affinities for the activating and/or inhibitory Fc γ receptors. In particular, the invention contemplates molecules with variant Fc regions, having one or more amino acid modifications, which modifications increase the affinity of the variant Fc region for Fc γ RIIB but decrease the affinity of the variant Fc region for Fc γ RIIA, relative to a comparable molecule with a wild-type Fc region. In other embodiments, the invention encompasses molecules with variant Fc regions, having one or more amino acid modifications, which modifications decrease the affinity of the variant Fc region for Fc γ RIIB and also decrease the affinity of the variant Fc regions for Fc γ RIIA relative to a comparable molecule with a wild-type Fc region. In yet other embodiments, the invention encompasses molecules with variant Fc regions, having one or more amino acid modifications, which modifications increase the affinity of the variant Fc region for Fc γ RIIB and also increase the affinity of the variant Fc regions for Fc γ RIIIA and preferably for Fc γ RIIA, relative to a comparable molecule with a wild-type Fc region. In yet other embodiments, the invention encompasses molecules with variant Fc regions, which modifications increase the affinity of the variant Fc region for Fc γ RIIIA and preferably for Fc γ RIIA but reduce the affinity of the variant Fc region for Fc γ RIIB relative to a comparable molecule with a wild-type Fc region.

[0046] In a specific embodiment, the molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions), which one or more modifications increase the affinity of the variant Fc region for Fc γ RIIIA and decrease the affinity of the variant Fc region for Fc γ RIIB, relative to a comparable molecule comprising a wild-type Fc region which binds Fc γ RIIIA and Fc γ RIIB with wild-type affinity. In a certain embodiment, the one or more amino acid modifications are not a substitution with alanine at any of positions 256, 298, 333, or 334.

[0047] In another specific embodiment, the molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions), which one or more modifications increase the affinity of the variant

Fc region for Fc γ R1IA and decrease the affinity of the variant Fc region for Fc γ R1IB, relative to a comparable molecule comprising a wild-type Fc region which binds Fc γ R1IA and Fc γ R1IB with wild-type affinity. In a certain embodiment, the one or more amino acid modifications is not a substitution with arginine at position 320.

[0048] In most preferred embodiments, the molecules of the invention with altered affinities for activating and/or inhibitory receptors having variant Fc regions, have one or more amino acid modifications, wherein said one or more amino acid modification is a substitution at position 288 with asparagine, at position 330 with serine and at position 396 with leucine (MgFc10) (See Tables 5 & 6); or a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine (MgFc13); or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid (MgFc27); or a substitution at position 392 with threonine, and at position 396 with leucine (MgFc38); or a substitution at position 221 with glutamic acid, at position 270 with glutamic acid, at position 308 with alanine, at position 311 with histidine, at position 396 with leucine, and at position 402 with aspartic acid (MgFc42); or a substitution at position 240 with alanine, and at position 396 with leucine (MgFc52); or a substitution at position 410 with histidine, and at position 396 with leucine (MgFc53); or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine, and at position 396 with leucine (MgFc54); or a substitution at position 255 with isoleucine, and at position 396 with leucine (MgFc55); or a substitution at position 370 with glutamic acid and at position 396 with leucine (MgFc59); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine (MgFc88); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine (MgFc88A); or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine (MgFc155); or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 292 with proline; or a substitution at position 243 with leucine; or a substitution at position 273 with phenylalanine. In a related embodiment, the variant Fc region further comprises one or more amino acid modifications disclosed in tables 5, 6, 7, and 8. *infra*.

[0049] The preferred method for screening and identifying molecules comprising variant Fc regions with altered Fc γ R affinities (e.g., enhanced Fc γ R1IIIA affinity) is yeast surface display technology (for review see Boder and Wittrup, 2000, Methods in Enzymology, 328: 430-444. Specifically, the yeast surface display is a genetic method whereby polypeptides comprising Fc mutants are expressed on the yeast cell wall in a form accessible for interacting with Fc γ R. Yeast surface display of the mutant Fc containing polypeptides of the invention may be performed in accordance with any of the techniques known to those skilled in the art or the specific methods described herein. Yeast display offers the advantage of utilizing actual binding to a desired receptor to identify variant Fc regions that have enhanced binding to that receptor.

[0050] One aspect of the invention provides a method for selecting mutant Fc fusion proteins with a desirable binding property, e.g., the ability of the mutant Fc fusion protein to bind Fc γ R1IIIA with a greater affinity than a comparable polypeptide comprising a wild-type Fc region binds Fc γ R1IIIA. Yeast cells displaying the mutant Fc fusion proteins can be screened and characterized by any biochemical or immunological based assays known to those skilled in the art for assessing binding interactions. In a specific embodiment, screening of mutant Fc fusion proteins is done using one or more biochemical based assays, e.g., an ELISA assay.

[0051] In preferred embodiments, screening and identifying molecules comprising variant Fc regions with altered Fc γ R affinities (e.g., enhanced Fc γ R1IIIA affinity) are done using the yeast display technology as described herein in combination with one or more biochemical based assays, preferably in a high throughput manner. The one or more biochemical assays can be any assay known in the art for identifying Fc-Fc γ R interaction, *i.e.*, specific binding of an Fc region to an Fc γ R, including, but not limited to, an ELISA assay, surface plasmon resonance assays, immunoprecipitation assay, affinity chromatography, and equilibrium dialysis. In some embodiments, screening and identifying molecules comprising variant Fc regions with altered Fc γ R affinities (e.g., enhanced Fc γ R1IIIA affinity) are done using the yeast display technology as described herein in combination with one or more functional based assays, preferably in a high throughput manner. The functional based assays can be any assay known in the art for characterizing one or more Fc γ R mediated effector cell function such as those described herein in Section 5.2.6. Non-limiting examples of effector cell functions that can be used in accordance with the methods of the invention, include but are not limited to, antibody-dependent cell mediated cytotoxicity (ADCC), antibody-dependent phagocytosis, phagocytosis, opsonization, opsonophagocytosis, cell binding, rosetting, C1q binding, and complement dependent cell mediated cytotoxicity. In some embodiments, screening and identifying molecules comprising variant Fc regions with altered Fc γ R affinities (e.g., enhanced Fc γ R1IIIA affinity) are done using the yeast display technology as described herein in combination with one or more biochemical based assays in combination or in parallel with one or more functional based assays, preferably in a high throughput manner.

[0052] A preferred method for measuring the Fc γ R-Fc interaction in accordance with the invention is an assay developed by the inventors, which allows detection and quantitation of the interaction, despite the inherently weak affinity of the receptor for its ligand, e.g., in the micromolar range for Fc γ R1IB and Fc γ R1IIIA. The method involves the formation of an Fc γ R complex (e.g., Fc γ R1IIIA, Fc γ R1IB) that has an improved avidity for an Fc region, relative to an uncomplexed Fc γ R. In a specific embodiment, the invention encompasses a method for producing a tetrameric Fc γ R complex, wherein said

tetrameric complex has an enhanced affinity for an Fc region, relative to the affinity of a monomeric Fc γ R for the Fc region, said method comprising: (i) producing a fusion protein, such that a 15 amino acid AVITAG sequence operably linked to the soluble region of Fc γ R; (ii) biotinylating the protein produced using an *E. coli* BirA enzyme; (iii) mixing the biotinylated protein produced with streptaividn-phycoerythrin in an appropriate molar ratio, such that a tetrameric Fc γ R complex is formed.

[0053] In a preferred embodiment of the invention, polypeptides comprising Fc regions bind the tetrameric Fc γ R complexes, formed according to the methods of the invention, with at least an 8-fold higher affinity than they bind the monomeric uncomplexed Fc γ R. The binding of polypeptides comprising Fc regions to the tetrameric Fc γ R complexes may be determined using standard techniques known to those skilled in the art, such as for example, fluorescence activated cell sorting (FACS), radioimmunoassays, ELISA assays, *etc.*

[0054] The invention encompasses the use of the immune complexes formed according to the methods described above for determining the functionality of molecules comprising an Fc region in cell-based or cell-free assays.

[0055] In a specific embodiment, the invention provides modified immunoglobulins comprising a variant Fc region with an enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA. Such immunoglobulins include IgG molecules that naturally contain Fc γ R binding regions (*e.g.*, Fc γ R1IIIA and/or Fc γ R1IIB binding regions), or immunoglobulin derivatives that have been engineered to contain an Fc γ R binding region (*e.g.*, Fc γ R1IIIA and/or Fc γ R1IIB binding regions). The modified immunoglobulins of the invention include any immunoglobulin molecule that binds, preferably, immunospecifically, *i.e.*, competes off nonspecific binding as determined by immunoassays well known in the art for assaying specific antigen-antibody binding, an antigen and contains an Fc γ R binding region (*e.g.*, a Fc γ R1IIIA and/or Fc γ R1IIB binding region). Such antibodies include, but are not limited to, polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, disulfide-linked Fvs, and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds an antigen, in certain cases, engineered to contain or fused to an Fc γ R binding region.

[0056] In certain embodiment, the invention encompasses immunoglobulins comprising a variant Fc region with an enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA such that the immunoglobulin has an enhanced effector function, *e.g.*, antibody dependent cell mediated cytotoxicity. The effector function of the molecules of the invention can be assayed using any assay described herein or known to those skilled in the art. In some embodiments, immunoglobulins comprising a variant Fc region with an enhanced affinity for Fc γ R1IIIA and/or Fc γ R1IIA have an enhanced ADCC activity relative to wild-type by at least 2-fold, at least 4-fold, at least 8-fold, at least 10-fold, at least 50-fold, or at least 100-fold.

[0057] The invention encompasses engineering human or humanized therapeutic antibodies (*e.g.*, tumor specific monoclonal antibodies) in the Fc region by modification (*e.g.*, substitution, insertion, deletion) of one or more amino acid residues, which modifications modulate the affinity of the therapeutic antibody for an Fc γ R activating receptor and/or an Fc γ R inhibitory receptor. In one embodiment, the invention relates to engineering human or humanized therapeutic antibodies (*e.g.*, tumor specific monoclonal antibodies) in the Fc region by modification of one or more amino acid residues, which modifications increase the affinity of the Fc region for Fc γ R1IIIA and preferably also for Fc γ R1IIA. In another embodiment, the invention relates to engineering human or humanized therapeutic antibodies (*e.g.*, tumor specific monoclonal antibodies) in the Fc region by modification of one or more amino acid residues, which modification increases the affinity of the Fc region for Fc γ R1IIIA and preferably also for Fc γ R1IIA and further decreases the affinity of the Fc region for Fc γ R1IIB. The engineered therapeutic antibodies may further have an enhanced effector function, *e.g.*, enhanced ADCC activity, phagocytosis activity, *etc.*, as determined by standard assays known to those skilled in the art.

[0058] In a specific embodiment, the invention encompasses engineering a humanized monoclonal antibody specific for Her2/neu protooncogene (*e.g.*, Ab4D5 humanized antibody as disclosed in Carter et al., 1992, Proc. Natl. Acad. Sci. USA 89:4285-9) by modification (*e.g.*, substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another specific embodiment, modification of the humanized Her2/neu monoclonal antibody may also further decrease the affinity of the Fc region for Fc γ R1IIB. In yet another specific embodiment, the engineered humanized monoclonal antibodies specific for Her2/neu may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein.

[0059] In another specific embodiment, the invention encompasses engineering an anti-CD20 antibody by modification (*e.g.*, substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and preferably also for Fc γ R1IIA. In a related embodiment, the anti-CD20 antibody is mouse human chimeric anti-CD20 monoclonal antibody, 2H7 Further nonlimiting examples of anti-CD20 antibodies that can be used in the methods of the invention are disclosed in U.S. Patent Application No.: 11/271,140, filed November 10, 2005 (Published as US 2006 0134709). In another specific embodiment, modification of the anti-CD20 monoclonal antibody, 2H7 may also further decrease the affinity of the Fc region for Fc γ R1IIB. In yet another specific embodiment, the engineered anti-CD20 monoclonal antibody, 2H7 may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein.

[0060] In another specific embodiment, the invention encompasses engineering an anti-Fc γ R1IIB antibody, in particular an anti-Fc γ R1IIB antibody that specifically binds human Fc γ R1IIB, more particularly native human Fc γ R1IIB, by modification

(e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ RIIIA and preferably also for Fc γ RIIA. Non-limiting examples of representative anti-Fc γ RIIB antibodies are disclosed in U.S. Provisional Application No. 60/403,266 filed on August 12, 2002; U.S. Application No. 10/643,857 filed on August 14, 2003 (published as US 2004 0185045); and U.S. Patent Application Publication No.s: 2004-0185045;

5

2005-0260213; and 2006-0013810. Examples of anti-Fc γ RIIB antibodies that may be engineered in accordance with the methods of the invention are the monoclonal antibodies produced by clone 2B6, 3H7, 8B5.4.3, 1D5, 2E1, 2H9, 2D11 and 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTCA-5959, respectively (deposited at ATCC, 10801 University Boulevard, Manassas, VA 02209-2011, all of which are incorporated herein by reference), or chimeric, humanized or other engineered versions thereof.

10

[0061] In a specific embodiment, the invention encompasses engineering a humanized antibody comprising the heavy chain variable domain and/or light chain variable domain of 2B6, 3H7 or 8B5.3.4. In another specific embodiment, the invention encompasses engineering a humanized antibody comprising the CDRs of 2B6, 3H7 or 8B5.3.4. In a specific embodiment, the invention encompasses engineering a humanized antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3 and the light chain variable domain having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO: 8. In a specific embodiment, the invention encompasses engineering a humanized antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO:9 and the light chain variable domain having the amino acid sequence of SEQ ID NO:10.

15

20

[0062] In another specific embodiment, modification of the anti-Fc γ RIIB antibody may also further decrease the affinity of the Fc region for Fc γ RIIB. In yet another specific embodiment, the engineered anti-Fc γ RIIB antibody may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein. In a specific embodiment, the anti-Fc γ RIIB monoclonal antibody comprises a modification at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine (MgFc13); or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid (MgFc27); or a substitution at position 243 with isoleucine, at position 379 with leucine, and at position 420 with valine (MgFc29); or a substitution at position 392 with threonine and at position 396 with leucine (MgFc38); or a substitution at position 221 with glutamic acid, at position 270 with glutamic acid, at position 308 with alanine, at position 311 with histidine, at position 396 with leucine, and at position 402 with aspartic (MgFc42); or a substitution at position 410 with histidine, and at position 396 with leucine (MgFc53); or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine, and at position 396 with leucine (MgFc54); or a substitution at position 255 with isoleucine, and at position 396 with leucine (MgFc55); or a substitution at position 370 with glutamic acid, and at position 396 with leucine (MgFc59); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine (MgFc88); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine (MgFc88A); or a substitution at position 234 with leucine, at position 292 with proline, and at position 300 with leucine (MgFc155); or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 292 with proline; or a substitution at position 243 with leucine; or a substitution at position 273 with phenylalanine. In a related embodiment, the variant Fc region further comprises one or more amino acid modifications disclosed in tables 5, 6, 7, and 8, *infra*.

25

30

35

40

45

[0063] The present invention also includes polynucleotides that encode a molecule of the invention, including polypeptides and antibodies, identified by the methods of the invention. The polynucleotides encoding the molecules of the invention may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. The invention relates to an isolated nucleic acid encoding a molecule of the invention. The invention also provides a vector comprising said nucleic acid. The invention further provides host cells containing the vectors or polynucleotides of the invention.

50

[0064] The invention further provides methods for the production of the molecules of the invention. The molecules of the invention, including polypeptides and antibodies, can be produced by any method known to those skilled in the art, in particular, by recombinant expression. In a specific embodiment, the invention relates to a method for recombinantly producing a molecule of the invention, said method comprising: (i) culturing in a medium a host cell comprising a nucleic acid encoding said molecule, under conditions suitable for the expression of said molecule; and (ii) recovery of said molecule from said medium.

55

[0065] The molecules identified in accordance with the methods of the invention are useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc γ R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. Accordingly, the invention also provides the

use according to claim 14, 15, 16 or 17.

[0066] In one embodiment, the antibody according to the invention can be used in a method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering a therapeutically effective amount of a therapeutic antibody that binds the cancer antigen, which has been engineered in accordance with the methods of the invention. In a specific embodiment, the antibody according to the invention can be used in a method for treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering a therapeutically effective amount of a therapeutic antibody that specifically binds said cancer antigen, said therapeutic antibody comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said therapeutic antibody specifically binds Fc γ R111A with a greater affinity than the therapeutic antibody comprising the wild-type Fc region binds Fc γ R111A, provided that said variant Fc region does not have a substitution at positions 329, 331, or 332, and does not have an alanine at any of positions 256, 290, 298, 312, 333, 334, 359, 360, or 430; a lysine at position 330; a threonine at position 339; a methionine at position 320; a serine at position 326; an asparagine at position 326; an aspartic acid at position 326; a glutamic acid at position 326; a glutamine at position 334; a glutamic acid at position 334; a methionine at position 334; a histidine at position 334; a valine at position 334; or a leucine at position 334. In another specific embodiment, the antibody according to the invention can be used in a method for treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering a therapeutically effective amount of a therapeutic antibody that specifically binds a cancer antigen, said therapeutic antibody comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region such that said therapeutic antibody specifically binds Fc γ R111A with a greater affinity than a therapeutic antibody comprising the wild-type Fc region binds Fc γ R111A, and said therapeutic antibody further specifically binds Fc γ R112B with a lower affinity than a therapeutic antibody comprising the wild-type Fc region binds Fc γ R112B, provided that said variant Fc region does not have an alanine at any of positions 256, 298, 333, or 334. The invention encompasses a method for treating cancer in a patient characterized by a cancer antigen, said method comprising administering a therapeutically effective amount of a therapeutic antibody that specifically binds said cancer antigen and said therapeutic antibody comprises a variant Fc region so that the antibody has an enhanced ADCC activity.

[0067] The molecules of the invention can be used in a method of treating an autoimmune disorder and/or inflammatory disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild type Fc region, such that said molecule specifically binds Fc γ R112B with a greater affinity than a comparable molecule comprising the wild type Fc region, and said molecule further specifically binds Fc γ R111A with a lower affinity than a comparable molecule comprising the wild type Fc region., and said molecule binds an immune complex (e.g., an antigen/antibody complex). The molecule of the invention can be used in a method of treating an autoimmune disorder and/or inflammatory disorder further comprising administering one or more additional prophylactic or therapeutic agents, e.g., immunomodulatory agents, anti-inflammatory agents, used for the treatment and/or prevention of such diseases.

[0068] The molecules of the invention also can be used in methods for treating or preventing an infectious disease in a subject comprising administering a therapeutically or prophylactically effective amount of one or more molecules of the invention that bind an infectious agent or cellular receptor therefor. Infectious diseases that can be treated or prevented by the molecules of the invention are caused by infectious agents including but not limited to viruses, bacteria, fungi, protozoae, and viruses.

[0069] According to one aspect of the invention, molecules of the invention comprising variant Fc regions have an enhanced antibody effector function towards an infectious agent, e.g., a pathogenic protein, relative to a comparable molecule comprising a wild-type Fc region. In a specific embodiment, molecules of the invention enhance the efficacy of treatment of an infectious disease by enhancing phagocytosis and/or opsonization of the infectious agent causing the infectious disease. In another specific embodiment, molecules of the invention enhance the efficacy of treatment of an infectious disease by enhancing ADCC of infected cells causing the infectious disease.

[0070] In some embodiments, the molecules of the invention may be administered in combination with a therapeutically or prophylactically effective amount of one or additional therapeutic agents known to those skilled in the art for the treatment and/or prevention of an infectious disease. The invention contemplates the use of the molecules of the invention in combination with antibiotics known to those skilled in the art for the treatment and or prevention of an infectious disease.

[0071] The invention provides pharmaceutical compositions comprising a molecule of the invention, e.g., a polypeptide comprising a variant Fc region, an immunoglobulin comprising a variant Fc region, a therapeutic antibody engineered in accordance with the invention, and a pharmaceutically acceptable carrier. The invention additionally provides pharmaceutical compositions further comprising one or more additional therapeutic agents, including but not limited to anti-cancer agents, anti-inflammatory agents, immunomodulatory agents.

3.1 DEFINITIONS

[0072] As used herein, the term "Fc region" is used to define a C-terminal region of an IgG heavy chain. Although the boundaries may vary slightly, the human IgG heavy chain Fc region is defined to stretch from Cys226 to the carboxy terminus. The Fc region of an IgG comprises two constant domains, CH2 and CH3. The CH2 domain of a human IgG Fc region (also referred to as "C γ 2" domain) usually extends from amino acid 231 to amino acid 338. The CH3 domain of a human IgG Fc region usually extends from amino acids 342 to 447. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG.

[0073] Throughout the present specification, the numbering of the residues in an IgG heavy chain is that of the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, NH1, MD (1991), expressly incorporated herein by references. The "EU index as in Kabat" refers to the numbering of the human IgG1 EU antibody.

[0074] The "hinge region" is generally defined as stretching from Glu216 to Pro230 of human IgG1. Hinge regions of other IgG isotypes may be aligned with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions.

[0075] As used herein, the terms "antibody" and "antibodies" refer to monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, polyclonal antibodies, camelized antibodies, single-chain Fvs (scFv), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked bispecific Fvs (sdFv), intrabodies, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂) or subclass.

[0076] As used herein, the term "derivative" in the context of polypeptides or proteins refers to a polypeptide or protein that comprises an amino acid sequence which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The term "derivative" as used herein also refers to a polypeptide or protein which has been modified, *i.e.*, by the covalent attachment of any type of molecule to the polypeptide or protein. For example, but not by way of limitation, an antibody may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, *etc.* A derivative polypeptide or protein may be produced by chemical modifications using techniques known to those of skill in the art, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, *etc.* Further, a derivative polypeptide or protein derivative possesses a similar or identical function as the polypeptide or protein from which it was derived.

[0077] As used herein, the term "derivative" in the context of a non-proteinaceous derivative refers to a second organic or inorganic molecule that is formed based upon the structure of a first organic or inorganic molecule. A derivative of an organic molecule includes, but is not limited to, a molecule modified, e.g., by the addition or deletion of a hydroxyl, methyl, ethyl, carboxyl or amine group. An organic molecule may also be esterified, alkylated and/or phosphorylated.

[0078] As used herein, the terms "disorder" and "disease" are used interchangeably to refer to a condition in a subject. In particular, the term "autoimmune disease" is used interchangeably with the term "autoimmune disorder" to refer to a condition in a subject characterized by cellular, tissue and/or organ injury caused by an immunologic reaction of the subject to its own cells, tissues and/or organs. The term "inflammatory disease" is used interchangeably with the term "inflammatory disorder" to refer to a condition in a subject characterized by inflammation, preferably chronic inflammation. Autoimmune disorders may or may not be associated with inflammation. Moreover, inflammation may or may not be caused by an autoimmune disorder. Thus, certain disorders may be characterized as both autoimmune and inflammatory disorders.

[0079] As used herein, the term "cancer" refers to a neoplasm or tumor resulting from abnormal uncontrolled growth of cells. As used herein, cancer explicitly includes, leukemias and lymphomas. In some embodiments, cancer refers to a benign tumor, which has remained localized. In other embodiments, cancer refers to a malignant tumor, which has invaded and destroyed neighboring body structures and spread to distant sites. In some embodiments, the cancer is associated with a specific cancer antigen.

[0080] As used herein, the term "immunomodulatory agent" and variations thereof refer to an agent that modulates a host's immune system. In certain embodiments, an immunomodulatory agent is an immunosuppressant agent. In certain other embodiments, an immunomodulatory agent is an immunostimulatory agent. Immunomodulatory agents include, but are not limited to, small molecules, peptides, polypeptides, fusion proteins, antibodies, inorganic molecules, mimetic agents, and organic molecules.

[0081] As used herein, the term "epitope" refers to a fragment of a polypeptide or protein or a non-protein molecule having antigenic or immunogenic activity in an animal, preferably in a mammal, and most preferably in a human. An

epitope having immunogenic activity is a fragment of a polypeptide or protein that elicits an antibody response in an animal. An epitope having antigenic activity is a fragment of a polypeptide or protein to which an antibody immunospecifically binds as determined by any method well-known to one of skill in the art, for example by immunoassays. Antigenic epitopes need not necessarily be immunogenic.

5 **[0082]** As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least contiguous 80 amino acid residues, at least contiguous 90 amino acid
10 residues, at least contiguous 100 amino acid residues, at least contiguous 125 amino acid residues, at least 150 contiguous amino acid residues, at least contiguous 175 amino acid residues, at least contiguous 200 amino acid residues, or at least contiguous 250 amino acid residues of the amino acid sequence of another polypeptide. In a specific embodiment, a fragment of a polypeptide retains at least one function of the polypeptide.

15 **[0083]** As used herein, the terms "nucleic acids" and "nucleotide sequences" include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), combinations of DNA and RNA molecules or hybrid DNA/RNA molecules, and analogs of DNA or RNA molecules. Such analogs can be generated using, for example, nucleotide analogs, which include, but are not limited to, inosine or tritylated bases. Such analogs can also comprise DNA or RNA molecules comprising modified backbones that lend beneficial attributes to the molecules such as, for example, nuclease resistance or an increased ability to cross cellular membranes. The nucleic acids or nucleotide sequences can be single-stranded,
20 double-stranded, may contain both single-stranded and double-stranded portions, and may contain triple-stranded portions, but preferably is double-stranded DNA.

[0084] As used herein, a "therapeutically effective amount" refers to that amount of the therapeutic agent sufficient to treat or manage a disease or disorder. A therapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease, *e.g.*, delay or minimize the spread of cancer. A therapeutically
25 effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease. Further, a therapeutically effective amount with respect to a therapeutic agent of the invention means the amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of a disease.

30 **[0085]** As used herein, the terms "prophylactic agent" and "prophylactic agents" refer to any agent(s) which can be used in the prevention of a disorder, or prevention of recurrence or spread of a disorder. A prophylactically effective amount may refer to the amount of prophylactic agent sufficient to prevent the recurrence or spread of hyperproliferative disease, particularly cancer, or the occurrence of such in a patient, including but not limited to those predisposed to hyperproliferative disease, for example those genetically predisposed to cancer or previously exposed to carcinogens. A prophylactically effective amount may also refer to the amount of the prophylactic agent that provides a prophylactic
35 benefit in the prevention of disease. Further, a prophylactically effective amount with respect to a prophylactic agent of the invention means that amount of prophylactic agent alone, or in combination with other agents, that provides a prophylactic benefit in the prevention of disease.

40 **[0086]** As used herein, the terms "prevent", "preventing" and "prevention" refer to the prevention of the recurrence or onset of one or more symptoms of a disorder in a subject as result of the administration of a prophylactic or therapeutic agent.

[0087] As used herein, the term "in combination" refers to the use of more than one prophylactic and/or therapeutic agents. The use of the term "in combination" does not restrict the order in which prophylactic and/or therapeutic agents are administered to a subject with a disorder. A first prophylactic or therapeutic agent can be administered prior to (*e.g.*,
45 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (*e.g.*, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second prophylactic or therapeutic agent to a subject with a disorder.

50 **[0088]** "Effector function" as used herein is meant a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include but are not limited to antibody dependent cell mediated cytotoxicity (ADCC), antibody dependent cell mediated phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). Effector functions include both those that operate after the binding of an antigen and those that operate independent of antigen binding..

55 **[0089]** "Effector cell" as used herein is meant a cell of the immune system that expresses one or more Fc receptors and mediates one or more effector functions. Effector cells include but are not limited to monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans' cells, natural killer (NK) cells, and may be from any organism including but not limited to humans, mice, rats, rabbits, and monkeys.

[0090] "Fc ligand" as used herein is meant a molecule, preferably a polypeptide, from any organism that binds to the Fc region of an antibody to form an Fc-ligand complex. Fc ligands include but are not limited to Fc γ Rs, Fc γ Rs, Fc γ Rs, FcRn, C1q, C3, staphylococcal protein A, streptococcal protein G, and viral Fc γ R. Fc ligands may include undiscovered molecules that bind Fc.

5

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 SCHEMATIC OF SEQUENCE OF 8B5.3.4 VARIABLE LIGHT CHAIN DOMAIN

[0091] Depiction of the 8B5.3.4 VL nucleotide and amino acid sequence (SEQ ID NOS:11 and 10, respectively).

10

FIG. 2 SCHEMATIC OF SEQUENCE OF 8B5.3.4 VARIABLE HEAVY CHAIN DOMAIN

[0092] Depiction of the of the 8B5.3.4 VH nucleotide and amino acid sequence (SEQ ID NOS:12 and 9, respectively).

15

FIG. 3 SDS-PAGE ANALYSIS OF RECOMBINANT SOLUBLE Fc γ R

[0093] The purity of recombinant soluble Fc γ R proteins was assessed by 10% polyacrylamide gel electrophoresis. The gels were stained with Coomassie blue. Lane 1: purified recombinant soluble Fc γ R11IA; Lane 2: molecular weight marker; Lane 3: molecular weight marker; Lane 4: purified recombinant soluble Fc γ R11B. The dashes refer to the molecular weight of the markers, from top to bottom, they correspond to a molecular weight of 98, 50, 36, and 22 KDa respectively.

20

FIG. 4 ELISA ASSAY OF RECOMBINANT SOLUBLE Fc γ R

[0094] The direct binding of purified recombinant soluble Fc γ R11IA to aggregated and monomeric IgG was determined using an ELISA assay. Binding of (▲) aggregated IgG with 3G8; (◆) Biotinylated IgG; (■) aggregated IgG; (X) aggregated IgG with mouse IgG1.

25

FIGs. 5 A and B CHARACTERIZATION OF Fc γ R11IA TETRAMERIC COMPLEX USING AN ELISA ASSAY

30

[0095]

A. Soluble tetrameric Fc γ R11IA complex binds soluble monomeric human IgG specifically. Binding of soluble tetrameric Fc γ R11IA to human IgG is blocked by 3G8 (◆), a mouse anti-Fc γ 11IA monoclonal antibody; the 4-4-20 monoclonal antibody harboring the D265A mutation was not able to block the binding of soluble tetrameric Fc γ R11IA to aggregated human IgG (Δ).

35

B. Binding of soluble tetrameric Fc γ R11IA complex to soluble monomeric human IgG (■) is compared to the binding of monomeric soluble Fc γ R11IA to soluble monomeric human IgG (◆).

40

FIGS. 6 A and B CHARACTERIZATION OF Fc γ R11IA TETRAMERIC COMPLEX USING A MAGNETIC BEAD ASSAY

[0096]

A. Fc γ R11IA Complex: two Fc γ R11IA (filled shape) are joined by a monoclonal antibody DJ130c (1st Ab); the anti-mouse F(ab)₂ is conjugated to PE (circle).

45

B. FACS analysis of Fc γ R11IA bound to Fc coated beads: (a) beads alone; (b) complex without Fc γ R11IA; (c) complex with Fc γ R11IA; (d) complex with Fc γ R11IA and LNK16.

50

FIG. 7 SCHEMATIC PRESENTATION OF Fc CONTAINING CONSTRUCTS

[0097] A schematic diagram of the IgG1 Fc domains cloned into pYD1 is presented. The open box represents the hinge-CH2-CH3 domains; parallel vertical lines represent the CH1 domain. In the case of the GIF206 and 227 constructs; the N-terminal amino acids are shown. The underlined residues correspond to the hinge region; the * represents the Xpress epitope tag; hatched boxes represent the Gly4-Ser linker, and the stippled boxes represent the Aga2p gene.

55

FIGS. 8A-H FACS ANALYSIS OF THE Fc FUSION PROTEINS ON THE YEAST CELL WALL

5 [0098] Cells were incubated with either a PE-conjugated polyclonal goat anti-human Fc antibody (FIGS. 8A-D) or with HP6017 (Sigma), a mouse anti-human IgG1 Fc (CH3) specific monoclonal antibody (FIGS. 8E-H). A and E represent vector alone; Panels B and F represent the CH1-CH3 construct; Panels C and G represent the GIF227; and Panels D and H represent the GIF 206 construct.

FIGS. 9A-C BINDING OF SOLUBLE TETRAMERIC Fc γ RIIIA TO THE SURFACE DISPLAYED Fc FUSION PROTEINS

10 [0099] Cells containing pYD1-CH1 (A); pYD-CH1-D265A (B); and pYD vector (C) were grown under conditions to express Aga2p fusion proteins on the cell surface. Cells were incubated with Fc γ RIIIA at 0.15 mM, 7.5 mM, and 7.5 mM, respectively, and analyzed by FACS.

15 **FIG. 10 CHARACTERIZATION OF THE BINDING OF SOLUBLE TETRAMERIC Fc γ RIIIA TO THE SURFACE DISPLAYED Fc FUSION PROTEINS**

[0100] Binding of Fc γ RIIIA tetrameric complex to Fc fusion proteins on the yeast cell surface was analyzed. PE-conjugated Fc γ RIIIA tetrameric complexes were pre-incubated with different concentrations of 3G8 (\blacklozenge), LNK (\blacktriangle) or an irrelevant isotype control (\blacksquare), and subsequently incubated with the yeast cells. Cells were analyzed by FACS for PE fluorescence. The percent cells that bound the Fc γ RIIIA tetrameric complex were plotted on the y-axis.

FIG. 11 EXAMPLE OF SORT GATE FOR SELECTING Fc MUTANTS WITH INCREASED BINDING TO Fc γ RIIIA

25 [0101] Cells were stained with PE-conjugated Fc γ RIIIA tetrameric complexes (y-axis) and anti-Fc-FITC conjugated antibody (x-axis). Boxed area represents sort gate set to select ~1.0% of the cell population.

FIGS. 12A-N FACS ANALYSIS OF SOME OF THE Fc MUTANTS IDENTIFIED HAVING AN INCREASED AFFINITY FOR Fc γ RIIIA TETRAMERIC COMPLEXES

30 [0102] Individual clones harboring the pYD-CH1 plasmid containing independent Fc mutations were amplified in selective media containing glucose, induced for Fc expression in selective media containing galactose, and subsequently analyzed by FACS. FIGS. 12A and B represent cells harboring wild-type Fc; FIGS. 12C and D represent mutant # 5; FIGS. 12E and F represent mutant # 20; FIGS. 12G and H represent mutant # 21; FIGS. 12I and J represent mutant # 24; FIGS. 12K and L represent mutant # 25; FIGS. 12M and N represent mutant # 27. Cells were stained with Fc γ RIIIA tetrameric complex (FIGS. 12A, C, E, G, I, K, and M) or Fc γ RIIIB tetrameric complex (FIGS. 12B, D, F, H, J, L, and N).

FIGS. 13 A-B CHARACTERIZATION OF Fc MUTANTS IN THE 4-4-20 MONOCLONAL ANTIBODY BY ELISA

40 [0103] Fc domains from the pYD-CH1 plasmids were cloned into the heavy chain of the chimeric 4-4-20 monoclonal antibody. The 4-4-20 monoclonal antibody was expressed in 293 cells and supernatants were collected. ELISA plates were coated with fluoresceine conjugated BSA to capture the chimeric 4-4-20 mutant antibodies. Fc γ RIIIA (A) and Fc γ RIIIB (B) receptors were then coated onto the ELISA plates to which the 4-4-20 monoclonal antibodies had been absorbed in order to determine the relative affinities of the variant receptors to the Fc domains. Mutants # 15 and # 29 were non-binding isolates included as controls.

FIG. 14 ADCC ACTIVITY OF MUTANTS IN THE 4-4-20 MONOCLONAL ANTIBODY

50 [0104] 4-4-20 antibodies containing mutant Fc regions were assessed for their ADCC activity, and compared to the ADCC activity of a wild type 4-4-20 antibody. The mutants analyzed are as follows: MGFc-10 (K288N, A330S, P396L), MGFc-26 (D265A), MGFc-27 (G316D, A378V, D399E), MGFc-28 (N315I, A379M, D399E), MGFc-29 (F243I, V379L, G420V), MGFc-30 (F275V), MGFc-31 (P247L, N421K), MGFc-32 (D280E, S354F, A431D, L441I), MGFc-33 (K317N, F423 deleted), MGFc-34 (F241L, E258G), MGFc-35 (R255Q, K326E), MGFc-36 (K218R, G281D, G385R)

FIGS. 15 A and B ADCC ACTIVITY OF MUTANTS IN THE HER2/NEU HUMANIZED MONOCLONAL ANTIBODY

55 [0105]

A. Humanized HER2/neu monoclonal antibodies containing mutant Fc regions were assessed for their ADCC activity

EP 2 573 114 B1

and compared to the ADCC activity of a wild type Her2/neu antibody. The mutants analyzed are as follows: MGFc-5 (V379M), MGFc-9 (F243I, V379L), MGFc-10 (K288N, A330S, P396L), MGFc-13 (K334E, T359N, T366S), MGFc-27 (G316D, A378V, D399E).

5 B. ADCC activity of additional mutants in the context of the humanized Her2/neu monoclonal antibody MGFc-37 (K248M), MGFc-39 (E293V Q295E, A327T), MGFc-38 (K392T, P396L), MGFc-41 (H268N, P396L), MGFc23 (K334E, R292L), MGFc-44, MGFc-45. Two independent clones were tested for each mutant.

FIG. 16 CAPTURE OF CH 4-4-20 ANTIBODY ON BSA-FITC SURFACE

10 **[0106]** 6 μ L of antibody at a concentration of approximately 20 μ g/mL was injected at 5 μ L/min over a BSA- fluorescein isothiocyanate (FITC) surface. BIAcore sensogram of the binding of ch 4-4-20 antibodies with mutant Fc regions on the surface of the BSA-FITC immobilized sensor chip is shown. The marker was set on wild-type captured antibody response.

15 FIG. 17 SENSOGRAM OF REAL TIME BINDING OF Fc γ R1IIIA TO CH 4-4-20 ANTIBODIES CARRYING VARIANT Fc REGIONS

[0107] Binding of Fc γ R1IIIA to ch-4-4-20 antibodies carrying variant Fc regions was analyzed at 200 nM concentration. Responses were normalized at the level of ch-4-4-20 antibody obtained for wild-type.

20 **[0108]** Mutants used were as follows: Mut 6 (S219V), Mut 10 (P396L, A330S, K288N); Mut 18 (K326E); Mut 14 (K334E, K288N); Mut 11 (R255L, F243L); Mut 16 (F372Y); Mut 19 (K334N, K246I).

FIGS. 18 A-H ANALYSIS OF KINETIC PARAMETERS OF Fc γ R1IIIA BINDING TO ANTIBODIES CARRYING VARIANT Fc REGIONS

25 **[0109]** Kinetic parameters for Fc γ R1IIIA binding to antibodies carrying variant Fc regions were obtained by generating separate best fit curves for 200 nM and 800 nM. Solid line indicates an association fit which was obtained based on the k_{off} values calculated for the dissociation curves in the 32-34 sec interval. K_d and k_{off} values represent the average from two concentrations.

30 FIG. 19 SENSOGRAM OF REAL TIME BINDING OF Fc γ R1IIB-Fc FUSION PROTEINS TO ANTIBODIES CARRYING VARIANT Fc REGIONS

[0110] Binding of Fc γ R1IIB-Fc fusion proteins to ch-4-4-20 antibodies carrying variant Fc regions was analyzed at 200 nM concentration. Responses were normalized at the level of ch-4-4-20 antibody obtained for wild type.

35 FIGS. 20 A-C ANALYSIS OF KINETIC PARAMETERS Fc γ R1IIB-Fc FUSION PROTEINS TO ANTIBODIES CARRYING VARIANT Fc REGIONS

40 **[0111]** Kinetic parameters for Fc γ R1IIB-Fc binding to antibodies carrying variant Fc regions were obtained by generating separate best fit curves for 200 nM and 800 nM. Solid line indicates an association fit which was obtained based on the k_{off} values calculated for the dissociation curves in the 32-34 sec. interval. K_d and k_{off} values represent the average from two concentrations.

[0112] Mutants used were as follows: Mut 6 (S219V), Mut 10 (P396L, A330S, K288N); Mut 18 (K326E); Mut 14 (K334E, K288N); Mut 11 (R255L, F243L); Mut 16 (F372Y); Mut 19 (K334N, K246I).

45 FIG. 21 RATIOS OF k_{off} (WT)/ k_{off} (MUT) FOR Fc γ R1IIIA-Fc PLOTTED AGAINST ADCC DATA

50 **[0113]** Numbers higher than one show a decreased dissociation rate for Fc γ R1IIIA binding and increased dissociation rate for Fc γ R1IIB-Fc binding relative to wild-type. Mutants in the box have lower off rate for Fc γ R1IIIA binding and higher off rate for Fc γ R1IIB-Fc binding.

FIG. 22 COMPETITION WITH UNLABELED Fc γ R1IIIA

55 **[0114]** A kinetic screen was implemented to identify Fc region mutants with improved k_{off} rates for binding Fc γ R1IIIA. A library of Fc region variants containing P396L mutation was incubated with 0.1 μ M biotinylated Fc γ R1IIIA-Linker-Avitag for one hour and then washed. Subsequently 0.8 μ M unlabeled Fc γ R1IIIA was incubated with the labeled yeast for different time points. Yeast was spun down and unlabeled Fc γ R1IIIA was removed, Receptor bound yeast was stained with SA (streptavidin):PE (phycoerythrin) for FACS analysis.

FIGS. 23 A-C FACS ANALYSIS BASED ON THE KINETIC SCREEN

[0115] Based on the calculated K_{off} from the data presented in FIG. 22, a one minute time point selection was chosen. A 10-fold excess of library was incubated with 0.1 μ M biotinylated Fc γ R1IIIA-Linker-Avitag monomer; cells were washed and incubated with unlabeled ligand for one minute; then washed and labeled with SA:PE. The cells were then sorted by FACS, selecting the top 0.3% binders. The nonselected P396L library was compared to the yeast cells selected for improved binding by FACS. The histograms show the percentage of cells that are costained with both Fc γ R1IIIA /PE and goat anti-human Fc/FITC.

FIGS. 24 A-B SELECTION BASED ON SOLID PHASE DEPLETION OF Fc γ R1IIB Fc BINDERS**[0116]**

A. The P396L library was screened based on Fc γ R1IIB depletion and Fc γ R1IIIA selection using magnetic beads. The Fc γ R1IIB depletion by magnetic beads was repeated 5 times. The resulting yeast population was analyzed and found to show greater than 50% cell staining with goat anti-human Fc and a very small percentage of cells stained with Fc γ R1IIIA. Subsequently cells were selected twice by FACS using 0.1 μ M biotinylated Fc γ R1IIIA linker-avitag. Yeast cells were analyzed for both Fc γ R1IIIA and Fc γ R1IIB binding after each sort and compared to wild type binding.

B. Fc Mutants were selected from the Fc γ R1IIB depleted yeast population using biotinylated Fc γ R1IIIA 158F linker aitag monomer as a ligand. The sort gate was set to select the top 0.25% Fc γ R1IIIA 158F binders. The resulting enriched population was analyzed by FACS for binding to the different Fc γ R1IIIA (158F and 158V), Fc γ R1IIB and Fc γ R1IIA (131R).

FIG. 25 RELATIVE RATES OF SKBR3 TARGET CELL LYSIS MEDIATED BY CHIMERIC 4D5 HARBORING Fc MUTANTS

[0117] Relative rates of lysis was calculated for each Fc mutant tested. Lysis rates for 4D5 antibody with Fc mutants were divided by the rate of lysis mediated by wild type 4D5 antibody. Data from at least 2 independent assays were averaged and plotted on the histogram. For each Fc mutant data from two different antibody concentrations are shown. The antibody concentrations were chosen to flank the point along the curve at which lysis was ~50%.

FIG. 26 RELATIVE RATES OF DAUDI CELL LYSIS MEDIATED BY CHIMERIC 2H7 HARBORING Fc MUTANTS

[0118] Relative rates of lysis was calculated for each Fc mutant tested. Lysis rates for 2H7 antibody with Fc mutants were divided by the rate of lysis mediated by wild type 2H7 antibody. Data from at least 1- 2 independent assays were averaged and plotted on the histogram. For each Fc mutant, data from two different antibody concentrations are shown. The antibody concentrations were chosen based on the point along the curve at which lysis was ~50%.

FIG. 27 SCHEME FOR LIBRARY PRODUCTION.

[0119] DNA strands are represented. Forward arrows represent primers containing mutant codons. Reverse arrow represent reverse gene specific oligo.

FIG. 28 STRATEGY FOR PRODUCTION OF LIBRARIES BY BUILD A GENE PROTOCOL.

[0120] The rectangular boxes represent the hinge, CH2, and CH3 domains, respectively. The short black lines represent the double stranded oligos with 5' overhangs.

FIG. 29 NOVEL Fc MUTANTS IMPROVE PBMC MEDIATED ADCC IN SKBR3 CELLS.

[0121] The plot shows linear regression analysis of a standard ADCC assay. Antibody was titrated over 3 logs using an effector to target ratio of 75:1. % lysis = (Experimental release - SR)/(MR-SR) * 100.

FIG. 30 NOVEL Fc MUTANTS IMPROVE PBMC MEDIATED ADCC IN DAUDI CELLS.

[0122] The plot shows linear regression analysis of a standard ADCC assay. Antibody was titrated over 3 logs using an effector to target ratio of 75:1. % lysis = (Experimental release - SR)/(MR-SR) * 100.

FIG. 31 Fc RECEPTOR PROFILES VIA FACS UPON CYTOKINE TREATMENT OF MONOCYTES.

[0123] Cytokine treatment of monocytes increases low affinity Fc receptor expression. Elutriated monocytes were cultured using specific cytokines in serum free media. Fc receptor profiles were assayed using FACS.

5

FIG. 32 IMPROVED TUMOR CELL KILLING USING FC MUTANTS IN MACROPHAGE-DERIVED MONOCYTES BASED ADCC.

[0124] Ch4D5 MAb concentration over 2 logs was tested using effector:target ratio of 35:1. Percent lysis was calculated as in FIG. 30.

10

FIG. 33 COMPLEMENT DEPENDENT CYTOTOXICITY ASSAY FLOW CHART.

[0125] The flow chart summarizes the CDC assays used.

15

FIG.34 COMPLEMENT DEPENDENT CYTOTOXICITY ACTIVITY

[0126] Fc mutants that show enhanced binding to Fc γ RIIIA also showed improved complement activity. Anti-CD20 ChMAb over 3 orders of magnitude was titrated. Percent lysis was calculated as in as in FIG. 30.

20

FIG. 35 DECISION TREE FOR SELECTION OF Fc MUTANTS

[0127] An exemplary protocol for selecting Fc mutants.

25

FIG. 36 C1q BINDING TO 2B6 ANTIBODY

[0128]

- A. The diagram depicts the BIAcore format for analysis of 2B6 binding to the first component of the complement cascade.
- B. Sensogram of real time binding of 2B6 antibody carrying variant Fc regions to C1q.

30

FIGS. 37 A-D C1q BINDING TO 2B6 MUTANT ANTIBODY.

[0129] Sensogram of real time binding of 2B6 mutants to C1q (3.25nM). Mutants depicted at MgFc51 (Q419H, P396L); MgFc51/60 in Panel A; MgFc55 and MgFc55/60 (Panel B), MgFc59 and MgFc59/60 (Panel C); and MgFc31/60 (Panel D).

35

FIGS. 38 A-D Fc VARIANTS WITH DECREASED BINDING TO Fc γ RIIB

[0130] Binding of FcR to ch4D5 antibodies to compare effect of D270E (60) on R255L, P396L double mutant (MgFc55). K_D was analyzed at different concentrations of FcR; 400nM CD16A 158V; 800nM CD16A 158F; 200nM CD32B; 200nM CD32A 131H. Analysis was performed using separate K_D using Biacore 3000 software.

40

FIGS. 39 A-D KINETIC CHARACTERISTICS OF 4D5 MUTANTS SELECTED FROM Fc γ RIIB DEPLETIONS/Fc γ RIIAH131 SELECTION

[0131] Binding of FcR to ch4D5 antibodies carrying different Fc mutations selected by CD32B depletion and CD32A H131 screening strategy. K_D was analyzed at different concentrations of FcR; 400nM CD16A 158V; 800nM CD16A 158F; 200nM CD32B; 200nM CD32A 131H. Analysis was performed using separate K_D using Biacore 3000 software.

50

FIG. 40. PLOT OF MDM ADCC DATA AGAINST THE K_{OFF} DETERMINED FOR CD32A 131H BINDING AS DETERMINED BY BIACORE.

[0132] The mutants are as follows: MgFc 25 (E333A, K334A, S298A); MgFc68 (D270E); MgFc38 (K392T, P396L); MgFc55 (R255L, P396L); MgFc31 (P247L, N421K); MgFc59(K370E, P396L).

55

FIGS. 41 A-B. ADCC ACTIVITY OF MUTANTS IN A HER2/NEU CHIMERIC MONOCLONAL ANTIBODY

[0133] Chimeric HER2/neu monoclonal antibodies containing mutant Fc regions were assessed, in duplicate, for their ADCC activity and compared to the ADCC activity of the wild type, chimeric Her2/neu antibody. The mutants analyzed are as follows: MGFc88 (F243L, R292P, Y300L, V305I, P396L), MGFc88A (F243L, R292P, Y300L, P396L), MGFc155 (F243L, R292P, Y300L).

FIGS. 42 A-B. ESTIMATED TUMOR WEIGHT IN MICE TREATED WITH WILD-TYPE OR Fc MUTANT h2B6

[0134] Balb/c nude mice were inoculated subcutaneously with Daudi cells and administered 25 μ g, 2.5 μ g or 0.25 μ g weekly doses of either wild-type h2B6 (**A**) or h2B6 harboring Fc mutant MGFc 0088 (F243L, R292P, Y300L, V305I, P396L) (**B**). Mice administered buffer alone were used as control. Tumor weight was calculated based on the estimated volume of the subcutaneous tumor according to the formula (width² X length)/2.

FIGS. 43 A-B. SURVIVAL IN TUMOR BEARING MICE TREATED WITH WILD-TYPE OR Fc MUTANT h2B6

[0135] Nude mice were inoculated with Daudi cells and administered 25 μ g, 2.5 μ g or 0.25 μ g weekly doses of either wild-type h2B6 (**A**) or h2B6 harboring Fc mutant MGFc 0088 (F243L, R292P, Y300L, V305I, P396L) (**B**). Mice administered buffer alone were used as control.

5. DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0136] The present invention relates to molecules, preferably polypeptides, and more preferably immunoglobulins (e.g., antibodies), comprising a variant Fc region, having one or more amino acid modifications (e.g., substitutions, but also including insertions or deletions) in one or more regions, which modifications alter, e.g., increase or decrease, the affinity of the variant Fc region for an Fc γ R. In some embodiments, the invention comprises modifications to the Fc region including but not limited to any of the modifications disclosed in U.S. Application Serial No. 10/754,922 filed January 9, 2004; U.S. Provisional Application Serial No. 60/439,498 filed January 9, 2003; U.S. Provisional Application Serial No. 60/456,041 filed March 19, 2003; U.S. Provisional Application Serial No. 60/514,549 filed October 23, 2003 and U.S. Provisional Application Serial No. 60/587,251 filed July 12, 2004. In some embodiments, the invention provides molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ RIIIA with a greater affinity, relative to a comparable molecule, i.e., being the same as said molecule with a variant Fc region but not having the one or more amino acid modifications, comprising the wild-type Fc region as determined by methods known to one skilled in the art for determining Fc-Fc γ R interactions and methods disclosed herein, for example, an ELISA assay or a surface plasmon resonance assay.

[0137] In a preferred embodiment, the molecules of the invention further specifically bind Fc γ RIIB (via the Fc region) with a lower affinity than a comparable molecule comprising the wild-type Fc region binds Fc γ RIIB. In some embodiments, the invention encompasses molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ RIIIA and Fc γ RIIB with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. In other embodiments, the invention encompasses molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ RIIB with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. In other embodiments, the invention encompasses molecules comprising variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ RIIB with a reduced affinity, relative to a comparable molecule comprising the wild-type Fc region.

[0138] In a specific embodiment, the invention encompasses molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild type Fc region, which variant Fc region only binds one Fc γ R, wherein said Fc γ R is Fc γ RIIA. The invention particularly relates to the modification of human or humanized therapeutic antibodies (e.g., tumor specific anti-angiogenic or antiinflammatory monoclonal antibodies) for enhancing the efficacy of therapeutic antibodies by enhancing, for example, the effector function of the therapeutic antibodies, e.g., enhancing ADCC.

[0139] The affinities and binding properties of the molecules of the invention for an Fc γ R are initially determined using *in vitro* assays (biochemical or immunological based assays) known in the art for determining Fc-Fc γ R interactions, i.e., specific binding of an Fc region to an Fc γ R including but not limited to ELISA assay, surface plasmon resonance assay, immunoprecipitation assays (See Section 5.2.5.1). Preferably, the binding properties of the molecules of the invention are also characterized by *in vitro* functional assays for determining one or more Fc γ R mediator effector cell functions (See Section 5.2.7). In most preferred embodiments, the molecules of the invention have similar binding properties in

EP 2 573 114 B1

in vivo models (such as those described and disclosed herein) as those in *in vitro* based assays. However, the present invention does not exclude molecules of the invention that do not exhibit the desired phenotype in *in vitro* based assays but do exhibit the desired phenotype *in vivo*.

5 **[0140]** In some embodiments, the molecules of the invention comprising a variant Fc region comprise at least one amino acid modification in the CH3 domain of the Fc region, which is defined as extending from amino acids 342-447. In other embodiments, the molecules of the invention comprising a variant Fc region comprise at least one amino acid modification in the CH2 domain of the Fc region, which is defined as extending from amino acids 231-341. In some embodiments, the molecules of the invention comprise at least two amino acid modifications, wherein one modification is in the CH3 region and one modification is in the CH2 region. The invention further encompasses amino acid modification
10 in the hinge region. Molecules of the invention with one or more amino acid modifications in the CH2 and/or CH3 domains have altered affinities for an FcγR as determined using methods described herein or known to one skilled in the art.

[0141] In a particular embodiment, the invention encompasses amino acid modification in the CH1 domain of the Fc region.

15 **[0142]** In particularly preferred embodiments, the invention encompasses molecules comprising a variant Fc region wherein said variant has an increased binding to FcγRIIA (CD32A) and/or an increased ADCC activity, as measured using methods known to one skilled in the art and exemplified herein. The ADCC assays used in accordance with the methods of the invention may be NK dependent or macrophage dependent.

[0143] The Fc variants of the present invention may be combined with other known Fc modifications including but not limited to modifications which alter effector function and modification which alter FcγR binding affinity. In a particular
20 embodiment, an Fc variant of the invention comprising a first amino acid modification in the CH3 domain, CH2 domain or the hinge region may be combined with a second Fc modification such that the second Fc modification is not in the same domain as the first so that the first Fc modification confers an additive, synergistic or novel property on the second Fc modification. In some embodiments, the Fc variants of the invention do not have any amino acid modification in the CH2 domain.

25 **[0144]** The Fc variants of the present invention may be combined with any of the known Fc modifications in the art such as those disclosed in Table 2 below.

TABLE 2.

	Substitution(s)
30	V264A
	V264L
	V264I
	F241W
35	F241L
	F243W
	F243L
	F241L/F243L/V262I/V264I
	F241W/F243W
40	F241W/F243W/V262A/V264A
	F241L/V262I
	F243L/V264I
	F243L/V262I/V264W
45	F241Y/F243Y/V262T/V264T
	F241E/F243R/V262E/V264R
	F241E/F243Q/V262T/V264E
	F241R/F243Q/V262T/V264R
50	F241E/F243Y/V252T/V264R
	L328M
	L328E
	L328F
	I332E
55	L328M/I332E
	P244H
	P245A

EP 2 573 114 B1

(continued)

Substitution(s)

5

K320Q

K320E

K320R

K322E

K326S

10

K326D

K326E

A330K

T335E

15

S267A, E258A

S267A, R255A

S267A, D280A

S267A, E272A

S267A, E293A

20

S267A, E258A, D280A, R255A

P238A

D265A

E269A

D270A

25

N297A

P329A

A327Q

S239A

30

E294A

Q295A

V303A

K246A

I253A

35

T260A

K274A

V282A

K288A

40

Q311A

K317A

E318A

K338A

K340A

45

Q342A

R344A

E345A

Q347A

50

R355A

E356A

M358A

K360A

N361A

55

Q362A

Y373A

S375A

EP 2 573 114 B1

(continued)

	Substitution(s)
5	D376A
	E380A
	E382A
	S383A
	N384A
10	Q386A
	E388A
	N389A
	N390A
	Y391A
15	K392A
	L398A
	S400A
	D401A
20	D413A
	K414A
	S415A
	R416A
	Q418A
25	Q419A
	N421A
	V422A
	S424A
30	E430A
	H433A
	N434A
	H435A
	Y436A
35	T437A
	Q438A
	K439A
	S440A
40	S442A
	S444A
	K447A
	K246M
	K248M
45	Y300F
	A330Q
	K338M
	K340M
50	A378Q
	Y391F

[0145] In other embodiments, the Fc variants of the present invention may be combined with any of the known Fc modifications in the art such as those disclosed in Tables 3 A and B below.

55

EP 2 573 114 B1

TABLE 3A

	Starting Variant	Position 300	Position 298	Position 296	Position 295	Position 294
5	Y300I + →	-	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
10	Y300L + →	-	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
15	S298N + →	Y300I, Y300L, or Y300F.	-	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
20	S298V + →	Y300I, Y300L, or Y300F.	-	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
25	S298D + →	Y300I, Y300L, or Y300F.	-	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
30	S298P + →	Y300I, Y300L, or Y300F.	-	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
35	Y296P + →	Y300I, Y300L, or Y300F.	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	-	Q295K, Q295L, or Q295A.	E294N, E294A, E294Q, or E294D.
40	Q295K + →	Y300I, Y300L, or Y300F,	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	Y296P, Y296F, or N276Q,	-	E294N, E294A, E294Q, or E294D.
45	Q295L + →	Y300I, Y300L, or Y300F.	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	Y296P, Y296F, or N276Q.	-	E294N, E294A, E294Q, or E294D.
50	E294N + →	Y300I, Y300L, or Y300F.	S298N, S298V, S298D, S298P, S298A, S298G, S298T, or S298L.	Y296P, Y296F, or N276Q.	Q295K, Q295L, or Q295A.	-
** Note that table uses EU numbering as in Kabat						

50

55

EP 2 573 114 B1

TABLE 3B

	Starting Variant	Position 334	Position 333	Position 324	Position 286	Position! 276
5	Y3001 + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
10	Y300L + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
15	S298N + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
20	S298V + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
25	S298D + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
30	S298P + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
35	Y296P + →	K334A, K334R, K334Q, k334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
40	Q295K + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
45	Q295L + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.
50						

55

EP 2 573 114 B1

(continued)

Starting Variant	Position 334	Position 333	Position 324	Position 286	Position 276
E294N + →	K334A, K334R, K334Q, K334N, K334S, K334E, K334D, K334M, K334Y, K334W, K334H, K334V, or K334L.	E33A, E333Q, E333N, E333S, E333K, E333R, E333D, or E333G.	S324A, S324N, S324Q, S324K, or S324E.	N286Q, N286S, N286A, or N286D.	N276Q, N276A, or N276K.

** Note that table uses EU numbering as in Kabat.

[0146] In a preferred specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule has an altered affinity for an FcγR, provided that said variant Fc region does not have a substitution at positions that make a direct contact with FcγR based on crystallographic and structural analysis of Fc-FcγR interactions such as those disclosed by Sondermann et al., 2000 (Nature, 406: 267-273 which is incorporated herein by reference in its entirety). Examples of positions within the Fc region that make a direct contact with FcγR are amino acids 234-239 (hinge region), amino acids 265-269 (B/C loop), amino acids 297-299 (C'/E loop), and amino acids 327-332 (F/G) loop. In some embodiments, the molecules of the invention comprising variant Fc regions comprise modification of at least one residue that makes a direct contact with an FcγR based on structural and crystallographic analysis.

[0147] The FcγR interacting domain maps to the lower hinge region and select sites within the CH2 and CH3 domains of the IgG heavy chain. Amino acid residues flanking the actual contact positions and amino acid residues in the CH3 domain play a role in IgG/FcγR interactions as indicated by mutagenesis studies and studies using small peptide inhibitors, respectively (Sondermann et al., 2000 Nature, 406: 267-273; Diesenhofer et al., 1981, Biochemistry, 20: 2361-2370; Shields et al., 2001, J. Biol. Chem. 276: 6591-6604). Direct contact as used herein refers to those amino acids that are within at least 1 Å, at least 2, or at least 3 angstroms of each other or within 1 Å, 1.2 Å, 1.5 Å, 1.7 Å or 2 Å Van Der Waals radius. An exemplary list of previously identified sites on the Fc that effect binding of Fc interacting proteins is listed in the Table 4 below. In some embodiments, the invention encompasses Fc variants that do not have any modifications at the sites listed below. In other embodiments, the invention encompasses Fc variants comprising amino acid modifications at one or more sites listed below in combination with other modifications disclosed herein such that such modification has a synergistic or additive effect on the property of the mutant.

TABLE 4. PREVIOUSLY IDENTIFIED SITES ON THE Fc THAT EFFECT BINDING OF Fc INTERACTING PROTEINS.

FcR-Fc	Domain	residue	FcRI	FcRII	FcRIII	C1q	FcRn
	<u>CH2</u>	<u>233</u>	<u>C</u>	<u>C</u>	<u>c</u>	<u>C</u>	<u>C</u>
<u>A,B</u>	<u>CH2</u>	<u>234</u>	<u>C</u>	<u>C</u>	<u>C</u>	<u>G</u>	<u>C</u>
<u>A,B</u>	<u>CH2</u>	<u>235</u>	<u>C</u>	<u>C</u>	<u>C</u>	<u>G</u>	<u>C</u>
<u>A,B</u>	<u>CH2</u>	<u>236</u>	<u>C</u>	<u>C</u>	<u>C</u>		<u>C</u>
<u>A,B</u>	<u>CH2</u>	<u>237</u>					
<u>A,B</u>	<u>CH2</u>	<u>238</u>	<u>D</u>				
<u>A,B</u>	<u>CH2</u>	<u>239</u>			<u>C</u>		
	<u>CH2</u>	<u>241</u>	<u>D</u>				
	<u>CH2</u>	<u>243</u>	<u>D</u>				
	<u>CH2</u>	<u>246</u>	<u>D</u>				
	<u>CH2</u>	<u>250</u>					<u>E</u>
	<u>CH2</u>	<u>254</u>					<u>C</u>
	<u>CH2</u>	<u>255</u>		<u>C</u>			
	<u>CH2</u>	<u>256</u>		<u>C</u>	<u>C</u>		

EP 2 573 114 B1

(continued)

	<u>FcR-Fc</u>	<u>Domain</u>	<u>residue</u>	<u>FcRI</u>	<u>FcRII</u>	<u>FcRIII</u>	<u>C1q</u>	<u>FcRn</u>
		<u>CH2</u>	<u>258</u>		<u>C</u>			
5	<u>B</u>	<u>CH2</u>	<u>265</u>	<u>C</u>	<u>C</u>	<u>C</u>	<u>F</u>	<u>C</u>
	<u>B</u>	<u>CH2</u>	<u>267</u>		<u>C</u>			
		<u>CH2</u>	<u>268</u>		<u>C</u>	<u>C</u>		
10	<u>B</u>	<u>CH2</u>	<u>269</u>			<u>C</u>		
		<u>CH2</u>	<u>270</u>		<u>C</u>	<u>C</u>	<u>F</u>	
		<u>CH2</u>	<u>272</u>		<u>C</u>			
15		<u>CH2</u>	<u>276</u>		<u>C</u>			
		<u>CH2</u>	<u>285</u>		<u>C</u>			
		<u>CH2</u>	<u>286</u>		<u>C</u>			
		<u>CH2</u>	<u>288</u>					<u>C</u>
20		<u>CH2</u>	<u>290</u>		<u>C</u>	<u>C</u>		
		<u>CH2</u>	<u>292</u>		<u>C</u>			
		<u>CH2</u>	<u>293</u>			<u>C</u>		
25		<u>CH2</u>	<u>295</u>		<u>C</u>	<u>C</u>		
		<u>CH2</u>	<u>296</u>			<u>C</u>		
	<u>B</u>	<u>CH2</u>	<u>297</u>	<u>X</u>	<u>X</u>	<u>X</u>	<u>X</u>	
	<u>B</u>	<u>CH2</u>	<u>298</u>					
30	<u>B</u>	<u>CH2</u>	<u>299</u>					
		<u>CH2</u>	<u>301</u>	<u>D</u>	<u>C</u>	<u>C</u>		
		<u>CH2</u>	<u>311</u>					<u>C</u>
35		<u>CH2</u>	<u>312</u>					<u>C</u>
		<u>CH2</u>	<u>J15</u>		<u>C</u>			
		<u>CH2</u>	<u>317</u>					<u>C</u>
		<u>CH2</u>	<u>322</u>		<u>C</u>	<u>C</u>	<u>F</u>	
40		<u>CH2</u>	<u>326</u>		<u>C</u>		<u>F</u>	
	<u>A,B</u>	<u>CH2</u>	<u>327</u>	<u>D,C</u>	<u>C</u>	<u>C</u>		
	<u>A</u>	<u>CH2</u>	<u>328</u>					
45	<u>A</u>	<u>CH2</u>	<u>329</u>	<u>D,C</u>	<u>C</u>	<u>C</u>	<u>F</u>	
	<u>A</u>	<u>CH2</u>	<u>330</u>					
		<u>CH2</u>	<u>331</u>		<u>C</u>		<u>F</u>	
	<u>A</u>	<u>CH2</u>	<u>332</u>					
50		<u>CH2</u>	<u>333</u>			<u>C</u>	<u>F</u>	
		<u>CH2</u>	<u>334</u>			<u>C</u>		
		<u>CH2</u>	<u>337</u>		<u>C</u>			
55		<u>CH2</u>	<u>338</u>			<u>C</u>		
		<u>CH3</u>	<u>339</u>			<u>C</u>		
		<u>CH3</u>	<u>360</u>					<u>C</u>

EP 2 573 114 B1

(continued)

<u>FcR-Fc</u>	<u>Domain</u>	<u>residue</u>	<u>FcRI</u>	<u>FcRII</u>	<u>FcRIII</u>	<u>C1q</u>	<u>FcRn</u>
	<u>CH3</u>	<u>362</u>					<u>C</u>
	<u>CH3</u>	<u>376</u>			<u>C</u>		
	<u>CH3</u>	<u>378</u>		<u>C</u>			
	<u>CH3</u>	<u>380</u>					<u>C</u>
	<u>CH3</u>	<u>382</u>					<u>C</u>
	<u>CH3</u>	<u>414</u>		<u>C</u>			
	<u>CH3</u>	<u>415</u>					<u>C</u>
	<u>CH3</u>	<u>424</u>					<u>C</u>
	<u>CH3</u>	<u>428</u>					<u>E</u>
	<u>CH3</u>	<u>430</u>		<u>C</u>			
	<u>CH3</u>	<u>433</u>					<u>C</u>
	<u>CH3</u>	<u>434</u>					<u>C</u>
	<u>CH3</u>	<u>435</u>					<u>C</u>
	<u>CH3</u>	<u>436</u>					<u>C</u>

[0148] Table 4 lists sites within the Fc region that have previously been identified to be important for the Fc-FcR interaction. Columns labeled FcR-Fc identifies the Fc chain contacted by the FcR. Letters identify the reference in which the data was cited. C is Shields et al., 2001, J. Biol. Chem. 276: 6591-6604; D is Jefferis et al., 1995, Immunol. Lett. 44: 111-7; E is Hinton et al; 2004, J. Biol. Chem. 279(8): 6213-6; F is Idusogie et al., 2000, J. Immunol. 164: 4178-4184

[0149] In another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with an altered affinity relative to a molecule comprising a wild-type Fc region, provided that said variant Fc region does not have or is not solely a substitution at any of positions 255, 256, 258, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 300, 301, 303, 305, 307, 309, 312, 320, 322, 326, 329, 330, 332, 331, 333, 334, 335, 337, 338, 339, 340, 359, 360, 373, 376, 416, 419, 430, 434, 435, 437, 438, 439. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with an altered affinity relative to a molecule comprising a wild-type Fc region, provided that said variant Fc region does not have or is not solely a substitution at any of positions 255, 258, 267, 269, 270, 276, 278, 280, 283, 285, 289, 292, 293, 294, 295, 296, 300, 303, 305, 307, 309, 322, 329, 332, 331, 337, 338, 340, 373, 376, 416, 419, 434, 435, 437, 438, 439 and does not have an alanine at any of positions 256, 290, 298, 312, 333, 334, 359, 360, 326, or 430; a lysine at position 330; a threonine at position 339; a methionine at position 320; a serine at position 326; an asparagine at position 326; an aspartic acid at position 326; a glutamic acid at position 326; a glutamine at position 334; a glutamic acid at position 334; a methionine at position 334; a histidine at position 334; a valine at position 334; or a leucine at position 334; a lysine at position 335 an asparagine at position 268; a glutamine at position 272; a glutamine, serine, or aspartic acid at position 286; a serine at position 290; a methionine, glutamine, glutamic acid, or arginine at position 320; a glutamic acid at position 322; a serine, glutamic acid, or aspartic acid at position 326; a lysine at position 330; a glutamine at position 335; or a methionine at position 301.

[0150] In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region does not have or is not solely a substitution at any of positions 268, 269, 270, 272, 276, 278, 283, 285, 286, 289, 292, 293, 301, 303, 305, 307, 309, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 416, 419, 430, 434, 435, 437, 438 or 439 and does not have a histidine, glutamine, or tyrosine at position 280; a serine, glycine, threonine or tyrosine at position 290, a leucine or isoleucine at position 300; an asparagine at position 294, a proline at position 296; a proline, asparagine, aspartic acid, or valine at position 298; a lysine at position 295. In yet another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an Fc γ R with a reduced affinity relative to a molecule comprising a wild-type Fc region provided that said variant Fc region does not have or is not solely a substitution at any of positions 252, 254, 265, 268, 269, 270, 278, 289, 292, 293, 294, 295, 296, 298, 300,

EP 2 573 114 B1

301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438, or 439. In yet another preferred embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule binds an FcγR with an enhanced affinity relative to a molecule comprising a wild-type Fc region provided that said variant Fc region does not have or is not solely a substitution at any of positions 280, 283, 285, 286, 290, 294, 295, 298, 300, 301, 305, 307, 309, 312, 315, 331, 333, 334, 337, 340, 360, 378, 398, or 430.

[0151] In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region does not include or are not solely a substitution at any of positions 330, 243, 247, 298, 241, 240, 244, 263, 262, 235, 269, or 328 and does not have a leucine at position 243, an asparagine at position 298, a leucine at position 241, and isoleucine or an alanine at position 240, a histidine at position 244, a valine at position 330, or an isoleucine at position 328.

[0152] In most preferred embodiments, the molecules of the invention with altered affinities for activating and/or inhibitory receptors having variant Fc regions, have one or more amino acid modifications, wherein said one or more amino acid modification is a substitution at position 288 with asparagine, at position 330 with serine and at position 396 with leucine (MgFc10)(See Tables 5 & 6); or a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine (MgFc13); or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid (MgFc27); or a substitution at position 392 with threonine, and at position 396 with leucine (MgFc38); or a substitution at position 221 with glutamic acid, at position 270 with glutamic acid, at position 308 with alanine, at position 311 with histidine, at position 396 with leucine, and at position 402 with aspartic acid (MgFc42); or a substitution at position 240 with alanine, and at position 396 with leucine (MgFc52); or a substitution at position 410 with histidine, and at position 396 with leucine (MgFc53); or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine, and at position 396 with leucine (MgFc54); or a substitution at position 255 with isoleucine, and at position 396 with leucine (MgFc55); or a substitution at position 370 with glutamic acid and at position 396 with leucine (MgFc59) ; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine (MgFc88); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine (MgFc88A); or a substitution at position 234 with leucine, at position 292 with proline, and at position 300 with leucine (MgFc155); or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 292 with proline; or a substitution at position 243 with leucine; or a substitution at position 273 with phenylalanine.

[0153] In one specific embodiment, the invention encompasses a molecule comprising a variant Fc region wherein said variant Fc region comprises a substitution at position 396 with leucine, at position 270 with glutamic acid and at position 243 with leucine. In another specific embodiment the molecule further comprises one or more amino acid modification such as those disclosed herein.

[0154] In some embodiments, the invention encompasses molecules comprising a variant Fc region having an amino acid modification at one or more of the following positions: 119, 125, 132, 133, 141, 142, 147, 149, 162, 166, 185, 192, 202, 205, 210, 214, 217, 219, 215, 216, 217, 218, 219, 221, 222, 223, 224, 225, 227, 288, 229, 231, 232, 233, 235, 240, 241, 242, 243, 244, 246, 247, 248, 250, 251, 252, 253, 254, 255, 256, 258, 261, 262, 263, 268, 269, 270, 272, 273, 274, 275, 276, 279, 280, 281, 282, 284, 287, 288, 289, 290, 291, 292, 293, 295, 298, 300, 301, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 315, 316, 317, 318, 319, 320, 323, 326, 327, 328, 330, 333, 334, 335, 337, 339, 340, 343, 344, 345, 347, 348, 352, 353, 354, 355, 358, 359, 360, 361, 362, 365, 366, 367, 369, 370, 371, 372, 375, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 404, 406, 407, 408, 409, 410, 411, 412, 414, 415, 416, 417, 419, 420, 421, 422, 423, 424, 427, 428, 431, 433, 435, 436, 438, 440, 441, 442, 443, 446, 447. Preferably such mutations result in molecules that have an altered affinity for an FcγR and/or have an altered effector cell mediated function as determined using methods disclosed and exemplified herein and known to one skilled in the art.

[0155] The invention encompasses molecules comprising variant Fc regions consisting of or comprising any of the mutations listed in the table below in Table 5.

TABLE 5. EXEMPLARY MUTATIONS

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
K392R	Q347H, A339V
N315I	S415I, L251F
S132I	K290E, L142P

EP 2 573 114 B1

(continued)

5
10
15
20
25
30
35
40
45
50
55

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
P396L	G285E, P247H
P396H	K409R, S166N
A162V	E334A, K334A
R292L	R292L, K334E
T359N	K288N, A330S
T366S	R255L, E318K
V379L	F243L, E318K
K288N	V279L, P395S
A330S	K246T, Y319F
F243L	F243I, V379L
E318K	K288M, K334E
V379M	K334E, E308D
S219Y	E233D, K334E
V282M	K246T, P396H
D401V	H268D, E318D
K222N	K246I, K334N
K334I	K320E, K326E
K334E	S375C, P396L
I377F	K288N, K326N
P247L	P247L, N421K
F372Y	S298N, W381R
K326E	R255Q, K326E
H224L	V284A, F372L
F275Y	T394M, V397M
L398V	P247L, E389G
K334N	K290T, G371D
S400P	P247L, L398Q
S407I	P247L, I377F
F372Y	K326E, G385E
T366N	S298N, S407R
K414N	E258D, N384K
M352L	F241L, E258G
T225S	K370N, S440N
I377N	K317N, F423-DELETED
K248M	P227S, K290E
R292G	K334E, E380D
S298N	P291S, P353Q
D270E	V240I, V281M

EP 2 573 114 B1

(continued)

5

10

15

20

25

30

35

40

45

50

55

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
E233G	P232S, S304G
R292P	P247L, L406F
V273	D399E, M428L
	L251F, F372L
	D399E, G402D
	D399E, M428L
	K392T, P396L
	H268N, P396L
	K326I, P396L
	H268D, P396L
	K210M, P396L
	L358P, P396L
	K334N, P396L
	V379M, P396L
	P227S, P396L
	P217S, P396L
	Q419H, P396L
	K370E, P396L
	L242F, P396L
	R255L, P396L
	V240A, P396L
	T250A, P396L
	P247S, P396L
	L410H, P396L
	Q419L, P396L
	V427A, P396L
	E258D, P396L
	N384K, P396L
	V323I, P396L
	P244H, P396L
	V305L, P396L
	S400F, P396L
V303I, P396L	
A330V, Q419H	
V263Q, E272D	
K326E, A330T	
F243L, R292P	
F243L, P396L	

[0156] In yet other embodiments, the invention encompasses molecules comprising variant Fc regions having more than two amino acid modifications. A non-limiting example of such variants is listed in the table below (Table 6). The invention encompasses mutations listed in Table 6 which further comprise one or more amino acid modifications such as those disclosed herein.

5

TABLE 6. EXEMPLARY COMBINATION VARIANTS

10

15

20

25

30

35

40

45

50

55

D399E, R292L, V185M
R301C, M252L, S192T
P291S, K288E, H268L, A141V
S383N, N384K, T256N, V262L, K218E, R214I, K205E, F149Y, K133M
S408I, V215I, V125L
G385E, P247H
V348M, K334N, F275I, Y202M, K147T
H310Y, T289A, Y407V, E258D
R292L, P396L, T359N
F275I, K334N, V348M
F243L, R255L, E318K
K334E, T359N, T366S
T256S, V305I, K334E, N390S
T335N, K370E, A378V, T394M, S424L
K334E, T359N, T366S, Q386R
K288N, A330S, P396L
P244H, L358M, V379M, N384K, V397M
P217S, A378V, S408R
P247L, I253N, K334N
D312E, K327N, I378S
D280E, S354F, A431D, L441I
K218R, G281D, G385R
P247L, A330T, S440G
T355N, P387S, H435Q
P247L, A431V, S442F
P343S, P353L, S375I, S383N
E216D, E345K, S375I
K288N, A330S, P396L
K222N, T335N, K370E, A378V, T394M
G316D, A378V, D399E
N315I, V379M, T394M
K326Q, K334E, T359N, T366S
A378V, N390I, V422I
V282E, V369I, L406F
V397M, T411A, S415N
T223I, T256S, L406F

EP 2 573 114 B1

(continued)

	L235P,V382M,S304G,V305I,V323I
5	P247L,W313R,E388G
	D221Y,M252I,A330G,A339T,T359N,V422I,H433L
	F243I,V379L,G420V
	A231V,Q386H,V412M
10	T215P,K274N,A287G,K334N,L365V,P396L
	P244A,K326I,C367R,S375I,K447T
	R301H, K340E,D399E
15	C229Y,A287T,V379M,P396L,L443V
	E269K,K290N,Q311R,H433Y
	E216D,K334R,S375I
	T335N,P387S,H435Q
20	K246I,Q362H,K370E
	K334E,E380D,G446V
	V303I,V369F,M428L
25	K246E,V284M,V308A
	E293V,Q295E,A327T
	Y319F,P352L,P396L
30	D221E, D270E, V308A, Q311H, P396L, G402D
	K290T, N390I, P396L
	K288R, T307A, K344E,P396L
	V273I, K326E, L328I, P396L
35	K326I, S408N, P396L
	K261N, K210M, P396L
	F243L, V305I, A378D, F404S, P396L
	K290E, V369A, T393A, P396L
40	K210N, K222I, K320M, P396L
	P217S, V305I, I309L, N390H, P396L
	K246N, Q419R, P396L
45	P217A, T359A, P396L
	V215I, K290V, P396L
	F275L, Q362H, N384K, P396L
	A330V, H433Q, V427M
50	V263Q, E272D, Q419H
	N276Y, T393N, W417R
	V282L, A330V, H433Y, T436R
55	V284M, S298N, K334E, R355W
	A330V, G427M, K438R
	S219T, T225K, D270E, K360R

(continued)

5	K222E, V263Q, S298N
	E233G, P247S, L306P
	S219T, T225K, D270E
	S254T, A330V, N361D, P243L
10	V284M, S298N, K334E, R355W R416T
	D270E,G316D,R416G
	K392T, P396L, D270E
	R255L, P396L, D270E
15	V240A, P396L, D270E
	Q419H, P396L, D270E
	K370E, P396L, D270E
	P247L, N421K, D270E
20	R292P, V305I
	R292P, V305I, F243L
	V284M, R292L, K370N
25	R292P, V305I, P396L
	F243L, R292P, Y300L
	F243L, R292P, P396L
	F243L, R292P, V305L
30	F243L, Y300L, V305I, P396L
	F243L, R292P, V305I, P396L
	F243L, R292P, Y300L, P396L
35	F243I, R292P, Y300L, V305I, P396L

[0157] In some embodiments, the molecules, preferably the immunoglobulins of the invention further comprise one or more glycosylation sites, so that one or more carbohydrate moieties are covalently attached to the molecule. Preferably, the antibodies of the invention with one or more glycosylation sites and/or one or more modifications in the Fc region have an enhanced antibody mediated effector function, e.g., enhanced ADCC activity. In some embodiments, the invention further comprises antibodies comprising one or more modifications of amino acids that are directly or indirectly known to interact with a carbohydrate moiety of the antibody, including but not limited to amino acids at positions 241, 243, 244, 245, 249, 256, 258, 260, 262, 264, 265, 296, 299, and 301. Amino acids that directly or indirectly interact with a carbohydrate moiety of an antibody are known in the art, see, e.g., Jefferis et al., 1995 Immunology Letters, 44: 111-7.

[0158] The invention encompasses antibodies that have been modified by introducing one or more glycosylation sites into one or more sites of the antibodies, preferably without altering the functionality of the antibody, e.g., binding activity to FcγR. Glycosylation sites may be introduced into the variable and/or constant region of the antibodies of the invention. As used herein, "glycosylation sites" include any specific amino acid sequence in an antibody to which an oligosaccharide (i.e., carbohydrates containing two or more simple sugars linked together) will specifically and covalently attach. Oligosaccharide side chains are typically linked to the backbone of an antibody via either N- or O-linkages. N-linked glycosylation refers to the attachment of an oligosaccharide moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of an oligosaccharide moiety to a hydroxyamino acid, e.g., serine, threonine. The antibodies of the invention may comprise one or more glycosylation sites, including N-linked and O-linked glycosylation sites. Any glycosylation site for N-linked or O-linked glycosylation known in the art may be used in accordance with the instant invention. An exemplary N-linked glycosylation site that is useful in accordance with the methods of the present invention, is the amino acid sequence: Asn-X-Thr/Ser, wherein X may be any amino acid and Thr/Ser indicates a threonine or a serine. Such a site or sites may be introduced into an antibody of the invention using methods well known in the art

to which this invention pertains. See, for example, "In Vitro Mutagenesis," Recombinant DNA: A Short Course, J. D. Watson, et al. W.H. Freeman and Company, New York, 1983, chapter 8, pp. 106-116. An exemplary method for introducing a glycosylation site into an antibody of the invention may comprise: modifying or mutating an amino acid sequence of the antibody so that the desired Asn-X-Thr/Ser sequence is obtained.

5 **[0159]** In some embodiments, the invention encompasses methods of modifying the carbohydrate content of an antibody of the invention by adding or deleting a glycosylation site. Methods for modifying the carbohydrate content of antibodies are well known in the art and encompassed within the invention, see, e.g., U.S. Patent No. 6,218,149; EP 0 359 096 B1; U.S. Publication No. US 2002/0028486; WO 03/035835; U.S. Publication No. 2003/0115614; U.S. Patent No. 6,218,149; U.S. Patent No. 6,472,511. In other embodiments, the invention encompasses methods of modifying the carbohydrate content of an antibody of the invention by deleting one or more endogenous carbohydrate moieties of the antibody. In a specific embodiment, the invention encompasses shifting the glycosylation site of the Fc region of an antibody, by modifying positions adjacent to 297. In a specific embodiment, the invention encompasses modifying position 296 so that position 296 and not position 297 is glycosylated.

15 5.1 POLYPEPTIDES AND ANTIBODIES WITH VARIANT Fc REGIONS

[0160] The present invention is based, in part, on the identification of mutant human IgG1 heavy chain Fc regions, with altered affinities for different Fc γ R receptors, using a yeast display system. Accordingly, the invention relates to molecules, preferably polypeptides, and more preferably immunoglobulins (e.g., antibodies), comprising a variant Fc region, having one or more amino acid modifications (e.g., substitutions, but also including insertions or deletions) in one or more regions, which modifications alter the affinity of the variant Fc region for an Fc γ R.

20 **[0161]** It will be appreciated by one skilled in the art that aside from amino acid substitutions, the present invention contemplates other modifications of the Fc region amino acid sequence in order to generate an Fc region variant with one or more altered properties, e.g., altered effector function. The invention contemplates deletion of one or more amino acid residues of the Fc region in order to reduce binding to an Fc γ R. Preferably, no more than 5, no more than 10, no more than 20, no more than 30, no more than 50 Fc region residues will be deleted according to this embodiment of the invention. The Fc region herein comprising one or more amino acid deletions will preferably retain at least about 80%, and preferably at least about 90%, and most preferably at least about 95%, of the wild type Fc region. In some embodiments, one or more properties of the molecules are maintained such as for example, non-immunogenicity, Fc γ RIIIA binding, Fc γ RIIA binding, or a combination of these properties.

30 **[0162]** In alternate embodiments, the invention encompasses amino acid insertion to generate the Fc region variants, which variants have altered properties including altered effector function. In one specific embodiment, the invention encompasses introducing at least one amino acid residue, for example one to two amino acid residues and preferably no more than 10 amino acid residues adjacent to one or more of the Fc region positions identified herein. In alternate embodiments, the invention further encompasses introducing at least one amino acid residue, for example one to two amino acid residues and preferably no more than 10 amino acid residues adjacent to one or more of the Fc region positions known in the art as impacting Fc γ R interaction and/or binding.

35 **[0163]** The invention further encompasses incorporation of unnatural amino acids to generate the Fc variants of the invention. Such methods are known to those skilled in the art such as those using the natural biosynthetic machinery to allow incorporation of unnatural amino acids into proteins, see, e.g., Wang et al., 2002 Chem. Comm. 1: 1-11; Wang et al., 2001, Science, 292: 498-500; van Hest et al., 2001. Chem. Comm. 19: 1897-1904. Alternative strategies focus on the enzymes responsible for the biosynthesis of amino acyl-tRNA, see, e.g., Tang et al., 2001, J. Am. Chem. 123(44): 11089-11090; Kiick et al., 2001, FEBS Lett. 505(3): 465.

40 **[0164]** The affinities and binding properties of the molecules of the invention for an Fc γ R are initially determined using *in vitro* assays (biochemical or immunological based assays) known in the art for determining Fc-Fc γ R interactions, *i.e.*, specific binding of an Fc region to an Fc γ R including but not limited to ELISA assay, surface plasmon resonance assay, immunoprecipitation assays (See Section 5.2.5.1). Preferably, the binding properties of the molecules of the invention are also characterized by *in vitro* functional assays for determining one or more Fc γ R mediator effector cell functions (See Section 5.2.7). In most preferred embodiments, the molecules of the invention have similar binding properties in *in vivo* models (such as those described and disclosed herein) as those in *in vitro* based assays. However, the present invention does not exclude molecules of the invention that do not exhibit the desired phenotype in *in vitro* based assays but do exhibit the desired phenotype *in vivo*. A representative flow chart of the screening and characterization of molecules of the invention is described in FIG. 35.

45 **[0165]** The invention encompasses molecules comprising a variant Fc region that binds with a greater affinity to one or more Fc γ Rs. Such molecules preferably mediate effector function more effectively as discussed *infra*. In other embodiments, the invention encompasses molecules comprising a variant Fc region that bind with a weaker affinity to one or more Fc γ Rs. Reduction or elimination of effector function is desirable in certain cases for example in the case of antibodies whose mechanism of action involves blocking or antagonism but not killing of the cells bearing a target antigen.

Reduction or elimination of effector function would be desirable in cases of autoimmune disease where one would block Fc γ R activating receptors in effector cells (This type of function would be present in the host cells). In general increased effector function would be directed to tumor and foreign cells.

5 **[0166]** The Fc variants of the present invention may be combined with other Fc modifications, including but not limited to modifications that alter effector function. The invention encompasses combining an Fc variant of the invention with other Fc modifications to provide additive, synergistic, or novel properties in antibodies or Fc fusions. Preferably the Fc variants of the invention enhance the phenotype of the modification with which they are combined. For example, if an Fc variant of the invention is combined with a mutant known to bind Fc γ R111A with a higher affinity than a comparable molecule comprising a wild type Fc region; the combination with a mutant of the invention results in a greater fold
10 enhancement in Fc γ R111A affinity.

[0167] In one embodiment, the Fc variants of the present invention may be combined with other known Fc variants such as those disclosed in Duncan et al, 1988, Nature 332:563-564; Lund et al., 1991, J. Immunol 147:2657-2662; Lund et al, 1992, Mol Immunol 29:53-59; Alegre et al, 1994, Transplantation 57:1537-1543; Hutchins et al., 1995, Proc Natl. Acad Sci U S A 92:11980-11984; Jefferis et al, 1995, Immunol Lett. 44:111-117; Lund et al., 1995, FASEB J 9:115-119; 15 Jefferis et al, 1996, Immunol Lett 54:101-104; Lund et al, 1996, J Immunol 157:4963-4969; Armour et al, 1999, Eur J Immunol 29:2613-2624; Idusogie et al, 2000, J Immunol 164:4178-4184; Reddy et al, 2000, J Immunol 164:1925-1933; Xu et al., 2000, Cell Immunol 200:16-26; Idusogie et al, 2001, J Immunol 166:2571-2575; Shields et al., 2001, J Biol Chem 276:6591-6604; Jefferis et al, 2002, Immunol Lett 82:57-65; Presta et al., 2002, Biochem Soc Trans 30:487-490; US 5,624,821; US 5,885,573; US 6,194,551; PCT WO 00/42072; PCT WO 99/58572.

20 **[0168]** In some embodiments, the Fc variants of the present invention are incorporated into an antibody or Fc fusion that comprises one or more engineered glycoforms, *i.e.*, a carbohydrate composition that is covalently attached to a molecule comprising an Fc region, wherein said carbohydrate composition differs chemically from that of a parent molecule comprising an Fc region. Engineered glycoforms may be useful for a variety of purposes, including but not limited to enhancing or reducing effector function. Engineered glycoforms may be generated by any method known to one skilled in the art, for example by using engineered or variant expression strains, by co-expression with one or more enzymes, for example DI N-acetylglucosaminyltransferase III (GnT111), by expressing a molecule comprising an Fc region in various organisms or cell lines from various organisms, or by modifying carbohydrate(s) after the molecule comprising Fc region has been expressed. Methods for generating engineered glycoforms are known in the art, and include but are not limited to those described in Umana et al, 1999, Nat. Biotechnol 17:176-180; Davies et al., 2007
25 Biotechnol Bioeng 74:288-294; Shields et al, 2002, J Biol Chem 277:26733-26740; Shinkawa et al, 2003, J Biol Chem 278:3466-3473) US 6,602,684; USSN 10/277,370; USSN 10/113,929; PCT WO 00/61739A1; PCT WO 01/292246A1; PCT WO 02/311140A1; PCT WO 02/30954A1; Potillegent™ technology (Biowa, Inc. Princeton, NJ); GlycoMAB™ glycosylation engineering technology (GLYCART biotechnology AG, Zurich, Switzerland. See, e.g., WO 00061739; EA01229125; US 20030115614; Okazaki et al., 2004, JMB, 336: 1239-49.

30 **[0169]** The Fc variants of the present invention may be optimized for a variety of properties. Properties that may be optimized include but are not limited to enhanced or reduced affinity for an Fc γ R, enhanced or reduced effector function. In a preferred embodiment, the Fc variants of the present invention are optimized to possess enhanced affinity for a human activating Fc γ R, preferably Fc γ R, Fc γ R11A, Fc γ R11c, Fc γ R111A, and Fc γ R111B, most preferably Fc γ R111A. In an alternate preferred embodiment, the Fc variants are optimized to possess reduced affinity for the human inhibitory receptor Fc γ R11B. These preferred embodiments are anticipated to provide antibodies and Fc fusions with enhanced therapeutic properties in humans, for example enhanced effector function and greater anticancer potency as described and exemplified herein. These preferred embodiments are anticipated to provide antibodies and Fc fusions with enhanced tumor elimination in mouse xenograft tumor models.

35 **[0170]** In an alternate embodiment the Fc variants of the present invention are optimized to have reduced affinity for a human Fc γ R, including but not limited to Fc γ R1, Fc γ R11A, Fc γ R11B, Fc γ R11c, and Fc γ R111B. These embodiments are anticipated to provide antibodies and Fc fusions with enhanced therapeutic properties in humans, for example reduced effector function and reduced toxicity.

40 **[0171]** In alternate embodiments the Fc variants of the present invention possess enhanced or reduced affinity for Fc γ Rs from non-human organisms, including but not limited to mice, rats, rabbits, and monkeys. Fc variants that are optimized for binding to a non-human Fc γ R may find use in experimentation. For example, mouse models are available for a variety of diseases that enable testing of properties such as efficacy, toxicity, and pharmacokinetics for a given drug candidate. As is known in the art, cancer cells can be grafted or injected into mice to mimic a human cancer, a process referred to as xenografting. Testing of antibodies or Fc fusions that comprise Fc variants that are optimized for one or more mouse Fc γ R, may provide valuable information with regard to the efficacy of the antibody or Fc fusion, its
45 mechanism of action.

50 **[0172]** While it is preferred to alter binding to an Fc γ R, the instant invention further contemplates Fc variants with altered binding affinity to the neonatal receptor (FcRn). Although not intending to be bound by a particular mechanism of action, Fc region variants with improved affinity for FcRn are anticipated to have longer serum half-lives, and such

molecules will have useful applications in methods of treating mammals where long half-life of the administered polypeptide is desired, e.g., to treat a chronic disease or disorder. Although not intending to be bound by a particular mechanism of action, Fc region variants with decreased FcRn binding affinity, on the contrary, are expected to have shorter half-lives, and such molecules may, for example, be administered to a mammal where a shortened circulation time may be advantageous, e.g., for in vivo diagnostic imaging or for polypeptides which have toxic side effects when left circulating in the blood stream for extended periods. Fc region variants with decreased FcRn binding affinity are anticipated to be less likely to cross the placenta, and thus may be utilized in the treatment of diseases or disorders in pregnant women.

[0173] In other embodiments, these variants may be combined with other known Fc modifications with altered FcRn affinity such as those disclosed in International Publication Nos. WO 98/23289; and WO 97/34631; and U.S. Patent No. 6,277,375.

[0174] The invention encompasses any other method known in the art for generating antibodies having an increased half-life *in vivo*, for example, by introducing one or more amino acid modifications (*i.e.*, substitutions, insertions or deletions) into an IgG constant domain, or FcRn binding fragment thereof (preferably a Fc or hinge-Fc domain fragment). See, e.g., International Publication Nos. WO 98/23289; and WO 97/34631; and U.S. Patent No. 6,277,375. Further, antibodies of the invention can be conjugated to albumin in order to make the antibody or antibody fragment more stable *in vivo* or have a longer half-life *in vivo*. The techniques well-known in the art, see, e.g., International Publication Nos. WO 93/15199, WO 93/15200, and WO 01/77137, and European Patent No. EP 413,622.

[0175] The variant(s) described herein may be subjected to further modifications, often times depending on the intended use of the variant. Such modifications may involve further alteration of the amino acid sequence (substitution, insertion and/or deletion of amino acid residues), fusion to heterologous polypeptide(s) and/or covalent modifications. Such further modifications may be made prior to, simultaneously with, or following, the amino acid modification(s) disclosed herein which results in altered properties such as an alteration of Fc receptor binding and/or ADCC activity.

[0176] Alternatively or additionally, the invention encompasses combining the amino acid modifications disclosed herein with one or more further amino acid modifications that alter C1q binding and/or complement dependent cytotoxicity function of the Fc region as determined in vitro and/or in vivo. Preferably, the starting molecule of particular interest herein is usually one that binds to C1q and displays complement dependent cytotoxicity (CDC). The further amino acid substitutions described herein will generally serve to alter the ability of the starting molecule to bind to C1q and/or modify its complement dependent cytotoxicity function, e.g., to reduce and preferably abolish these effector functions. In other embodiments molecules comprising substitutions at one or more of the described positions with improved C1q binding and/or complement dependent cytotoxicity (CDC) function are contemplated herein. For example, the starting molecule may be unable to bind C1q and/or mediate CDC and may be modified according to the teachings herein such that it acquires these further effector functions. Moreover, molecules with preexisting C1q binding activity, optionally further having the ability to mediate CDC may be modified such that one or both of these activities are altered, e.g., enhanced. In some embodiments, the invention encompasses variant Fc regions with altered CDC activity without any alteration in C1q binding. In yet other embodiments, the invention encompasses variant Fc regions with altered CDC activity and altered C1q binding.

[0177] To generate an Fc region with altered C1q binding and/or complement dependent cytotoxicity (CDC) function, the amino acid positions to be modified are generally selected from positions 270, 322, 326, 327, 329, 331, 333, and 334, where the numbering of the residues in an IgG heavy chain is that of the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (199). These amino acid modifications may be combined with one or more Fc modifications disclosed herein to provide a synergistic or additive effect on C1q binding and/or CDC activity. In other embodiments, the invention encompasses Fc variants with altered C1q binding and/or complement dependent cytotoxicity (CDC) function comprising an amino acid substitution at position 396 with leucine and at position 255 with leucine; or an amino acid substitution at position 396 with leucine and at position 419 with histidine; an amino acid substitution at position 396 with leucine and at position 370 with glutamic acid; an amino acid substitution at position 396 with leucine and at position 240 with alanine; an amino acid substitution at position 396 with leucine and at position 392 with threonine; an amino acid substitution at position 247 with leucine and at position 421 with lysine. The invention encompasses any known modification of the Fc region which alters C1q binding and/or complement dependent cytotoxicity (CDC) function such as those disclosed in Idusogie et al., 2001, J. Immunol. 166(4) 2571-5; Idusogie et al., J. Immunol. 2000 164(8): 4178-4184.

[0178] As disclosed above, the invention encompasses an Fc region with altered effector function, e.g., modified C1q binding and/or FcR binding and thereby altered CDC activity and/or ADCC activity. In specific embodiments, the invention encompasses variant Fc regions with improved C1q binding and improved Fc γ R111 binding; e.g. having both improved ADCC activity and improved CDC activity. In alternative embodiments, the invention encompasses a variant Fc region with reduced CDC activity and/or reduced ADCC activity. In other embodiments, one may increase only one of these activities, and optionally also reduce the other activity, e.g. to generate an Fc region variant with improved ADCC activity, but reduced CDC activity and vice versa.

A. MUTANTS WITH ENHANCED ALTERED AFFINITIES FOR Fc γ R114 and/or Fc γ R11A

[0179] The invention encompasses molecules comprising a variant Fc region, having one or more amino acid modifications (e.g., substitutions) in one or more regions, wherein such modifications alter the affinity of the variant Fc region for an activating Fc γ R. In some embodiments, molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions) in one or more regions, which modifications increase the affinity of the variant Fc region for Fc γ R114 and preferably also for Fc γ R11A by at least 2-fold, relative to a comparable molecule comprising a wild-type Fc region. In another specific embodiment, molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions) in one or more regions, which modifications increase the affinity of the variant Fc region for Fc γ R114 and preferably also for Fc γ R11A by greater than 2 fold, relative to a comparable molecule comprising a wild-type Fc regions. In other embodiments of the invention the one or more amino acid modifications increase the affinity of the variant Fc region for Fc γ R114 and preferably also for Fc γ R11A by at least 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, or 10-fold relative to a comparable molecule comprising a wild-type Fc region. In yet other embodiments of the invention the one or more amino acid modifications decrease the affinity of the variant Fc region for Fc γ R11A by at least 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, or 10-fold relative to a comparable molecule comprising a wild-type Fc region. Such fold increases are preferably determined by an ELISA or surface plasmon resonance assays. In a specific embodiment, the one or more amino acid modifications do not include or are not solely a substitution at any one of positions 329, 331, or 322 with any amino acid. In certain embodiments, the one or more amino acid modifications do not include or are not solely a substitution with any one of alanine at positions 256, 290, 298, 312, 333, 334, 359, 360, or 430; with lysine at position 330; with threonine at position 339; with methionine at position 320; with serine, asparagine, aspartic acid, or glutamic acid at position 326 with glutamine, glutamic acid, methionine, histidine, valine, or leucine at position 334. In another specific embodiment, the one or more amino acid modifications do not include or are not solely a substitution at any of positions 280, 290, 300, 294, or 295. In another more specific embodiment, the one or more amino acid modifications do not include or are not solely a substitution at position 300 with leucine or isoleucine; at position 295 with lysine; at position 294 with asparagine; at position 298 with valine; aspartic acid proline, asparagine, or valine; at position 280 with histidine, glutamine or tyrosine; at position 290 with serine, glycine, threonine or tyrosine.

[0180] In another specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ R11A with a greater affinity than a comparable molecule comprising the wild-type Fc region binds Fc γ R11A, provided that said variant Fc region does not have an alanine at any of positions 256, 290, 326, 255, 258, 267, 272, 276, 280, 283, 285, 286, 331, 337, 268, 272, or 430; an asparagine at position 268; a glutamine at position 272; a glutamine, serine, or aspartic acid at position 286; a serine at position 290; a methionine, glutamine, glutamic acid, or arginine at position 320; a glutamic acid at position 322; a serine, glutamic acid, or aspartic acid at position 326; a lysine at position 330; a glutamine at position 335; or a methionine at position 301. In a specific embodiment, molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions) in one or more regions, which modifications increase the affinity of the variant Fc region for Fc γ R11A by at least 2-fold, relative to a comparable molecule comprising a wild-type Fc region. In another specific embodiment, molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (e.g., substitutions) in one or more regions, which modifications increase the affinity of the variant Fc region for Fc γ R11A by greater than 2 fold, relative to a comparable molecule comprising a wild-type Fc region. In other embodiments of the invention the one or more amino acid modifications increase the affinity of the variant Fc region for Fc γ R11A by at least 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, or 10-fold relative to a comparable molecule comprising a wild-type Fc region

[0181] In a specific embodiment, the invention encompasses molecules, preferably polypeptides, and more preferably immunoglobulins (e.g., antibodies), comprising a variant Fc region, having one or more amino acid modifications (e.g., substitutions but also include insertions or deletions), which modifications increase the affinity of the variant Fc region for Fc γ R114 and preferably also for Fc γ R11A by at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, at least 150%, and at least 200%, relative to a comparable molecule comprising a wild-type Fc region.

[0182] In a specific embodiment, the one or more amino acid modifications which increase the affinity of the variant Fc region for one or more activating Fc γ Rs comprise a substitution at position 347 with histidine, and at position 339 with valine; or a substitution at position 425 with isoleucine and at position 215 with phenylalanine; or a substitution at position 408 with isoleucine, at position 215 with isoleucine, and at position 125 with leucine; or a substitution at position 385 with glutamic acid and at position 247 with histidine; or a substitution at position 348 with methionine, at position 334 with asparagine, at position 275 with isoleucine, at position 202 with methionine, and at position 147 with threonine; or a substitution at position 275 with isoleucine, at position 334 with asparagine, and at position 348 with methionine; or a substitution at position 279 with leucine and at position 395 with serine; or a substitution at position 246 with threonine and at position 319 with phenylalanine; or a substitution at position 243 with isoleucine and at position 379 with leucine;

or a substitution at position 243 with leucine, at position 255 with leucine and at position 318 with lysine; or a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine; or a substitution at position 288 with methionine and at position 334 with glutamic acid; or a substitution at position 334 with glutamic acid and at position 380 with aspartic acid; or a substitution at position 256 with serine, at position 305 with isoleucine, at position 334 with glutamic acid and at position 390 with serine; or a substitution at position 335 with asparagine, at position 370 with glutamic acid, at position 378 with valine, at position 394 with methionine, and at position 424 with leucine; or a substitution at position 233 with aspartic acid and at position 334 with glutamic acid; or a substitution at position 334 with glutamic acid, at position 359 with asparagine, at position 366 with serine, and at position 386 with arginine; or a substitution at position 246 with threonine and at position 396 with histidine; or a substitution at position 268 with aspartic acid and at position 318 with aspartic acid; or a substitution at position 288 with asparagine, at position 330 with serine, and at position 396 with leucine; or a substitution at position 244 with histidine, at position 358 with methionine, at position 379 with methionine, at position 384 with lysine and at position 397 with methionine; or a substitution at position 217 with serine, at position 378 with valine, and at position 408 with arginine; or a substitution at position 247 with leucine, at position 253 with asparagine, and at position 334 with asparagine; or a substitution at position 246 with isoleucine, and at position 334 with asparagine; or a substitution at position 320 with glutamic acid and at position 326 with glutamic acid; or a substitution at position 375 with cysteine and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine; or a substitution at position 234 with leucine, at position 292 with proline, and at position 300 with leucine; or a substitution at position 234 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 234 with leucine, at position 292 with proline, and at position 305 with isoleucine; or a substitution at position 234 with leucine and at position 292 with proline; or a substitution at position 234 with leucine. Examples of other amino acid substitutions that results in an enhanced affinity for Fc γ R11A in vitro are disclosed below and summarized in Table 5.

[0183] The invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 243 with isoleucine and at position 379 with leucine, such that said molecule binds Fc γ R11A with about a 1.5 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 288 with asparagine, at position 330 with serine, and at position 396 with leucine, such that said molecule binds Fc γ R11A with about a 5 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 243 with leucine and at position 255 with leucine such that said molecule binds Fc γ R11A with about a 1 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine, such that said molecule binds Fc γ R11A with about a 1.5 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 288 with methionine and at position 334 with glutamic acid, such that said molecule binds Fc γ R11A with about a 3 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid, such that said molecule binds Fc γ R11A with about a 1.5 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 315 with isoleucine, at position 379 with methionine, and at position 399 with glutamic acid, such that said molecule binds Fc γ R11A with about a 1 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 243 with isoleucine, at position 379 with leucine, and at position 420 with valine, such that said molecule binds Fc γ R11A with about a 2.5 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 247 with leucine, and at position 421 with lysine, such that said molecule binds Fc γ R11A with about a 3 fold higher affinity than a comparable molecule comprising the wild type Fc region binds Fc γ R11A, as determined by an ELISA assay. In a specific embodiment, the invention encompasses a molecule comprising a variant Fc region, wherein said variant Fc region comprises a substitution at position 392 with threonine and at position 396 with leucine such that

invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ R111A with a greater affinity than a comparable polypeptide comprising the wild-type Fc region, wherein said at least one amino acid modification comprises substitution at position 396 with leucine. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ R111A with a greater affinity than a comparable polypeptide comprising the wild-type Fc region, wherein said at least one amino acid modification comprises substitution at position 273 with phenylalanine.

[0188] In a specific embodiment, the invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ R111A with about a 2 fold greater affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 379 with methionine. In another specific embodiment, the invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ R111A with about a 1.5 fold greater affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 248 with methionine.

[0189] In some embodiments, the molecules of the invention have an altered affinity for Fc γ R111A and/or Fc γ R11A as determined using *in vitro* assays (biochemical or immunological based assays) known in the art for determining Fc-Fc γ R interactions, *i.e.*, specific binding of an Fc region to an Fc γ R including but not limited to ELISA assay, surface plasmon resonance assay, immunoprecipitation assays (See Section 5.2.5.1). Preferably, the binding properties of these molecules with altered affinities for activating Fc γ R receptors are also correlated to their activity as determined by *in vitro* functional assays for determining one or more Fc γ R mediator effector cell functions (See Section 5.2.7), *e.g.*, molecules with variant Fc regions with enhanced affinity for Fc γ R111A have an enhanced ADCC activity. In most preferred embodiments, the molecules of the invention that have an altered binding property for an activating Fc receptor, *e.g.*, Fc γ R111A in an *in vitro* assay also have an altered binding property in *in vivo* models (such as those described and disclosed herein). However, the present invention does not exclude molecules of the invention that do not exhibit an altered Fc γ R binding in *in vitro* based assays but do exhibit the desired phenotype *in vivo*.

B. MUTANTS WITH ENHANCED AFFINITY FOR Fc γ R111A AND REDUCED OR NO AFFINITY FOR Fc γ R11B

[0190] In a specific embodiment, the molecules of the invention comprise a variant Fc region, having one or more amino acid modifications (*i.e.*, substitutions) in one or more regions, which one or more modifications increase the affinity of the variant Fc region for Fc γ R111A and decreases the affinity of the variant Fc region for Fc γ R11B, relative to a comparable molecule comprising a wild-type Fc region which binds Fc γ R111A and Fc γ R11B with wild-type affinity. In a certain embodiment, the one or more amino acid modifications do not include or are not solely a substitution with alanine at any of positions 256, 298, 333, 334, 280, 290, 294, 298, or 296; or a substitution at position 298 with asparagine, valine, aspartic acid, or proline; or a substitution 290 with serine. In certain amino acid modifications, the one or more amino acid modifications increases the affinity of the variant Fc region for Fc γ R111A by at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, at least 200%, at least 300%, at least 400% and decreases the affinity of the variant Fc region for Fc γ R11B by at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, at least 200%, at least 300%, at least 400%.

[0191] In a specific embodiment, the molecule of the invention comprising a variant Fc region with an enhanced affinity for Fc γ R111A and a lowered affinity or no affinity for Fc γ R11B, as determined based on an ELISA assay and/or an ADCC based assay using ch-4-4-20 antibody, or a surface plasmon resonance assay using a chimeric 4D5 antibody, carrying the variant Fc region comprises a substitution at position 275 with isoleucine, at position 334 with asparagine, and at position 348 with methionine; or a substitution at position 279 with leucine and at position 395 with serine; or a substitution at position 246 with threonine and at position 319 with phenylalanine; or a substitution at position 243 with leucine, at position 255 with leucine, and at position 318 with lysine; or a substitution at position 334 with glutamic acid, at position 359 with asparagine and at position 366 with serine; or a substitution at position 334 with glutamic acid and at position 380 with aspartic acid; or a substitution at position 256 with serine, at position 305 with isoleucine, at position 334 with glutamic acid, and at position 390 with serine; or a substitution at position 335 with asparagine, at position 370 with glutamic acid, at position 378 with valine, at position 394 with methionine and at position 424 with leucine; or a substitution at position 233 with aspartic acid and at position 334 with glutamic acid; or a substitution at position 334 with glutamic acid, at position 359 with asparagine, at position 366 with serine and at position 386 with arginine; or a substitution at position 312 with glutamic acid, at position 327 with asparagine, and at position 378 with serine; or a substitution at position 288 with asparagine and at position 326 with asparagine; or a substitution at position 247 with leucine and at position 421 with lysine; or a substitution at position 298 with asparagine and at position 381 with arginine; or a substitution

at position 280 with glutamic acid, at position 354 with phenylalanine, at position 431 with aspartic acid, and at position 441 with isoleucine; or a substitution at position 255 with glutamine and at position 326 with glutamic acid; or a substitution at position 218 with arginine, at position 281 with aspartic acid and at position 385 with arginine; or a substitution at position 247 with leucine, at position 330 with threonine and at position 440 with glycine; or a substitution at position 284 with alanine and at position 372 with leucine; or a substitution at position 335 with asparagine, as position 387 with serine and at position 435 with glutamine; or a substitution at position 247 with leucine, at position 431 with valine and at position 442 with phenylalanine; or a substitution at position 243 with leucine, at position 292 with proline, at position 305 with isoleucine, and at position 396 with leucine; or a substitution at position 243 leucine, at position 292 with proline, and at position 305 with isoleucine; or a substitution at position 292 with proline, at position 305 with isoleucine, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 292 with proline; or a substitution at position 292 with proline; or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine; or a substitution at position 243 with leucine.

[0192] In a specific embodiment, the molecule of the invention comprising a variant Fc region with an enhanced affinity for Fc γ RIIIA and a lowered affinity or no affinity for Fc γ RIIB as determined based on an ELISA assay and/or an ADCC based assay using ch-4-4-20 antibody carrying the variant Fc region comprises a substitution at position 379 with methionine; at position 219 with tyrosine; at position 282 with methionine; at position 401 with valine; at position 222 with asparagine; at position 334 with isoleucine; at position 334 with glutamic acid; at position 275 with tyrosine; at position 398 with valine. In yet another specific embodiment, the molecule of the invention comprising a variant Fc region with an enhanced affinity for Fc γ RIIIA and a lowered affinity or no affinity for Fc γ RIIB as determined based on an ELISA assay and/or an ADCC based assay using ch-4-4-20 antibody, or a surface plasmon resonance assay using a chimeric 4D5 antibody, carrying the variant Fc region comprises a substitution at position 243 with leucine; at position 292 with proline; and at position 300 with leucine.

[0193] The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 3 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 288 with asparagine, at position 330 with serine, and at position 396 with leucine. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 10-15 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 10 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 315 with isoleucine, at position 379 with methionine, and at position 399 with glutamic acid. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 7 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 243 with isoleucine, at position 379 with leucine, and at position 420 with valine. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 3 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 392 with threonine and at position 396 with leucine. The invention encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 5 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 268 with asparagine and at position 396 with leucine. The invention also encompasses an isolated polypeptide comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said polypeptide specifically binds Fc γ RIIB with about a 2 fold lower affinity than a comparable polypeptide comprising the wild-type Fc region as determined by an ELISA assay, wherein said at least one amino acid modification comprises substitution at position 319 with phenylalanine, at position 352 with leucine, and at position 396 with leucine.

C. MUTANTS WITH ENHANCED AFFINITY TO Fc γ R11A AND Fc γ R11B

[0194] The invention encompasses molecules comprising variant Fc regions, having one or more amino acid modifications, which modifications increase the affinity of the variant Fc region for Fc γ R11A and Fc γ R11B by at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, at least 200%, at least 300%, at least 400% and decreases the affinity of the variant Fc region for Fc γ R11B by at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, at least 200%, at least 300%, at least 400%. In a specific embodiment, the molecule of the invention comprising a variant Fc region with an enhanced affinity for Fc γ R11A and an enhanced affinity for Fc γ R11B (as determined based on an ELISA assay and/or an ADCC based assay using ch-4-4-20 antibody, or a surface plasmon resonance assay using a chimeric 4D5 antibody, carrying the variant Fc region as described herein) comprises a substitution at position 415 with isoleucine and at position 251 with phenylalanine; or a substitution at position 399 with glutamic acid, at position 292 with leucine, and at position 185 with methionine; or a substitution at position 408 with isoleucine, at position 215 with isoleucine, and at position 125 with leucine; or a substitution at position 385 with glutamic acid and at position 247 with histidine; or a substitution at position 348 with methionine, at position 334 with asparagine, at position 275 with isoleucine, at position 202 with methionine and at position 147 with threonine; or a substitution at position 246 with threonine and at position 396 with histidine; or a substitution at position 268 with aspartic acid and at position 318 with aspartic acid; or a substitution at position 288 with asparagine, at position 330 with serine and at position 396 with leucine; or a substitution at position 244 with histidine, at position 358 with methionine, at position 379 with methionine, at position 384 with lysine and at position 397 with methionine; or a substitution at position 217 with serine, at position 378 with valine, and at position 408 with arginine; or a substitution at position 247 with leucine, at position 253 with asparagine, and at position 334 with asparagine; or a substitution at position 246 with isoleucine and at position 334 with asparagine; or a substitution at position 320 with glutamic acid and at position 326 with glutamic acid; or a substitution at position 375 with cysteine and at position 396 with leucine; or a substitution at position 343 with serine, at position 353 with leucine, at position 375 with isoleucine, at position 383 with asparagine; or a substitution at position 394 with methionine and at position 397 with methionine; or a substitution at position 216 with aspartic acid, at position 345 with lysine and at position 375 with isoleucine; or a substitution at position 288 with asparagine, at position 330 with serine, and at position 396 with leucine; or a substitution at position 247 with leucine and at position 389 with glycine; or a substitution at position 222 with asparagine, at position 335 with asparagine, at position 370 with glutamic acid, at position 378 with valine and at position 394 with methionine; or a substitution at position 316 with aspartic acid, at position 378 with valine and at position 399 with glutamic acid; or a substitution at position 315 with isoleucine, at position 379 with methionine, and at position 394 with methionine; or a substitution at position 290 with threonine and at position 371 with aspartic acid; or a substitution at position 247 with leucine and at position 398 with glutamine; or a substitution at position 326 with glutamine; at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine; or a substitution at position 247 with leucine and at position 377 with phenylalanine; or a substitution at position 378 with valine, at position 390 with isoleucine and at position 422 with isoleucine; or a substitution at position 326 with glutamic acid and at position 385 with glutamic acid; or a substitution at position 282 with glutamic acid, at position 369 with isoleucine and at position 406 with phenylalanine; or a substitution at position 397 with methionine; at position 411 with alanine and at position 415 with asparagine; or a substitution at position 223 with isoleucine, at position 256 with serine and at position 406 with phenylalanine; or a substitution at position 298 with asparagine and at position 407 with arginine; or a substitution at position 246 with arginine, at position 298 with asparagine, and at position 377 with phenylalanine; or a substitution at position 235 with proline, at position 382 with methionine, at position 304 with glycine, at position 305 with isoleucine, and at position 323 with isoleucine; or a substitution at position 247 with leucine, at position 313 with arginine, and at position 388 with glycine; or a substitution at position 221 with tyrosine, at position 252 with isoleucine, at position 330 with glycine, at position 339 with threonine, at position 359 with asparagine, at position 422 with isoleucine, and at position 433 with leucine; or a substitution at position 258 with aspartic acid, and at position 384 with lysine; or a substitution at position 241 with leucine and at position 258 with glycine; or a substitution at position 370 with asparagine and at position 440 with asparagine; or a substitution at position 317 with asparagine and a deletion at position 423; or a substitution at position 243 with isoleucine, at position 379 with leucine and at position 420 with valine; or a substitution at position 227 with serine and at position 290 with glutamic acid; or a substitution at position 231 with valine, at position 386 with histidine, and at position 412 with methionine; or a substitution at position 215 with proline, at position 274 with asparagine, at position 287 with glycine, at position 334 with asparagine, at position 365 with valine and at position 396 with leucine; or a substitution at position 293 with valine, at position 295 with glutamic acid and at position 327 with threonine; or a substitution at position 319 with phenylalanine, at position 352 with leucine, and at position 396 with leucine; or a substitution at position 392 with threonine and at position 396 with leucine; at a substitution at position 268 with asparagine and at position 396 with leucine; or a substitution at position 290 with threonine, at position 390 with isoleucine, and at position 396 with leucine; or a substitution at position 326 with isoleucine and at position 396 with leucine; or a substitution at position 268 with aspartic acid and at position 396 with leucine; or a substitution at position 210 with methionine and

at position 396 with leucine; or a substitution at position 358 with proline and at position 396 with leucine; or a substitution at position 288 with arginine, at position 307 with alanine, at position 344 with glutamic acid, and at position 396 with leucine; or a substitution at position 273 with isoleucine, at position 326 with glutamic acid, at position 328 with isoleucine and at position 396 with leucine; or a substitution at position 326 with isoleucine, at position 408 with asparagine and at position 396 with leucine; or a substitution at position 334 with asparagine and at position 396 with leucine; or a substitution at position 379 with methionine and at position 396 with leucine; or a substitution at position 227 with serine and at position 396 with leucine; or a substitution at position 217 with serine and at position 396 with leucine; or a substitution at position 261 with asparagine, at position 210 with methionine and at position 396 with leucine; or a substitution at position 419 with histidine and at position 396 with leucine; or a substitution at position 370 with glutamic acid and at position 396 with leucine; or a substitution at position 242 with phenylalanine and at position 396 with leucine; or a substitution at position 255 with leucine and at position 396 with leucine; or a substitution at position 240 with alanine and at position 396 with leucine; or a substitution at position 250 with serine and at position 396 with leucine; or a substitution at position 247 with serine and at position 396 with leucine; or a substitution at position 410 with histidine and at position 396 with leucine; or a substitution at position 419 with leucine and at position 396 with leucine; or a substitution at position 427 with alanine and at position 396 with leucine; or a substitution at position 258 with aspartic acid and at position 396 with leucine; or a substitution at position 384 with lysine and at position 396 with leucine; or a substitution at position 323 with isoleucine and at position 396 with leucine; or a substitution at position 244 with histidine and at position 396 with leucine; or a substitution at position 305 with leucine and at position 396 with leucine; or a substitution at position 400 with phenylalanine and at position 396 with leucine; or a substitution at position 303 with isoleucine and at position 396 with leucine; or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine and at position 396 with leucine; or a substitution at position 290 with glutamic acid, at position 369 with alanine, at position 393 with alanine and at position 396 with leucine; or a substitution at position 210 with asparagine, at position 222 with isoleucine, at position 320 with methionine and at position 396 with leucine; or a substitution at position 217 with serine, at position 305 with isoleucine, at position 309 with leucine, at position 390 with histidine and at position 396 with leucine; or a substitution at position 246 with asparagine; at position 419 with arginine and at position 396 with leucine; or a substitution at position 217 with alanine, at position 359 with alanine and at position 396 with leucine; or a substitution at position 215 with isoleucine, at position 290 with valine and at position 396 with leucine; or a substitution at position 275 with leucine, at position 362 with histidine, at position 384 with lysine and at position 396 with leucine; or a substitution at position 334 with asparagine; or a substitution at position 400 with proline; or a substitution at position 407 with isoleucine; or a substitution at position 372 with tyrosine; or a substitution at position 366 with asparagine; or a substitution at position 414 with asparagine; or a substitution at position 352 with leucine; or a substitution at position 225 with serine; or a substitution at position 377 with asparagine; or a substitution at position 248 with methionine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 396 with leucine; or at position 292 with proline, and at position 305 with isoleucine.

D. MUTANTS WITH ALTERED Fc γ R-MEDIATED EFFECTOR FUNCTIONS

[0195] The invention encompasses immunoglobulin comprising Fc variants with altered effector functions. In some embodiments, immunoglobulins comprising Fc variants mediate effector function more effectively in the presence of effector cells as determined using assays known in the art and exemplified herein. In other embodiments, immunoglobulins comprising Fc variants mediate effector function less effectively in the presence of effector cells as determined using assays known in the art and exemplified herein. In specific embodiments, the Fc variants of the invention may be combined with other known Fc modifications that alter effector function, such that the combination has an additive, synergistic effect. The Fc variants of the invention have altered effector function in vitro and/or in vivo.

[0196] In a specific embodiment, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and preferably for Fc γ R1IIA have an enhanced Fc γ R-mediated effector function as determined using ADCC activity assays disclosed herein. Examples of effector functions that could be mediated by the molecules of the invention include, but are not limited to, C1q binding, complement-dependent cytotoxicity, antibody-dependent cell mediated cytotoxicity (ADCC), phagocytosis, etc. The effector functions of the molecules of the invention can be assayed using standard methods known in the art, examples of which are disclosed in Section 5.2.6. In a specific embodiment, the immunoglobulins of the invention comprising a variant Fc region with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA mediate antibody dependent cell mediated cytotoxicity (ADCC) 2- fold more effectively, than an immunoglobulin comprising a wild-type Fc region. In other embodiments, the immunoglobulins of the invention comprising a variant Fc region with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA mediate antibody dependent cell mediated cytotoxicity (ADCC) at least 4- fold, at least 8-fold, at least 10-fold, at least 100-fold, at least 1000-fold, at least 10⁴-fold, at least

10⁵-fold more effectively, than an immunoglobulin comprising a wild-type Fc region. In another specific embodiment, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA have altered C1q binding activity. In some embodiments, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA have at least 2-fold, at least 4- fold, at least 8-fold, at least 10-fold, at least 100-fold, at least 1000-fold, at least 10⁴-fold, at least 10⁵-fold higher C1q binding activity than an immunoglobulin comprising a wild-type Fc region. In yet another specific embodiment, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA have altered complement dependent cytotoxicity. In yet another specific embodiment, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA have an enhanced complement dependent cytotoxicity than an immunoglobulin comprising a wild-type Fc region. In some embodiments, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIIA and/or Fc γ R1IIA have at least 2-fold, at least 4- fold, at least 8-fold, at least 10-fold, at least 100-fold, at least 1000-fold, at least 10⁴-fold, at least 10⁵-fold higher complement dependent cytotoxicity than an immunoglobulin comprising a wild-type Fc region.

[0197] In other embodiments, immunoglobulins of the invention with enhanced affinity for Fc γ R1IIA and preferably also for Fc γ R1IIA have enhanced phagocytosis activity relative to an immunoglobulin comprising a wild-type Fc region, as determined by standard assays known to one skilled in the art or disclosed herein. In some embodiments, the immunoglobulins of the invention with enhanced affinity for Fc γ R1IIA and preferably also for Fc γ R1IIA have at least 2-fold, at least 4- fold, at least 8-fold, at least 10-fold higher phagocytosis activity relative to an immunoglobulin comprising a wild-type Fc region.

[0198] In a specific embodiment, the invention encompasses an immunoglobulin comprising a variant Fc region with one or more amino acid modifications, with an enhanced affinity for Fc γ R1IIIA and preferably also for Fc γ R1IIA such that the immunoglobulin has an enhanced effector function, e.g., antibody dependent cell mediated cytotoxicity, or phagocytosis. In a specific embodiment, the one or more amino acid modifications which increase the affinity of the variant Fc region for Fc γ R1IIIA and preferably also for Fc γ R1IIA and increase the ADCC activity of the immunoglobulin comprise a substitution at position 379 with methionine; or a substitution at position 243 with isoleucine and at position 379 with leucine; or a substitution at position 288 with asparagine, at position 330 with serine, and at position 396 with leucine; or a substitution at position 243 leucine and at position 255 with leucine; or a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine; or a substitution at position 288 with methionine and at position 334 with glutamic acid; or a substitution at position 334 with glutamic acid and at position 292 with leucine; or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid; or a substitution at position 315 with isoleucine, at position 379 with methionine, and at position 399 with glutamic acid; or a substitution at position 243 with isoleucine, at position 379 with leucine, and at position 420 with valine; or a substitution at position 247 with leucine and at position 421 with lysine; or a substitution at position 248 with methionine; or a substitution at position 392 with threonine and at position 396 with leucine; or a substitution at position 293 with valine, at position 295 with glutamic acid, and at position 327 with threonine; or a substitution at position 268 with asparagine and at position 396 with leucine; or a substitution at position 319 with phenylalanine, at position 352 with leucine, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine.

[0199] In another specific embodiment, the one or more amino acid modifications which increase the ADCC activity of the immunoglobulin is any of the mutations listed below, in table 7.

TABLE 7. AMINO ACID MODIFICATION WHICH INCREASE ADCC

E333A, K334A
R292L, K334E
V379M
S219Y
V282M
K222N
F243I, V379L
F243L, R255L, E318K
K334I
K334E, T359N, T366S

EP 2 573 114 B1

(continued)

	K288M, K334E
5	K288N, A330S, P396L
	K326E
	G316D, A378V, D399E
10	N315I, V379M, T394M
	F243I, V379L, G420V
	E293V, Q295E, A327T
	Y319F, P352L, P396L
15	K392T, P396L
	K248M
	H268N, P396L
20	K290T, N390I, P396L
	K326I, P396L
	H268D, P396L
	K210M, P396L
25	L358P, P396L
	K288R, T307A, K344E, P396L
	V273I, K326E, L328I, P396L
30	K326I, S408N, P396L
	K334N, P396L
	V379M, P396L
	P227S, P396L
35	P217S, P396L
	K261N, K210M, P396L
	Q419H, P396L
40	K370E, P396L
	L242F, P396L
	F243L, V305I, A378D, F404S, P396L
	R255L, P396L
45	V240A, P396L
	T250S, P396L
	P247S, P396L
50	K290E, V369A, T393A, P396L
	K210N, K222I, K320M, P396L
	L414H, P396L
	Q419L, P396L
55	V427A, P396L
	P217S, V305I, I309L, N390H, P396L
	E258D, P396L

EP 2 573 114 B1

(continued)

	N384K, P396L
5	V323I, P396L
	K246N, Q419R, P396L
	P217A, T359A, P396L
10	P244H, P396L
	V215I, K290V, P396L
	F275L, Q362H, N384K, P396L
	V305L, P396L
15	S400F, P396L
	V303I, P396L
	D270E, G316D, R416G
	P247L, N421K
20	P247L, N421K, D270E
	Q419H, P396L, D270E
	K370E, P396L, D270E
25	R255L, P396L, D270E
	V240A, P396L, D270E
	K392T, P396L, D270E
	F243L, R292P, Y300L, V305I, P396L
30	F243L, R292P, Y300L, P396L
	F243L, R292P, Y300L

[0200] Alternatively or additionally, it may be useful to combine the above amino acid modifications or any other amino acid modifications disclosed herein with one or more further amino acid modifications that alter C1q binding and/or complement dependent cytotoxicity function of the Fc region. The starting molecule of particular interest herein is usually one that binds to C1q and displays complement dependent cytotoxicity (CDC). The further amino acid substitutions described herein will generally serve to alter the ability of the starting molecule to bind to C1q and/or modify its complement dependent cytotoxicity function, e.g., to reduce and preferably abolish these effector functions. However, molecules comprising substitutions at one or more of the described positions with improved C1q binding and/or complement dependent cytotoxicity (CDC) function are contemplated herein. For example, the starting molecule may be unable to bind C1q and/or mediate CDC and may be modified according to the teachings herein such that it acquires these further effector functions. Moreover, molecules with preexisting C1q binding activity, optionally further having the ability to mediate CDC may be modified such that one or both of these activities are enhanced.

[0201] As disclosed above, one can design an Fc region with altered effector function, e.g., by modifying C1q binding and/or FcR binding and thereby changing CDC activity and/or ADCC activity. For example, one can generate a variant Fc region with improved C1q binding and improved Fc γ RIII binding; e.g., having both improved ADCC activity and improved CDC activity. Alternatively, where one desires that effector function be reduced or ablated, one may engineer a variant Fc region with reduced CDC activity and/or reduced ADCC activity. In other embodiments, one may increase only one of these activities, and optionally also reduce the other activity, e.g., to generate an Fc region variant with improved ADCC activity, but reduced CDC activity and vice versa.

[0202] The invention encompasses specific variants of the Fc region that have been identified using the methods of the invention from a yeast library of mutants after 2nd-4th-round of sorting are listed in Table 8. Table 8 summarizes the various mutants that were identified using the methods of the invention. The mutants were assayed using an ELISA assay for determining binding to Fc γ RIIIA and Fc γ RIIIB. The mutants were also tested in an ADCC assay, by cloning the Fc variants into a ch 4-4-20 antibody using methods disclosed and exemplified herein. Bolded items refer to experiments, in which the ch4-4-20 were purified prior the ADCC assay. The antibody concentration used was in the range 0.5 μ g/mL - 1.0 μ g/mL.

TABLE 8: MUTATIONS IDENTIFIED IN THE Fc REGION

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
pYD-CH1 library FACS screen with 3A tetramer				
Q347H; A339V	CH3	↑0.5x	NT	
S415I;L251F	CH2,CH3	↑0.5x	↑.75x	0.82
K392R	CH3	N/C	NT	
D399E; R292L; V185M	CH1,CH2,CH3	N/C	↑0.5x	0.65 0.9
K290E; L142P	CH1,CH2	N/C	NT	
R301C; M252L; S192T	CH1,CH2	↓.5x	NT	
P291S; K288E; H268L:A141V	CH1,CH2	↓.5x	NT	
N315I	CH2	N/C	↑.75x	
S132I	CH1	N/C	NT	
S383N;N384K;T256N;V262L;K218E;R2141;K205E;F149Y;K133M	All	↑0.5x	NT	
S408I; V215I; V125L	CH1,CH2,CH3	↑0.5x	↑.75x	0.62
P396L	CH3	↑1x	↑1x	0.55
G38E;P247H;	CH2, CH3	↑1x	t.75x	0.44
P396H	CH3	↑1x	↑1x	0.58
A162V	CH1	N/C	NT	
V348M; K334N; F275I; Y202M; K147T	CH1,CH2,CH3	↑0.5x	↑.75x	0.33
H310Y; T289A; G337E	CH2	↑.5x	NT	
S119F; G371S; Y407V; E258D	CH1,CH2,CH3	N/C	N/C	0.29
K409R; S166N	CH1, CH3	N/C	NT	
in vitro Site Directed mutants				
R292L	CH2	NT	NT	0.82

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
T359N	CH3	NT	NT	1.06
T366S	CH3	NT	NT	0.93
E333A, K334A	CH2	NT	NT	1.41
R292L, K334E	CH2	NT	NT	1.41; 1.64
R292L, P396L, T359N	CH2, CH3	NT	NT	0.89; 1.15
V379L	CH3	NT	NT	0.83
K288N	CH2	NT	NT	0.78
A330S	CH2	NT	NT	0.52
F243L	CH2	NT	NT	0.38
E318K	CH2	NT	NT	0.86
K288N, A330S	CH2	NT	NT	0.08
R255L, E318K	CH2	NT	NT	0.82
F243L, E318K	CH2	NT	NT	0.07
Mutants in 4-4-20 mini-library Increased FcγRIIIA binding, decreased or no change to FcγRIIB binding N/C means no change; N/B means no binding; NT means not tested				
V379M	CH3	↑2x	N/C	1.47
S219Y	Hinge	↑1x	↓or NIB	1.28
V282M	CH2	↑1x-	↓or NIB	1.25; 1
F275I, K334N, V348M	CH2	↑0.5x	N/C	
D401V	CH3	↑0.5x	N/C	
V279L, P395S	CH2	↑1x	N/C	
K222N	Hinge	↑1x	↓or N/B	1.33; 0.63

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
K246T, Y319F	CH2	↑1x	N/C	
F243I, V379L	CH2, CH3	↑1.5x	↓ or N/B	1.86; 1.35
F243L, R255L, E3181K	CH2	↑1x	↓ or N/B	1.81; 1.45
K334I	CH2	↑1x	N/C	2.1; 1.97
K334E, T359N, T366S	CH2, CH3	↑1.5x	N/C	1.49; 1.45
K288M, K334E	CH2	↑3x	↓ or NIB	1.61; 1.69
K334E, E380D	CH2, CH3	↑1.5x	N/C	
T256S, V305I, K334E, N390S	CH2, CH3	↑1.5x	N/C	
K334E	CH2	↑2.5x	N/C	1.75; 2.18
T335N, K370E, A378V, T394M, S424L	CH2, CH3	↑0.5x	N/C	
E233D, K334E	CH2	↑1.5x	N/C	0.94; 1.02
K334E, T359N, T366S, Q386R	CH2	↑1x	N/C	
Increased Binding to FcγIIIA and FcγRIIB				
K246T, P396H	CH2, CH3	↑1x	↑2.5x	
H268D, E318D	CH2	↑1.5x	↑5x	
K288N, A330S, P396L	CH2, CH3	↑5x	↑3x	2.34; 1.66; 2.54
I377F	CH3	↑1.5x	↑0.5x	
P244H, I358M, V379M, N384K, V397M	CH2, CH3	↑1.5x	↑1.5x	
P217S, A378V, S408R	Hinge, CH3	↑2x	↑4.5x	
P247L, I253N, K334N	CH2	↑3x	↑2.5x	
P247L	CH2	↑0.5x	↑4x	0.91; 0.84
F372Y	CH3	↑0.75x	↑5.5x	0.88; 0.59
K326E	CH2	↑2x	↑3.5x	1.63; 2

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
K246I, K334N	CH2	↑0.5x	↑4x	0.66; 0.6
K320E, K326E	CH2	↑1x	↑1x	
H224L	Hinge	↑0.5x	↑5x	0.55; 0.53
S375C, P396L	CH3	↑1.5x	↑4.5x	
D312E, K327N, I378S	CH2, CH3	↑0.5x	N/C	
K288N, K326N	CH2	↑1x	N/C	
F275Y	CH2	t3x	N/C	0.64
P247L, N421K	CH2, CH3	↑3x	N/C	2.0
S295N, W381R	CH2, CH3	↑2x	N/C	
D280B, S354F, A431D, L441I	CH2, CH3	↑3x	N/C	0.62
R255Q, K326E	CH2	↑2x	N/C	0.79
K218R, G281D, G385R	H, CH2, CH3	↑3.5x	N/C	0.67
L398V	CH3	↑1.5x	N/C	
P247L, A330T, S440G	CH2, CH3	↑0.75x	↓0.25x	
V284A, F372L	CH2, CH3	1x	N/C	
T335N, P387S, H435Q	CH2, CH3	1.25x	N/C	
P247L, A431V, S442F	CH2, CH3	1x	N/C	
Increased Binding to FcγRIIIA and FcγRIIB				
P343S, P353L, S375I, S383N	CH3	↑0.5x	↑6x	
T394M, V397M	CH3	↑0.5x	↑3x	
E216D, F345Y, S375I	H, CH2, CH3	↑0.5x	↑4x	
K334N,	CH2	↑0.5x	↑2x	
K288N, A330S, P396L	CH2, CH3	↑0.5x	↑9x	

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
P247L,E389G	CH2,CH3	↑1.5x	↑9x	
K222N,T335N,K370E,A378V,T394M	H,CH2,CH3	↑1x	↑7x	
G316D,A378V,D399E	CH2,CH3	↑1.5x	↑14x	2.24
N315I,V379M,T394M	CH2,CH3	↑1x	↑9x	1.37
K290T,G371D,	CH2,CH3	↑0.25x	↑6x	
P247L,L398Q	CH2,CH3	↑1.25x	↑10x	
K326Q,K334E,T359N,T366S	CH2,CH3	↑1.5x	↑5x	
S400P	CH3	↑1x	↑6x	
P247L,I377F	CH2,CH3	↑1x	↑5x	
A378V,N390I,V422I	CH3	↑0.5x	↑5x	
K326E,G385E	CH2,CH3	↑0.5x	↑15x	
V282E,V369I,L406F	CH2,CH3	↑0.5x	↑7x	
V397M,T411A,S415N	CH3	↑0.25x	↑5x	
T223I,T256S,L406F	H, CH2,CH3	↑0.25x	↑6x	
S298N,5407R	CH2,CH3	↑0.5x	↑7x	
K246R,S298N,I377F	CH2,CH3	↑1x	↑5x	
S407I	CH3	↑0.5x	↑4x	
F372Y	CH3	↑0.5x	↑4x	
L235F,V382M,S304G,V305I,V323I	CH2,CH3	↑2x	↑2x	
P247L,W313R,E388G	CH2,CH3	↑1.5x	↑1x	
D221Y,M252I,A330G,A339T,T359N,V422I,H433L	H,CH2,CH3	↑2.5x	↑6x	
E258D,N384K	CH2,CH3	↑1.25x	↑4x	
F241L,E258G	CH2	↑2x	t2.5x	-0.08
K370N,S440N	CH3	↑1x	T 3.5x	

(continued)

Mutations	Domain	Binding to Fc γ RIIIA (ELISA)	Binding to Fc γ RIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
K317N,F423-deleted	CH2,CH3	↑2.5x	↑7x	0.18
F243I,V379L,G420V	CH2,CH3	↑2.5x	↑3.5x	1.35
P227S,K290E	H,CH2	↑1x	↑0.5x	
A231V,Q386H,V412M	CH2,CH3	↑1.5x	↑6x	
T215P,K274N,A287G,K334N,L365V,P396L	H,CH2,CH3	↑2x	↑4x	
Increased Binding to FcγRIIB but not FcγRIIIA				
K334E,E380D	CH2,CH3	N/C	↑4.5x	
T366N	CH3	N/C	↑5x	
P244A,K326I,C367R,S375I,K447T	CH2,CH3	N/C	↑3x	
C229Y,A287T,V379M,P396L,L443V	H,CH2,CH3	↑0.25x	↑10x	
Decreased binding to FcγRIIIA and FcγRIIB				
R301H,K340E,D399E	CH2,CH3	↓0.50x	↓0.25x	
K414N	CH3	↓0.25x	N/B	
P291S,P353Q	CH2,CH3	↓0.50x	↓0.25x	
V240I,V281M	CH2	↓0.25x	↓0.25x	
P232S,S304G	CH2	N/B	N/B	
E269K,K290N,Q311R,H433Y	CH2,CH3	N/B	N/B	
M352L	CH3	N/B	N/B	
E216D,K334R,S375I	H,CH2,CH3	N/B	N/B	
P247L,L406F	CH2,CH3	N/B	N/B	
T335N,P387S,H435Q	CH2,CH3	N/B	N/B	
T225S	CH2	↓0.25x	↓0.50x	

5

10

15

20

25

30

35

40

45

50

55

(continued)

Mutations	Domain	Binding to Fc γ RIIIA (ELISA)	Binding to Fc γ RIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
D399E,M428L	CH3	↓ 0.50x	↓ 0.50x	
K246I,Q362H,K370E	CH2,CH3	N/B	↓ 0.50x	
K334E,E380D,G446V	CH2,CH3	N/B	N/B	
I377N	CH3	↓0.50x	N/B	
V303I,V369F,M428L	CH2,CH3	N/B	N/B	
L251F,F372L	CH2,CH3	N/B	N/B	
K246E,V284M,V308A	CH2,CH3	N/B	N/B	
D399E,G402D	CH3	N/B	N/B	
D399E,M428L	CH3	N/B	N/B	
FcγRIIB depletion/FcγRIIIA selection: Naive Fc library.				
E293V,Q295E,A327T	CH2	↑0.4x	↓ or N/B	4.29
Y319F,P352L,P396L	CH2,CH3	↑3.4x	↑2x	1.09
K392T,P396L	CH3	↑ 4.5x	↑ 2.5x	3.07
K248M	CH2	↑0.4x	↓ or N/B	4.03
H268N,P396L	CH2,CH3	↑ 2.2x	↑ 4.5x	2.24
Solution competition 40X FcγRIIB-G2:P396L Library				
D221E,D270E,V308A,Q311H,P396L,G402D		↑3.6x	↑0.1x	3.17
Equilibrium Screen: 0.8 μM FcγRIIIA monomer: P396L library				
K290T,N390I,P396L	CH2, CH3	↑2.8x	↑6.1x	1.93
K326I,P396L	CH2, CH3	↑2.9x	↑5.9x	1.16
H268D,P396L	CH2, CH3	↑3.8x	↑13.7x	2.15
K210M,P396L	CH1, CH3	↑1.9x	↑4.6x	2.02

5

10

15

20

25

30

35

40

45

50

55

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
L358P, P396L	CH3	↑1.9x	↑4.2x	1.58
K288R, T307A, K344E, P396L	CH2, CH3	↑4.1x	↑2.3x	3.3
V273I, K326E, L328I, P396L	CH2, CH3	↑1.3x	↑10.8x	0.78
K326I, S408N, P396L	CH2, CH3	↑4x	↑9.3x	1.65
K334N, P396L	CH2, CH3	↑3.1x	↑3x	2.43
V379M, P396L	CH3	↑1.9x	↑5.6x	2.01
P227S, P396L	CH2, CH3	↑1.5x	↑4x	2.01
P217S, P396L	H, CH3	↑1.6x	↑4.5x	2.04
K261N, K210M, P396L	CH2, CH3	↑2x	↑4.2x	2.06
Kinetic Screen: 0.8 μM, 1' with cold 8 μM FcγRIIIA: P396L Library				
term is M, P396L	CH3	↑1.9x	↑7.2x	3.09
Q419H, P396L	CH3	↑2x	↑6.9x	2.24
K370E, P396L	CH3	↑2x	↑6.6x	2.47
L242F, P396L	CH2, CH3	↑2.5x	↑4.1x	2.4
F243L, V305I, A378D, F404S, P396L	CH2, CH3	↑1.6x	↑5.4x	3.59
R255L, P396L	CH2, CH3	↑1.8x	↑6x	2.79
V240A, P396L	CH2, CH3	↑1.3x	↑4.2x	2.35
T250S, P396L	CH2, CH3	↑1.5x	↑6.8x	1.60
P247S, P396L	CH2, CH3	↑1.2x	↑4.2x	2.10
K290E, V369A, T393A, P396L	CH2, CH3	↑1.3x	↑6.7x	1.55
K210N, K222I, K320M, P396L	H, CH2, CH3	↑2.7x	↑8.7x	1.88
L410H, P396L	CH3	↑1.7x	↑4.5x	2.00
Q419L, P396L	CH3	↑2.2x	↑6.1x	1.70
V427A, P396L	CH3	↑1.9x	↑4.7x	1.67

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
P217S, V305I, I309L, N390H, P396L	H, CH2, CH3	↑2x	↑7x	1.54
E258D, P396L	CH2, CH3	↑1.9x	↑4.9x	1.54
N384K, P396L	CH3	↑2.2x	↑5.2x	1.49
V323I, P396L	CH2, CH3	↑1.1x	↑8.2x	1.29
K246N, Q419R, P396L	CH2, CH3	↑1.1x	↑4.8x	1.10
P217A, T359A, P396L	H, CH2, CH3	↑1.5x	↑4.8x	1.17
P244H, P396L	CH2, CH3	↑2.5x	↑4x	1.40
V215I, K290V, P396L	H, CH2, CH3	↑2.2x	↑4.6x	1.74
F275L, Q362H, N384K, P396L	CH2, CH3	↑2.2x	↑3.7x	1.51
V305L, P396L	CH2, CH3	↑1.3x	↑5.5x	1.50
S400F, P396L	CH3	↑1.5x	↑4.7x	1.19
V303I, P396L	CH3	↑1.1x	↑4x	1.01
FcγRIIB depletion FcγRIIIA 158V solid phase selection: Naive Library				
A330V, H433Q, V427M	CH2, CH3	NT	NT	NT
V263Q, E272D, Q419H	CH2, CH3	NT	NT	NT
N276Y, T393N, W417R	CH2, CH3	NT	NT	NT
V282L, A330V, H433Y, T436R	CH2, CH3	NT	NT	NT
A330V, Q419H	CH2, CH3	NT	NT	NT
V284M, S298N, K334E, R355W	CH2, CH3	NT	NT	NT
A330V, G427M, K438R	CH2, CH3	NT	NT	NT
S219T, T225K, D270E, K360R	CH2, CH3	NT	NT	NT
K222E, V263Q, S298N	CH2	NT	NT	NT
V263Q, E272D	CH2	NT	NT	NT

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Domain	Binding to FcγRIIIA (ELISA)	Binding to FcγRIIB (ELISA)	4-4-20 ADCC (Relative Lysis (Mut/Wt))
R292G	CH2	NT	NT	NT
S298N	CH2	NT	NT	NT
E233G, P247S, L306P	CH2	NT	NT	NT
D270E	CH2	NT	NT	NT
S219T, T225K, D270E	CH2	NT	NT	NT
K326E, A330T	CH2	NT	NT	NT
E233G	CH2	NT	NT	NT
S254T, A330V, N361D, P243L	CH2,CH3	NT	NT	NT
FcγRIIB depletion FcγRIIIA 158F solid phase selection: Naïve Library				
158F by FACS top 0.2%				
V284M, S298N, K334E, R355W R416T	CH2,CH3	NT	NT	
FcγRIIB depletion FcgRIIA 131H solid phase selection: Naïve Library				
R292P, V305I	CH2,CH2	NT	NT	
D270E, G316D, R416G	CH2,CH3	NT	NT	
V284M, R292L, K370N	CH2,CH3	NT	NT	
R292P, V305I, F243L	CH2	NT	NT	

[0203] In preferred embodiments, the invention provides modified immunoglobulin molecules (e.g., antibodies) with variant Fc regions, having one or more amino acid modifications, which one or more amino acid modifications increase the affinity of the molecule for Fc γ R1IIIA and preferably also for Fc γ R1IIA. Such immunoglobulins include IgG molecules that naturally contain Fc γ R binding regions (e.g., Fc γ R1IIIA and/or Fc γ R1IIB binding region), or immunoglobulin derivatives that have been engineered to contain an Fc γ R binding region (e.g., Fc γ R1IIIA and/or Fc γ R1IIB binding region). The modified immunoglobulins of the invention include any immunoglobulin molecule that binds, preferably, immunospecifically, i.e., competes off non-specific binding as determined by immunoassays well known in the art for assaying specific antigen-antibody binding, an antigen and contains an Fc γ R binding region (e.g., a Fc γ R1IIIA and/or Fc γ R1IIB binding region). Such antibodies include, but are not limited to, polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, disulfide-linked Fvs, and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds an antigen, in certain cases, engineered to contain or fused to an Fc γ R binding region.

[0204] In some embodiments, the molecules of the invention comprise portions of an Fc region. As used herein the term "portion of an Fc region" refers to fragments of the Fc region, preferably a portion with effector activity and/or Fc γ R binding activity (or a comparable region of a mutant lacking such activity). The fragment of an Fc region may range in size from 5 amino acids to the entire Fc region minus one amino acids. The portion of an Fc region may be missing up to 10, up to 20, up to 30 amino acids from the N-terminus or C-terminus.

[0205] The IgG molecules of the invention are preferably IgG1 subclass of IgGs, but may also be any other IgG subclasses of given animals. For example, in humans, the IgG class includes IgG1, IgG2, IgG3, and IgG4; and mouse IgG includes IgG1, IgG2a, IgG2b, IgG2c and IgG3.

[0206] The immunoglobulins (and other polypeptides used herein) may be from any animal origin including birds and mammals. Preferably, the antibodies are human, rodent (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described *infra* and, for example, in U.S. Patent No. 5,939,598 by Kucherlapati et al.

[0207] The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide or may be specific for heterologous epitopes, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol., 147:60-69, 1991; U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol., 148:1547-1553, 1992.

[0208] Multispecific antibodies have binding specificities for at least two different antigens. While such molecules normally will only bind two antigens (i.e. bispecific antibodies, BsAbs), antibodies with additional specificities such as trispecific antibodies are encompassed by the instant invention. Examples of BsAbs include without limitation those with one arm directed against a tumor cell antigen and the other arm directed against a cytotoxic molecule.

[0209] Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

[0210] According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when, the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

[0211] In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in

Enzymology, 121:210 (1986). According to another approach described in WO96/27011, a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0212] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[0213] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. See, e.g., Tutt et al. J. Immunol. 147: 60 (1991).

[0214] The antibodies of the invention include derivatives that are otherwise modified, *i.e.*, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding antigen and/or generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0215] For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science, 229:1202, 1985; Oi et al., BioTechniques, 4:214 1986; Gillies et al., J. Immunol. Methods, 125:191-202, 1989; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions and constant domains from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature, 332:323, 1988. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology, 28(4/5):489-498, 1991; Studnicka et al., Protein Engineering, 7(6):805-814, 1994; Roguska et al., Proc Natl. Acad. Sci. USA, 91:969-973, 1994), and chain shuffling (U.S. Patent No. 5,565,332). Humanized antibodies may be generated using any of the methods disclosed in U.S. Patent Nos. 5,693,762 (Protein Design Labs), 5,693,761, (Protein Design Labs) 5,585,089 (Protein Design Labs), 6,180,370 (Protein Design Labs),

and U.S. Publication Nos. 20040049014, 200300229208, each of which is incorporated herein by reference in its entirety.

[0216] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741.

[0217] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598. In addition, companies such as Abgenix, Inc. (Freemont, CA), Medarex (NJ) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using

technology similar to that described above.

[0218] Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., Bio/technology, 12:899-903, 1988).

[0219] The invention encompasses engineering human or humanized therapeutic antibodies (e.g., tumor specific monoclonal antibodies) in the Fc region, by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue, which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another embodiment, the invention relates to engineering human or humanized therapeutic antibodies (e.g., tumor specific monoclonal antibodies) in the Fc region, by modification of at least one amino acid residue, which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA and further decreases the affinity of the Fc region for Fc γ R1IIB. The engineered therapeutic antibodies may further have an enhanced effector function, e.g., enhanced ADCC activity, phagocytosis activity, etc., as determined by standard assays known to those skilled in the art.

[0220] In a specific embodiment, the invention encompasses engineering a humanized monoclonal antibody specific for Her2/neu protooncogene (e.g., Ab4D5 humanized antibody as disclosed in Carter et al., 1992, Proc. Natl. Acad. Sci. USA 89:4285-9) by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another specific embodiment, modification of the humanized Her2/neu monoclonal antibody may also further decrease the affinity of the Fc region for Fc γ R1IIB. In yet another specific embodiment, the engineered humanized monoclonal antibodies specific for Her2/neu may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein.

[0221] In another specific embodiment, the invention encompasses engineering a mouse human chimeric anti-CD20 monoclonal antibody, 2H7 by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another specific embodiment, modification of the anti-CD20 monoclonal antibody, 2H7 may also further decrease the affinity of the Fc region for Fc γ R1IIB. In yet another specific embodiment, the engineered anti-CD20 monoclonal antibody, 2H7 may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein.

[0222] In certain embodiments, the invention encompasses engineering an antibody (or chimeric, humanized or other engineered versions thereof), comprising the heavy chain variable domain and/or light chain variable domain of the monoclonal antibody produced by clone 2B6, 3H7, 8B5.4.3, 1D5, 2E1, 2H9, 2D11 or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively (deposited at ATCC, 10801 University Boulevard, Manassas, VA 02209-2011, all of which are incorporated herein by reference). In a specific embodiment, the invention encompasses engineering a humanized antibody comprising the heavy chain variable and/or light chain variable domains of 2B6, 3H7 or 8B5.3.4. In another specific embodiment, the invention encompasses engineering a humanized antibody comprising the CDRs of 2B6, 3H7 or 8B5.3.4. In another specific embodiment, the invention encompasses engineering a humanized antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3 and the light chain variable domain having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO: 8. In another specific embodiment, the invention encompasses engineering an anti-Fc γ R1IIB antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO:13 and the light chain variable domain having the amino acid sequence of SEQ ID NO:14. In another specific embodiment, the invention encompasses engineering a humanized anti-Fc γ R1IIB antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO:3 and the light chain variable domain having the amino acid sequence of SEQ ID NO:8. In another specific embodiment, the invention encompasses engineering a humanized anti-Fc γ R1IIB antibody comprising the heavy chain variable domain having the amino acid sequence of SEQ ID NO:9 and the light chain variable domain having the amino acid sequence of SEQ ID NO:10.

[0223] In another specific embodiment, the invention encompasses engineering an anti-Fc γ R1IIB antibody including but not limited to any of the antibodies disclosed in U.S. Provisional Application No. 60/403,266 filed on August 12, 2002, U.S. Application No. 10/643,857 filed on August 14, 2003 (published as US 2004-0185045), U.S. Provisional Application No. 60/562,804 filed on April 16, 2004, U.S. Provisional Application No. 60/582,044 filed on June 21, 2004, U.S. Provisional Application No. 60/582,045 filed on June 21, 2004, U.S. Provisional Application No. 60/636,663 filed on December 15, 2004 and U.S. Application Serial No. 10/524,134 filed February 11, 2005 (published as US 2005 0215767) by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another specific embodiment, the invention encompasses engineering a humanized anti-Fc γ R1IIB antibody including but not limited to any of the antibodies disclosed in U.S. Provisional Application No. 60/569,882 filed on May 10, 2004, U.S. Provisional Application No. 60/582, 043 filed on June 21, 2004 and U.S. Application No. - 11/126,978, filed on May 10, 2005 (published as US 2006 0013810) by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. Examples of anti-Fc γ R1IIB antibodies, which may or may not be humanized, that may be engineered in

accordance with the methods of the invention are 2B6 monoclonal antibody having ATCC accession number PTA-4591 and 3H7 having ATCC accession number PTA-4592, 1D5 monoclonal antibody having ATCC accession number PTA-5958, 1F2 monoclonal antibody having ATCC accession number PTA-5959, 2D11 monoclonal antibody having ATCC accession number PTA-5960, 2E1 monoclonal antibody having ATCC accession number PTA-5961, 8B5.3.4 having ATCC accession number PTA-7610, and 2H9 monoclonal antibody having ATCC accession number PTA-5962 (all deposited at 10801 University Boulevard, Manassas, VA 02209-2011), which are incorporated herein by reference. In another specific embodiment, modification of the anti-Fc γ R1IB antibody may also further decrease the affinity of the Fc region for Fc γ R1IB. In yet another specific embodiment, the engineered anti-Fc γ R1IB antibody may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein.

[0224] In a specific embodiment, the invention encompasses engineering an anti-Fc γ R1IB antibody according to methods of the present invention that comprises one or more complementarily determining regions (CDRs), preferably all 6 CDRs, of the antibody produced by clone 2B6, 3H7, or 8B5.3.4 with ATCC accession numbers PTA-4591, PTA-4592, and PTA-7610, respectively (e.g., the heavy chain CDR3). In a specific embodiment, an anti-Fc γ R1IB antibody engineered according to methods of the invention comprises one or more complementarily determining regions (CDRs), preferably all 6 CDRs, of the antibody produced by clone 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively (e.g., the heavy chain CDR3). In another embodiment, an anti-Fc γ R1IB antibody engineered according to methods of the invention binds to the same epitope as the mouse monoclonal antibody produced from clone 2B6, 3H7, or 8B5.3.4 with ATCC accession numbers PTA-4591, PTA-4592, and PTA-7610, respectively and/or competes with the mouse monoclonal antibody produced from clone 2B6, 3H7, or 8B5.3.4 with ATCC accession numbers PTA-4591, PTA-4592, and PTA-7610, respectively as determined, e.g., in an ELISA assay or other appropriate competitive immunoassay, and also binds Fc γ R1IB with a greater affinity than said antibody or a fragment thereof binds Fc γ R1IA. In another embodiment, an anti-Fc γ R1IB antibody engineered according to methods of the invention binds to the same epitope as the mouse monoclonal antibody produced from clone 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, and/or competes with the mouse monoclonal antibody produced from clone 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, as determined, e.g., in an ELISA assay or other appropriate competitive immunoassay, and also binds Fc γ R1IB, via its variable region, with a greater affinity than said antibody or a fragment thereof binds Fc γ R1IA.

[0225] The present invention also encompasses engineering an anti-Fc γ R1IB antibody comprising a heavy chain variable domain and/or light chain variable domain amino acid sequence that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the heavy chain variable domain and/or light chain variable domain of the mouse monoclonal antibody produced by clone 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively.

The present invention further encompasses the engineering of anti-Fc γ R1IB antibodies comprising an amino acid sequence of one or more CDRs that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of one or more CDRs of the mouse monoclonal antibody produced by clone 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. The determination of percent identity of two amino acid sequences can be determined by any method known to one skilled in the art, including BLAST protein searches.

[0226] The present invention also encompasses the the engineering of one or more anti-Fc γ R1IB antibodies comprising one or more variable domains encoded by a nucleotide sequence that hybridizes to the nucleotide sequence of one or more variable domains of a mouse monoclonal antibody produced by clone 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, under stringent conditions. In a preferred embodiment, the invention encompasses engineering one or more anti-Fc γ R1IB antibodies comprising a variable light chain and/or variable heavy chain domain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of the variable light chain and/or variable heavy chain domain of the mouse monoclonal antibody produced by clone 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, under stringent conditions. In another preferred embodiment, the invention provides engineering anti-Fc γ R1IB antibodies comprising one or more CDRs encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of one or more CDRs of the mouse monoclonal antibody produced by clone 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. Stringent hybridization conditions include, but are not limited to, hybridization to filter-bound DNA in 6X sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2X SSC/0.1% SDS at about 50-65°C, highly stringent conditions such as hybridization to filter-bound DNA in 6X SSC at about 45°C followed by one or more

washes in 0.1X SSC/0.2% SDS at about 60°C, or any other stringent hybridization conditions known to those skilled in the art (see, for example, Ausubel, F.M. et al., eds. 1989 Current Protocols in Molecular Biology, vol. 1, Green Publishing Associates, Inc. and John Wiley and Sons, Inc., NY at pages 6.3.1 to 6.3.6 and 2.10.3).

[0227] In a preferred embodiment, the engineered antibodies of the invention are humanized by any method known in the art or described herein and/or comprise the CDR regions of a humanized Fc γ R1IB specific antibody or humanized CD20 specific antibody, wherein said CDRs are derived from a murine antibody specific for Fc γ R1IB or CD20, respectively. In some embodiments, the humanized antibodies described herein comprise alterations, including but not limited to amino acid deletions, insertions, modifications, of the acceptor antibody, *i.e.*, human, heavy and/or light chain variable domain framework regions that are necessary for retaining binding specificity of the donor monoclonal antibody. In some embodiments, the framework regions of the humanized antibodies described herein do not necessarily consist of the precise amino acid sequence of the framework region of a natural occurring human antibody variable region, but contains various alterations, including but not limited to amino acid deletions, insertions, modifications that alter the property of the humanized antibody, for example, improve the binding properties of a humanized antibody variable region specific for the same target as the murine Fc γ R1IB or CD20 specific antibody. In most preferred embodiments, a minimal number of alterations are made to the framework region in order to avoid large-scale introductions of non-human framework residues and to ensure minimal immunogenicity of the humanized antibody of the invention in humans. The donor monoclonal antibody is preferably a monoclonal antibody produced by clones 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 (having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively) which bind Fc γ R1IB, or the monoclonal antibody is a CD20 antibody, such as rituximab or 2H7.

[0228] In a specific embodiment, the invention encompasses engineering a CDR-grafted antibody that comprises a heavy chain variable region domain comprising framework residues of the recipient antibody and residues from the donor monoclonal antibody, which specifically binds Fc γ R1IB, *e.g.*, monoclonal antibody produced from clones 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-7610, PTA-5958, PTA-5961, PTA-5962, and PTA-5959, respectively. In another specific embodiment, the invention encompasses engineering a CDR-grafted antibody that comprises a light chain variable region domain comprising framework residues of the recipient antibody and residues from the donor monoclonal antibody, which specifically binds Fc γ R1IB, *e.g.*, monoclonal antibody produced from clones 2B6, 3H7, 8B5.3.4, 1D5, 2E1, 2H9, 2D11, or 1F2.

[0229] Preferably the Fc γ R1IB humanized antibodies bind the extracellular domain of native human Fc γ R1IB. The humanized anti- Fc γ R1IB antibodies of the combinations can have a heavy chain variable region comprising the amino acid sequence of CDR1 (SEQ ID NO: 15 or SEQ ID NO: 16) and/or CDR2 (SEQ ID NO:17 or SEQ ID NO:18) and/or CDR3 (SEQ ID NO: 19 or SEQ ID NO:20) and/or a light chain variable region comprising the amino acid sequence of CDR1 (SEQ ID NO:21 or SEQ ID NO:22) and/or a CDR2 (SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, or SEQ ID NO:26) and/or CDR3 (SEQ ID NO:27 or SEQ ID NO:28).

[0230] In a specific embodiment, the invention encompasses the engineering of a humanized anti-Fc γ R1IB antibody with the heavy chain variable domain having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and a light chain variable domain having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6; SEQ ID NO:7 or SEQ ID NO:8.

[0231] In one specific embodiment, the invention encompasses engineering a humanized anti-Fc γ R1IB antibody, wherein the VH region of the Fc γ R1IB antibody consists of the FR segments from the human germline VH segment VH1-18 (Matsuda et al., 1998, J. Exp. Med. 188:2151062) and JH6 (Ravetch et al., 1981, Cell 27(3 Pt. 2): 583-91), and one or more CDR regions of a 2B6 VH, having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:17, or SEQ ID NO:19. In one embodiment, the 2B6 VH has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:29. In another specific embodiment, the humanized anti-Fc γ R1IB antibody further comprises a VL region, which consists of the FR segments of the human germline VL segment VK-A26 (Lautner-Rieske et al., 1992, Eur. J. Immunol. 22:1023-1029) and JK4 (Hieter et al., 1982, J. Biol. Chem. 257:1516-22), and one or more CDR regions of a 2B6VL, having the amino acid sequence of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:27. In one embodiment, the 2B6 VL has the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6; SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:30, and optionally in combination with one of the above-referenced 2B6 VH.

[0232] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VH chain and/or a VH domain comprising the amino acid sequence (H2B6VH-3):

QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVRQAPGQGLEWIGVIDPSDTPNYN
 KKFKGRVTMTVDTSTSTAYMELRSLRSDDTAVYYCARNGDSDYYSGM DYWGQGTTVTVSS
 (SEQ ID NO:3).

EP 2 573 114 B1

[0233] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VL chain and/or VL domain comprising the amino acid sequence (H2B6VL-5):

5 EIVLTQSPDFQSVTPKEKVTFTCRTSQSIGTNIHWYQQKPDQSPKLLIKEVSEISGVPSR
FSGSGSGTDFTLTINSLEAEDAATYYCQQSNTWPFTEGGGKVEIK
(SEQ ID NO:8).

10 [0234] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VH chain and/or VH domain comprising the amino acid sequence (H2B6VH-3):

15 QVQLVQSGAEVKKPGASVKVSCASGYFTFTNYWIHWVRQAPGQGLEWIGVIDPSDTPNYN
KKFKGRVTMTVDTSTSTAYMELRSLRSDDTAVYYCARNGDSDYSGMDYWGQGTITVTVSS
(SEQ ID NO:3),

20 and a VL chain and/or VL domain comprising the amino acid sequence (H2B6VL-5):

25 EIVLTQSPDFQSVTPKEKVTFTCRTSQSIGTNIHWYQQKPDQSPKLLIKEVSEISGVPSR
FSGSGSGTDFTLTINSLEAEDAATYYCQQSNTWPFTEGGGKVEIK
(SEQ ID NO:8).

30 [0235] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VH domain and/or VH chain comprising the amino acid sequence (8B5.3.4 VH, see FIG. 2):

35 EVKLEESGGGLVQPGGSMKLSCEASGFTFSDAWMDWVRQSPKGLEWVAEIRNKAKNHATY
YAESVIGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCGALGLDYWGQGTITLVSS
(SEQ ID NO:9).

40 [0236] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VL domain and/or VL chain comprising the amino acid sequence (8B5.3.4 VL, see FIG. 1):

45 DIQMTQSPSSLLAALGERVSLTCRASQEISGYLSWLQOKPDGTIKRLIYAASTLDGVPKR
FSGSESGSDYSLTISSEDFADYYCLQYFSYPLTFGAGTKLELK
(SEQ ID NO:10).

50 [0237] In some embodiments, the anti-Fc γ R1IB antibody engineered in accordance with the methods of the invention has a VH domain and/or VH chain comprising the amino acid sequence (8B5.3.4 VH):

55 EVKLEESGGGLVQPGGSMKLSCEASGFTFSDAWMDWVRQSPKGLEWVAEIRNKAKNHATY
YAESVIGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCGALGLDYWGQGTITLVSS
(SEQ ID NO:9, see FIG. 2),

see FIG. 2), and a VL domain and/or VL chain comprising the amino acid sequence (8B5.3.4 VL, see FIG 1):

DIQMTQSPSSLLAALGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKR
 FSGSESGSDYSLTISSESEDFADYYCLQYFSYPLTFGAGTKLELK
 5 (SEQ ID NO:10).

[0238] In another specific embodiment, the anti-Fc γ RIIB antibody engineered in accordance with the methods of the invention is a humanized 3H7 antibody, wherein the Fc γ RIIB VH region consists of the FR segments from a human germline VH segment and the CDR regions of the 3H7 VH, having the amino acid sequence of SED ID NO: 37. In another specific embodiment, the humanized 3H7 antibody further comprises a VL region, which consists of the FR segments of a human germline VL segment and the CDR regions of 3H7VL, having the amino acid sequence of SEQ ID NO:7.

[0239] In particular, the invention encompasses the engineering of an anti-Fc γ RIIB antibody wherein the antibody immunospecifically binds to an extracellular domain of native human Fc γ RIIB, said Fc γ RIIB antibody comprising (or alternatively, consisting of) CDR sequences of 2B6, 3H7, or 8B5.3.4 in any of the following combinations: a VH CDR1 and a VL CDR1; a VH CDR1 and a VL CDR2; a VH CDR1 and a VL CDR3; a VH CDR2 and a VL CDR1; VH CDR2 and VL CDR2; a VH CDR2 and a VL CDR3; a VH CDR3 and a VH CDR1; a VH CDR3 and a VL CDR2; a VH CDR3 and a VL CDR3; a VH1 CDR1, a VH CDR2 and a VL CDR1; a VH CDR1, a VH CDR2 and a VL CDR2; a VH CDR1, a VH CDR2 and a VL CDR3; a VH CDR2, a VH CDR3 and a VL CDR1, a VH CDR2, a VH CDR3 and a VL CDR2; a VH CDR2, a VH CDR2 and a VL CDR3; a VH CDR1, a VL CDR1 and a VL CDR2; a VH CDR1, a VL CDR1 and a VL CDR3; a VH CDR2, a VL CDR1 and a VL CDR2; a VH CDR2, a VL CDR1 and a VL CDR3; a VH CDR3, a VL CDR1 and a VL CDR2; a VH CDR2, a VH CDR3 and a VL CDR2; a VH CDR1, a VH CDR2, a VH CDR3 and a VL CDR1; a VH CDR1, a VH CDR2, a VH CDR3 and a VL CDR2; a VH CDR1, a VH CDR2, a VL CDR1 and a VL CDR3; a VH CDR1, a VH CDR3, a VL CDR1 and a VL CDR2; a VH CDR2, a VH CDR3, a VL CDR1 and a VL CDR3; a VH CDR2, a VH CDR3, a VL CDR2 and a VL CDR3; a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1 and a VL CDR2; a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1 and a VL CDR3; a VH CDR1, a VH CDR2, a VL CDR1, a VL CDR2, and a VL CDR3; a VH CDR1, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; or any combination thereof of the VH CDRs and VL CDRs disclosed herein.

[0240] In a specific embodiment, the anti-Fc γ RIIB monoclonal antibody comprises a modification at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine (MgFc13); or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid (MgFc27); or a substitution at position 243 with isoleucine, at position 379 with leucine, and at position 420 with valine (MgFc29); or a substitution at position 392 with threonine and at position 396 with leucine (MgFc38); or a substitution at position 221 with glutamic acid, at position 270 with glutamic acid, at position 308 with alanine, at position 311 with histidine, at position 396 with leucine, and at position 402 with aspartic (MgFc42); or a substitution at position 410 with histidine, and at position 396 with leucine (MgFc53); or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine, and at position 396 with leucine (MgFc54); or a substitution at position 255 with isoleucine, and at position 396 with leucine (MgFc55); or a substitution at position 370 with glutamic acid, and at position 396 with leucine (MgFc59); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine (MgFc88); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine (MgFc88A); or a substitution at position 234 with leucine, at position 292 with proline, and at position 300 with leucine (MgFc155); or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine; or a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine; or a substitution at position 243 with leucine, and at position 292 with proline; or a substitution at position 243 with leucine; or a substitution at position 273 with phenylalanine (See Tables 5 & 6).

5.1.1 POLYPEPTIDE AND ANTIBODY CONJUGATES

[0241] Molecules of the invention (*i.e.*, polypeptides, antibodies) comprising variant Fc regions may be recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to heterologous polypeptides (*i.e.*, an unrelated polypeptide; or portion thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences.

[0242] Further, molecules of the invention (*i.e.*, polypeptides, antibodies) comprising variant Fc regions may be con-

jugated to a therapeutic agent or a drug moiety that modifies a given biological response. Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin (*i.e.*, PE-40), or diphtheria toxin, ricin, gelonin, and pokeweed antiviral protein, a protein such as tumor necrosis factor, interferons including, but not limited to, α -interferon (IFN- α), β -interferon (IFN- β), nerve growth factor (NGF), platelet derived growth factor (PDGF), tissue plasminogen activator (TPA), an apoptotic agent (e.g., TNF- α , TNF- β , AIM I as disclosed in PCT Publication No. WO 97/33899), AIM II (*see*, PCT Publication No. WO 97/34911), Fas Ligand (Takahashi et al., J. Immunol., 6:1567-1574, 1994), and VEGF (PCT Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent (e.g., angiostatin or endostatin), or a biological response modifier such as, for example, a lymphokine (e.g., interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), and granulocyte colony stimulating factor ("G-CSF"), macrophage colony stimulating factor, ("M-CSF"), or a growth factor (e.g., growth hormone ("GH")); proteases, or ribonucleases.

[0243] Molecules of the invention (*i.e.*, polypeptides, antibodies) can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., 1989, Proc. Natl. Acad. Sci. USA, 86:821-824, for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell, 37:767 1984) and the "flag" tag (Knappik et al., Biotechniques, 17(4):754-761, 1994).

[0244] Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to alter the activities of molecules of the invention (e.g., antibodies with higher affinities and lower dissociation rates). See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., 1997, Curr. Opin. Biotechnol. 8:724-33; Harayama, 1998, Trends Biotechnol. 16:76; Hansson, et al., 1999, J. Mol. Biol. 287:265; and Lorenzo and Blasco, 1998, BioTechniques 24:308 (each of these patents and publications are hereby incorporated by reference in its entirety). Molecules of the invention comprising variant Fc regions, or the nucleic acids encoding the molecules of the invention, may be further altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. One or more portions of a polynucleotide encoding a molecule of the invention, may be recombined with one or more components, motifs, sections, parts, domains, fragments, *etc.* of one or more heterologous molecules.

[0245] The present invention also encompasses molecules of the invention comprising variant Fc regions (*i.e.*, antibodies, polypeptides) conjugated to a diagnostic or therapeutic agent or any other molecule for which serum half-life is desired to be increased and/or targeted to a particular subset of cells. The molecules of the invention can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the molecules of the invention to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the molecules of the invention or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Such diagnosis and detection can be accomplished by coupling the molecules of the invention to detectable substances including, but not limited to, various enzymes, enzymes including, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic group complexes such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials such as, but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent material such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, and aequorin; radioactive material such as, but not limited to, bismuth (^{213}Bi), carbon (^{14}C), chromium (^{51}Cr), cobalt (^{57}Co), fluorine (^{18}F), gadolinium (^{153}Gd , ^{159}Gd), gallium (^{68}Ga , ^{67}Ga), germanium (^{68}Ge), holmium (^{166}Ho), indium (^{115}In , ^{113}In , ^{112}In , ^{111}In), iodine (^{131}I , ^{125}I , ^{123}I , ^{121}I), lanthanum (^{140}La), lutetium (^{177}Lu), manganese (^{54}Mn), molybdenum (^{99}Mo), palladium (^{103}Pd), phosphorous (^{32}P), praseodymium (^{142}Pr), promethium (^{149}Pm), rhenium (^{186}Re , ^{188}Re), rhodium (^{105}Rh), ruthenium (^{97}Ru), samarium

[0246] (^{153}Sm), scandium (^{47}Sc), selenium (^{75}Se), strontium (^{85}Sr), sulfur (^{35}S), technetium (^{99}Tc), thallium (^{201}Tl), tin (^{113}Sn , ^{117}Sn), tritium (^3H), xenon (^{133}Xe), ytterbium (^{169}Yb , ^{175}Yb), yttrium (^{90}Y), zinc (^{65}Zn); positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions.

[0247] Molecules of the invention (*i.e.*, antibodies, polypeptides) comprising a variant Fc region may be conjugated

to a therapeutic moiety such as a cytotoxin (e.g., a cytostatic or cytotoxic agent), a therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.). Cytotoxins or cytotoxic agents include any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0248] Moreover, a molecule of the invention can be conjugated to therapeutic moieties such as a radioactive materials or macrocyclic chelators useful for conjugating radiometal ions (see above for examples of radioactive materials). In certain embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule. Such linker molecules are commonly known in the art and described in Denardo et al., 1998, *Clin Cancer Res.* 4:2483-90; Peterson et al., 1999, *Bioconjug. Chem.* 10:553; and Zimmerman et al., 1999, *Nucl. Med. Biol.* 26:943-50.

[0249] Techniques for conjugating such therapeutic moieties to antibodies are well known; see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), 1985, pp. 243-56, Alan R. Liss, Inc.; Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery (2nd Ed.)*, Robinson et al. (eds.), 1987, pp. 623-53, Marcel Dekker, Inc.; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), 1985, pp. 475-506; "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), 1985, pp. 303-16, Academic Press; and Thorpe et al., *Immunol. Rev.*, 62:119-58, 1982.

[0250] In one embodiment, where the molecule of the invention is an antibody comprising a variant Fc region, it can be administered with or without a therapeutic moiety conjugated to it, administered alone, or in combination with cytotoxic factor(s) and/or cytokine(s) for use as a therapeutic treatment. Alternatively, an antibody of the invention can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980. Antibodies of the invention may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

5.2 SCREENING OF MOLECULES WITH VARIANT Fc REGIONS FOR ENHANCED FcγRIII BINDING AND CHARACTERIZATION OF SAME

[0251] In preferred embodiments, screening and identifying molecules comprising variant Fc regions with altered FcγR affinities (e.g., enhanced FcγRIIIA affinity) are done using the yeast display technology as described herein in combination with one or more biochemical based assays, preferably in a high throughput manner. The one or more biochemical assays can be any assay known in the art for identifying Fc-FcγR interaction, i.e., specific binding of an Fc region to an FcγR, including, but not limited to, an ELISA assay, surface plasmon resonance assays, immunoprecipitation assay, affinity chromatography, and equilibrium dialysis. In some embodiments, screening and identifying molecules comprising variant Fc regions with altered FcγR affinities (e.g., enhanced FcγRIIIA affinity) are done using the yeast display technology as described herein in combination with one or more functional based assays, preferably in a high throughput manner. The functional based assays can be any assay known in the art for characterizing one or more FcγR mediated effector cell functions such as those described herein in Section 5.2.7. Non-limiting examples of effector cell functions that can be used in accordance with the methods of the invention, include but are not limited to, antibody-dependent cell mediated cytotoxicity (ADCC), antibody-dependent phagocytosis, phagocytosis, opsonization, opsonophagocytosis, cell binding, resetting, C1q binding, and complement dependent cell mediated cytotoxicity. In some embodiments, screening and identifying molecules comprising variant Fc regions with altered FcγR affinities (e.g., enhanced FcγRIIIA affinity) are done using the yeast display technology as described herein in combination with one or more biochemical based assays in combination or in parallel with one or more functional based assays, preferably in a high throughput manner.

[0252] The term "specific binding" of an Fc region to an FcγR refers to an interaction of the Fc region and a particular FcγR which has an affinity constant of at least about 150 nM, in the case of monomeric FcγRIIIA and at least about 60 nM in the case of dimeric FcγRIIB as determined using, for example, an ELISA or surface plasmon resonance assay (e.g., a BiAcore™). The affinity constant of an Fc region for monomeric FcγRIIIA may be 150 nM, 200 nM or 300nM. The affinity constant of an Fc region for dimeric FcγRIIB may be 60 nM, 80 nM, 90 nM, or 100 nM. Dimeric FcγRIIB for use in the methods of the invention may be generated using methods known to one skilled in the art. Typically, the

extracellular region of Fc γ R1B is covalently linked to a heterologous polypeptide which is capable of dimerization, so that the resulting fusion protein is a dimer, e.g., see, U.S. Application No. 60/439,709 filed on January 13, 2003 (Attorney Docket No. 11183-005-888). A specific interaction generally is stable under physiological conditions, including, for example, conditions that occur in a living individual such as a human or other vertebrate or invertebrate, as well as conditions that occur in a cell culture such conditions as used for maintaining and culturing mammalian cells or cells from another vertebrate organism or an invertebrate organism.

[0253] In a specific embodiment, screening for and identifying molecules comprising variant Fc regions and altered Fc γ R affinities comprise: displaying the molecule comprising a variant Fc region on the yeast surface; and characterizing the binding of the molecule comprising the variant Fc region to a Fc γ R (one or more), using a biochemical assay for determining Fc-Fc γ R interaction, preferably, an ELISA based assay. Once the molecule comprising a variant Fc region has been characterized for its interaction with one or more Fc γ Rs and determined to have an altered affinity for one or more Fc γ Rs, by at least one biochemical based assay, e.g., an ELISA assay, the molecule maybe engineered into a complete immunoglobulin, using standard recombinant DNA technology methods known in the art, and the immunoglobulin comprising the variant Fc region expressed in mammalian cells for further biochemical characterization. The immunoglobulin into which a variant Fc region of the invention is introduced (e.g., replacing the Fc region of the immunoglobulin) can be any immunoglobulin including, but not limited to, polyclonal antibodies, monoclonal antibodies, bispecific antibodies, multi-specific antibodies, humanized antibodies, and chimeric antibodies. In preferred embodiments, a variant Fc region is introduced into an immunoglobulin specific for a cell surface receptor, a tumor antigen, or a cancer antigen. The immunoglobulin into which a variant Fc region of the invention is introduced may specifically bind a cancer or tumor antigen for example, including, but not limited to, KS 1/4 pan-carcinoma antigen (Perez and Walker, 1990, J. Immunol. 142: 3662-3667; Bumal, 1988, Hybridoma 7(4): 407-415), ovarian carcinoma antigen (CA125) (Yu et al., 1991, Cancer Res. 51(2): 468-475), prostatic acid phosphate (Tailor et al., 1990, Nucl. Acids Res. 18(16): 4928), prostate specific antigen (Henttu and Vihko, 1989, Biochem. Biophys. Res. Comm. 160(2): 903-910; Israeli et al., 1993, Cancer Res. 53: 227-230), melanoma-associated antigen p97 (Estin et al., 1989, J. Natl. Cancer Instit. 81(6): 445-446), melanoma antigen gp75 (Vijayasardahl et al., 1990, J. Exp. Med. 171(4): 1375-1380), high molecular weight melanoma antigen (HMW-MAA) (Natali et al., 1987, Cancer 59: 55-63; Mittelman et al., 1990, J. Clin. Invest. 86: 2136-2144), prostate specific membrane antigen, carcinoembryonic antigen (CEA) (Foon et al., 1994, Proc. Am. Soc. Clin. Oncol. 13: 294), polymorphic epithelial mucin antigen, human milk fat globule antigen, colorectal tumor-associated antigens such as: CEA, TAG-72 (Yokata et al., 1992, Cancer Res. 52: 3402-3408), CO17-1A (Ragnhammar et al., 1993, Int. J. Cancer 53: 751-758); GICA 19-9 (Herlyn et al., 1982, J. Clin. Immunol. 2: 135), CTA-1 and LEA, Burkitt's lymphoma antigen-38.13, CD19 (Ghetie et al., 1994, Blood 83: 1329-1336), human B-lymphoma antigen-CD20 (Reff et al., 1994, Blood 83:435-445), CD33 (Sgouros et al., 1993, J. Nucl. Med. 34:422-430), melanoma specific antigens such as ganglioside GD2 (Saleh et al., 1993, J. Immunol., 151, 3390-3398), ganglioside GD3 (Shitara et al., 1993, Cancer Immunol. Immunother. 36:373-380), ganglioside GM2 (Livingston et al., 1994, J. Clin. Oncol. 12: 1036-1044), ganglioside GM3 (Hoon et al., 1993, Cancer Res. 53: 5244-5250), tumor-specific transplantation type of cell-surface antigen (TSTA) such as virally-induced tumor antigens including T-antigen DNA tumor viruses and Envelope antigens of RNA tumor viruses, oncofetal antigen-alpha-fetoprotein such as CEA of colon, bladder tumor oncofetal antigen (Hellstrom et al., 1985, Cancer. Res. 45:2210-2188), differentiation antigen such as human lung carcinoma antigen L6, L20 (Hellstrom et al., 1986, Cancer Res. 46: 3917-3923), antigens of fibrosarcoma, human leukemia T cell antigen-Gp37 (Bhattacharya-Chatterjee et al., 1988, J. of Immun. 141:1398-1403), neoglycoprotein, sphingolipids, breast cancer antigen such as EGFR (Epidermal growth factor receptor), HER2 antigen (p185^{HER2}), polymorphic epithelial mucin (PEM) (Hilkens et al., 1992, Trends in Bio. Chem. Sci. 17:359), malignant human lymphocyte antigen-APO-1 (Bernhard et al., 1989, Science 245: 301-304), differentiation antigen (Feizi, 1985, Nature 314: 53-57) such as I antigen found in fetal erythrocytes, primary endoderm I antigen found in adult erythrocytes, preimplantation embryos, I(Ma) found in gastric adenocarcinomas, M18, M39 found in breast epithelium, SSEA-1 found in myeloid cells, VEP8, VEP9, Myl, VIM-D5, D₁56-22 found in colorectal cancer, TRA-1-85 (blood group H), C14 found in colonic adenocarcinoma, F3 found in lung adenocarcinoma, AH6 found in gastric cancer, Y hapten, Le^y found in embryonal carcinoma cells, TL5 (blood group A), EGF receptor found in A431 cells, E₁ series (blood group B) found in pancreatic cancer, FC10.2 found in embryonal carcinoma cells, gastric adenocarcinoma antigen, CO-514 (blood group Le^a) found in Adenocarcinoma, NS-10 found in adenocarcinomas, CO-43 (blood group Le^b), G49 found in colon cancer, gastric cancer mucins, T₅A₇ found in myeloid cells, R₂₄ found in melanoma, 4.2, G_{D3}, D1.1, OFA-1, G_{M2}, OFA-2, G_{D2}, and M1:22:25:8 found in embryonal carcinoma cells, and SSEA-3 and SSEA-4 found in 4 to 8-cell stage embryos. In one embodiment, the antigen is a T cell receptor derived peptide from a Cutaneous Tcell Lymphoma (see, Edelson, 1998, *The Cancer Journal* 4:62).

[0254] In some embodiments, a variant Fc region of the invention is introduced into an anti-fluoresceine monoclonal antibody, 4-4-20 (Kranz et al., 1982 J. Biol. Chem. 257(12): 6987-6995). In other embodiments, a variant Fc region of the invention is introduced into a mouse-human chimeric anti-CD20 monoclonal antibody 2H7, which recognizes the CD20 cell surface phosphoprotein on B cells (Liu et al., 1987, Journal of Immunology, 139: 3521-6). In yet other em-

bodiments, a variant Fc region of the invention is introduced into a humanized antibody (Ab4D5) against the human epidermal growth factor receptor 2 (p185 HER2) as described by Carter et al. (1992, Proc. Natl. Acad. Sci. USA 89: 4285-9). In yet other embodiments, a variant Fc region of the invention is introduced into a humanized anti-TAG72 antibody (CC49) (Sha et al., 1994 Cancer Biother. 9(4): 341-9). In other embodiments, a variant Fc region of the invention is introduced into Rituxan which is used for treating lymphomas.

[0255] In another specific embodiment, the invention encompasses engineering an anti-Fc γ R1IB antibody including but not limited to any of the antibodies disclosed in U.S. Provisional Application No. 60/403,266 filed on August 12, 2002, U.S. Application No. 10/643,857 filed on August 14, 2003, U.S. Provisional Application No. 60/562,804 filed on April 16, 2004, U.S. Provisional Application No. 60/582,044 filed on June 21, 2004, U.S. Provisional Application No. 60/582,045 filed on June 21, 2004, U.S. Provisional Application No. 60/636,663 filed on December 15, 2004 and U.S. Application Serial No. 10/524,134 filed February 11, 2005 by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. In another specific embodiment, the invention encompasses engineering a humanized anti-Fc γ R1IB antibody including but not limited to any of the antibodies disclosed in U.S. Provisional Application No. 60/569,882 filed on May 10, 2004, U.S. Provisional Application No. 60/582, 043 filed on June 21, 2004 and U.S. Application No. 11/126,978, filed on May 10, 2005 by modification (e.g., substitution, insertion, deletion) of at least one amino acid residue which modification increases the affinity of the Fc region for Fc γ R1IIIA and/or Fc γ R1IIA. Examples of anti-Fc γ R1IB antibodies, which may or may not be humanized, that may be engineered in accordance with the methods of the invention are 2B6 monoclonal antibody having ATCC accession number PTA-4591 and 3H7 having ATCC accession number PTA-4592, 1D5 monoclonal antibody having ATCC accession number PTA-5958, 1F2 monoclonal antibody having ATCC accession number PTA-5959, 2D11 monoclonal antibody having ATCC accession number PTA-5960, 2E1 monoclonal antibody having ATCC accession number PTA-5961 and 2H9 monoclonal antibody having ATCC accession number PTA-5962 (all deposited at 10801 University Boulevard, Manassas, VA 02209-2011), which are incorporated herein by reference. In another specific embodiment, modification of the anti-Fc γ R1IB antibody may also further decrease the affinity of the Fc region for Fc γ R1IB. In yet another specific embodiment, the engineered anti-Fc γ R1IB antibody may further have an enhanced effector function as determined by standard assays known in the art and disclosed and exemplified herein. In some embodiments, a variant Fc region of the invention is introduced into a therapeutic monoclonal antibody specific for a cancer antigen or cell surface receptor including but not limited to, ErbituxTM (also known as IMC-C225) (ImClone Systems Inc.), a chimerized monoclonal antibody against EGFR; HERCEPTIN[®] (Trastuzumab) (Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; REOPRO[®] (abciximab) (Centocor) which is an anti-glycoprotein IIb/IIIa receptor on the platelets for the prevention of clot formation; ZENAPAX[®] (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection. Other examples are a humanized anti-CD18 F(ab')₂ (Genentech); CDP860 which is a humanized anti-CD18 F(ab')₂ (Celltech, UK); PRO542 which is an anti-HIV gp120 antibody fused with CD4 (Progenics/Genzyme Transgenics); C14 which is an anti-CD 14 antibody (ICOS Pharm); a humanized anti-VEGF IgG1 antibody (Genentech); OVAREXTM which is a murine anti-CA 125 antibody (Altarex); PANOREXTM which is a murine anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); IMC-C225 which is a chimeric anti-EGFR IgG antibody (ImClone System); VITAXINTM which is a humanized anti- α V β 3 integrin antibody (Applied Molecular Evolution/MedImmune); Campath 1H/LDP-03 which is a humanized anti CD52 IgG1 antibody (LeukoSite); Smart M195 which is a humanized anti-CD33 IgG antibody (Protein Design Lab/Kanebo); RITUXANTM which is a chimeric anti-CD20 IgG1 antibody (IDEC Pharm/Genentech, Roche/Zettyaku); LYMPHOCIDETM which is a humanized anti-CD22 IgG antibody (Immunomedics); Smart ID10 which is a humanized anti-HLA antibody (Protein Design Lab); ONCOLYMTM (Lym-1) is a radiolabelled murine anti-HLA DR antibody (Techniclone); anti-CD11a is a humanized IgG1 antibody (Genetech/Xoma); ICM3 is a humanized anti-ICAM3 antibody (ICOS Pharm); IDEC-114 is a primatized anti-CD80 antibody (IDEC Pharm/Mitsubishi); ZEVALINTM is a radio labelled murine anti-CD20 antibody (IDEC/Schering AG); IDEC-131 is a humanized anti-CD40L antibody (IDEC/Eisai); IDEC-151 is a primatized anti-CD4 antibody (IDEC); IDEC-152 is a primatized anti-CD23 antibody (IDEC/Seikagaku); SMART anti-CD3 is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1 is a humanized anti-complement factor 5 (C5) antibody (Alexion Pharm); IDEC-151 is a primatized anti-CD4 IgG1 antibody (IDEC Pharm/SmithKline Beecham); MDX-CD4 is a human anti-CD4 IgG antibody (Medarex/Eisai/Genmab); CDP571 is a humanized anti-TNF- α IgG4 antibody (Celltech); LDP-02 is a humanized anti- α 4 β 7 antibody (LeukoSite/Genentech); OrthoClone OKT4A is a humanized anti-CD4 IgG antibody (Ortho Biotech); ANTOVATM is a humanized anti-CD40L IgG antibody (Biogen); ANTEGRENTM is a humanized anti-VLA-4 IgG antibody (Elan); MDX-33 is a human anti-CD64 (Fc γ R) antibody (Medarex/Centeon);; rhuMab-E25 is a humanized anti-IgE IgG1 antibody (Genentech/Norvartis/Tanox Biosystems); IDEC-152 is a primatized anti-CD23 antibody (IDEC Pharm); ABX-CBL is a murine anti CD-147 IgM antibody (Abgenix); BTI-322 is a rat anti-CD2 IgG antibody (Medimmune/Bio Transplant); Orthoclone/OKT3 is a murine anti-CD3 IgG2a antibody (ortho Biotech); SIMULECTTM is a chimeric anti-CD25 IgG1 antibody (Novartis Pharm); LDP-01 is a humanized anti- β ₂-integrin IgG antibody (LeukoSite); Anti-LFA-1 is a murine anti CD18 F(ab')₂ (Pasteur-Merieux/Immuntotech); CAT-152 is a human anti-TGF- β ₂ antibody (Cambridge

Ab Tech); and Corsevin M is a chimeric anti-Factor VII antibody (Centocor).

[0256] The variant Fc regions of the invention, preferably in the context of an immunoglobulin, can be further characterized using one or more biochemical assays and/or one or more functional assays, preferably in a high throughput manner. In some alternate embodiments, the variant Fc regions of the inventions are not introduced into an immunoglobulin and are further characterized using one or more biochemical based assays and/or one or more functional assays, preferably in a high throughput manner. The one or more biochemical assays can be any assay known in the art for identifying Fc-Fc γ R interactions, including, but not limited to, an ELISA assay, and surface plasmon resonance-based assay for determining the kinetic parameters of Fc-Fc γ R interaction, e.g., BIAcore assay. The one or more functional assays can be any assay known in the art for characterizing one or more Fc γ R mediated effector cell function as known to one skilled in the art or described herein. In specific embodiments, the immunoglobulins comprising the variant Fc regions are assayed in an ELISA assay for binding to one or more Fc γ Rs, e.g., Fc γ R1IIIA, Fc γ R1IIA, Fc γ R1IIA; followed by one or more ADCC assays. In some embodiments, the immunoglobulins comprising the variant Fc regions are assayed further using a surface plasmon resonance-based assay, e.g., BIAcore. Surface plasmon resonance-based assays are well known in the art, and are further discussed in Section 5.2.7, and exemplified herein in Example 6.8.

[0257] An exemplary high throughput assay for characterizing immunoglobulins comprising variant Fc regions may comprise: introducing a variant Fc region of the invention, e.g., by standard recombinant DNA technology methods, in a 4-4-20 antibody; characterizing the specific binding of the 4-4-20 antibody comprising the variant Fc region to an Fc γ R (e.g., Fc γ R1IIIA, Fc γ R1IIB) in an ELISA assay; characterizing the 4-4-20 antibody comprising the variant Fc region in an ADCC assay (using methods disclosed herein) wherein the target cells are opsonized with the 4-4-20 antibody comprising the variant Fc region; the variant Fc region may then be cloned into a second immunoglobulin, e.g., 4D5, 2H7, and that second immunoglobulin characterized in an ADCC assay, wherein the target cells are opsonized with the second antibody comprising the variant Fc region. The second antibody comprising the variant Fc region is then further analyzed using an ELISA-based assay to confirm the specific binding to an Fc γ R.

[0258] Preferably, a variant Fc region of the invention binds Fc γ R1IIIA and/or Fc γ R1IIA with a higher affinity than a wild type Fc region as determined in an ELISA assay. Most preferably, a variant Fc region of the invention binds Fc γ R1IIIA and/or Fc γ R1IIA with a higher affinity and binds Fc γ R1IIB with a lower affinity than a wild type Fc region as determined in an ELISA assay. In some embodiments, the variant Fc region binds Fc γ R1IIIA and/or Fc γ R1IIA with at least 2-fold higher, at least 4-fold higher, more preferably at least 6-fold higher, most preferably at least 8 to 10-fold higher affinity than a wild type Fc region binds Fc γ R1IIIA and/or Fc γ R1IIA and binds Fc γ R1IIB with at least 2-fold lower, at least 4-fold lower, more preferably at least 6-fold lower, most preferably at least 8 to 10-fold lower affinity than a wild type Fc region binds Fc γ R1IIB as determined in an ELISA assay.

[0259] The immunoglobulin comprising the variant Fc regions may be analyzed at any point using a surface plasmon based resonance based assay, e.g., BIAcore, for defining the kinetic parameters of the Fc-Fc γ R interaction, using methods disclosed herein and known to those of skill in the art. Preferably, the K_d of a variant Fc region of the invention for binding to a monomeric Fc γ R1IIIA and/or Fc γ R1IIA as determined by BIAcore analysis is about 100 nM, preferably about 70 nM, most preferably about 40 nM.; and the K_d of the variant Fc region of the invention for binding a dimeric Fc γ R1IIB is about 80 nM, about 100 nM, more preferably about 200 nM.

[0260] In most preferred embodiments, the immunoglobulin comprising the variant Fc regions is further characterized in an animal model for interaction with an Fc γ R. Preferred animal models for use in the methods of the invention are, for example, transgenic mice expressing human Fc γ Rs, e.g., any mouse model described in U.S. Patent No. 5,877,397, and 6,676,927. Transgenic mice for use in the methods of the invention include, but are not limited to, nude knockout Fc γ R1IIIA mice carrying human Fc γ R1IIIA; nude knockout Fc γ R1IIA mice carrying human Fc γ R1IIA; nude knockout Fc γ R1IIB mice carrying human Fc γ R1IIB and human Fc γ R1IIIA; nude knockout Fc γ R1IIA mice carrying human Fc γ R1IIB and human Fc γ R1IIA; nude knockout Fc γ R1IIIA and Fc γ R1IIA mice carrying human Fc γ R1IIIA and Fc γ R1IIA and nude knockout Fc γ R1IIA, Fc γ R1IIA and Fc γ R1IIB mice carrying human Fc γ R1IIIA, Fc γ R1IIA and Fc γ R1IIB.

5.2.1 DESIGN STRATEGIES

[0261] The present invention encompasses engineering methods to generate Fc variants including but not limited to computational design strategies, library generation methods, and experimental production and screening methods. These strategies may be applied individually or in various combinations to engineer the Fc variants of the instant invention.

[0262] In most preferred embodiments, the engineering methods of the invention comprise methods in which amino acids at the interface between an Fc region and the Fc ligand are not modified. Fc ligands include but are not limited to Fc γ Rs, C1q, FcRn, C3, mannose receptor, protein A, protein G, mannose receptor, and undiscovered molecules that bind Fc. Amino acids at the interface between an Fc region and an Fc ligand is defined as those amino acids that make a direct and/or indirect contact between the Fc region and the ligand, play a structural role in determining the conformation of the interface, or are within at least 3 angstroms, preferably at least 2 angstroms of each other as determined by structural analysis, such as x-ray crystallography and molecular modeling. The amino acids at the interface between an

Fc region and an Fc ligand include those amino acids that make a direct contact with an Fc γ R based on crystallographic and structural analysis of Fc-Fc γ R interactions such as those disclosed by Sondermann et al., (2000, Nature, 406: 267-273). Examples of positions within the Fc region that make a direct contact with Fc γ R are amino acids 234-239 (hinge region), amino acids 265-269 (B/C loop), amino acids 297-299 (C'/E loop), and amino acids 327-332 (F/G) loop.

5 In some embodiments, the molecules of the invention comprising variant Fc regions comprise modification of at least one residue that does not make a direct contact with an Fc γ R based on structural and crystallographic analysis, e.g., is not within the Fc-Fc γ R binding site.

[0263] Preferably, the engineering methods of the invention do not modify any of the amino acids as identified by Shields et al., which are located in the CH2 domain of an Fc region proximal to the hinge region, e.g., Leu234-Pro238; Ala327, Pro329, and affect binding of an Fc region to all human Fc γ Rs.

[0264] In other embodiments, the invention encompasses Fc variants with altered Fc γ R affinities and/or altered effector functions, such that the Fc variant does not have an amino acid modification at a position at the interface between an Fc region and the Fc ligand. Preferably, such Fc variants in combination with one or more other amino acid modifications which are at the interface between an Fc region and the Fc ligand have a further impact on the particular altered property, e.g. altered Fc γ R affinity. Modifying amino acids at the interface between Fc and an Fc ligand may be done using methods known in the art, for example based on structural analysis of Fc-ligand complexes. For example but not by way of limitation by exploring energetically favorable substitutions at Fc positions that impact the binding interface, variants can be engineered that sample new interface conformations, some of which may improve binding to the Fc ligand, some of which may reduce Fc ligand binding, and some of which may have other favorable properties. Such new interface conformations could be the result of, for example, direct interaction with Fc ligand residues that form the interface, or indirect effects caused by the amino acid modifications such as perturbation of side chain or backbone conformations.

[0265] The invention encompasses engineering Fc variants comprising any of the amino acid modifications disclosed herein in combination with other modifications in which the conformation of the Fc carbohydrate at position 297 is altered. The invention encompasses conformational and compositional changes in the N297 carbohydrate that result in a desired property, for example increased or reduced affinity for an Fc γ R. Such modifications may further enhance the phenotype of the original amino acid modification of the Fc variants of the invention. Although not intending to be bound by a particular mechanism of actions such a strategy is supported by the observation that the carbohydrate structure and conformation dramatically affect Fc-Fc γ R and Fc/Cl q binding (Umaha et al., 1999, Nat Biotechnol 17:176-180; Davies et al., 2001, Biotechnol Bioeng 74:288-294; Mimura et al., 2001, J Biol Chem 276:45539; Radaev et al., 2001, J Biol Chem 276:16478-16483; Shields et al., 2002, J Biol Chem 277:26733-26740; Shinkawa et al., 2003, J Biol Chem 278:3466-3473).

[0266] Another design strategy for generating Fc variants in accordance with the invention is provided in which the Fc region is reengineered to eliminate the structural and functional dependence on glycosylation. This design strategy involves the optimization of Fc structure, stability, solubility, and/or Fc function (for example affinity of Fc for one or more Fc ligands) in the absence of the N297 carbohydrate. In one approach, positions that are exposed to solvent in the absence of glycosylation are engineered such that they are stable, structurally consistent with Fc structure, and have no tendency to aggregate. Approaches for optimizing aglycosylated Fc may involve but are not limited to designing amino acid modifications that enhance aglycosylated Fc stability and/or solubility by incorporating polar and/or charged residues that face inward towards the Cg2-Cg2 dimer axis, and by designing amino acid modifications that directly enhance the aglycosylated Fc-Fc γ R interface or the interface of aglycosylated Fc with some other Fc ligand.

[0267] The Fc variants of the present invention may be combined with other Fc modifications, including but not limited to modifications that alter effector function. The invention encompasses combining an Fc variant of the invention with other Fc modifications to provide additive, synergistic, or novel properties in antibodies or Fc fusions. Such modifications may be in the CH1, CH2, or CH3 domains or a combination thereof. Preferably the Fc variants of the invention enhance the property of the modification with which they are combined. For example, if an Fc variant of the invention is combined with a mutant known to bind Fc γ R111A with a higher affinity than a comparable molecule comprising a wild type Fc region; the combination with a mutant of the invention results in a greater fold enhancement in Fc γ R111A affinity.

[0268] In one embodiment, the Fc variants of the present invention may be combined with other known Fc variants such as those disclosed in Duncan et al, 1988, Nature 332:563-564; Lund et al., 1991, J. Immunol 147:2657-2662; Lund et al, 1992, Mol Immunol 29:53-59; Alegre et al, 1994, Transplantation 57:1537-1543; Hutchins et al., 1995, Proc Natl. Acad Sci U S A 92:11980-11984; Jefferis et al, 1995, Immunol Lett. 44:111-117; Lund et al., 1995, FASEB J 9:115-119; Jefferis et al, 1996, Immunol Lett 54:101-104; Lund et al, 1996, J Immunol 157:4963-4969; Armour et al, 1999, Eur J Immunol 29:2613-2624; Idusogie et al, 2000, J Immunol 164:4178-4184; Reddy et al, 2000, J Immunol 164:1925-1933; Xu et al., 2000, Cell Immunol 200:16-26; Idusogie et al, 2001, J Immunol 166:2571-2575; Shields et al., 2001, J Biol Chem 276:6591-6604; Jefferis et al, 2002, Immunol Lett 82:57-65; Presta et al., 2002, Biochem Soc Trans 30:487-490; US 5,624,821; US 5,885,573; US 6,194,551; PCT WO 00/42072; PCT WO 99/58572.

5.2.2 Fc γ R-Fc BINDING ASSAY

[0269] An Fc γ R-Fc binding assay was developed for determining the binding of the molecules of the invention comprising variant Fc regions to Fc γ R, which allowed detection and quantitation of the interaction, despite the inherently weak affinity of the receptor for its ligand, e.g., in the micromolar range for Fc γ RIIB and Fc γ RIIA. The method involves the formation of an Fc γ R complex that has an improved avidity for an Fc region, relative to an uncomplexed Fc γ R. According to the invention, the preferred molecular complex is a tetrameric immune complex, comprising: (a) the soluble region of Fc γ R (e.g., the soluble region of Fc γ RIIA, Fc γ RIIA or Fc γ RIIB); (b) a biotinylated 15 amino acid AVITAG sequence (AVITAG) operably linked to the C-terminus of the soluble region of Fc γ R (e.g., the soluble region of Fc γ RIIA, Fc γ RIIA or Fc γ RIIB); and (c) streptavidin-phycoerythrin (SA-PE); in a molar ratio to form a tetrameric Fc γ R complex (preferably in a 5:1 molar ratio). According to a preferred embodiment of the invention, the fusion protein is biotinylated enzymatically, using for example, the *E. coli* Bir A enzyme, a biotin ligase which specifically biotinylates a lysine residue in the 15 amino acid AVITAG sequence. In a specific embodiment of the invention, 85% of the fusion protein is biotinylated, as determined by standard methods known to those skilled in the art, including but not limited to streptavidin shift assay. According to preferred embodiments of the invention, the biotinylated soluble Fc γ R proteins are mixed with SA-PE in a 1X SA-PE:5X biotinylated soluble Fc γ R molar ratio to form a tetrameric Fc γ R complex.

[0270] In a preferred embodiment of the invention, polypeptides comprising Fc regions bind the tetrameric Fc γ R complexes, formed according to the methods of the invention, with at least an 8-fold higher affinity than the monomeric uncomplexed Fc γ R. The binding of polypeptides comprising Fc regions to the tetrameric Fc γ R complexes may be determined using standard techniques known to those skilled in the art, such as for example, fluorescence activated cell sorting (FACS), radioimmunoassays, ELISA assays, etc.

[0271] The invention encompasses the use of the immune complexes formed according to the methods described above, for determining the functionality of molecules comprising an Fc region in cell-based or cell-free assays.

[0272] As a matter of convenience, the reagents may be provided in an assay kit, i.e., a packaged combination of reagents for assaying the ability of molecules comprising variant Fc regions to bind Fc γ R tetrameric complexes. Other forms of molecular complexes for use in determining Fc-Fc γ R interactions are also contemplated for use in the methods of the invention, e.g., fusion proteins formed as described in U.S. Provisional Application 60/439,709, filed on January 13, 2003 (Attorney Docket No. 11183-005-888).

5.2.3 MUTAGENESIS AND CONSTRUCTION OF YEAST DISPLAY LIBRARIES

[0273] Molecular interactions between the IgG Fc and Fc receptors have been previously studied by both structural and genetic techniques. These studies identified amino acid residues that are critical for functional binding of Fc to different Fc γ R. None of these changes have been shown to improve human Fc γ R mediated efficacy of therapeutic antibodies in animal models. A complete analysis of all potential amino acid changes at these residues or other potentially important residues has not been reported. The platform described herein has the ability to both construct mutant libraries with all possible amino acid changes, screen libraries using multiple functional assays, and finally analyze libraries in relevant humanized animal models.

[0274] The instant invention encompasses construction of multiple libraries based on both genetic and structural data known in the art or being developed. The method described and exemplified herein incorporates building individual libraries that contain mutants testing all 20 amino acid changes at between 3-6 residues in the Fc region. The complete set of mutations will be assembled in all possible combinations of mutations. The number of independent mutations generated is based on the number of sites being saturated during library assembly (Table 9 below). Library size will determine the choice of primary screen and therefore the choice of vector for initial cloning steps.

Table 9: Number of Independent mutants based on number of targeted sites.

Library	# of residues	# independent mutants	Primary screen
Small	3 or less	8000 max.	ELISA
Large	4 - 6	1.6×10^5 - 6.4×10^7	Surface display

[0275] The instant invention encompasses construction of combinatorial libraries, focusing on a limited number of critical residues (e.g., 3-6). Using a library of randomly mutagenized IgG1 Fc and the screening assays described and exemplified herein Fc variants will be identified. In the initial rounds, the best 5 mutations, based on both FcR binding profile and functional activity will be selected. It will take 20^5 individual mutants to cover all possible amino acid changes and their combinations at five locations. A library with at least 10-fold coverage for each mutant will be generated. In addition regions will be chosen based on available information, e.g., crystal structure data, Mouse/Human isotype Fc γ R

binding differences, genetic data, and additional sites identified by mutagenesis.

[0276] The biggest disadvantage of current site directed mutagenic protocols is production of bias populations, over-representing variations in some regions and under-representing or completely lacking mutations in others. The present invention overcomes this problem by generating unbiased arrays of desirable Fc mutants using a well-developed gene building technology to eliminate the bias introduced in library construction by PCR based approaches such as overlapping PCR and inverted PCR. The key distinctions of the approach of the present invention are: 1) Employment of equimolar mix of 20 individual oligos for every targeted codon instead of degenerated primers. This way each amino acid is represented by a single, most used codon, whereas degenerated primers over represent those amino acids encoded by more codons over those encoded by fewer codons. 2) Building mutants by a chain replacement approach. This insures unbiased introduction of all desirable changes into the final product.

[0277] An exemplary protocol comprises of the following steps: 1) phosphorylated oligos, representing desirable changes at one or several locations, all complementary to the same strand, added to the template along with a thermostable, 5'>3' exonuclease deficient, DNA polymerase and ligase (FIG. 27 a). 2) assembled mix undergoes a number of polymerization/ligation cycles, sufficient to generate desirable amount of product. Use of a 5'>3' exonuclease deficient DNA polymerase insures integrity of the primer sequence and its phosphate residue, when a thermostable ligase assembles individual primer-extended fragments into a contiguous single-stranded chain. Reaction cycles can continue until complete exhaustion of the oligos pool without introducing bias into the final product (FIG. 27 b). 3) generated pool of single-stranded mutants is converted into double-stranded DNA by adding a reverse gene-specific primer to the reaction (FIG. 27 1c). 4) double-stranded product gets digested at the end-designed restriction sites and cloned into an appropriate expression vector (FIG. 27 1d)

[0278] To insure quality of the library, PCR amplified fragments will be analyzed by electrophoresis to determine the length of the final PCR products. The reaction will be characterized as successful if >99% of the PCR products are of the expected length. The final library will be cloned into an expression vector. A fraction of the mutant library will be sequenced to determine the rate of mutant codon incorporation. The number of fragments sequenced will be based on the number of target sites mutated and library validation will be determined by the observed rate of mutation at targeted sites (Table 10). The rate of vector without inserts should be less than 2 %. The rate of mutation at non-targeted sites should be less than 8%. Libraries containing clones with >90% correct inserts will allow us to maintain screening timelines.

TABLE 10 Expected rates of Mutation for Libraries

Targeted		Approx. rates of mutation for library validation					
Residues	# of seq. reactions	Single	Double	Triple	Quad.	Pent.	Hex.
3	20	42%	43%	15%	NA	NA	NA
4	50	29%	43%	21%	7%	NA	NA
5	75	18%	35%	32%	11%	4%	NA
6	100	12%	20%	40%	20%	6%	2%

[0279] In other embodiments, the invention encompasses overlapping or inverted PCR for construction of libraries. In order to remain unbiased, individual primers for each codon will be used rather than degenerative primers. A similar validation scheme as disclosed supra will be employed.

[0280] Most preferably automated protocols will be employed for high throughput library production. Automation allows for improved throughput, walk away operation, and an overall reduction in experimental error for tasks requiring tedious repetitive operations. Oligo synthesis capabilities is based on 2 Mermade DNA synthesizers (Bioautomation, Inc.) with a total output capability of 575 60mer Oligos/12 hrs. Proprietary software handles all aspects of design, synthesis, and storage of the final oligonucleotides. Robotic liquid handlers will be employed to set up oligos for synthesis of full length Fc mutants and ligation reactions for incorporating the mutant Fcs into antibody heavy chain expression vectors will be set up. After ligation it is estimated that it would take 1 FTE~10 days to array the library clones and generate ~8000 minipreps, equivalent to a combinatorial library saturated at 3 sites. Subsequent to bacterial transformation a Qpix-2 clone picker robot will be used for picking colonies into 96 deep well plates. Culture growth will be done using a magnetic levitation stirrer, capable of incubating 12 plates and resulting in dense growth in 12 -16 hr at 37° C. A Qiagen miniprep robot will be used to perform DNA preps at the rate of 4 96 well plates in 2.5 hrs. By overlapping tasks 5 such libraries could be constructed in 9 months with 1 FTE

[0281] Affinity maturation requires the assembly of a new set of combinations of mutations, from a preselected mutant pool or members of a gene family, which can be enriched by a selection protocol. The process is repeated several times until the isolation of a mutant with the desired phenotype is achieved. The disadvantage of the current enzymatic approach, DNA shuffling, to accomplish this process is bias which can be introduced due to specific sites within gene that are hot spots for nucleases, dominance of specific mutants in the final reassembled pool and loss of some of the

original mutants in the final pool. In order to overcome this shortcoming a build-a-gene (BAG) technology will be used to generate a highly complex library of Fc mutants containing random amino acid changes at all potential locations that may be important for receptor(s) binding. Sets of degenerated oligos covering specific regions of the IgG Fc will be used (See FIG. 28).

5 **[0282]** Oligos will be ~30 nt and and degenerate oligos synthesized to change one (4 oligos) or two AAs (8 oligos) will be constructed. The oligos are designed to be overlapping with no gaps. It will take ~200 oligos to accommodate all single AA changes and ~2000 to change two AAs per oligonucleotide. All 2000+ oligos will be used individually and in combinations to generate arrays of Fc mutants using the protocol outlined above (A.20). We will use a home-written randomizer program and a robotic liquid handler for pooling selected combinations of mutant and wild type oligos. Large
10 libraries will be cloned into vectors that will allow for screening using yeast surface display. This approach utilizes a magnetic bead selection followed by flow cytometry and has been successfully applied to libraries with a complexity $>10^9$ (Feldhaus et al., 2003, Nat. Biotech. 21(2): 163-170). This limits the number of sites to test at any one pool to 7, resulting in $\sim 1.3 \times 10^9$ possible mutations/pool.

15 **[0283]** To insure quality of the library PCR amplified fragments will be analyzed by electrophoresis to determine the length of the final PCR products. The reaction will be characterized as successful if $>99\%$ of the PCR products are of the expected length. A fraction of the mutant library will be sequenced to determine the rate of mutant codon incorporation. The number of fragments sequenced will be based on the number of target sites mutated and library validation will be determined by the observed rate of mutation at targeted sites (Table 10). The rate of vectors without inserts should be less than 2 %. The rate of mutation at non-targeted sites should be less than 8%.

20 **[0284]** The ability to generate the desired level of efficiency of mutagenesis by this approach will be determined by sequencing of a subset of clones. The alternative to BAG will be using a "DNA shuffle" protocol. This requires pooling all of the mutants, single, double, triple, etc. Following DNA preparation, Fc regions will be amplified by PCR using flanking primers that selectively amplify the mutated region of the Fc, ~700 bp. Novel mutants are constructed by reshuffling of mutations in the Fc via DNaseI treatment of the amplified DNA and isolation of 150-200 bp fragments (see, e.g., Stemmer et al., 1994, Proc. Natl. Acad. Sci. U.S.A. 91: 10747-51). Fragments will be religated, PCR amplified with
25 nested primers and cloned into the yeast surface display vector, pYD1. The recombined library will be reselected in the yeast Fc display screen as described and exemplified herein.

30 **[0285]** BAG libraries will utilize most of the same equipment as the combinatorial library. However cloning will be in a vector suitable for yeast surface display and will not require arraying of individual clones as the yeast surface display will initially be employed for enrichment of large libraries. Subsequent to the appropriate level of enrichment individual clones will be arrayed.

35 **[0286]** An initial library of molecules comprising variant Fc regions is produced using any random based mutagenesis techniques known in the art. It will be appreciated by one of skill in the art that amino acid sequence variants of Fc regions may be obtained by any mutagenesis technique known to those skilled in the art. Some of these techniques are briefly described herein, however, it will be recognized that alternative procedures may produce an equivalent result. In a preferred embodiment molecules of the invention comprising variant Fc regions are prepared by error-prone PCR as exemplified in Example 6, *infra* (See Leung et al., 1989, Technique, 1:11). It is especially preferred to have error rates of 2-3 bp/Kb for use in the methods of the invention. In one embodiment, using error prone PCR a mutation frequency of 2-3 mutations/kb is obtained.

40 **[0287]** Mutagenesis may be performed in accordance with any of the techniques known in the art including, but not limited to, synthesizing an oligonucleotide having one or more modifications within the sequence of the Fc region of an antibody or a polypeptide comprising an Fc region (e.g., the CH2 or CH3 domain) to be modified. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient
45 size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 30 to about 45 nucleotides or more in length is preferred, with about 10 to about 25 or more residues on both sides of the junction of the sequence being altered. A number of such primers introducing a variety of different mutations at one or more positions may be used to generated a library of mutants.

50 **[0288]** The technique of site-specific mutagenesis is well known in the art, as exemplified by various publications (see, e.g., Kunkel et al., Methods Enzymol., 154:367-82, 1987). In general, site-directed mutagenesis is performed by first obtaining a single-stranded vector or melting apart of two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as T7 DNA polymerase, in order to complete the synthesis of the mutation-bearing
55 strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform or transfect appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement. As will be appreciated, the technique typically employs a phage vector which exists in both a single stranded and

double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M 13 phage. These phage are readily commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.

5 [0289] Alternatively, the use of PCR™ with commercially available thermostable enzymes such as *Taq* DNA polymerase may be used to incorporate a mutagenic oligonucleotide primer into an amplified DNA fragment that can then be cloned into an appropriate cloning or expression vector. See, e.g., Tomic et al., *Nucleic Acids Res.*, 18(6):1656, 1987, and Upende et al., *Biotechniques*, 18(1):29-30, 32, 1995, for PCR™-mediated mutagenesis procedures. PCR™ employing a thermostable ligase in addition to a thermostable polymerase may also be used to incorporate a phosphorylated
10 mutagenic oligonucleotide into an amplified DNA fragment that may then be cloned into an appropriate cloning or expression vector (see e.g., Michael, *Biotechniques*, 16(3):410-2, 1994)

[0290] Another method for preparing variants for use in the invention, is cassette mutagenesis based on the technique described by Wells et al. (1985, *Gene*, 34: 315). The starting material is the plasmid comprising the desired DNA encoding the protein to be mutated (e.g., the DNA encoding a polypeptide comprising an Fc region). The codon(s) in the DNA
15 sequence to be mutated are identified; there must be a unique restriction endonuclease site on each side of the identified mutations site(s). If no such restriction site exists, it may be generated by oligonucleotide directed mutagenesis. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites and linearized. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the mutation is synthesized using standard procedures known to those skilled in the art. The double stranded oligonucleotide is referred to as the
20 cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid.

[0291] Other methods known to those of skill in the art for producing sequence variants of the Fc region of an antibody or polypeptides comprising an Fc region can be used. For example, recombinant vectors encoding the amino acid sequence of the constant domain of an antibody or a fragment thereof may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.
25

[0292] Once a mutant library is produced according to the methods described, the mutagenized library is transformed into a yeast strain, preferably EBY100 (Invitrogen), *MATa ura3-52 trp1 leu2Δ1 his3Δ200 pep4::HIS3 prb1Δ1.6R can1 GAL::GAL-AGA1* using a standard lithium acetate transformation protocol known to those skilled in the art (ref).
30

[0293] It will be appreciated by one of skill in the art, that once molecules of the invention with desired binding properties (e.g., molecules with variant Fc regions with at least one amino acid modification, which modification enhances the affinity of the variant Fc region for FcγRIIIA relative to a comparable molecule, comprising a wild-type Fc region) have been identified (See Section 5.1 and Table 2) according to the methods of the invention, other molecules (i.e., therapeutic antibodies) may be engineered using standard recombinant DNA techniques and any known mutagenesis techniques, as described in this section to produce engineered molecules carrying the identified mutation sites.
35

5.2.4 YEAST SURFACE DISPLAY

[0294] The preferred method for screening and identifying molecules comprising variant Fc regions with altered FcγR affinities (i.e., enhanced FcγRIIIA affinity and/or FcγRIIA) is yeast surface display technology (for review see Boder and Wittrup, 2000, *Methods in Enzymology*, 328: 430-444) which addresses the deficiency in the prior art for screening binding interactions of extracellular post-translationally modified proteins. Specifically, the yeast surface display is a genetic method whereby polypeptides comprising Fc mutants are expressed on the yeast cell wall in a form accessible for interacting with FcγR. Yeast surface display of the mutant Fc containing polypeptides of the invention may be performed in accordance with any of the techniques known to those skilled in the art. See U.S. Patent No.'s 6,423,538; 6,114,147; and 6,300,065. See Boder et al., 1997 *Nat. Biotechnol.*, 15:553-7; Boder et al., 1998 *Biotechnol. Prog.*, 14:55-62; Boder et al., 2000 *Methods Enzymol.*, 328:430-44; Boder et al., 2000 *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97:10701-5; Shusta et al., 1998 *Nat. Biotechnol.*, 1998, 16:773-7; Shusta et al., 1999 *J. Mol. Biol.*, 292:949-56; Shusta et al., 1999 *Curr. Opin. Biotechnol.*, 10:117-22; Shusta et al., 2000 *Nat. Biotechnol.*, 18:754-9; Wittrup et al., 1994 *Ann. N.Y. Acad. Sci.*, 745:321-30; Wittrup et al., 1994 *Cytometry*, 16:206-13; Wittrup, 1995 *Curr. Opin. Biotechnol.*, 6:203-8; Wittrup, 1999
40 Trends Biotechnol., 17:423-4; Wittrup, 2000 *Nat. Biotechnol.*, 18:1039-40; Wittrup, 2001 *Curr. Opin. Biotechnol.*, 12:395-9.
45

[0295] Yeast Surface Display will be used to enrich libraries containing >10⁷ independent clones. This approach will provide the ability to enrich large libraries >20-fold in single sort. Fc mutant libraries with >10,000 independent mutants (4 or more sites) will be cloned into the appropriate vectors for yeast surface display and enriched by FACS sorting until
50 < 8000 mutants are able to be tested by other biochemical and functional assays as described below.
55

[0296] The invention provides methods for constructing an Fc mutant library in yeast for displaying molecules comprising Fc regions, which have been mutated as described in Section 5.2.2. Preferably, the Fc mutant libraries for use in the methods of the invention contain at least 10⁷ cells, up to 10⁹ cells. One exemplary method for constructing a Fc

library for use in the methods of the invention comprises the following: nucleic acids encoding molecules comprising Fc regions are cloned into the multiple cloning site of a vector derived from a yeast replicating vector, e.g., pCT302; such that the Fc encoding nucleic acids are expressed under the control of the GAL1 galactose-inducible promoter and in-frame with a nucleotide sequence encoding Aga2p, the mating agglutinin cell wall protein. In a preferred embodiment, nucleic acids encoding molecules comprising Fc regions are cloned C-terminal to the Aga2p coding region, such that a Fc-region Aga2p fusion protein is encoded. A fusion protein comprising the Aga2p protein and polypeptides comprising Fc regions will be secreted extracellularly and displayed on the cell wall via disulfide linkage to the Aga1p protein, an integral cell wall protein, using the preferred construct of the invention. In an alternative embodiment, the constructs may further comprise nucleotide sequences encoding epitope tags. Any epitope tag nucleotide coding sequence known to those skilled in the art can be used in accordance with the invention, including, but not limited to nucleotide sequences encoding hemagglutinin (HA), c-myc Xpress TAG, His - TAG, or V5TAG. The presence of the fusion protein on the yeast cell surface may be detected using FACS analysis, confocal fluorescence microscopy or standard immunostaining methods, all of which are known to those skilled in the art. In one embodiment, the presence of the Fc fusion proteins of the invention on the yeast cell surface are detected using Fc-specific monoclonal antibodies (CH3 specific), including but not limited to IgG1 Fc-specific monoclonal antibody, HP6017 (Sigma), JL512 (Immunotech), and any antibody disclosed in Partridge et al., 1986, *Molecular Immunology*, 23 (12): 1365-72. In another embodiment, the presence of the Fc fusion proteins of the invention are detected by immunofluorescent labeling of epitope tags using techniques known to those skilled in the art. It is particularly useful in the methods of the invention, to use nucleotide sequences encoding epitope tags to flank the nucleic acids encoding the Fc fusion proteins, as an internal control, to detect if the fusion proteins are displayed on the cell wall in a partially proteolyzed form.

5.2.5 SCREENING OF YEAST DISPLAY LIBRARIES

[0297] The invention encompasses screening the yeast display libraries using immunological based assays including but not limited to cell based assays, solution based assays, and solid phase based assays.

[0298] In some embodiments, the invention encompasses identification of Fc mutants with altered Fc γ R affinities using affinity maturation methods which are known to those skilled in the art and encompassed herein. Briefly, affinity maturation creates novel alleles by randomly recombining individual mutations present in a mutant library, see, e.g., Hawkins et al., 1992, *J. Mol. Biol.* 226: 889-896; Stemmer et al., 1994 *Nature*, 370: 389-91; both of which are incorporated herein by reference in their entireties. It has been used successfully to increase the affinity of antibodies, T cell receptors and other proteins. The invention encompasses using mutations that show increased Fc γ R binding as a baseline to construct new mutant libraries with enhanced phenotypes. Using the methods of the invention, a population of IgG1 Fc mutants enriched by yeast surface display for increased binding to an Fc γ R, e.g., Fc γ R11IA, may be selected. Following DNA preparation, Fc regions can be amplified by PCR using flanking primers that selectively amplify the mutated region of the Fc, which is about ~700 bp using methods known to one skilled in the art and exemplified or disclosed herein. Novel mutants can thus be constructed by reshuffling of mutations in the Fc region for example via DNaseI treatment of the amplified DNA and isolation of fragments using methods such as those disclosed by Stemmer et al., 1994 *Proc. Natl. Acad. Sci. USA* 91: 10747-51. Fragments can then be religated, PCR amplified with nested primers and cloned into the yeast display vector, e.g., pYD1 using methods known to one skilled in the art. The recombined library can then be reselected in the yeast Fc display screen. As the K_D decreases, below 10 nM, conditions can be established to allow for further increases in affinity based on the reduction of the off rate of the Fc γ R11IA ligand from the Fc receptor using methods known in the art such as those disclosed in Boder et al., 1998, *Biotechnol. Prog.* 14: 55-62. The invention encompasses a kinetic screen of the yeast library. A kinetic screen may be established by labeling of the Fc displaying cells to saturation with a labeled ligand, e.g., a fluorescent ligand followed by incubation with an excess of non-labeled ligand for a predetermined period. After termination of the reaction by the addition of excess buffer (e.g., 1X PBS, 0.5 mg/ml BSA) cells will be analyzed by FACS and sort gates set for selection. After each round of enrichment individual mutants can be tested for fold increases in affinity and sequenced for diversity. The *in vitro* recombination process can be repeated. In some embodiments, the *in vitro* is repeated at least 3 times.

[0299] Selection of the Fc variants of the invention may be done using any Fc γ R including but not limited to polymorphic variants of Fc γ R. In some embodiments, selection of the Fc variants is done using a polymorphic variant of Fc γ R11IA which contains a phenylalanine at position 158. In other embodiments, selection of the Fc variants is done using a polymorphic variant of Fc γ R11IA which contains a valine at position 158. Fc γ R11IA 158V displays a higher affinity for IgG1 than 158F and an increased ADCC activity (see, e.g., Koene et al., 1997, *Blood*, 90:1109-14; Wu et al., 1997, *J. Clin. Invest.* 100: 1059-70, both of which are incorporated herein by reference in their entireties); this residue in fact directly interacts with the lower hinge region of IgG1 as recently shown by IgG1-Fc γ R11IA co-crystallization studies, see, e.g., Sonderman et al., 2000, *Nature*, 100: 1059-70. Studies have shown that in some cases therapeutic antibodies have improved efficacy in Fc γ R11IA-158V homozygous patients. For example, humanized anti-CD20 monoclonal antibody Rituximab was therapeutically more effective in Fc γ R11IA158V homozygous patients compared to Fc γ R11IA 158F ho-

mozygous patients (See, e.g., Cartron et al., 2002 Blood, 99(3): 754-8). Although not intending to be bound by a particular mechanism of action, selection of Fc variants of the invention with Fc γ R111A 158F allotype may provide for variants that once engineered into therapeutic antibodies will be clinically more efficacious for Fc γ R111A 158F homozygous patients.

[0300] The invention encompasses screening yeast libraries based on Fc γ R111B depletion and Fc γ R111A selection so that Fc mutants are selected that not only have an enhanced affinity for Fc γ R111A but also have a reduced affinity for Fc γ R111B. Yeast libraries may be enriched for clones that have a reduced affinity for Fc γ R111B by sequential depletion methods, for example, by incubating the yeast library with magnetic beads coated with Fc γ R111B. Fc γ R111B depletion is preferably carried out sequentially so that the library is enriched in clones that have a reduced affinity for Fc γ R111B. In some embodiments, the Fc γ R111B depletion step results in a population of cells so that only 30% , preferably only 10%, more preferably only 5%, most preferably less than 1% bind Fc γ R111B. In some embodiments, Fc γ R111B depletion is carried out in at least 3 cycles, at least 4 cycles, at least 6 cycles. The Fc γ R111B depletion step is preferably combined with an Fc γ R111A selection step, for example using FACS sorting so that Fc variants with an enhanced affinity for Fc γ R111A are selected.

5.2.5.1 FACS ASSAYS; SOLID PHASED ASSAYS AND IMMUNOLOGICAL BASED ASSAYS

[0301] The invention encompasses characterization of the mutant Fc fusion proteins that are displayed on the yeast surface cell wall, according to the methods described in Section 5.2.3. One aspect of the invention provides a method for selecting mutant Fc fusion proteins with a desirable binding property, specifically, the ability of the mutant Fc fusion protein to bind Fc γ R111A and/or Fc γ R111A with a greater affinity than a comparable polypeptide comprising a wild-type Fc region binds Fc γ R111A and/or Fc γ R111A. In another embodiment, the invention provides a method for selecting mutant Fc fusion proteins with a desirable binding property, specifically, the ability of the mutant Fc fusion protein to bind Fc γ R111A and/or Fc γ R111A with a greater affinity than a comparable polypeptide comprising a wild-type Fc region binds Fc γ R111A and/or Fc γ R111A, and further the ability of the mutant Fc fusion protein to bind Fc γ R111B with a lower affinity than a comparable polypeptide comprising a wild-type Fc region binds Fc γ R111B. It will be appreciated by one skilled in the art, that the methods of the invention can be used for identifying and screening any mutations in the Fc regions of molecules, with any desired binding characteristic.

[0302] Yeast cells displaying the mutant Fc fusion proteins can be screened and characterized by any biochemical or immunological based assays known to those skilled in the art for assessing binding interactions.

[0303] Preferably, fluorescence activated cell sorting (FACS), using any of the techniques known to those skilled in the art, is used for screening the mutant Fc fusion proteins displayed on the yeast cell surface for binding Fc γ R111A, preferably the Fc γ R111A tetrameric complex, or optionally Fc γ R111B. Flow sorters are capable of rapidly examining a large number of individual cells that contain library inserts (e.g., 10-100 million cells per hour) (Shapiro et al., Practical Flow Cytometry, 1995). Additionally, specific parameters used for optimization including, but not limited to, ligand concentration (i.e., Fc γ R111A tetrameric complex), kinetic competition time, or FACS stringency may be varied in order to select for the cells which display Fc fusion proteins with specific binding properties, e.g., higher affinity for Fc γ R111A compared to a comparable polypeptide comprising a wild-type Fc region. Flow cytometers for sorting and examining biological cells are well known in the art. Known flow cytometers are described, for example, in U.S. Patent Nos. 4,347,935; 5,464,581; 5,483,469; 5,602,039; 5,643,796; and 6,211,477. Other known flow cytometers are the FACS Vantage™ system manufactured by Becton Dickinson and Company, and the COPAS™ system manufactured by Union Biometrica.

[0304] According to a preferred embodiment of the invention, yeast cells are analyzed by fluorescence activated cell sorting (FACS). In most preferred embodiments, the FACS analysis of the yeast cells is done in an iterative manner, at least twice, at least three times, or at least 5 times. Between each round of selection cells are regrown and induced so the Fc regions are displayed on the maximum number of yeast cell surfaces. Although not intending to be bound by a particular mode of action, this iterative process helps enrich the population of the cells with a particular phenotype, e.g., high binding to Fc γ R111A.

[0305] In preferred embodiments, screening for Fc variants of the invention comprises a selection process that has multiple rounds of screening, e.g., at least two rounds of screening. In one embodiment, screening for Fc variants that have an enhanced affinity for Fc γ R111A may comprise the following steps: in the first round of screening, a library of yeast cells, e.g., a naive library of 10⁷ cells is enriched by FACS, preferably in an iterative manner, using for example labeled tetrameric Fc γ R111A to select for Fc variants that have an enhanced affinity for Fc γ R111A; the variant Fc region that is selected with the desired phenotype, e.g., enhanced binding to Fc γ R111A, is then introduced into an antibody, e.g., a 4-4-20 antibody, and the engineered antibody is assayed using a secondary screen, e.g., ELISA for binding to an Fc γ R. In the second round of screening, a single mutation library may be generated based on the first screen so that the Fc region harbors the variant displaying the enhanced affinity for Fc γ R111A; and enriched by FACS using for example labeled monomeric Fc γ R111A in both the presence and absence of unlabeled receptor; and the variant Fc region is then introduced into an antibody, e.g., a 4-4-20 antibody, and the engineered antibody is assayed using a secondary screen, e.g., ELISA for binding to an Fc γ R. In some embodiments, the secondary screen may further comprise characterizing the antibodies

comprising Fc variants in an ADCC or BIAcore based assay using methods disclosed herein

[0306] The invention encompasses FACS screening of the mutant yeast library under equilibrium or kinetic conditions. When the screening is performed under equilibrium conditions, an excess of the yeast library carrying Fc mutants is incubated with Fc γ R1IIIA, preferably labeled Fc γ R1IIIA at a concentration 5-10 fold below the K_d, for at least one hour to allow binding of Fc mutants to Fc γ R1IIIA under equilibrium conditions. When the screening is performed under kinetic conditions, the mutant yeast library is incubated with labeled Fc γ R1IIIA; the cells are then incubated with equimolar unlabeled Fc γ R1IIIA for a pre-selected time, bound Fc γ R1IIIA is then monitored.

[0307] One exemplary method of analyzing the yeast cells expressing mutant Fc fusion proteins with FACS is costaining the cells with Fc γ R1IIIA-tetrameric complex which has been labeled with a fluorescent label such as, PE and an anti-Fc antibody, such as F(ab)₂ anti-Fc which has been fluorescently labeled. Fluorescence measurements of a yeast library produced according to the methods of the invention preferably involves comparisons with controls; for example, yeast cells that lack the insert encoding molecules comprising an Fc region (negative control). The flow sorter has the ability not only to measure fluorescence signals in cells at a rapid rate, but also to collect cells that have specified fluorescent properties. This feature may be employed in a preferred embodiment of the invention to enrich the initial library population for cells expressing Fc fusion proteins with specific binding characteristics, e.g., higher affinity for Fc γ R1IIIA compared to a comparable polypeptide comprising a wild-type Fc region. In a preferred embodiment of the invention, yeast cells are analyzed by FACS and sort gates established to select for cells that show the highest affinity for Fc γ R1IIIA relative to the amount of Fc expression on the yeast cell surface. According to a preferred embodiment, four consecutive sorts are established, wherein the gates for each successive sort is 5.5%, 1%, 0.2%, and 0.1%. It is preferred that the yeast display library formed according to the methods of the invention be over-sampled by at least 10-fold to improve the probability of isolating rare clones (e.g., analyze ~10⁸ cells from a library of 10⁷ clones). Alternatively, 2-5 sorts are established to select for cells of the desired phenotype. Sort gates can be established empirically by one skilled in the art.

[0308] In other preferred embodiments, mutant Fc fusion proteins displayed on the yeast cell surface are screened using solid phase based assays, for example assays using magnetic beads, e.g., supplied by Dynal, preferably in a high throughput manner for binding to an Fc γ R, e.g., Fc γ R1IIIA. In one embodiment, magnetic bead assays may be used to identify mutants with enhanced affinity for Fc γ R1IIIA and/or reduced affinity for Fc γ R1IIB. An exemplary assay to identify mutants with enhanced affinity for Fc γ R1IIIA and reduced affinity for Fc γ R1IIB may comprise selecting mutants by a sequential solid phase depletion using magnetic beads coated with Fc γ R1IIB followed by selection with magnetic beads coated with Fc γ R1IIIA. For example one assay may comprise the following steps: incubating the library of yeast cells generated in accordance with the methods of the invention with magnetic beads coated with Fc γ R1IIB; separating yeast cells bound to beads from the non bound fraction by placing the mixture in a magnetic field, removing the non-bound yeast cells and placing them in a fresh media; binding the yeast cells to beads coated with Fc γ R1IIIA, separating yeast cells bound to beads from the non bound fraction by placing the mixture in a magnetic field, removing the non-bound yeast cells; removing the bound cells by rigorous vortexing; growing the recovered cells in glucose containing media; re-inducing in selective media containing galactose. The selection process is repeated at least once. Inserts containing the Fc domain are then amplified using common methodologies known in the art, e.g., PCR, and introduced into an antibody by methods already described for further characterization.

[0309] In an alternative embodiment, a non-yeast based system is used to characterize the binding properties of the molecules of the invention. One exemplary system for characterizing the molecules of the invention comprises a mammalian expression vector containing the heavy chain of the anti-fluorescein monoclonal antibody 4-4-20, into which the nucleic acids encoding the molecules of the invention with variant Fc regions are cloned. The resulting recombinant clone is expressed in a mammalian host cell line (i.e., human kidney cell line 293H), and the resulting recombinant immunoglobulin is analyzed for binding to Fc γ R using any standard assay known to those in the art, including but not limited to ELISA and FACS.

[0310] Molecules of the present invention (e.g., antibodies, fusion proteins, conjugated molecules) may be characterized in a variety of ways. In particular, molecules of the invention comprising modified Fc regions may be assayed for the ability to immunospecifically bind to a ligand, e.g., Fc γ R1IIIA tetrameric complex. Such an assay may be performed in solution (e.g., Houghten, Bio/Techniques, 13:412-421, 1992), on beads (Lam, Nature, 354:82-84, 1991, on chips (Fodor, Nature, 364:555-556, 1993), on bacteria (U.S. Patent No. 5,223,409), on spores (U.S. Patent Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (Cull et al., Proc. Natl. Acad. Sci. USA, 89:1865-1869, 1992) or on phage (Scott and Smith, Science, 249:386-390, 1990; Devlin, Science, 249:404-406, 1990; Cwirla et al., Proc. Natl. Acad. Sci. USA, 87:6378-6382, 1990; and Felici, J. Mol. Biol., 222:301-310, 1991). Molecules that have been identified to immunospecifically bind to a ligand, e.g., Fc γ R1IIIA can then be assayed for their specificity and affinity for the ligand.

[0311] Molecules of the invention that have been engineered to comprise modified Fc regions (e.g., therapeutic antibodies) or have been identified in the yeast display system to have the desired phenotype (see Section 5.1) may be assayed for immunospecific binding to an antigen (e.g., cancer antigen and cross-reactivity with other antigens (e.g., Fc γ R) by any method known in the art. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as

western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York).

[0312] The binding affinity of the molecules of the present invention comprising modified Fc regions to a ligand, e.g., Fc γ R tetrameric complex and the off-rate of the interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled ligand, such as tetrameric Fc γ R (e.g., ^3H or ^{125}I) with a molecule of interest (e.g., molecules of the present invention comprising modified Fc regions) in the presence of increasing amounts of unlabeled ligand, such as tetrameric Fc γ R, and the detection of the molecule bound to the labeled ligand. The affinity of the molecule of the present invention for the ligand and the binding off-rates can be determined from the saturation data by scatchard analysis.

[0313] In a preferred embodiment, BIAcore kinetic analysis is used to determine the binding on and off rates of molecules of the present invention to a ligand such as Fc γ R. BIAcore kinetic analysis comprises analyzing the binding and dissociation of a ligand from chips with immobilized molecules (e.g., molecules comprising modified Fc regions) on their surface.

5.2.6 SEQUENCING OF MUTANTS

[0314] Any of a variety of sequencing reactions known in the art can be used to directly sequence the molecules of the invention comprising variant Fc regions. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert (Proc. Natl. Acad. Sci. USA, 74:560, 1977) or Sanger (Proc. Natl. Acad. Sci. USA, 74:5463, 1977). It is also contemplated that any of a variety of automated sequencing procedures can be utilized (Bio/Techniques, 19:448, 1995), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101, Cohen et al., Adv. Chromatogr., 36:127-162, 1996, and Griffin et al., Appl. Biochem. Biotechnol., 38:147-159, 1993).

5.2.7 FUNCTIONAL ASSAYS OF MOLECULES WITH VARIANT Fc REGIONS

[0315] The invention encompasses characterization of the molecules of the invention (e.g., an antibody comprising a variant Fc region identified by the yeast display technology described *supra*; or therapeutic monoclonal antibodies engineered according to the methods of the invention) using assays known to those skilled in the art for identifying the effector cell function of the molecules. In particular, the invention encompasses characterizing the molecules of the invention for Fc γ R-mediated effector cell function. Examples of effector cell functions that can be assayed in accordance with the invention, include but are not limited to, antibody-dependent cell mediated cytotoxicity, phagocytosis, opsonization, opsonophagocytosis, C1q binding, and complement dependent cell mediated cytotoxicity. Any cell-based or cell free assay known to those skilled in the art for determining effector cell function activity can be used (For effector cell assays, see Perussia et al., 2000, Methods Mol. Biol. 121: 179-92; Baggiolini et al., 1998 Experientia, 44(10): 841-8; Lehmann et al., 2000 J. Immunol. Methods, 243(1-2): 229-42; Brown EJ. 1994, Methods Cell Biol., 45: 147-64; Munn et al., 1990 J. Exp. Med., 172: 231-237, Abdul-Majid et al., 2002 Scand. J. Immunol. 55: 70-81; Ding et al., 1998, Immunity 8:403-411).

[0316] In one embodiment, the molecules of the invention can be assayed for Fc γ R-mediated phagocytosis in human monocytes. Alternatively, the Fc γ R-mediated phagocytosis of the molecules of the invention may be assayed in other phagocytes, e.g., neutrophils (polymorphonuclear leukocytes; PMN); human peripheral blood monocytes, monocyte-derived macrophages, which can be obtained using standard procedures known to those skilled in the art (e.g., see Brown EJ. 1994, Methods Cell Biol., 45: 147-164). In one embodiment, the function of the molecules of the invention is characterized by measuring the ability of THP-1 cells to phagocytose fluoresceinated IgG-opsonized sheep red blood cells (SRBC) by methods previously described (Tridandapani et al., 2000, J. Biol. Chem. 275: 20480-7). For example, an exemplary assay for measuring phagocytosis of the molecules of the invention comprising variant Fc regions with enhanced affinities for Fc γ R1IIIA, comprises of: treating THP-1 cells with a molecule of the invention or with a control antibody that does not bind to Fc γ R1IIIA, comparing the activity levels of said cells, wherein a difference in the activities of the cells (e.g., rosetting activity (the number of THP-1 cells binding IgG-coated SRBC), adherence activity (the total number of SRBC bound to THP-1 cells), and phagocytic rate) would indicate the functionality of the molecule of the invention. It can be appreciated by one skilled in the art that this exemplary assay can be used to assay any of the molecules identified by the methods of the invention.

[0317] Another exemplary assay for determining the phagocytosis of the molecules of the invention is an antibody-dependent opsonophagocytosis assay (ADCP) which can comprise the following: coating a target bioparticle such as *Escherichia coli*-labeled FITC (Molecular Probes) or *Staphylococcus aureus*-FITC with (i) wild-type 4-4-20 antibody, an

antibody to fluorescein (See Bedzyk et al., 1989, J. Biol. Chem, 264(3): 1565-1569), as the control antibody for Fc γ R-dependent ADCP; or (ii) 4-4-20 antibody harboring the D265A mutation that knocks out binding to Fc γ R111, as a background control for Fc γ R-dependent ADCP (iii) 4-4-20 antibody carrying variant Fc regions identified by the methods of the invention and produced as exemplified in Example 6.6; and forming the opsonized particle; adding any of the opsonized particles described (i-iii) to THP-1 effector cells (a monocytic cell line available from ATCC) in a 60:1 ratio to allow Fc γ R-mediated phagocytosis to occur; preferably incubating the cells and *E. coli*-FITC/antibody at 37°C for 1.5 hour; adding trypan blue after incubation (preferably at room temperature for 2-3 min.) to the cells to quench the fluorescence of the bacteria that are adhered to the outside of the cell surface without being internalized; transferring cells into a FACS buffer (e.g., 0.1%, BSA in PBS, 0.1%, sodium azide), analyzing the fluorescence of the THP1 cells using FACS (e.g., BD FACS Calibur). Preferably, the THP-1 cells used in the assay are analyzed by FACS for expression of Fc γ R on the cell surface. THP-1 cells express both CD32A and CD64. CD64 is a high affinity Fc γ R that is blocked in conducting the ADCP assay in accordance with the methods of the invention. The THP-1 cells are preferably blocked with 100 μ g/mL soluble IgG1 or 10% human serum. To analyze the extent of ADCP, the gate is preferably set on THP-1 cells and median fluorescence intensity is measured. The ADCP activity for individual mutants is calculated and reported as a normalized value to the wild type chMab 4-4-20 obtained. The opsonized particles are added to THP-1 cells such that the ratio of the opsonized particles to THP-1 cells is 30:1 or 60:1. In most preferred embodiments, the ADCP assay is conducted with controls, such as *E. coli*-FITC in medium, *E. coli*-FITC and THP-1 cells (to serve as Fc γ R-independent ADCP activity), *E. coli*-FITC, THP-1 cells and wild-type 4-4-20 antibody (to serve as Fc γ R-dependent ADCP activity), *E. coli*-FITC, THP-1 cells, 4-4-20 D265A (to serve as the background control for Fc γ R-dependent ADCP activity).

[0318] In another embodiment, the molecules of the invention can be assayed for Fc γ R-mediated ADCC activity in effector cells, e.g., natural killer cells, using any of the standard methods known to those skilled in the art (See e.g., Perussia et al., 2000, Methods Mol. Biol. 121: 179-92). An exemplary assay for determining ADCC activity of the molecules of the invention is based on a ⁵¹Cr release assay comprising of: labeling target cells with [⁵¹Cr]Na₂CrO₄ (this cell-membrane permeable molecule is commonly used for labeling since it binds cytoplasmic proteins and although spontaneously released from the cells with slow kinetics, it is released massively following target cell necrosis); opsonizing the target cells with the molecules of the invention comprising variant Fc regions; combining the opsonized radiolabeled target cells with effector cells in a microtitre plate at an appropriate ratio of target cells to effector cells; incubating the mixture of cells for 16-18 hours at 37°C; collecting supernatants; and analyzing radioactivity. The cytotoxicity of the molecules of the invention can then be determined, for example using the following formula: % lysis = (experimental cpm - target leak cpm)/(detergent lysis cpm - target leak cpm) x 100%. Alternatively, % lysis = (ADCC-AICC)/(maximum release-spontaneous release). Specific lysis can be calculated using the formula: specific lysis = % lysis with the molecules of the invention - % lysis in the absence of the molecules of the invention. A graph can be generated by varying either the target: effector cell ratio or antibody concentration.

[0319] In yet another embodiment, the molecules of the invention are characterized for antibody dependent cellular cytotoxicity (ADCC) see, e.g., Ding et al., Immunity, 1998, 8:403-11.

[0320] Preferably, the effector cells used in the ADCC assays of the invention are peripheral blood mononuclear cells (PBMC) that are preferably purified from normal human blood, using standard methods known to one skilled in the art, e.g., using Ficoll-Paque density gradient centrifugation. Preferred effector cells for use in the methods of the invention express different Fc γ R activating receptors. The invention encompasses, effector cells, THP-1, expressing Fc γ R1, Fc γ R1IA and Fc γ R1IB, and monocyte derived primary macrophages derived from whole human blood expressing both Fc γ R1IA and Fc γ R1IB, to determine if Fc antibody mutants show increased ADCC activity and phagocytosis relative to wild type IgG1 antibodies.

[0321] The human monocyte cell line, THP-1, activates phagocytosis through expression of the high affinity receptor Fc γ R1 and the low affinity receptor Fc γ R1IA (Fleit et al., 1991, J. Leuk. Biol. 49: 556). THP-1 cells do not constitutively express Fc γ R1IA or Fc γ R1IB. Stimulation of these cells with cytokines effects the FcR expression pattern (Pricop et al., 2000 J. Immunol. 166: 531-7). Growth of THP-1 cells in the presence of the cytokine IL4 induces Fc γ R1IB expression and causes a reduction in Fc γ R1IA and Fc γ R1 expression. Fc γ R1IB expression can also be enhanced by increased cell density (Tridandapani et al., 2002, J. Biol Chem. 277: 5082-9). In contrast, it has been reported that IFN γ can lead to expression of Fc γ R1IA (Pearse et al., 1993 PNAS USA 90: 4314-8). The presence or absence of receptors on the cell surface can be determined by FACS using common methods known to one skilled in the art. Cytokine induced expression of Fc γ R on the cell surface provides a system to test both activation and inhibition in the presence of Fc γ R1IB. If THP-1 cells are unable to express the Fc γ R1IB the invention also encompasses another human monocyte cell line, U937. These cells have been shown to terminally differentiate into macrophages in the presence of IFN γ and TNF (Koren et al., 1979, Nature 279: 328-331).

[0322] Fc γ R dependent tumor cell killing is mediated by macrophage and NK cells in mouse tumor models (Clynes et al., 1998, PNAS USA 95: 652-656). The invention encompasses the use of elutriated monocytes from donors as effector cells to analyze the efficiency Fc mutants to trigger cell cytotoxicity of target cells in both phagocytosis and ADCC assays. Expression patterns of Fc γ R1, Fc γ R1IA, and Fc γ R1IB are affected by different growth conditions. Fc γ R expression from

frozen elutriated monocytes, fresh elutriated monocytes, monocytes maintained in 10% FBS, and monocytes cultured in FBS + GM-CSF and or in human serum may be determined using common methods known to those skilled in the art. For example, cells can be stained with Fc γ R specific antibodies and analyzed by FACS to determine FcR profiles. Conditions that best mimic macrophage *in vivo* Fc γ R expression is then used for the methods of the invention.

5 **[0323]** In some embodiments, the invention encompasses the use of mouse cells especially when human cells with the right Fc γ R profiles are unable to be obtained. In some embodiments, the invention encompasses the mouse macrophage cell line RAW264.7(ATCC) which can be transfected with human Fc γ R11A and stable transfectants isolated using methods known in the art, *see, e.g.*, Ralph et al., J. Immunol. 119: 950-4). Transfectants can be quantitated for Fc γ R11A expression by FACS analysis using routine experimentation and high expressors can be used in the ADCC assays of the invention. In other embodiments, the invention encompasses isolation of spleen peritoneal macrophage expressing human Fc γ R from knockout transgenic mice such as those disclosed herein.

10 **[0324]** Lymphocytes may be harvested from peripheral blood of donors (PBM) using a Ficoll-Paque gradient (Pharmacia). Within the isolated mononuclear population of cells the majority of the ADCC activity occurs via the natural killer cells (NK) containing Fc γ R11A but not Fc γ R11B on their surface. Results with these cells indicate the efficacy of the mutants on triggering NK cell ADCC and establish the reagents to test with elutriated monocytes.

15 **[0325]** Target cells used in the ADCC assays of the invention include, but are not limited to, breast cancer cell lines, *e.g.*, SK-BR-3 with ATCC accession number HTB-30 (*see, e.g.*, Tremp et al., 1976, Cancer Res. 33-41); B-lymphocytes; cells derived from Burkitts lymphoma, *e.g.*, Raji cells with ATCC accession number CCL-86 (*see, e.g.*, Epstein et al., 1965, J. Natl. Cancer Inst. 34: 231-240), and Daudi cells with ATCC accession number CCL-213 (*see, e.g.*, Klein et al., 1968, Cancer Res. 28: 1300-10). The target cells must be recognized by the antigen binding site of the immunoglobulin to be assayed.

20 **[0326]** The ADCC assay is based on the ability of NK cells to mediate cell death via an apoptotic pathway. NK cells mediate cell death in part by Fc γ R11A's recognition of IgG bound to an antigen on a cell surface. The ADCC assays used in accordance with the methods of the invention may be radioactive based assays or fluorescence based assays. The ADCC assay used to characterize the molecules of the invention comprising variant Fc regions comprises labeling target cells, *e.g.*, SK-BR-3, MCF-7, OVCAR3, Raji, Daudi cells, opsonizing target cells with an antibody that recognizes a cell surface receptor on the target cell via its antigen binding site; combining the labeled opsonized target cells and the effector cells at an appropriate ratio, which can be determined by routine experimentation; harvesting the cells; detecting the label in the supernatant of the lysed target cells, using an appropriate detection scheme based on the label used. The target cells may be labeled either with a radioactive label or a fluorescent label, using standard methods known in the art. For example the labels include, but are not limited to, [⁵¹Cr]Na₂CrO₄; and the acetoxymethyl ester of the fluorescence enhancing ligand, 2,2':6',2"-terpyridine-6-6"-dicarboxylate (TDA).

25 **[0327]** In a specific preferred embodiment, a time resolved fluorimetric assay is used for measuring ADCC activity against target cells that have been labeled with the acetoxymethyl ester of the fluorescence enhancing ligand, 2,2':6',2"-terpyridine-6-6"-dicarboxylate (TDA). Such fluorimetric assays are known in the art, *e.g.*, *see*, Blomberg et al., 1996, Journal of Immunological Methods, 193: 199-206. Briefly, target cells are labeled with the membrane permeable acetoxymethyl diester of TDA (bis(acetoxymethyl) 2,2':6',2"-terpyridine-6-6"-dicarboxylate, (BATDA), which rapidly diffuses across the cell membrane of viable cells. Intracellular esterases split off the ester groups and the regenerated membrane impermeable TDA molecule is trapped inside the cell. After incubation of effector and target cells, *e.g.*, for at least two hours, up to 3.5 hours, at 37°C, under 5% CO₂, the TDA released from the lysed target cells is chelated with Eu³⁺ and the fluorescence of the Europium-TDA chelates formed is quantitated in a time-resolved fluorometer (*e.g.*, Victor 1420, Perkin Elmer/Wallac).

30 **[0328]** In another specific embodiment, the ADCC assay used to characterize the molecules of the invention comprising variant Fc regions comprises the following steps: Preferably 4-5x10⁶ target cells (*e.g.*, SK-BR-3, MCF-7, OVCAR3, Raji cells) are labeled with bis(acetoxymethyl) 2,2':6',2"-terpyridine-t-6"-dicarboxylate (DELFLIA BATDA Reagent, Perkin Elmer/Wallac). For optimal labeling efficiency, the number of target cells used in the ADCC assay should preferably not exceed 5x10⁶. BATDA reagent is added to the cells and the mixture is incubated at 37°C preferably under 5% CO₂, for at least 30 minutes. The cells are then washed with a physiological buffer, *e.g.*, PBS with 0.125 mM sulfapyrazole, and media containing 0.125 mM sulfapyrazole. The labeled target cells are then opsonized (coated) with a molecule of the invention comprising a variant Fc region, *i.e.*, an immunoglobulin comprising a variant Fc region of the invention, including, but not limited to, a polyclonal antibody, a monoclonal antibody, a bispecific antibody, a multi-specific antibody, a humanized antibody, or a chimeric antibody. In preferred embodiments, the immunoglobulin comprising a variant Fc region used in the ADCC assay is specific for a cell surface receptor, a tumor antigen, or a cancer antigen. The immunoglobulin into which a variant Fc region of the invention is introduced may specifically bind any cancer or tumor antigen, such as those listed in section 5.4. Additionally, the immunoglobulin into which a variant Fc region of the invention is introduced may be any therapeutic antibody specific for a cancer antigen, such as those listed in section 5.4. In some embodiments, the immunoglobulin comprising a variant Fc region used in the ADCC assay is an anti-fluorescein monoclonal antibody, 4-4-20 (Kranz et al., 1982 J. Biol. Chem. 257(12): 6987-6995) a mouse-human chimeric anti-CD20 monoclonal antibody

2H7 (Liu et al., 1987, Journal of Immunology, 139: 3521-6); or a humanized antibody (Ab4D5) against the human epidermal growth factor receptor 2 (p185 HER2) (Carter et al. (1992, Proc. Natl. Acad. Sci. USA 89: 4285-9). The target cells in the ADCC assay are chosen according to the immunoglobulin into which a variant Fc region of the invention has been introduced so that the immunoglobulin binds a cell surface receptor of the target cell specifically. Preferably, the ADCC assays of the invention are performed using more than one engineered antibody, e.g., anti Her2/neu, 4-4-20, 2B6, Rituxan, and 2H7, harboring the Fc variants of the invention. In a most preferred embodiment, the Fc variants of the invention are introduced into at least 3 antibodies and their ADCC activities are tested. Although not intending to be bound by a particular mechanism of action, examining at least 3 antibodies in these functional assays will diminish the chance of eliminating a viable Fc mutation erroneously.

[0329] Oponized target cells are added to effector cells, e.g., PBMC, to produce effector:target ratios of approximately 50:1, 75:1, or 100:1. In a specific embodiment, when the immunoglobulin comprising a variant Fc region has the variable domain of 4-4-20, the effector:target is 75:1. The effector and target cells are incubated for at least two hours, up to 3.5 hours, at 37°C, under 5% CO₂. Cell supernatants are harvested and added to an acidic europium solution (e.g., DELFIA Europium Solution, Perkin Elmer/Wallac). The fluorescence of the Europium-TDA chelates formed is quantitated in a time-resolved fluorometer (e.g., Victor 1420, Perkin Elmer/Wallac). Maximal release (MR) and spontaneous release (SR) are determined by incubation of target cells with 1% TX-100 and media alone, respectively. Antibody independent cellular cytotoxicity (AICC) is measured by incubation of target and effector cells in the absence of antibody. Each assay is preferably performed in triplicate. The mean percentage specific lysis is calculated as: $\text{Experimental release (ADCC) - AICC} / (\text{MR} - \text{SR}) \times 100$.

[0330] The invention encompasses characterization of the Fc variants in both NK-dependent and macrophage dependent ADCC assays. Fc variants of the invention have altered phenotypes such as an altered effector function as assayed in an NK dependent or macrophage dependent assay.

[0331] The invention encompasses assays known in the art and exemplified herein, to bind C1q and mediate complement dependent cytotoxicity (CDC). To determine C1q binding, a C1q binding ELISA may be performed. An exemplary assay may comprise the following: assay plates may be coated overnight at 4C with polypeptide variant or starting polypeptide (control) in coating buffer. The plates may then be washed and blocked. Following washing, an aliquot of human C1q may be added to each well and incubated for 2 hrs at room temperature. Following a further wash, 100 uL of a sheep anti-complement C1q peroxidase conjugated antibody may be added to each well and incubated for 1 hour at room temperature. The plate may again be washed with wash buffer and 100 ul of substrate buffer containing OPD (O-phenylenediamine dihydrochloride (Sigma)) may be added to each well. The oxidation reaction, observed by the appearance of a yellow color, may be allowed to proceed for 30 minutes and stopped by the addition of 100 ul of 4.5 NH₂ SO₄. The absorbance may then read at (492-405) nm.

[0332] A preferred variant in accordance with the invention is one that displays a significant reduction in C1q binding, as detected and measured in this assay or a similar assay. Preferably the molecule comprising an Fc variant displays about 50 fold reduction, about 60 fold, about 80 fold, or about 90 fold reduction in C1q binding compared to a control antibody having a nonmutated IgG1 Fc region. In the most preferred embodiment, the molecule comprising an Fc variant does not bind C1q, i.e. the variant displays about 100 fold or more reduction in C1q binding compared to the control antibody.

[0333] Another exemplary variant is one which has a better binding affinity for human C1q than the molecule comprising wild type Fc region. Such a molecule may display, for example, about two-fold or more, and preferably about five-fold or more, improvement in human C1q binding compared to the parent molecule comprising wild type Fc region. For example, human C1q binding may be about two-fold to about 500-fold, and preferably from about two-fold or from about five-fold to about 1000-fold improved compared to the molecule comprising wild type Fc region.

[0334] To assess complement activation, a complement dependent cytotoxicity (CDC) assay may be performed, e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996). Briefly, various concentrations of the molecule comprising a variant Fc region and human complement may be diluted with buffer. Cells which express the antigen to which the molecule comprising a variant Fc region binds may be diluted to a density of about 1×10^6 cells/ml. Mixtures of the molecule comprising a variant Fc region, diluted human complement and cells expressing the antigen may be added to a flat bottom tissue culture 96 well plate and allowed to incubate for 2 hrs at 37C. and 5% CO₂ to facilitate complement mediated cell lysis. 50 uL of alamar blue (Accumed International) may then be added to each well and incubated overnight at 37 C. The absorbance is measured using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. The results may be expressed in relative fluorescence units (RFU). The sample concentrations may be computed from a standard curve and the percent activity as compared to nonvariant molecule, i.e., a molecule comprising wild type Fc region, is reported for the variant of interest.

[0335] In some embodiments, an Fc variant of the invention does not activate complement Preferably the variant does not appear to have any CDC activity in the above CDC assay. The invention also pertains to a variant with enhanced CDC compared to a parent molecule (a molecule comprising wild type Fc region), e.g., displaying about two-fold to about 100-fold improvement in CDC activity in vitro or in vivo (e.g., at the IC₅₀ values for each molecule being compared).

Complement assays may be performed with guinea pig, rabbit or human serum. Complement lysis of target cells may be detected by monitoring the release of intracellular enzymes such as lactate dehydrogenase (LDH), as described in Korzeniewski et al., 1983 Immunol. Methods 64(3): 313-20; and Decker et al., 1988 J. Immunol Methods 115(1): 61-9; or the release of an intracellular label such as europium, chromium 51 or indium 111 in which target cells are labeled as described herein.

5.2.8 OTHER ASSAYS

[0336] The molecules of the invention comprising variant Fc regions may also be assayed using any surface plasmon resonance based assays known in the art for characterizing the kinetic parameters of Fc-Fc γ R interaction binding. Any SPR instrument commercially available including, but not limited to, BIAcore Instruments, available from Biacore AB (Uppsala, Sweden); IAsys instruments available from Affinity Sensors (Franklin, MA.); IBIS system available from Windsor Scientific Limited (Berks, UK), SPR-CELLIA systems available from Nippon Laser and Electronics Lab (Hokkaido, Japan), and SPR Detector Spreeta available from Texas Instruments (Dallas, TX) can be used in the instant invention. For a review of SPR-based technology see Mullet et al., 2000, Methods 22: 77-91; Dong et al., 2002, Review in Mol. Biotech., 82: 303-23; Fivash et al., 1998, Current Opinion in Biotechnology 9: 97-101; Rich et al., 2000, Current Opinion in Biotechnology 11: 54-61. Additionally, any of the SPR instruments and SPR based methods for measuring protein-protein interactions described in U.S. Patent No.'s 6,373,577; 6,289,286; 5,322,798; 5,341,215; 6,268,125 are contemplated in the methods of the invention.

[0337] Briefly, SPR based assays involve immobilizing a member of a binding pair on a surface, and monitoring its interaction with the other member of the binding pair in solution in real time. SPR is based on measuring the change in refractive index of the solvent near the surface that occurs upon complex formation or dissociation. The surface onto which the immobilization occur is the sensor chip, which is at the heart of the SPR technology; it consists of a glass surface coated with a thin layer of gold and forms the basis for a range of specialized surfaces designed to optimize the binding of a molecule to the surface. A variety of sensor chips are commercially available especially from the companies listed *supra*, all of which may be used in the methods of the invention. Examples of sensor chips include those available from BIAcore AB, Inc., e.g., Sensor Chip CM5, SA, NTA, and HPA. A molecule of the invention may be immobilized onto the surface of a sensor chip using any of the immobilization methods and chemistries known in the art, including but not limited to, direct covalent coupling via amine groups, direct covalent coupling via sulfhydryl groups, biotin attachment to avidin coated surface, aldehyde coupling to carbohydrate groups, and attachment through the histidine tag with NTA chips.

[0338] In some embodiments, the kinetic parameters of the binding of molecules of the invention comprising variant Fc regions, e.g., immunoglobulins comprising variant Fc region, to an Fc γ R may be determined using a BIAcore instrument (e.g., BIAcore instrument 1000, BIAcore Inc., Piscataway, NJ). Any Fc γ R can be used to assess the interaction with the molecules of the invention comprising variant Fc regions. In a specific embodiment the Fc γ R is Fc γ R1IIIA, preferably a soluble monomeric Fc γ R1IIIA. For example, in one embodiment, the soluble monomeric Fc γ R1IIIA is the extracellular region of Fc γ R1IIIA joined to the linker-AVITAG sequence (see, U.S. Provisional Application No. 60/439,498, filed on January 9, 2003 (Attorney Docket No. 11183-004-888) and U.S. Provisional Application No. 60/456,041 filed on March 19, 2003) In another specific embodiment, the Fc γ R is Fc γ R1IIB, preferably a soluble dimeric Fc γ R1IIB. For example in one embodiment, the soluble dimeric Fc γ R1IIB protein is prepared in accordance with the methodology described in U.S. Provisional application No. 60/439,709 filed on January 13, 2003.

[0339] An exemplary assay for determining the kinetic parameters of a molecule comprising a variant Fc region, wherein the molecule is the 4-4-20 antibody, to an Fc γ R using a BIAcore instrument comprises the following: BSA-FITC is immobilized on one of the four flow cells of a sensor chip surface, preferably through amine coupling chemistry such that about 5000 response units (RU) of BSA-FITC is immobilized on the surface. Once a suitable surface is prepared, 4-4-20 antibodies carrying the Fc mutations are passed over the surface, preferably by one minute injections of a 20 μ g/mL solution at a 5 μ L/mL flow rate. The level of 4-4-20 antibodies bound to the surface ranges between 400 and 700 RU. Next, dilution series of the receptor (Fc γ R1IIA and Fc γ R1IIB-Fc fusion protein) in HBS-P buffer (20mM HEPES, 150 mM NaCl, 3mM EDTA, pH 7.5) are injected onto the surface at 100 μ L/min Antibody regeneration between different receptor dilutions is carried out preferably by single 5 second injections of 100mM NaHCO₃ pH 9.4; 3M NaCl. Any regeneration technique known in the art is contemplated in the method of the invention.

[0340] Once an entire data set is collected, the resulting binding curves are globally fitted using computer algorithms supplied by the SPR instrument manufacturer, e.g., BIAcore, Inc. (Piscataway, NJ). These algorithms calculate both the K_{on} and K_{off} , from which the apparent equilibrium binding constant, K_d is deduced as the ratio of the two rate constants (*i.e.*, K_{off}/K_{on}). More detailed treatments of how the individual rate constants are derived can be found in the BIAevaluation Software Handbook (BIAcore, Inc., Piscataway, NJ). The analysis of the generated data may be done using any method known in the art. For a review of the various methods of interpretation of the kinetic data generated see Myszkowski, 1997, Current Opinion in Biotechnology 8: 50-7; Fisher et al., 1994, Current Opinion in Biotechnology 5: 389-95; O'Shannessy,

1994, Current Opinion in Biotechnology, 5:65-71; Chaiken et al., 1992, Analytical Biochemistry, 201: 197-210; Morton et al., 1995, Analytical Biochemistry 227: 176-85; O'Shannessy et al., 1996, Analytical Biochemistry 236: 275-83.

[0341] In preferred embodiments, the kinetic parameters determined using an SPR analysis, e.g., BIAcore, may be used as a predictive measure of how a molecule of the invention will function in a functional assay, e.g., ADCC. An exemplary method for predicting the efficacy of a molecule of the invention based on kinetic parameters obtained from an SPR analysis may comprise the following: determining the K_{off} values for binding of a molecule of the invention to Fc γ R11A and Fc γ R11B; plotting (1) $K_{off}(wt)/K_{off}(mut)$ for Fc γ R11A; (2) $K_{off}(mut)/K_{off}(wt)$ for Fc γ R11B against the ADCC data. Numbers higher than one show a decreased dissociation rate for Fc γ R11A and an increased dissociation rate for Fc γ R11B relative to wild type; and possess and enhanced ADCC function.

5.3 METHODS OF RECOMBINANTLY PRODUCING MOLECULES OF THE INVENTION

5.3.1 POLYNUCLEOTIDES ENCODING MOLECULES OF THE INVENTION

[0342] The present invention also includes polynucleotides that encode the molecules, including the polypeptides and antibodies, of the invention identified by the methods of the invention. The polynucleotides encoding the molecules of the invention may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art.

[0343] Once the nucleotide sequence of the molecules (e.g., antibodies) that are identified by the methods of the invention is determined, the nucleotide sequence may be manipulated using methods well known in the art, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY), to generate, for example, antibodies having a different amino acid sequence, for example by generating amino acid substitutions, deletions, and/or insertions.

[0344] In a specific embodiment, when the nucleic acids encode antibodies, one or more of the CDRs are inserted within framework regions using routine recombinant DNA techniques. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., 1998, J. Mol. Biol. 278: 457-479 for a listing of human framework regions).

[0345] In another embodiment, human libraries or any other libraries available in the art, can be screened by standard techniques known in the art, to clone the nucleic acids encoding the molecules of the invention.

5.3.2 RECOMBINANT EXPRESSION OF MOLECULES OF THE INVENTION

[0346] Once a nucleic acid sequence encoding molecules of the invention (i.e., antibodies) has been obtained, the vector for the production of the molecules may be produced by recombinant DNA technology using techniques well known in the art. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequences for the molecules of the invention and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. (See, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al. eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY).

[0347] An expression vector comprising the nucleotide sequence of a molecule identified by the methods of the invention (i.e., an antibody) can be transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation) and the transfected cells are then cultured by conventional techniques to produce the molecules of the invention. In specific embodiments, the expression of the molecules of the invention is regulated by a constitutive, an inducible or a tissue, specific promoter.

[0348] The host cells used to express the molecules identified by the methods of the invention may be either bacterial cells such as *Escherichia coli*, or, preferably, eukaryotic cells, especially for the expression of whole recombinant immunoglobulin molecule. In particular, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for immunoglobulins (Foecking et al., 1998, Gene 45:101; Cockett et al., 1990, Bio/Technology 8:2).

[0349] A variety of host-expression vector systems may be utilized to express the molecules identified by the methods of the invention. Such host-expression systems represent vehicles by which the coding sequences of the molecules of the invention may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express the molecules of the invention *in situ*. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing coding sequences for the molecules

identified by the methods of the invention; yeast (e.g., *Saccharomyces Pichia*) transformed with recombinant yeast expression vectors containing sequences encoding the molecules identified by the methods of the invention; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the sequences encoding the molecules identified by the methods of the invention; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing sequences encoding the molecules identified by the methods of the invention; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 293T, 3T3 cells, lymphotic cells (see U.S. 5,807,715), Per C.6 cells (human retinal cells developed by Crucell) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0350] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the antibody coding sequence may be ligated individually into the vector in frame with the *lac Z* coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster 1989, J. Biol. Chem. 24:5503-5509). pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0351] In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).

[0352] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the immunoglobulin molecule in infected hosts (e.g., see Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:355-359). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., 1987, Methods in Enzymol. 153:51-544).

[0353] In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 293T, 3T3, WI38, BT483, Hs578T, HTB2, BT20 and T47D, CRL7030 and Hs578Bst.

[0354] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express an antibody of the invention may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibodies of the invention. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibodies of the invention.

[0355] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine

kinase (Wigler et al., 1977, Cell 11: 223), hypoxanthineguanine phosphoribosyltransferase (Szybalska & Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48: 202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22: 817) genes can be employed in tk-, hgprt- or apt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78: 2072); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12: 488-505; Wu and Wu, 1991, 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1; and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147).

[0356] The expression levels of an antibody of the invention can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3 (Academic Press, New York, 1987). When a marker in the vector system expressing an antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell. Biol. 3:257).

[0357] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52; Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0358] Once a molecule of the invention (*i.e.*, antibodies) has been recombinantly expressed, it may be purified by any method known in the art for purification of polypeptides or antibodies, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of polypeptides or antibodies.

5.4 PROPHYLACTIC AND THERAPEUTIC METHODS

[0359] The present invention encompasses administering one or more of the molecules of the invention (e.g., antibodies) to an animal, preferably a mammal, and most preferably a human, for preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc γ R is desired. The methods and compositions of the invention are particularly useful for the treatment or prevention of primary or metastatic neoplastic disease (*i. e.*, cancer), and infectious diseases. Molecules of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein. As detailed below, the molecules of the invention can be used in methods of treating or preventing cancer (particularly in passive immunotherapy), autoimmune disease, inflammatory disorders or infectious diseases.

[0360] The molecules of the invention may also be advantageously utilized in combination with other therapeutic agents known in the art for the treatment or prevention of a cancer, autoimmune disease, inflammatory disorders or infectious diseases. In a specific embodiment, molecules of the invention may be used in combination with monoclonal or chimeric antibodies, lymphokines, or hematopoietic growth factors (such as, *e.g.*, IL-2, IL-3 and IL-7), which, for example, serve to increase the number or activity of effector cells which interact with the molecules and, increase immune response. The molecules of the invention may also be advantageously utilized in combination with one or more drugs used to treat a disease, disorder, or infection such as, for example anti-cancer agents, anti-inflammatory agents or antiviral agents, *e.g.*, as detailed in sections 5.4.1.2 and 5.4.2.1 below.

5.4.1 CANCERS

[0361] The invention encompasses compositions for treatment or prevention of cancer or metastasis in a subject comprising administering to the subject a therapeutically effective amount of one or more molecules comprising a variant Fc region.

[0362] Molecules of the invention (*i.e.*, polypeptides, antibodies) comprising variant Fc regions can be used to prevent, inhibit or reduce the growth of primary tumors or metastasis of cancerous cells. In one embodiment, the molecule of the

invention comprises a variant Fc that binds Fc γ R11A and/or Fc γ R11A with a greater affinity than a comparable polypeptide comprising a wild type Fc region binds Fc γ R11A and/or Fc γ R11A, and/or said variant Fc region has an enhanced effector function, e.g., ADCC, CDC, phagocytosis, opsonization, etc. Such molecules can be used alone to treat or prevent cancer. In another embodiment, the molecule of the invention comprises a variant Fc region that binds Fc γ R11A and/or Fc γ R11A with a greater affinity than a comparable polypeptide comprising a wild type Fc region binds Fc γ R11A and/or Fc γ R11A, and further binds Fc γ R11B with a lower affinity than a comparable polypeptide comprising a wild-type Fc region binds Fc γ R11B, and/or said variant Fc region has an enhanced effector function, e.g., ADCC, CDC, phagocytosis, opsonization, etc. Such molecules can also be used alone to treat or prevent cancer.

[0363] In some embodiments, the invention encompasses compositions for the treatment or prevention of cancer in a subject with Fc γ R polymorphisms such as those homozygous for the Fc γ R11A-158V or Fc γ R11A-158F alleles. In some embodiments, the invention encompasses engineering therapeutic antibodies, e.g., tumor specific monoclonal antibodies in accordance with the methods of the invention such that the engineered antibodies have enhanced efficacy in patients homozygous for the low affinity allele of Fc γ R11A (158F). In other embodiments, the invention encompasses engineering therapeutic antibodies, e.g., tumor specific monoclonal antibodies in accordance with the methods of the invention such that the engineered antibodies have enhanced efficacy in patients homozygous for the high affinity allele of Fc γ R11A (158V).

[0364] In some embodiments, the engineered antibodies of the invention are particularly effective in treating and/or preventing non-Hodgkin's lymphoma (NHL). The engineered antibodies of the invention are therapeutically more effective than current therapeutic regimens for NHL, including but not limited to chemotherapy, and immunotherapy using anti-CD20 mAb, Rituximab. The efficacy of anti-CD20 monoclonal antibodies however depends on the Fc γ R polymorphism of the subject (Carton et al., 2002 Blood, 99: 754-8; Weng et al., 2003 J Clin Oncol.21(21):3940-7). These receptors are expressed on the surface of the effector cells and mediate ADCC. High affinity alleles, of the low affinity activating receptors, improve the effector cells' ability to mediate ADCC. The methods of the invention allow engineering anti-CD20 antibodies harboring Fc mutations to enhance their affinity to Fc γ R on effector cells via their altered Fc domains. The engineered antibodies of the invention provide better immunotherapy reagents for patients regardless of their Fc γ R polymorphism.

[0365] An exemplary method for determining the efficacy of the engineered anti-CD20 antibodies in a subject may include the following: Plasmids harboring chimeric anti-HER2/neu heavy chain genes with Fc mutations that show substantially increased killing in ADCC can be used as a backbone to transfer in the variable domain from the Rituximab heavy chain gene. The variable region from the anti-HER2/neu Fc variant is replaced with the variable region from Rituximab. Plasmids containing wild type Fc domains or a D265A mutation to abrogate FcR binding, or the anti-CD20 Fc variants are transiently cotransfected with the Rituximab light chain gene into 293H cells, conditioned media and the antibody is purified over a protein G column using routine methods.

[0366] Anti-CD20 mAbs harboring the Fc variants are tested by ADCC using a cultured B cell line to determine the ability of the Fc mutations to enhance ADCC. Standard ADCC is performed using methods disclosed herein. Lymphocytes are harvested from peripheral blood using a Ficoll-Paque gradient (Pharmacia). Target Daudi cells, a B-cell line expressing CD20, are loaded with Europium (PerkinElmer) and incubated with effectors for 4 hrs at 37°C. Released Europium is detected using a fluorescent plate reader (Wallac). The resulting ADCC data indicates the efficacy of the Fc variants to trigger NK cell mediated cytotoxicity and establish which anti-CD20 Fc variants can be tested with both patient samples and elutriated monocytes. Fc variants showing the greatest potential for enhancing the efficacy of the anti-CD20 antibody are then tested in an ADCC assay using PBMCs from patients. PBMC from healthy donors are used as effector cells. *In vitro* ADCC assays using anti-CD20 variants and Rituximab are performed in primary lymphoma cells from patients with follicular lymphoma. The specific Fc γ R polymorphism of the donors is determined and cataloged using methods known in the art. ADCC assay is performed by effector cells from patients with different Fc γ R11A and Fc γ R11A genotypes.

[0367] According to an aspect of the invention, molecules (e.g., antibodies) of the invention comprising variant Fc regions enhance the efficacy of cancer immunotherapy by increasing the potency of the antibody effector function relative to a molecule containing the wild-type Fc region, e.g., ADCC, CDC, phagocytosis, opsonization, etc. In a specific embodiment, antibody dependent cellular toxicity and/or phagocytosis of tumor cells is enhanced using the molecules of the invention with variant Fc regions. Molecules of the invention may enhance the efficacy of immunotherapy cancer treatment by enhancing at least one antibody-mediated effector function. In one particular embodiment, a molecule of the invention comprising a variant Fc region enhances the efficacy of immunotherapy treatment by enhancing the complement dependent cascade. In another embodiment of the invention, the molecule of the invention comprising a variant Fc region enhances the efficacy of immunotherapy treatment by enhancing the phagocytosis and/or opsonization of the targeted tumor cells. In another embodiment of the invention, the molecule of the invention comprising a variant Fc region enhances the efficacy of treatment by enhancing antibody-dependent cell-mediated cytotoxicity ("ADCC") in destruction of the targeted tumor cells.

[0368] The invention further contemplates engineering therapeutic antibodies (e.g., tumor specific monoclonal antibodies) for enhancing the therapeutic efficacy of the therapeutic antibody, for example, by enhancing the effector function

of the therapeutic antibody (e.g., ADCC). Preferably the therapeutic antibody is a cytotoxic and/or opsonizing antibody. It will be appreciated by one of skill in the art, that once molecules of the invention with desired binding properties (e.g., molecules with variant Fc regions with at least one amino acid modification, which modification enhances the affinity of the variant Fc region for Fc γ R1IIIA and/or Fc γ R1IIA relative to a comparable molecule, comprising a wild-type Fc region) have been identified (See Section 5.2 and Table 8) according to the methods of the invention, therapeutic antibodies may be engineered using standard recombinant DNA techniques and any known mutagenesis techniques, as described in Section 5.2.2 to produce engineered therapeutic carrying the identified mutation sites with the desired binding properties. Any of the therapeutic antibodies listed in Table 9 that have demonstrated therapeutic utility in cancer treatment, may be engineered according to the methods of the invention, for example, by modifying the Fc region to have an enhanced affinity for Fc γ R1IIIA and/or Fc γ R1IIA compared to a therapeutic antibody having a wild-type Fc region, and used for the treatment and or prevention of a cancer characterized by a cancer antigen. Other therapeutic antibodies include those against pathogenic agents such as those against *Streptococcus pneumoniae* Serotype 6B, see, e.g., Sun et al., 1999, *Infection and Immunity*, 67(3): 1172-9.

[0369] The Fc variants of the invention may be incorporated into therapeutic antibodies such as those disclosed herein or other Fc fusion clinical candidates, *i.e.*, a molecule comprising an Fc regions which has been approved for use in clinical trials or any other molecule that may benefit from the Fc variants of the instant invention, humanized, affinity matured, modified or engineered versions thereof

[0370] The invention also encompasses engineering any other polypeptide comprising an Fc region which has therapeutic utility, including but not limited to ENBREL, according to the methods of the invention, in order to enhance the therapeutic efficacy of such polypeptides, for example, by enhancing the effector function of the polypeptide comprising an Fc region.

TABLE 9. THERAPEUTIC ANTIBODIES THAT CAN BE ENGINEERED ACCORDING TO THE METHODS OF THE INVENTION

Company	Product	Disease	Target
Abgenix	ABX-EGF	Cancer	EGF receptor
AltaRex	OvaRex	ovarian cancer	tumor antigen CA125
	BravaRex	metastatic cancers	tumor antigen MUC1
Antisoma	Theragyn (pentumomabytrrium-90)	ovarian cancer	PEM antigen
	Therex	breast cancer	PEM antigen
Boehringer Ingelheim	Blvatuzumab	head & neck cancer	CD44
Centocor/J&J	Panorex	Colorectal cancer	17-1A
	ReoPro	PTCA	gp IIIb/IIIa
	ReoPro	Acute MI	gp IIIb/IIIa
	ReoPro	Ischemic stroke	gp IIIb/IIIa
Corixa	Bexocar	NHL	CD20
CRC Technology	MAb, idiotypic 105AD7	colorectal cancer vaccine	gp72
Crucell	Anti-EpCAM	cancer	Ep-CAM
Cytoclonal	MAb, lung cancer	non-small cell lung cancer	NA
Genentech	Herceptin	metastatic breast cancer	HER-2
	Herceptin	early stage breast cancer	HER-2
	Rituxan	Relapsed/refractory low-grade or follicular NHL	CD20
	Rituxan	intermediate & high-grade NHL	CD20
	MAb-VEGF	NSCLC, metastatic	VEGF
	MAb-VEGF	Colorectal cancer, metastatic	VEGF

EP 2 573 114 B1

(continued)

	Company	Product	Disease	Target
5		AMD Fab E-26 (2 nd gen. IgE)	age-related macular degeneration allergic asthma & rhinitis	CD18 IgE
	IDEC	Zevalin (Rituxan + yttrium-90)	low grade of follicular, relapsed or refractory, CD20-positive, B-cell NHL and Rituximab-refractory NHL	CD20
10	ImClone	Cetuximab + innotecan Cetuximab + cisplatin & radiation Cetuximab + gemcitabine	refractory colorectal carcinoma newly diagnosed or recurrent head & neck cancer newly diagnosed metastatic pancreatic carcinoma	EGF receptor EGF receptor EGF receptor
15		Cetuximab + cisplatin + 5FU or Taxol Cetuximab + carboplatin + paclitaxel	recurrent or metastatic head & neck cancer newly diagnosed non-small cell lung carcinoma	EGF receptor EGF receptor
20		Cetuximab + cisplatin Cetuximab + radiation	head & neck cancer (extensive incurable local-regional disease & distant metastases) locally advanced head & neck carcinoma	EGF receptor EGF receptor
25		BEC2 + Bacillus Calmette Guerin BEC2 + Bacillus Calmette Guerin IMC-1C11	small cell lung carcinoma melanoma colorectal cancer with liver metastases	mimics ganglioside GD3 mimics ganglioside GD3 VEGF-receptor
	ImmonoGen	nuC242-DM1	Colorectal, gastric, and pancreatic cancer	nuC242
30	ImmunoMedics	LymphoCide LymphoCide Y-90 CEA-Cide CEA-Cide Y-90	Non-Hodgkins lymphoma Non-Hodgkins lymphoma metastatic solid tumors metastatic solid tumors	CD22 CD22 CEA CEA
35		CEA-Scan (Tc-99m-labeled arcitumomab) CEA-Scan (Tc-99m-labeled arcitumomab)	colorectal cancer (radio imaging) Breast cancer (radioimaging)	CEA CEA
40		CEA-Scan (Tc-99m-labeled arcitumomab) CEA-Scan (Tc-99m-labeled arcitumomab)	lung cancer (radioimaging) intraoperative tumors (radio imaging)	CEA CEA
45		LeukoScan (Tc-99m-labeled sulesomab) LymphoScan (Tc-99m-labeled) AFP-Scan (Tc-99m-labeled)	soft tissue infection (radioimaging) lymphomas (radioimaging) liver 7 gem-cell cancers (radioimaging)	CEA CD22 AFP
50	Intracel	HumaRAD-HN (+ yttrium-90) HumaSPECT	head & neck cancer colorectal imaging	NA NA
55	Medarex	MDX-101 (CTLA-4) MDX-210 (her-2 overexpression) MDX-210/MAK	Prostate and other cancers Prostate cancer Cancer	CTLA-4 HER-2 HER-2
	MedImmune	Vitaxin	Cancer	$\alpha v \beta_3$

EP 2 573 114 B1

(continued)

Company	Product	Disease	Target
5 Merck KGaA	MAb 425	Various cancers	EGF receptor
	IS-IL-2	Various cancers	Ep-CAM
10 Millennium NeoRx	Campath (alemtuzumab)	chronic lymphocytic leukemia	CD52
	CD20-streptavidin (+ biotin-yttrium 90)	Non-Hodgkins lymphoma	CD20
	Avidicin (albumin + NRLU13)	metastatic cancer	NA
15 Peregrine	Oncolym (+ iodine-131)	Non-Hodgkins lymphoma	HLA-DR 10 beta
	Cotara (+ iodine-131)	unresectable malignant glioma	DNA-associated proteins
20 Pharmacia Corporation	C215 (+ staphylococcal enterotoxin)	pancreatic cancer	NA
	MAb, lung/kidney cancer	lung & kidney cancer	NA
	nacolomab tafenatox (C242 + staphylococcal enterotoxin)	colon & pancreatic cancer	NA
25 Protein Design Labs	Nuvion	T cell malignancies	CD3
	SMART M195	AML	CD33
	SMART 1D10	NHL	HLA-DR antigen
	Titan	CEAVac	colorectal cancer, advanced
TriGem		metastatic melanoma &	GD2-ganglioside
30	TriAb	small cell lung cancer metastatic breast cancer	MUC-1
	35 Trilex	CEAVac	colorectal cancer, advanced
TriGem		metastatic melanoma & small cell lung cancer	GD2-ganglioside
TriAb		metastatic breast cancer	MUC-1
40 Viventia Biotech	NovoMAb-G2 radiolabeled	Non-Hodgkins lymphoma	NA
	Monopharm C	colorectal & pancreatic carcinoma	SK-1 antigen
45 Xoma	GlioMAb-H (+ gelonin toxin)	glioma, melanoma & neuroblastoma	NA
	Rituxan	Relapsed/refractory low-grade or follicular NHL	CD20
	Rituxan ING-1	intermediate & high-grade NHL adenomcarcino ma	CD20 Ep-CAM

[0371] Accordingly, the invention provides methods of preventing or treating cancer characterized by a cancer antigen, using a therapeutic antibody that binds a cancer antigen and is cytotoxic and has been modified at one or more sites in the Fc region, according to the invention, to bind Fc γ R1IA and/or Fc γ R1IA with a higher affinity than the parent therapeutic antibody, and/or mediates effector function (e.g., ADCC, phagocytosis) more effectively. In another embodiment, the invention provides molecules for use in methods of preventing or treating cancer characterized by a cancer antigen, using a therapeutic antibody that binds a cancer antigen and is cytotoxic, and has been engineered according to the invention to bind Fc γ R1IA and/or Fc γ R1IA with a higher affinity and bind Fc γ R1IB with a lower affinity than the parent therapeutic antibody, and/or mediates effector function (e.g., ADCC, phagocytosis) more effectively. The therapeutic antibodies that have been engineered according to the invention are useful for prevention or treatment of cancer, since they have an enhanced cytotoxic activity (e.g., enhanced tumor cell killing and/or enhanced for example, ADCC activity or CDC activity).

[0372] Cancers associated with a cancer antigen may be treated or prevented by administration of a therapeutic

antibody that binds a cancer antigen and is cytotoxic, and has been engineered according to the methods of the invention to have, for example, an enhanced effector function. In one particular embodiment, the therapeutic antibodies engineered according to the methods of the invention enhance the antibody-mediated cytotoxic effect of the antibody directed at the particular cancer antigen. For example, but not by way of limitation, cancers associated with the following cancer antigens may be treated or prevented by the compositions of the invention: KS 1/4 pancarcinoma antigen (Perez and Walker, 1990, *J. Immunol.* 142:32-37; Bumal, 1988, *Hybridoma* 7(4):407-415), ovarian carcinoma antigen (CA125) (Yu et al., 1991, *Cancer Res.* 51(2):48-475), prostatic acid phosphate (Tailor et al., 1990, *Nucl. Acids Res.* 18(1):4928), prostate specific antigen (Henttu and Vihko, 1989, *Biochem. Biophys. Res. Comm.* 10(2):903-910; Israeli et al., 1993, *Cancer Res.* 53:227-230), melanoma-associated antigen p97 (Estin et al., 1989, *J. Natl. Cancer Instit.* 81(6):445-44), melanoma antigen gp75 (Vijayasardahl et al., 1990, *J. Exp. Med.* 171(4):1375-1380), high molecular weight melanoma antigen (HMW-MAA) (Natali et al., 1987, *Cancer* 59:55-3; Mittelman et al., 1990, *J. Clin. Invest.* 86:2136-2144), prostate specific membrane antigen, carcinoembryonic antigen (CEA) (Foon et al., 1994, *Proc. Am. Soc. Clin. Oncol.* 13:294), polymorphic epithelial mucin antigen, human milk fat globule antigen, Colorectal tumor-associated antigens such as: CEA, TAG-72 (Yokata et al., 1992, *Cancer Res.* 52:3402-3408), CO17-1A (Ragnhammar et al., 1993, *Int. J. Cancer* 53:751-758); GICA 19-9 (Herlyn et al., 1982, *J. Clin. Immunol.* 2:135), CTA-1 and LEA, Burkitt's lymphoma antigen-38.13, CD19 (Ghetie et al., 1994, *Blood* 83:1329-1336), human B-lymphoma antigen-CD20 (Reff et al., 1994, *Blood* 83:435-445), CD33 (Sgouros et al., 1993, *J. Nucl. Med.* 34:422-430), melanoma specific antigens such as ganglioside GD2 (Saleh et al., 1993, *J. Immunol.*, 151, 3390-3398), ganglioside GD3 (Shitara et al., 1993, *Cancer Immunol. Immunother.* 36:373-380), ganglioside GM2 (Livingston et al., 1994, *J. Clin. Oncol.* 12:1036-1044), ganglioside GM3 (Hoon et al., 1993, *Cancer Res.* 53:5244-5250), tumor-specific transplantation type of cell-surface antigen (TSTA) such as virally-induced tumor antigens including T-antigen DNA tumor viruses and envelope antigens of RNA tumor viruses, oncofetal antigen-alpha-fetoprotein such as CEA of colon, bladder tumor oncofetal antigen (Hellstrom et al., 1985, *Cancer. Res.* 45:2210-2188), differentiation antigen such as human lung carcinoma antigen L6, L20 (Hellstrom et al., 1986, *Cancer Res.* 46:3917-3923), antigens of fibrosarcoma, human leukemia T cell antigen-Gp37 (Bhattacharya-Chatterjee et al., 1988, *J. of Immun.* 141:1398-1403), neoglycoprotein, sphingolipids, breast cancer antigen such as EGFR (Epidermal growth factor receptor), HER2 antigen (p185^{HER2}), polymorphic epithelial mucin (PEM) (Hilkens et al., 1992, *Trends in Bio. Chem. Sci.* 17:359), malignant human lymphocyte antigen-APO-1 (Bernhard et al., 1989, *Science* 245:301-304), differentiation antigen (Feizi, 1985, *Nature* 314:53-57) such as I antigen found in fetal erythrocytes and primary endoderm, I(Ma) found in gastric adenocarcinomas, M18 and M39 found in breast epithelium, SSEA-1 found in myeloid cells, VEP8, VEP9, MyI, VIM-D5, and D₁56-22 found in colorectal cancer, TRA-1-85 (blood group H), C14 found in colonic adenocarcinoma, F3 found in lung adenocarcinoma, AH6 found in gastric cancer, Y hapten, Le^y found in embryonal carcinoma cells, TL5 (blood group A), EGF receptor found in A431 cells, E₁ series (blood group B) found in pancreatic cancer, FC10.2 found in embryonal carcinoma cells, gastric adenocarcinoma, CO-514 (blood group Le^a) found in adenocarcinoma, NS-10 found in adenocarcinomas, CO-43 (blood group Le^b), G49, EGF receptor, (blood group ALe^b/Le^y) found in colonic adenocarcinoma, 19.9 found in colon cancer, gastric cancer mucins, T₅A₇ found in myeloid cells, R₂₄ found in melanoma, 4.2, G_{D3}, D₁.1, OFA-1, G_{M2}, OFA-2, G_{D2}, M1:22:25:8 found in embryonal carcinoma cells and SSEA-3, SSEA-4 found in 4-8-cell stage embryos. In another embodiment, the antigen is a T cell receptor derived peptide from a cutaneous T cell lymphoma (see Edelson, 1998, *The Cancer Journal* 4:62).

[0373] Cancers and related disorders that can be treated or prevented by compositions of the present invention include, but are not limited to, the following: Leukemias including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome, chronic leukemias such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenström's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas such as but not limited to bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors including but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers including but not limited to, Cushing's disease,

prolactin-secreting tumor, acromegaly, and diabetes insipidus; eye cancers including but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancers, including but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers including but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers including but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers including but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancers including but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers including but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; rectal cancers; liver cancers including but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancers including but not limited to, adenocarcinoma; cholangiocarcinomas including but not limited to, papillary, nodular, and diffuse; lung cancers including but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancers including but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers including but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancers; oral cancers including but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancers including but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers including but not limited to, squamous cell cancer, and verrucous; skin cancers including but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers including but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/ or uterer); Wilms' tumor; bladder cancers including but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphoendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas (for a review of such disorders, see Fishman et al., 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, *Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery*, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[0374] Accordingly, the compositions of the invention are also useful in the treatment or prevention of a variety of cancers or other abnormal proliferative diseases, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, prostate, cervix, thyroid and skin; including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burketts lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xenoderma pigmentosum, keratoactanthoma, seminoma, thyroid follicular cancer and teratocarcinoma. It is also contemplated that cancers caused by aberrations in apoptosis would also be treated by the compositions of the invention. Such cancers may include but not be limited to follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis, and myelodysplastic syndromes. In specific embodiments, malignancy or dysproliferative changes (such as metaplasias and dysplasias), or hyperproliferative disorders, are treated or prevented by the compositions of the invention in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus. In other specific embodiments, sarcoma, melanoma, or leukemia is treated or prevented by the compositions of the invention.

[0375] In a specific embodiment, a molecule of the invention (e.g., an antibody comprising a variant Fc region, or a therapeutic monoclonal antibody engineered according to the methods of the invention) inhibits or reduces the growth of primary tumor or metastasis of cancerous cells by at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to the growth of primary tumor or metastasis in the absence of said molecule of the invention.

5.4.1.1 COMBINATION THERAPY

[0376] The invention further encompasses administering the molecules of the invention in combination with other therapies known to those skilled in the art for the treatment or prevention of cancer, including but not limited to, current

standard and experimental chemotherapies, hormonal therapies, biological therapies, immunotherapies, radiation therapies, or surgery. In some embodiments, the molecules of the invention may be administered in combination with a therapeutically or prophylactically effective amount of one or more anti-cancer agents, therapeutic antibodies (e.g., antibodies listed in Table 9), or other agents known to those skilled in the art for the treatment and/or prevention of cancer (See Section 5.4.1.2).

[0377] In certain embodiments, one or more molecule of the invention is administered to a mammal, preferably a human, concurrently with one or more other therapeutic agents useful for the treatment of cancer. The term "concurrently" is not limited to the administration of prophylactic or therapeutic agents at exactly the same time, but rather it is meant that a molecule of the invention and the other agent are administered to a mammal in a sequence and within a time interval such that the molecule of the invention can act together with the other agent to provide an increased benefit than if they were administered otherwise. For example, each prophylactic or therapeutic agent (e.g., chemotherapy, radiation therapy, hormonal therapy or biological therapy) may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. Each therapeutic agent can be administered separately, in any appropriate form and by any suitable route. In various embodiments, the prophylactic or therapeutic agents are administered less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In preferred embodiments, two or more components are administered within the same patient visit.

[0378] In other embodiments, the prophylactic or therapeutic agents are administered at about 2 to 4 days apart, at about 4 to 6 days apart, at about 1 week apart, at about 1 to 2 weeks apart, or more than 2 weeks apart. In preferred embodiments, the prophylactic or therapeutic agents are administered in a time frame where both agents are still active. One skilled in the art would be able to determine such a time frame by determining the half life of the administered agents.

[0379] In certain embodiments, the prophylactic or therapeutic agents of the invention are cyclically administered to a subject. Cycling therapy involves the administration of a first agent for a period of time, followed by the administration of a second agent and/or third agent for a period of time and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.

[0380] In certain embodiments, prophylactic or therapeutic agents are administered in a cycle of less than about 3 weeks, about once every two weeks, about once every 10 days or about once every week. One cycle can comprise the administration of a therapeutic or prophylactic agent by infusion over about 90 minutes every cycle, about 1 hour every cycle, about 45 minutes every cycle. Each cycle can comprise at least 1 week of rest, at least 2 weeks of rest, at least 3 weeks of rest. The number of cycles administered is from about 1 to about 12 cycles, more typically from about 2 to about 10 cycles, and more typically from about 2 to about 8 cycles.

[0381] In yet other embodiments, the therapeutic and prophylactic agents of the invention are administered in metronomic dosing regimens, either by continuous infusion or frequent administration without extended rest periods. Such metronomic administration can involve dosing at constant intervals without rest periods. Typically the therapeutic agents, in particular cytotoxic agents, are used at lower doses. Such dosing regimens encompass the chronic daily administration of relatively low doses for extended periods of time. In preferred embodiments, the use of lower doses can minimize toxic side effects and eliminate rest periods. In certain embodiments, the therapeutic and prophylactic agents are delivered by chronic low-dose or continuous infusion ranging from about 24 hours to about 2 days, to about 1 week, to about 2 weeks, to about 3 weeks to about 1 month to about 2 months, to about 3 months, to about 4 months, to about 5 months, to about 6 months. The scheduling of such dose regimens can be optimized by the skilled oncologist.

[0382] In other embodiments, courses of treatment are administered concurrently to a mammal, *i.e.*, individual doses of the therapeutics are administered separately yet within a time interval such that molecules of the invention can work together with the other agent or agents. For example, one component may be administered one time per week in combination with the other components that may be administered one time every two weeks or one time every three weeks. In other words, the dosing regimens for the therapeutics are carried out concurrently even if the therapeutics are not administered simultaneously or within the same patient visit.

[0383] When used in combination with other prophylactic and/or therapeutic agents, the molecules of the invention and the prophylactic and/or therapeutic agent can act additively or, more preferably, synergistically. In one embodiment, a molecule of the invention is administered concurrently with one or more therapeutic agents in the same pharmaceutical composition. In another embodiment, a molecule of the invention is administered concurrently with one or more other therapeutic agents in separate pharmaceutical compositions. In still another embodiment, a molecule of the invention is administered prior to or subsequent to administration of another prophylactic or therapeutic agent. The invention contemplates administration of a molecule of the invention in combination with other prophylactic or therapeutic agents

by the same or different routes of administration, e.g., oral and parenteral. In certain embodiments, when a molecule of the invention is administered concurrently with another prophylactic or therapeutic agent that potentially produces adverse side effects including, but not limited to, toxicity, the prophylactic or therapeutic agent can advantageously be administered at a dose that falls below the threshold that the adverse side effect is elicited.

5 **[0384]** The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The dosage and frequency further will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity and type of cancer, the route of administration, as well as age, body weight, response, and the past medical history of the patient. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician's Desk Reference (56th ed., 2002).

5.4.1.2 OTHER THERAPEUTIC/PROPHYLACTIC AGENTS

15 **[0385]** In a specific embodiment, the methods of the invention encompass the administration of one or more molecules of the invention with one or more therapeutic agents used for the treatment and/or prevention of cancer. In one embodiment, angiogenesis inhibitors may be administered in combination with the molecules of the invention. Angiogenesis inhibitors that can be used in the compositions of the invention include but are not limited to: Angiostatin (plasminogen fragment); antiangiogenic antithrombin III; Angiozyme; ABT-627; Bay 12-9566; Benefin; Bevacizumab; BMS-275291; cartilage-derived inhibitor (CDI); CAI; CD59 complement fragment; CEP-7055; Col 3; Combretastatin A-4; Endostatin (collagen XVIII fragment); Fibronectin fragment; Gro-beta; Halofuginone; Heparinases; Heparin hexasaccharide fragment; HMV833; Human chorionic gonadotropin (hCG); IM-862; Interferon alpha/beta/gamma; Interferon inducible protein (IP-10); Interleukin-12; Kringle 5 (plasminogen fragment); Marimastat; Metalloproteinase inhibitors (TIMPs); 2-Methoxyestradiol; MMI 270 (CGS 27023A); MoAb IMC-1C11; Neovastat; NM-3; Panzem; PI-88; Placental ribonuclease inhibitor; Plasminogen activator inhibitor; Platelet factor-4 (PF4); Prinomastat; Prolactin 16kD fragment; Proliferin-related protein (PRP); PTK 787/ZK 222594; Retinoids; Solimastat; Squalamine; SS 3304; SU 5416; SU6668; SU11248; Tetrahydrocortisol-S; tetrathiomolybdate; thalidomide; Thrombospondin-1 (TSP-1); TNP-470; Transforming growth factor-beta (TGF-b); Vasculostatin; Vasostatin (calreticulin fragment); ZD6126; ZD 6474; farnesyl transferase inhibitors (FTI); and bisphosphonates.

30 **[0386]** Anti-cancer agents that can be used in combination with the molecules of the invention in the various embodiments of the invention, including pharmaceutical compositions and dosage forms and kits of the invention, include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambo-mycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropiramine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; el-samitracin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1 ; interferon alfa-n3; interferon beta-l a; interferon gamma-lb; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedopa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; pipsulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycin sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other anti-cancer drugs include, but are not limited to: 20-kepi-1,25 dihy-

droxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycininate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetorelix; chlorIn3; chloroquinoline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplata; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebse-
 5 len; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitetur; epirubicin; episteride; estramustine ana-
 10 logue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine;
 20 fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride;
 forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase
 inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic
 acid; idarubicin; idoxifene; idramantone; ilmofofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
 25 insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin;
 ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamel-
 30 larin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor;
 leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine ana-
 35 logue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol;
 lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine;
 40 mannostatin A; marimastat; masoprocil; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril;
 merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched
 double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-
 45 saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophos-
 phoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor
 50 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldi-
 naline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; ne-
 daplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide
 antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondanset-
 55 ron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues;
 40 paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine;
 pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alco-
 hol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim;
 placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine com-
 45 plex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein
 A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phos-
 phatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin
 polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras in-
 50 hibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide;
 roglitimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sar-
 gramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction
 inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocap-
 55 tate; sodium phenylacetate; solverol; somatostatin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine;
 splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhib-
 itors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic gly-
 60 cosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapy-
 rylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;
 thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrnan; thyroid
 stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem

cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. Preferred additional anti-cancer drugs are 5-fluorouracil and leucovorin.

[0387] Examples of therapeutic antibodies that can be used in methods of the invention include but are not limited to ZENAPAX® (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection; PANOREX™ which is a murine anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a murine anti-idiotypic (GD3 epitope) IgG antibody (ImClone System); IMC-C225 which is a chimeric anti-EGFR IgG antibody (ImClone System); VITAXIN™ which is a humanized anti- α V β 3 integrin antibody (Applied Molecular Evolution/MedImmune); SmartM195 which is a humanized anti-CD33 IgG antibody (Protein Design Lab/Kanebo); LYMPHOCIDE™ which is a humanized anti-CD22 IgG antibody (Immunomedics); ICM3 is a humanized anti-ICAM3 antibody (ICOS Pharm); IDEC-114 is a primatized anti-CD80 antibody (IDEC Pharm/Mitsubishi); IDEC-131 is a humanized anti-CD40L antibody (IDEC/Eisai); IDEC-151 is a primatized anti-CD4 antibody (IDEC); IDEC-152 is a primatized anti-CD23 antibody (IDEC/Seikagaku); SMART anti-CD3 is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1 is a humanized anti-complement factor 5 (C5) antibody (Alexion Pharm); D2E7 is a humanized anti-TNF- α antibody (CAT/BASF); CDP870 is a humanized anti-TNF- α Fab fragment (Celltech); IDEC-151 is a primatized anti-CD4 IgG1 antibody (IDEC Pharm/SmithKline Beecham); MDX-CD4 is a human anti-CD4 IgG antibody (Medarex/Eisai/Genmab); CDP571 is a humanized anti-TNF- α IgG4 antibody (Celltech); LDP-02 is a humanized anti- α 4 β 7 antibody (LeukoSite/Genentech); OrthoClone OKT4A is a humanized anti-CD4 IgG antibody (Ortho Biotech); ANTOVA™ is a humanized anti-CD40L IgG antibody (Biogen); ANTEGREN™ is a humanized anti-VLA-4 IgG antibody (Elan); and CAT-152 is a human anti-TGF- β 2 antibody (Cambridge Ab Tech). Other examples of therapeutic antibodies that can be used in accordance with the invention are presented in Table 9.

5.4.2 AUTOIMMUNE DISEASE AND INFLAMMATORY DISEASES

[0388] In some embodiments, molecules of the invention comprise a variant Fc region, having one or more amino acid modifications in one or more regions, which modification increases the affinity of the variant Fc region for Fc γ R1IB but decreases the affinity of the variant Fc region for Fc γ R1IA. Molecules of the invention with such binding characteristics are useful in regulating the immune response, e.g., in inhibiting the immune response in connection with autoimmune diseases or inflammatory diseases. Although not intending to be bound by any mechanism of action, molecules of the invention with an enhanced affinity for Fc γ R1IB and a decreased affinity for Fc γ R1IA may lead to dampening of the activating response to Fc γ R and inhibition of cellular responsiveness.

[0389] In some embodiments, a molecule of the invention comprising a variant Fc region is not an immunoglobulin, and comprises at least one amino acid modification which modification increases the affinity of the variant Fc region for Fc γ R1IB relative to a molecule comprising a wild-type Fc region. In other embodiments, said molecule further comprises one or more amino acid modifications, which modifications decreases the affinity of the molecule for an activating Fc γ R. In some embodiments, the molecule is a soluble (*i.e.*, not membrane bound) Fc region. The invention contemplates other amino acid modifications within the soluble Fc region which modulate its affinity for various Fc receptors, including those known to one skilled in the art as described herein. In other embodiments, the molecule (e.g., the Fc region comprising at least one or more amino acid modification) is modified using techniques known to one skilled in the art and as described herein to increase the *in vivo* half life of the Fc region. Such molecules have therapeutic utility in treating and/or preventing an autoimmune disorder. Although not intending to be bound by any mechanism of actions, such molecules with enhanced affinity for Fc γ R1IB will lead to a dampening of the activating receptors and thus a dampening of the immune response and have therapeutic efficacy for treating and/or preventing an autoimmune disorder.

[0390] In certain embodiments, the one or more amino acid modifications, which increase the affinity of the variant Fc region for Fc γ R1IB but decrease the affinity of the variant Fc region for Fc γ R1IIA comprise a substitution at position 246 with threonine and at position 396 with histidine; or a substitution at position 268 with aspartic acid and at position 318 with aspartic acid; or a substitution at position 217 with serine, at position 378 with valine, and at position 408 with arginine; or a substitution at position 375 with cysteine and at position 396 with leucine; or a substitution at position 246 with isoleucine and at position 334 with asparagine. In one embodiment, the one or more amino acid modifications, which increase the affinity of the variant Fc region for Fc γ R1IB but decrease the affinity of the variant Fc region for Fc γ R1IIA comprise a substitution at position 247 with leucine. In another embodiment, the one or more amino acid modification, which increases the affinity of the variant Fc region for Fc γ R1IB but decreases the affinity of the variant Fc region for Fc γ R1IIA comprise a substitution at position 372 with tyrosine. In yet another embodiment, the one or more amino acid modification, which increases the affinity of the variant Fc region for Fc γ R1IB but decreases the affinity of the variant Fc region for Fc γ R1IIA comprise a substitution at position 326 with glutamic acid. In one embodiment, the one or more amino acid modification, which increases the affinity of the variant Fc region for Fc γ R1IB but decreases the affinity of the variant

Fc region for Fc γ R11A comprise a substitution at position 224 with leucine.

[0391] The variant Fc regions that have an enhanced affinity for Fc γ R11B and a decreased affinity for Fc γ R11A and/or Fc γ R11A relative to a comparable molecule comprising a wild-type Fc region, may be used to treat or prevent autoimmune diseases or inflammatory diseases. The molecules of the present invention can be used in methods of preventing, treating, or managing one or more symptoms associated with an autoimmune or inflammatory disorder in a subject, comprising administering to said subject a therapeutically or prophylactically effective amount of one or more molecules of the invention with variant Fc regions that have an enhanced affinity for Fc γ R11B and a decreased affinity for Fc γ R11A and/or Fc γ R11A relative to a comparable molecule comprising a wild type Fc region.

[0392] The molecules of the invention can also be used in methods for preventing, treating, or managing one or more symptoms associated with an inflammatory disorder in a subject further comprising, administering to said subject a therapeutically or prophylactically effective amount of one or more anti-inflammatory agents. The molecules of the invention can also be used in methods for preventing, treating, or managing one or more symptoms associated with an autoimmune disease further comprising, administering to said subject a therapeutically or prophylactically effective amount of one or more immunomodulatory agents. Section 5.4.2.1 provides non-limiting examples of anti-inflammatory agents and immunomodulatory agents.

[0393] Examples of autoimmune disorders that may be treated by administering the molecules of the present invention include, but are not limited to, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erthematosus, Ménière's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, Rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, systemic lupus erythematosus, lupus erythematosus, takayasu arteritis, temporal arteritis/ giant cell arteritis, ulcerative colitis, uveitis, vasculitides such as dermatitis herpetiformis vasculitis, vitiligo, and Wegener's granulomatosis. Examples of inflammatory disorders include, but are not limited to, asthma, encephillitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacteria infections. As described herein in Section 2.2.2, some autoimmune disorders are associated with an inflammatory condition. Thus, there is overlap between what is considered an autoimmune disorder and an inflammatory disorder. Therefore, some autoimmune disorders may also be characterized as inflammatory disorders. Examples of inflammatory disorders which can be prevented, treated or managed using the molecules of the invention include, but are not limited to, asthma, encephillitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacteria infections.

[0394] A non-limiting example of the antibodies that are used for the treatment or prevention of inflammatory disorders which can be engineered according to the disclosure is presented in Table 10A, and a non-limiting example of the antibodies that are used for the treatment or prevention of autoimmune disorder is presented in Table 10B.

TABLE 10A: ANTIBODIES FOR INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES THAT CAN ENGINEERED IN ACCORDANCE WITH THE DISCLOSURE.

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
5G1.1	Complement (C5)	Humanized	IgG	Alexion Pharm Inc	Rheumatoid Arthritis
5G1.1	Complement (C5)	Humanized	IgG	Alexion Pharm Inc	SLE
5G1.1	Complement (C5)	Humanized	IgG	Alexion Pharm Inc	Nephritis

EP 2 573 114 B1

(continued)

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
5G1.1-SC	Complement (C5)	Humanized	ScFv	Alexion Pharm Inc	Cardiopulmonary Bypass
5G1.1-SC	Complement (C5)	Humanized	ScFv	Alexion Pharm Inc	Myocardial Infarction
5G1.1-SC	Complement (C5)	Humanized	ScFv	Alexion Pharm Inc	Angioplasty
ABX-CBL	CBL	Human		Abgenix Inc	GvHD
ABX-CBL	CD 147	Murine	IgG	Abgenix Inc	Allograft rejection
ABX-IL8	IL-8	Human	IgG2	Abgenix Inc	Psoriasis
Antegren	VLA-4	Humanized	IgG	Athena/Elan	Multiple Sclerosis
Anti-CD11a	CD11a	Humanized	IgG1	Genentech Inc/Xoma	Psoriasis
Anti-CD18	CD18	Humanized	Fab'2	Genentech Inc	Myocardial infarction
Anti-LFA1	CD18	Murine	Fab'2	Pasteur-Merieux/ Immunotech	Allograft rejection
Antova	CD40L	Humanized	IgG	Biogen	Allograft rejection
Antova	CD40L	Humanized	IgG	Biogen	SLE
BTI-322	CD2	Rat	IgG	Medimmune Inc	GvHD, Psoriasis
CDP571	TNF-alpha	Humanized	IgG4	Celltech	Crohn's
CDP571	TNF-alpha	Humanized	IgG4	Celltech	Rheumatoid Arthritis
CDP850	E-selectin	Humanized		Celltech	Psoriasis
Corsevin M	Fact VII	Chimeric		Centocor	Anticoagulant
D2E7	TNF-alpha	Human		CAT/BASF	Rheumatoid Arthritis
Hu23F2G	CD11/18	Humanized		ICOS Pharm Inc	Multiple Sclerosis
Hu23F2G	CD11/18	Humanized	IgG	ICOS Pharm Inc	Stroke
IC14	CD14			ICOS Pharm Inc	Toxic shock
ICM3	ICAM-3	Humanized		ICOS Pharm Inc	Psoriasis
IDEC-114	CD80	Primates		IDEC Pharm/Mitsubishi	Psoriasis
IDEC-131	CD40L	Humanized		IDEC Pharm/Eisai	SLE
IDEC-131	CD40L	Humanized		IDEC Pharm/Eisai	Multiple Sclerosis
IDEC-151	CD4	Primates	IgG1	IDEC Pharm/Glaxo SmithKline	Rheumatoid Arthritis
IDEC-152	CD23	Primates		IDEC Pharm	Asthma/Allergy
Infliximab	TNF-alpha	Chimeric	IgG1	Centocor	Rheumatoid Arthritis
Infliximab	TNF-alpha	Chimeric	IgG1	Centocor	Crohn's
LDP-01	beta2-integrin	Humanized	IgG	Millennium Inc (LeukoSite Inc.)	Stroke
LDP-01	beta2-integrin	Humanized	IgG	Millennium Inc (LeukoSite Inc.)	Allograft rejection

EP 2 573 114 B1

(continued)

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
LDP-02	alpha4beta7	Humanized		Millennium Inc (LeukoSite Inc.)	Ulcerative Colitis
MAK-195F	TNF alpha	Murine	Fab'2	Knoll Pharm, BASF	Toxic shock
MDX-33	CD64 (FcR)	Human		Medarex/Cent eon	Autoimmune haematological disorders
MDX-CD4	CD4	Human	IgG	Medarex/Eisai / Genmab	Rheumatoid Arthritis
MEDI-507	CD2	Humanized		Medimmune Inc	Psoriasis
MEDI-507	CD2	Humanized		Medimmune Inc	GvHD
OKT4A	CD4	Humanized	IgG	Ortho Biotech	Allograft rejection
OrthoClone OKT4A	CD4	Humanized	IgG	Ortho Biotech	Autoimmune disease
Orthoclone/anti-CD3 OKT3	CD3	Murine	mIgG2a	Ortho Biotech	Allograft rejection
RepPro/ Abciximab	gpIIb/IIIa	Chimeric	Fab	Centocor/Lilly	Complications of coronary angioplasty
rhuMab-E25	IgE	Humanized	IgG1	Genentech/Novartis/Tanox Biosystems	Asthma/Allergy
SB-240563	IL5	Humanized		GlaxoSmithKline	Asthma/Allergy
SB-240683	IL-4	Humanized		GlaxoSmithKline	Asthma/Allergy
SCH55700	IL-5	Humanized		Celltech/Schering	Asthma/Allergy
Simulect	CD25	Chimeric	IgG1	Novartis Pharm	Allograft rejection
SMART a-CD3	CD3	Humanized		Protein Design Lab	Autoimmune disease
SMART a-CD3	CD3	Humanized		Protein Design Lab	Allograft rejection
SMART a-CD3	CD3	Humanized	IgG	Protein Design Lab	Psoriasis
Zenapax	CD25	Humanized	IgG1	Protein Design Lab/Hoffman-La Roche	Allograft rejection

TABLE 10B: ANTIBODIES FOR AUTOIMMUNE DISORDERS THAT CAN BE ENGINEERED IN ACCORDANCE WITH THE DISCLOSURE

Antibody	Indication	Target Antigen
ABX-RB2		antibody to CBL antigen on T cells, B cells and NK cells fully human antibody from the Xenomouse
5c8 (Anti CD-40 ligand antibody)	Phase II trials were halted in Oct. 99 examine "adverse events"	CD-40
IDEC 131	systemic lupus erythematous (SLE)	anti CD40 humanized
IDEC 151	rheumatoid arthritis	primatized ; anti-CD4
IDEC 152	Asthma	primatized; anti-CD23

EP 2 573 114 B1

(continued)

Antibody	Indication	Target Antigen
5 IDEC 114	Psoriasis	primatized anti-CD80
MEDI-507	rheumatoid arthritis; multiple sclerosis Crohn's disease Psoriasis	anti-CD2
10 LDP-02 (anti-b7 mAb)	inflammatory bowel disease Chron's disease ulcerative colitis	a4b7 integrin receptor on white blood cells (leukocytes)
SMART Anti-Gamma Interferon antibody	autoimmune disorders	Anti-Gamma Interferon
15 Verteportin	rheumatoid arthritis	
MDX-33	blood disorders caused by autoimmune reactions Idiopathic Thrombocytopenia Purpurea (ITP) autoimmune hemolytic anemia	monoclonal antibody against FcRI receptors
20 MDX-CD4	treat rheumatoid arthritis and other autoimmunity	monoclonal antibody against CD4 receptor molecule
25 VX-497	autoimmune disorders multiple sclerosis rheumatoid arthritis inflammatory bowel disease lupus psoriasis	inhibitor of inosine monophosphate dehydrogenase (enzyme needed to make new RNA and DNA used in production of nucleotides needed for lymphocyte proliferation)
30 VX-740	rheumatoid arthritis	inhibitor of ICE interleukin-1 beta (converting enzyme controls pathways leading to aggressive immune response)
VX-745	specific to inflammation involved in chemical signalling of immune response onset and progression of inflammation	inhibitor of P38MAP kinase mitogen activated protein kinase
35 Enbrel (etanercept)		targets TNF (tumor necrosis factor)
40 IL-8		fully human monoclonal antibody against IL-8 (interleukin 8)
45 Apogen MP4		recombinant antigen selectively destroys disease associated T-cells induces apoptosis T-cells eliminated by programmed cell death no longer attack body's own cells specific apogens target specific T-cells

5.4.2.1 IMMUNOMODULATORY AGENTS AND ANTI-INFLAMMATORY AGENTS

50 [0395] The molecules of the present invention can be used in methods of treatment for autoimmune diseases and inflammatory diseases comprising administration of the molecules with variant Fc regions having an enhanced affinity for Fc γ R1IB and a decreased affinity for Fc γ R1IIIA and/or Fc γ R1IA in conjunction with other treatment agents. Examples of immunomodulatory agents include, but are not limited to, methothrexate, ENBREL, REMICADE™, leflunomide, cyclophosphamide, cyclosporine A, and macrolide antibiotics (e.g., FK506 (tacrolimus)), methylprednisolone (MP), corticosteroids, steroids, mycophenolate mofetil, rapamycin (sirolimus), mizoribine, deoxyspergualin, brequinar, malononitriloamindes (e.g., leflunamide), T cell receptor modulators, and cytokine receptor modulators.

55 [0396] Anti-inflammatory agents have exhibited success in treatment of inflammatory and autoimmune disorders and are now a common and a standard treatment for such disorders. Any anti-inflammatory agent well-known to one of skill in the art can be used in the methods of the invention. Non-limiting examples of anti-inflammatory agents include non-

steroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs, beta-agonists, anticholinergic agents, and methyl xanthines. Examples of NSAIDs include, but are not limited to, aspirin, ibuprofen, celecoxib (CELEBREX™), diclofenac (VOLTAREN™), etodolac (LODINE™), fenoprofen (NALFON™), indomethacin (INDOCIN™), ketoralac (TORADOL™), oxaprozin (DAYPRO™), nabumentone (RELAFEN™), sulindac (CLINORIL™), tolmetin (TOLECTIN™), rofecoxib (VIOXX™), naproxen (ALEVE™, NAPROSYN™), ketoprofen (ACTRON™) and nabumetone (RELAFEN™). Such NSAIDs function by inhibiting a cyclooxygenase enzyme (e.g., COX-1 and/or COX-2). Examples of steroidal anti-inflammatory drugs include, but are not limited to, glucocorticoids, dexamethasone (DECADRON™), cortisone, hydrocortisone, prednisone (DELTASONE™), prednisolone, triamcinolone, azulfidine, and eicosanoids such as prostaglandins, thromboxanes, and leukotrienes.

5.4.3 INFECTIOUS DISEASE

[0397] The molecules of the invention can be used in methods for treating or preventing an infectious disease in a subject comprising administering a therapeutically or prophylactically effective amount of one or more molecules of the invention. Infectious diseases that can be treated or prevented by the molecules of the invention are caused by infectious agents including but not limited to viruses, bacteria, fungi, protozoa, and viruses.

[0398] Viral diseases that can be treated or prevented using the molecules of the invention in conjunction with the methods of the present invention include, but are not limited to, those caused by hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus, small pox, Epstein Barr virus, human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), and agents of viral diseases such as viral meningitis, encephalitis, dengue or small pox.

[0399] Bacterial diseases that can be treated or prevented using the molecules of the invention in conjunction with the methods of the present invention, that are caused by bacteria include, but are not limited to, mycobacteria rickettsia, mycoplasma, neisseria, S. pneumonia, Borrelia burgdorferi (Lyme disease), Bacillus anthracis (anthrax), tetanus, streptococcus, staphylococcus, mycobacterium, tetanus, pertissus, cholera, plague, diphtheria, chlamydia, S. aureus and legionella.

[0400] Protozoal diseases that can be treated or prevented using the molecules of the invention in conjunction with the methods of the present invention, that are caused by protozoa include, but are not limited to, leishmania, kokzidioa, trypanosoma or malaria.

[0401] Parasitic diseases that can be treated or prevented using the molecules of the invention in conjunction with the methods of the present invention, that are caused by parasites include, but are not limited to, chlamydia and rickettsia.

[0402] According to one aspect of the invention, molecules of the invention comprising variant Fc regions have an enhanced antibody effector function towards an infectious agent, e.g., a pathogenic protein, relative to a comparable molecule comprising a wild-type Fc region. Examples of infectious agents include but are not limited to bacteria (e.g., *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Enterococcus faecialis*, *Candida albicans*, *Proteus vulgaris*, *Staphylococcus viridans*, and *Pseudomonas aeruginosa*), a pathogen (e.g., B-lymphotropic papovavirus (LPV); Bordatella pertussis; Borna Disease virus (BDV); Bovine coronavirus; Choriomeningitis virus; Dengue virus; a virus, E. coli; Ebola; Echovirus 1; Echovirus-11 (EV); Endotoxin (LPS); Enteric bacteria; Enteric Orphan virus; Enteroviruses; Feline leukemia virus; Foot and mouth disease virus; Gibbon ape leukemia virus (GALV); Gram-negative bacteria; Helicobacter pylori; Hepatitis B virus (HBV); Herpes Simplex Virus; HIV-1; Human cytomegalovirus; Human coronavirus; Influenza A, B & C; Legionella; Leishmania mexicana; Listeria monocytogenes; Measles virus; Meningococcus; Morbilliviruses; Mouse hepatitis virus; Murine leukemia virus; Murine gamma herpes virus; Murine retrovirus; Murine coronavirus mouse hepatitis virus; Mycobacterium avium-M; Neisseria gonorrhoeae; Newcastle disease virus; Parvovirus B19; Plasmodium falciparum; Pox Virus; Pseudomonas; Rotavirus; Samonella typhurium; Shigella; Streptococci; T-cell lymphotropic virus 1; Vaccinia virus).

[0403] In a specific embodiment, molecules of the invention enhance the efficacy of treatment of an infectious disease by enhancing phagocytosis and/or opsonization of the infectious agent causing the infectious disease. In another specific embodiment, molecules of the invention enhance the efficacy of treatment of an infectious disease by enhancing ADCC of infected cells causing the infectious disease.

[0404] In some embodiments, the molecules of the invention may be administered in combination with a therapeutically or prophylactically effective amount of one or additional therapeutic agents known to those skilled in the art for the treatment and/or prevention of an infectious disease. The invention contemplates the use of the molecules of the invention in combination with antibiotics known to those skilled in the art for the treatment and or prevention of an infectious disease. Antibiotics that can be used in combination with the molecules of the invention include, but are not limited to, macrolide (e.g., tobramycin (Tobi®)), a cephalosporin (e.g., cephalexin (Keflex®), cephadrine (Velosef®), cefuroxime (Ceftin®), cefprozil (Cefzil®), cefaclor (Ceclor®), cefixime (Suprax®) or cefadroxil (Duricef®)), a clarithromycin (e.g.,

clarithromycin (Biaxin®), an erythromycin (e.g., erythromycin (EMycin®)), a penicillin (e.g., penicillin V (V-Cillin K® or Pen Vee K®)) or a quinolone (e.g., ofloxacin (Floxin®), ciprofloxacin (Cipro®) or norfloxacin (Noroxin®)), aminoglycoside antibiotics (e.g., apramycin, arbekacin, bambarmycins, butirosin, dibekacin, neomycin, neomycin, undecylenate, netilmicin, paromomycin, ribostamycin, sisomicin, and spectinomycin), amphenicol antibiotics (e.g., azidamfenicol, chloramphenicol, florfenicol, and thiamphenicol), ansamycin antibiotics (e.g., rifamide and rifampin), carbacephems (e.g., loracarbef), carbapenems (e.g., biapenem and imipenem), cephalosporins (e.g., cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, ceftazopran, cefpimizole, cefpiramide, and cefpirome), cephamycins (e.g., cefbuperazone, cefmetazole, and cefminox), monobactams (e.g., aztreonam, carumonam, and tigemonam), oxacephems (e.g., flomoxef, and moxalactam), penicillins (e.g., amdinocillin, amdinocillin pivoxil, amoxicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, epicillin, fenbenicillin, floxacillin, penamccillin, penethamate hydriodide, penicillin o-benethamine, penicillin O, penicillin V, penicillin V benzathine, penicillin V hydrabamine, penimepicycline, and phencihicillin potassium), lincosamides (e.g., clindamycin, and lincomycin), amphomycin, bacitracin, capreomycin, colistin, enduracidin, enviomycin, tetracyclines (e.g., apicycline, chlortetracycline, clomocycline, and demeclocycline), 2,4-diaminopyrimidines (e.g., brodimoprim), nitrofurans (e.g., furaltadone, and furazolium chloride), quinolones and analogs thereof (e.g., cinoxacin, clinafloxacin, flumequine, and grepagloxacin), sulfonamides (e.g., acetyl sulfamethoxypyrazine, benzylsulfamide, nopylsulfamide, phthalylsulfacetamide, sulfachrysoidine, and sulfacytine), sulfones (e.g., diathymosulfone, glucosulfone sodium, and solasulfone), cycloserine, mupirocin and tuberlin.

[0405] In certain embodiments, the molecules of the invention can be administered in combination with a therapeutically or prophylactically effective amount of one or more antifungal agents. Antifungal agents that can be used in combination with the molecules of the invention include but are not limited to amphotericin B, itraconazole, ketoconazole, fluconazole, intrathecal, flucytosine, miconazole, butoconazole, clotrimazole, nystatin, terconazole, tioconazole, ciclopirox, econazole, haloprogrin, naftifine, terbinafine, undecylenate, and griseofulvin.

[0406] In some embodiments, the molecules of the invention can be administered in combination with a therapeutically or prophylactically effective amount of one or more anti-viral agent. Useful anti-viral agents that can be used in combination with the molecules of the invention include, but are not limited to, protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside analogs. Examples of antiviral agents include but are not limited to zidovudine, acyclovir, gangcyclovir, vidarabine, idoxuridine, trifluridine, and ribavirin, as well as foscarnet, amantadine, rimantadine, saquinavir, indinavir, amprenavir, lopinavir, ritonavir, the alpha-interferons; adefovir, clevalidine, entecavir, pleconaril.

5.5 VACCINE THERAPY

[0407] The invention further encompasses using a composition of the invention to induce an immune response against an antigenic or immunogenic agent, including but not limited to cancer antigens and infectious disease antigens (examples of which are disclosed *infra*). The vaccine compositions of the invention comprise one or more antigenic or immunogenic agents to which an immune response is desired, wherein the one or more antigenic or immunogenic agents is coated with a variant antibody of the invention that has an enhanced affinity to Fc γ R1IIIA. Although not intending to be bound by a particular mechanism of action, coating an antigenic or immunogenic agent with a variant antibody of the invention that has an enhanced affinity to Fc γ R1IIIA, enhances the immune response to the desired antigenic or immunogenic agent by inducing humoral and cell-mediated responses. The vaccine compositions of the invention are particularly effective in eliciting an immune response, preferably a protective immune response against the antigenic or immunogenic agent.

[0408] In some embodiments, the antigenic or immunogenic agent in the vaccine compositions of the invention comprise a virus against which an immune response is desired. The viruses may be recombinant or chimeric, and are preferably attenuated. Production of recombinant, chimeric, and attenuated viruses may be performed using standard methods known to one skilled in the art. The invention encompasses a live recombinant viral vaccine or an inactivated recombinant viral vaccine to be formulated in accordance with the invention. A live vaccine may be preferred because multiplication in the host leads to a prolonged stimulus of similar kind and magnitude to that occurring in natural infections, and therefore, confers substantial, long-lasting immunity. Production of such live recombinant virus vaccine formulations may be accomplished using conventional methods involving propagation of the virus in cell culture or in the allantois of the chick embryo followed by purification.

[0409] In a specific embodiment, the recombinant virus is non-pathogenic to the subject to which it is administered. In this regard, the use of genetically engineered viruses for vaccine purposes may require the presence of attenuation characteristics in these strains. The introduction of appropriate mutations (e.g., deletions) into the templates used for transfection may provide the novel viruses with attenuation characteristics. For example, specific missense mutations which are associated with temperature sensitivity or cold adaption can be made into deletion mutations. These mutations should be more stable than the point mutations associated with cold or temperature sensitive mutants and reversion frequencies should be extremely low. Recombinant DNA technologies for engineering recombinant viruses are known

in the art and encompassed in the invention. For example, techniques for modifying negative strand RNA viruses are known in the art, see, e.g., U.S. Patent No. 5,166,057, which is incorporated herein by reference in its entirety.

[0410] Alternatively, chimeric viruses with "suicide" characteristics may be constructed for use in the intradermal vaccine formulations of the invention. Such viruses would go through only one or a few rounds of replication within the host. When used as a vaccine, the recombinant virus would go through limited replication cycle(s) and induce a sufficient level of immune response but it would not go further in the human host and cause disease. Alternatively, inactivated (killed) virus may be formulated in accordance with the invention. Inactivated vaccine formulations may be prepared using conventional techniques to "kill" the chimeric viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to prepare inactivated vaccines, the chimeric virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or β -propiolactone, and pooled.

[0411] In certain embodiments, completely foreign epitopes, including antigens derived from other viral or non-viral pathogens can be engineered into the virus for use in the intradermal vaccine formulations of the invention. For example, antigens of non-related viruses such as HIV (gp160, gp120, gp41) parasite antigens (e.g., malaria), bacterial or fungal antigens or tumor antigens can be engineered into the attenuated strain.

[0412] Virtually any heterologous gene sequence may be constructed into the chimeric viruses of the invention for use in the intradermal vaccine formulations. Preferably, heterologous gene sequences are moieties and peptides that act as biological response modifiers. Preferably, epitopes that induce a protective immune response to any of a variety of pathogens, or antigens that bind neutralizing antibodies may be expressed by or as part of the chimeric viruses. For example, heterologous gene sequences that can be constructed into the chimeric viruses of the invention include, but are not limited to, influenza and parainfluenza hemagglutinin neuraminidase and fusion glycoproteins such as the HN and F genes of human PIV3. In yet another embodiment, heterologous gene sequences that can be engineered into the chimeric viruses include those that encode proteins with immuno-modulating activities. Examples of immuno-modulating proteins include, but are not limited to, cytokines, interferon type 1, gamma interferon, colony stimulating factors, interleukin -1, -2, -4, -5, -6, -12, and antagonists of these agents.

[0413] In yet other embodiments, the invention encompasses pathogenic cells or viruses, preferably attenuated viruses, which express the variant antibody on their surface.

[0414] In alternative embodiments, the vaccine compositions of the invention comprise a fusion polypeptide wherein an antigenic or immunogenic agent is operatively linked to a variant antibody of the invention that has an enhanced affinity for Fc γ R1IIIA. Engineering fusion polypeptides for use in the vaccine compositions of the invention is performed using routine recombinant DNA technology methods and is within the level of ordinary skill.

[0415] The invention further encompasses methods to induce tolerance in a subject by administering a composition of the invention. Preferably a composition suitable for inducing tolerance in a subject, comprises an antigenic or immunogenic agent coated with a variant antibody of the invention, wherein the variant antibody has a higher affinity to Fc γ R1IIB. Although not intending to be bound by a particular mechanism of action, such compositions are effective in inducing tolerance by activating the Fc γ R1IIB mediated inhibitory pathway.

5.6 COMPOSITIONS AND METHODS OF ADMINISTERING

[0416] The invention provides methods and pharmaceutical compositions comprising molecules of the invention (*i.e.*, antibodies, polypeptides) comprising variant Fc regions. The invention also provides methods of treatment, prophylaxis, and amelioration of one or more symptoms associated with a disease, disorder or infection by administering to a subject an effective amount of a fusion protein or a conjugated molecule of the invention, or a pharmaceutical composition comprising a fusion protein or a conjugated molecule of the invention. In a preferred aspect, an antibody, a fusion protein, or a conjugated molecule, is substantially purified (*i.e.*, substantially free from substances that limit its effect or produce undesired side-effects). In a specific embodiment, the subject is an animal, preferably a mammal such as non-primate (e.g., cows, pigs, horses, cats, dogs, rats *etc.*) and a primate (e.g., monkey such as, a cynomolgous monkey and a human). In a preferred embodiment, the subject is a human. In yet another preferred embodiment, the antibody of the invention is from the same species as the subject.

[0417] Various delivery systems are known and can be used to administer a composition comprising molecules of the invention (*i.e.*, antibodies, polypeptides), comprising variant Fc regions, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or fusion protein, receptor-mediated endocytosis (See, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, *etc.* Methods of administering a molecule of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). In a specific embodiment, the molecules of the invention are administered intramuscularly, intravenously, or subcutaneously. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and

intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Patent Nos. 6,019,968; 5,985,320; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903.

[0418] The invention also provides that the molecules of the invention (*i.e.*, antibodies, polypeptides) comprising variant Fc regions, are packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of antibody. In one embodiment, the molecules of the invention are supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, e.g., with water or saline to the appropriate concentration for administration to a subject. Preferably, the molecules of the invention are supplied as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at least 5 mg, more preferably at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, or at least 75 mg. The lyophilized molecules of the invention should be stored at between 2 and 8°C in their original container and the molecules should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In an alternative embodiment, molecules of the invention are supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of the molecule, fusion protein, or conjugated molecule. Preferably, the liquid form of the molecules of the invention are supplied in a hermetically sealed container at least 1 mg/ml, more preferably at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 100 mg/ml, at least 150 mg/ml, at least 200 mg/ml of the molecules.

[0419] The amount of the composition of the invention which will be effective in the treatment, prevention or amelioration of one or more symptoms associated with a disorder can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0420] For antibodies encompassed by the invention, the dosage administered to a patient is typically 0.0001 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention or fragments thereof may be reduced by enhancing uptake and tissue penetration of the antibodies by modifications such as, for example, lipidation.

[0421] In one embodiment, the dosage of the molecules of the invention administered to a patient are 0.01mg to 1000mg/day, when used as single agent therapy. In another embodiment the molecules of the invention are used in combination with other therapeutic compositions and the dosage administered to a patient are lower than when said molecules are used as a single agent therapy.

[0422] In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion, by injection, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a molecule of the invention, care must be taken to use materials to which the molecule does not absorb.

[0423] In another embodiment, the compositions can be delivered in a vesicle, in particular a liposome (See Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 3 17-327; see generally *ibid.*).

[0424] In yet another embodiment, the compositions can be delivered in a controlled release or sustained release system. Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more molecules of the invention. See, e.g., U.S. Patent No. 4,526,938; PCT publication WO 91/05548; PCT publication WO 96/20698; Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel," Radiotherapy & Oncology 39:179-189, Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions," PDA Journal of Pharmaceutical Science & Technology 50:372-397; Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application," Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854; and Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery," Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760.

[0425] In one embodiment, a pump may be used in a controlled release system (See Langer, *supra*; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:20; Buchwald et al., 1980, Surgery 88:507; and Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used to achieve controlled release of antibodies (see e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled

Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J., Macromol. Sci. Rev. Macromol. Chem. 23:61; See also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 7 1:105); U.S. Patent No. 5,679,377; U.S. Patent No. 5,916,597; U.S. Patent No. 5,912,015; U.S. Patent No. 5,989,463; U.S. Patent No. 5,128,326; PCT Publication No. WO 99/15154; and PCT Publication No. WO 99/20253). Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target (e.g., the lungs), thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). In another embodiment, polymeric compositions useful as controlled release implants are used according to Dunn et al. (See U.S. 5,945,155). This particular method is based upon the therapeutic effect of the in situ controlled release of the bioactive material from the polymer system. The implantation can generally occur anywhere within the body of the patient in need of therapeutic treatment. In another embodiment, a non-polymeric sustained delivery system is used, whereby a non-polymeric implant in the body of the subject is used as a drug delivery system. Upon implantation in the body, the organic solvent of the implant will dissipate, disperse, or leach from the composition into surrounding tissue fluid, and the non-polymeric material will gradually coagulate or precipitate to form a solid, microporous matrix (See U.S. 5,888,533).

[0426] Controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533). Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more therapeutic agents of the invention. See, e.g., U.S. Patent No. 4,526,938; International Publication Nos. WO 91/05548 and WO 96/20698; Ning et al., 1996, Radiotherapy & Oncology 39:179-189; Song et al., 1995, PDA Journal of Pharmaceutical Science & Technology 50:372-397; Cleek et al., 1997, Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854; and Lam et al., 1997, Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760.

[0427] In a specific embodiment where the composition of the invention is a nucleic acid encoding an antibody, the nucleic acid can be administered *in vivo* to promote expression of its encoded antibody, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (See U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (See e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression by homologous recombination.

[0428] For antibodies, the therapeutically or prophylactically effective dosage administered to a subject is typically 0.1 mg/kg to 200 mg/kg of the subject's body weight. Preferably, the dosage administered to a subject is between 0.1 mg/kg and 20 mg/kg of the subject's body weight and more preferably the dosage administered to a subject is between 1 mg/kg to 10 mg/kg of the subject's body weight. The dosage and frequency of administration of antibodies of the invention may be reduced also by enhancing uptake and tissue penetration (e.g., into the lung) of the antibodies or fusion proteins by modifications such as, for example, lipidation.

[0429] Treatment of a subject with a therapeutically or prophylactically effective amount of molecules of the invention can include a single treatment or, preferably, can include a series of treatments. In a preferred example, a subject is treated with molecules of the invention in the range of between about 0.1 to 30 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. In other embodiments, the pharmaceutical compositions of the invention are administered once a day, twice a day, or three times a day. In other embodiments, the pharmaceutical compositions are administered once a week, twice a week, once every two weeks, once a month, once every six weeks, once every two months, twice a year or once per year. It will also be appreciated that the effective dosage of the molecules used for treatment may increase or decrease over the course of a particular treatment.

5.6.1 PHARMACEUTICAL COMPOSITIONS

[0430] The compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g., impure or non-sterile compositions) and pharmaceutical compositions (i.e., compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms. Such compositions comprise a prophylactically or therapeutically effective amount of a prophylactic and/or therapeutic agent disclosed herein or a combination of those agents and a pharmaceutically acceptable carrier. Preferably, compositions of the invention comprise a prophylactically or therapeutically effective amount of one or more molecules of the invention and a pharmaceutically acceptable carrier.

[0431] In one particular embodiment, the pharmaceutical composition comprises a therapeutically effective amount

of one or more molecules of the invention comprising a variant Fc region, wherein said variant Fc region binds Fc γ R1IIIA and/or Fc γ R1IIA with a greater affinity than a comparable molecule comprising a wild-type Fc region binds Fc γ R1IIIA and/or Fc γ R1IIA and/or said variant Fc region mediates an effector function at least 2-fold more effectively than a comparable molecule comprising a wild-type Fc region, and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical composition comprises a therapeutically effective amount of one or more molecules of the invention comprising a variant Fc region, wherein said variant Fc region binds Fc γ R1IIIA with a greater affinity than a comparable molecule comprising a wild-type Fc region binds Fc γ R1IIIA, and said variant Fc region binds Fc γ R1IIB with a lower affinity than a comparable molecule comprising a wild-type Fc region binds Fc γ R1IIB, and/or said variant Fc region mediates an effector function at least 2-fold more effectively than a comparable molecule comprising a wild-type Fc region, and a pharmaceutically acceptable carrier. In another embodiment, said pharmaceutical compositions further comprise one or more anti-cancer agents.

[0432] The invention also encompasses pharmaceutical compositions comprising a therapeutic antibody (e.g., tumor specific monoclonal antibody) that is specific for a particular cancer antigen, comprising one or more amino acid modifications in the Fc region as determined in accordance with the instant invention, and a pharmaceutically acceptable carrier.

[0433] In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol.

[0434] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations.

[0435] Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0436] The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include, but are not limited to those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

5.6.2 GENE THERAPY

[0437] In a specific embodiment, nucleic acids comprising sequences encoding molecules of the invention, are administered to treat, prevent or ameliorate one or more symptoms associated with a disease, disorder, or infection, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded antibody or fusion protein that mediates a therapeutic or prophylactic effect.

[0438] Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

[0439] For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596; Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; May, 1993, *TIBTECH* 11(5):155-215. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

[0440] In a preferred aspect, a composition of the invention comprises nucleic acids encoding an antibody, said nucleic acids being part of an expression vector that expresses the antibody in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are

used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; and Zijlstra et al., 1989, Nature 342:435-438).

5 [0441] In another preferred aspect, a composition of the invention comprises nucleic acids encoding a fusion protein, said nucleic acids being a part of an expression vector that expresses the fusion protein in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to the coding region of a fusion protein, said promoter being inducible or constitutive, and optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the coding sequence of the fusion protein and any other desired sequences
10 are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the fusion protein.

[0442] Delivery of the nucleic acids into a subject may be either direct, in which case the subject is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the subject. These two approaches are known, respectively, as *in vivo* or *ex vivo*
15 gene therapy.

[0443] In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, *e.g.*, by infection using defective or attenuated retroviral or other viral vectors (see U.S. Patent No. 4,980,286),
20 or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (See, *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) (which can be used to target cell types specifically expressing the receptors), *etc.* In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing
25 the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (See, *e.g.*, PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188; WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc.
30 Natl. Acad. Sci. USA 86:8932-8935; and Zijlstra et al., 1989, Nature 342:435-438).

[0444] In a specific embodiment, viral vectors that contain nucleic acid sequences encoding a molecule of the invention (*e.g.*, an antibody or a fusion protein) are used. For example, a retroviral vector can be used (See Miller et al., 1993, Meth. Enzymol. 217:581-599). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody or a fusion
35 protein to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the nucleotide sequence into a subject. More detail about retroviral vectors can be found in Boesen et al., (1994, Biotherapy 6:291-302), which describes the use of a retroviral vector to deliver the *mdr 1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, J. Clin. Invest. 93:644-651; Klein et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg,
40 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.

[0445] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and
45 Wilson (Current Opinion in Genetics and Development 3:499-503, 1993, present a review of adenovirus-based gene therapy. Bout et al., (Human Gene Therapy, 5:3-10, 1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., 1991, Science 252:431-434; Rosenfeld et al., 1992, Cell 68:143-155; Mastrangeli et al., 1993, J. Clin. Invest. 91:225-234; PCT Publication WO94/12649; and Wang et al., 1995, Gene Therapy 2:775-783. In a preferred
50 embodiment, adenovirus vectors are used.

[0446] Adeno-associated virus (AAV) has also been proposed for use in gene therapy (see, *e.g.*, Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300 and U.S. Patent No. 5,436,146).

[0447] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer
55 includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a subject.

[0448] In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to,

transfection, electroporation, microinjection, infection with a viral or bacteriophage vector, containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, *etc.* Numerous techniques are known in the art for the introduction of foreign genes into cells (See, *e.g.*, Loeffler and Behr, 1993, *Meth. Enzymol.* 217:599-618, Cohen et al., 1993, *Meth. Enzymol.* 217:618-644; and *Clin. Pharma. Ther.* 29:69-92, 5 1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0449] The resulting recombinant cells can be delivered to a subject by various methods known in the art. Recombinant blood cells (*e.g.*, hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, *etc.*, and can be determined by one skilled in the art.

[0450] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, 15 megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, *etc.*

[0451] In a preferred embodiment, the cell used for gene therapy is autologous to the subject.

[0452] In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody or a fusion protein are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (See *e.g.*, PCT Publication WO 94/08598; Stemple and Anderson, 1992, *Cell* 71:973-985; Rheinwald, 1980, *Meth. Cell Bio.* 21A:229; and Pittelkow and Scott, 1986, *Mayo Clinic Proc.* 61:771).

[0453] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

5.6.3 KITS

[0454] The invention provides a pharmaceutical pack or kit comprising one or more containers filled with the molecules of the invention (*i.e.*, antibodies, polypeptides comprising variant Fc regions). Additionally, one or more other prophylactic or therapeutic agents useful for the treatment of a disease can also be included in the pharmaceutical pack or kit. The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0455] The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises one or more molecules of the invention. In another embodiment, a kit further comprises one or more other prophylactic or therapeutic agents useful for the treatment of cancer, in one or more containers. In another embodiment, a kit further comprises one or more cytotoxic antibodies that bind one or more cancer antigens associated with cancer. In certain embodiments, the other prophylactic or therapeutic agent is a chemotherapeutic. In other embodiments, the prophylactic or therapeutic agent is a biological or hormonal therapeutic.

5.7 CHARACTERIZATION AND DEMONSTRATION OF THERAPEUTIC UTILITY

[0456] Several aspects of the pharmaceutical compositions, prophylactic, or therapeutic agents of the invention are preferably tested *in vitro*, in a cell culture system, and in an animal model organism, such as a rodent animal model system, for the desired therapeutic activity prior to use in humans. For example, assays which can be used to determine whether administration of a specific pharmaceutical composition is desired, include cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise contacted with a pharmaceutical composition of the invention, and the effect of such composition upon the tissue sample is observed. The tissue sample can be obtained by biopsy from the patient. This test allows the identification of the therapeutically most effective prophylactic or therapeutic molecule(s) for each individual patient. In various specific embodiments, *in vitro* assays can be carried out with representative cells of cell types involved in an autoimmune or inflammatory disorder (*e.g.*, T cells), to determine if a pharmaceutical composition of the invention has a desired effect upon such cell types.

[0457] Combinations of prophylactic and/or therapeutic agents can be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not limited to, rats, mice, chicken, cows, monkeys, pigs,

dogs, rabbits, etc. Any animal system well-known in the art may be used. In a specific embodiment of the invention, combinations of prophylactic and/or therapeutic agents are tested in a mouse model system. Such model systems are widely used and well-known to the skilled artisan. Prophylactic and/or therapeutic agents can be administered repeatedly. Several aspects of the procedure may vary. Said aspects include the temporal regime of administering the prophylactic and/or therapeutic agents, and whether such agents are administered separately or as an admixture.

[0458] Preferred animal models for use in the methods of the invention are, for example, transgenic mice expressing human FcγRs on mouse effector cells, e.g., any mouse model described in U.S. 5,877,396 can be used in the present invention. Transgenic mice for use in the methods of the invention include, but are not limited to, mice carrying human FcγRIIIA; mice carrying human FcγRIIA; mice carrying human FcγRIIB and human FcγRIIIA; mice carrying human FcγRIIB and human FcγRIIA.

[0459] Preferably, mutations showing the highest levels of activity in the functional assays described above will be tested for use in animal model studies prior to use in humans. Antibodies harboring the Fc mutants identified using the methods of the invention and tested in ADCC assays, including ch4D5 and ch520C9, two anti-Erb-B2 antibodies, and chCC49, an anti-TAG72 antibody, are preferred for use in animal models since they have been used previously in xenograft mouse model (Hudsiak et al., 1989, Mol. Cell Biol. 9: 1165-72; Lewis et al., 1993, Cancer Immunol, Immunother. 37: 255-63; Bergman et al., 2001 Clin. Cancer Res. 7: 2050-6; Johnson et al., 1995, Anticancer Res. 1387-93). Sufficient quantities of antibodies may be prepared for use in animal models using methods described supra, for example using mammalian expression systems and IgG purification methods disclosed and exemplified herein. A typical experiment requires at least about 5.4 mg of mutant antibody. This calculation is based on average quantities of wild type antibody required to protect 8-10 30 g mice following a loading dose of 4 μg/g and a weekly maintenance dose, 2 μg/g, for ten weeks. invention encompasses tumor cell lines as a source for xenograft tumors, such as SK-BR-3, BT474 and HT29 cells which are derived from patients with breast adenocarcinoma. These cells have both Erb-B2 and the prolactin receptors on their surface. The SK-BR-3 cells have been used successfully in both ADCC and xenograft tumor models. In other assays OVCAR3 cells derived from a human ovarian adenocarcinoma may be used. These cells express the antigen TAG72 on the cell surface and can be used in conjunction with the chCC49 antibody. The use of different antibodies and multiple tumor models will circumvent loss of any specific mutations due to an antibody specific Fc mutant incompatibility.

[0460] Mouse xenograft models may be used for examining efficacy of mouse antibodies generated against a tumor specific target based on the affinity and specificity of the CDR regions of the antibody molecule and the ability of the Fc region of the antibody to elicit an immune response (Wu et al., 2001, Trends Cell Biol. 11: S2-9). Transgenic mice expressing human FcγRs on mouse effector cells are unique and are tailor-made animal models to test the efficacy of human Fc-FcγR interactions. Pairs of FcγRIIIA, FcγRIIB and FcγRIIA transgenic mouse lines generated in the lab of Dr. Jeffrey Ravetch (Through a licensing agreement with Rockefeller U. and Sloan Kettering Cancer center) can be used such as those listed in the Table 11 below.

Table 11: Mice Strains

Strain Background	Human FcR
Nude / CD 16A KO	none
Nude / CD16A KO	FcγRIIIA
Nude / CD16A KO	FcγR IIA
Nude / CD16A KO	FcγR IIA and IIIA
Nude / CD32B KO	none
Nude / CD32B KO	FcγR IIB

[0461] Preferably Fc mutants showing both enhanced binding to FcγRIIIA and reduced binding to FcγRIIB, increased activity in ADCC and phagocytosis assays are tested in animal model experiments. The animal model experiments examine the increase in efficacy of Fc mutant bearing antibodies in FcγRIIIA transgenic, nude mCD16A knockout mice compared to a control which has been administered native antibody. Preferably, groups of 8-10 mice are examined using a standard protocol. An exemplary animal model experiment may comprise the following steps: in a breast cancer model, ~2 x 10⁶ SK-BR-3 cells are injected subcutaneously on day 1 with 0.1 mL PBS mixed with Matrigel (Becton Dickinson). Initially a wild type chimeric antibody and isotype control are administered to establish a curve for the predetermined therapeutic dose, intravenous injection of 4D5 on day 1 with an initial dose of 4 μg/g followed by weekly injections of 2 μg/g. Tumor volume is monitored for 6-8 weeks to measure progress of the disease. Tumor volume should increase linearly with time in animals injected with the isotype control. In contrast very little tumor growth should occur

in the group injected with 4D5. Results from the standard dose study are used to set an upper limit for experiments testing the Fc mutants. These studies are done using subtherapeutic doses of the Fc mutant containing antibodies. A one tenth dose was used on xenograft models in experiments done in Fc γ R1IB knockout mice, see, Clynes et al., 2000, Nat. Med. 6: 443-6, with a resultant block in tumor cell growth. Since the mutants of the invention preferably show an increase in Fc γ R1IIIA activation and reduction in Fc γ R1IB binding the mutants are examined at one tenth therapeutic dose. Examination of tumor size at different intervals indicates the efficacy of the antibodies at the lower dose. Statistical analysis of the data using t test provides a way of determining if the data is significant. Fc mutants that show increased efficacy are tested at incrementally lower doses to determine the smallest possible dose as a measure of their efficacy.

[0462] The anti-inflammatory activity of the combination therapies of invention can be determined by using various experimental animal models of inflammatory arthritis known in the art and described in Crofford L.J. and Wilder R.L., "Arthritis and Autoimmunity in Animals", in Arthritis and Allied Conditions: A Textbook of Rheumatology, McCarty et al. (eds.), Chapter 30 (Lee and Febiger, 1993). Experimental and spontaneous animal models of inflammatory arthritis and autoimmune rheumatic diseases can also be used to assess the anti-inflammatory activity of the combination therapies of invention. The following are some assays provided as examples, and not by limitation.

[0463] The principle animal models for arthritis or inflammatory disease known in the art and widely used include: adjuvant-induced arthritis rat models, collagen-induced arthritis rat and mouse models and antigen-induced arthritis rat, rabbit and hamster models, all described in Crofford L.J. and Wilder R.L., "Arthritis and Autoimmunity in Animals", in Arthritis and Allied Conditions: A Textbook of Rheumatology, McCarty et al. (eds.), Chapter 30 (Lee and Febiger, 1993), incorporated herein by reference in its entirety.

[0464] The anti-inflammatory activity of the combination therapies of invention can be assessed using a carrageenan-induced arthritis rat model. Carrageenan-induced arthritis has also been used in rabbit, dog and pig in studies of chronic arthritis or inflammation. Quantitative histomorphometric assessment is used to determine therapeutic efficacy. The methods for using such a carrageenan-induced arthritis model is described in Hansra P. et al., "Carrageenan-Induced Arthritis in the Rat," Inflammation, 24(2): 141-155, (2000). Also commonly used are zymosan-induced inflammation animal models as known and described in the art.

[0465] The anti-inflammatory activity of the combination therapies of invention can also be assessed by measuring the inhibition of carrageenan-induced paw edema in the rat, using a modification of the method described in Winter C. A. et al., "Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs" Proc. Soc. Exp. Biol Med. 111, 544-547, (1962). This assay has been used as a primary *in vivo* screen for the anti-inflammatory activity of most NSAIDs, and is considered predictive of human efficacy. The anti-inflammatory activity of the test prophylactic or therapeutic agents is expressed as the percent inhibition of the increase in hind paw weight of the test group relative to the vehicle dosed control group.

[0466] Additionally, animal models for inflammatory bowel disease can also be used to assess the efficacy of the combination therapies of invention (Kim et al., 1992, Scand. J. Gastroentrol. 27:529-537; Strober, 1985, Dig. Dis. Sci. 30(12 Suppl):3S-10S). Ulcerative colitis and Crohn's disease are human inflammatory bowel diseases that can be induced in animals. Sulfated polysaccharides including, but not limited to amylopectin, carrageen, amylopectin sulfate, and dextran sulfate or chemical irritants including but not limited to trinitrobenzenesulphonic acid (TNBS) and acetic acid can be administered to animals orally to induce inflammatory bowel diseases.

[0467] Animal models for autoimmune disorders can also be used to assess the efficacy of the combination therapies of invention. Animal models for autoimmune disorders such as type 1 diabetes, thyroid autoimmunity, systemic lupus erthematosus, and glomerulonephritis have been developed (Flanders et al., 1999, Autoimmunity 29:235-246; Krogh et al., 1999, Biochimie 81:511-515; Foster, 1999, Semin. Nephrol. 19:12-24).

[0468] Further, any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utility of the combinatorial therapies disclosed herein for autoimmune and/or inflammatory diseases.

[0469] Toxicity and efficacy of the prophylactic and/or therapeutic protocols using molecules of the instant invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0470] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans. The dosage of such agents lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any agent used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the con-

centration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0471] The anti-cancer activity of the therapies used in accordance with the present invention also can be determined by using various experimental animal models for the study of cancer such as the SCID mouse model or transgenic mice or nude mice with human xenografts, animal models, such as hamsters, rabbits, *etc.* known in the art and described in Relevance of Tumor Models for Anticancer Drug Development (1999, eds. Fiebig and Burger); Contributions to Oncology (1999, Karger); The Nude Mouse in Oncology Research (1991, eds. Boven and Winograd); and Anticancer Drug Development Guide (1997 ed. Teicher), herein incorporated by reference in their entireties.

[0472] Preferred animal models for determining the therapeutic efficacy of the molecules of the invention are mouse xenograft models. Tumor cell lines that can be used as a source for xenograft tumors include but are not limited to, SKBR3 and MCF7 cells, which can be derived from patients with breast adenocarcinoma. These cells have both erbB2 and prolactin receptors. SKBR3 cells have been used routinely in the art as ADCC and xenograft tumor models. Alternatively, OVCAR3 cells derived from a human ovarian adenocarcinoma can be used as a source for xenograft tumors.

[0473] The protocols and compositions of the invention are preferably tested *in vitro*, and then *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. Therapeutic agents and methods may be screened using cells of a tumor or malignant cell line. Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring ³H-thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (*e.g.*, *fos*, *myc*) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, decreased growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, *etc.*

[0474] Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits, hamsters, *etc.*, for example, the animal models described above. The compounds can then be used in the appropriate clinical trials.

[0475] Further, any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utility of the combinatorial therapies disclosed herein for treatment or prevention of cancer, inflammatory disorder, or autoimmune disease.

6. EXAMPLES

[0476] Using a yeast display system, mutant human IgG1 heavy chain Fc regions were screened for modified affinity to different Fe receptors. In particular, a mutant Fc library was generated by error prone PCR (Genemorph, Stratagene), and then the mutant Fc proteins were fused to the Aga2p cell wall protein, which allowed the fusion protein to be secreted extracellularly and displayed on the yeast cell wall.

[0477] Soluble forms of the human receptors (Fc γ R1IIIA and Fc γ R1IIB) were cloned. Detection of the IgG1 Fc domains on the yeast cell surface, however, is hindered due to the low affinity of Fc γ R for its ligand. In order to circumvent this limitation, soluble Fc γ R tetrameric complexes were formed using an AVITAG sequence which could be enzymatically biotinylated and subsequently reacted with streptavidin conjugated to phycoerythrin (SA-PE; Molecular Probes) to form soluble tetrameric Fc γ R complexes. ELISA assays confirmed that the soluble Fc γ R tetrameric complexes had a higher avidity for human IgG1 relative to the monomeric Fc γ R. Fc fusion proteins on the yeast cell surface also bound the soluble Fc γ R tetrameric complexes as assessed by FACS analysis.

[0478] The differential binding of the Fc fusion proteins expressed on the yeast cell surface to soluble tetrameric Fc γ R complexes was monitored by a FACS analysis. Fc fusion proteins with altered affinities for one or more soluble tetrameric Fc γ R complexes were thus identified and were then incorporated into a complete immunoglobulin and expressed in mammalian cells. The mammalian expressed product was used in ELISA assays to confirm the results obtained in the yeast surface display system. Finally, the mutant Fc regions were sequenced to confirm the altered residue(s).

6.1 CLONING, EXPRESSION AND PURIFICATION OF Fc γ R1IIIA

MATERIALS AND METHODS

[0479] Soluble Fc γ R1IIB and Fc γ R1IIIA were cloned as follows. The cDNA clones for the human Fc γ R genes (Fc γ R1IIB and Fc γ R1IIIA) were obtained (gift from Ravetch lab). Soluble region of the Fc γ R1IIIA gene (amino acids 7- 203) was amplified by PCR (Table 12), digested with BamHI/HindIII and ligated into the pET25vector (Novagen). This vector was digested with Sall/NotI and a 370 by fragment was gel isolated. The vector hu3A, (gift from J. Ravetch) was digested with BamHI/Sall and a 270 by fragment containing the N-terminus of Fc γ R1IIIA was isolated. Both fragments were coligated into pcDNA3.1 cut with BamHI/NotI to create pcDNA3-Fc γ R1IIIA (amino acids 1- 203). The soluble region of Fc γ R1IIB

(amino acids 33 - 180) was amplified by PCR (Table 12), digested with BglIII/HindIII and ligated into pET25b(+) (Novagen). This vector was digested with BamHI/NotI and a 140 bp fragment was gel isolated. The vector huRIIb1 (gift from J. Ravetch) was digested with BamHI/EcoRI and a 440 bp N-terminal Fc γ RIIB fragment was isolated. Both of these fragments were coligated into pcDNA3.1 cut with BamHI/NotI to create pcDNA3-Fc γ RIIB (amino acids 1- 180). Recombinant clones were transfected into 293H cells, supernatants were collected from cell cultures, and soluble recombinant Fc γ R (rFc γ R) proteins were purified on an IgG sepharose column.

RESULTS

Recombinant soluble Fc γ RIIIA (rFc γ RIIIA) and Recombinant soluble Fc γ RIIB (r-Fc γ RIIB) were purified to homogeneity

[0480] Subsequent to expression and purification of the recombinant soluble Fc γ R proteins on an IgG sepharose column, the purity and apparent molecular weight of the recombinant purified soluble receptor proteins were determined by SDS-PAGE. As shown in FIG. 3, soluble rFc γ RIIIA (FIG. 3, lane 1) had the expected apparent molecular weight of ~35KDa and soluble rFc γ RIIB (FIG. 3, lane 4) had the expected apparent molecular weight of ~20KDa. As shown in FIG. 3, soluble rFc γ RIIIA migrates as a diffuse "fuzzy" band which has been attributed to the high degree of glycosylation normally found on Fc γ RIIIA (Jefferis, et al., 1995 Immunol Lett. 44, 111-117).

6.1.1 CHARACTERIZATION OF PURIFIED RECOMBINANT SOLUBLE Fc γ RIIIA

MATERIALS AND METHODS

[0481] Purified soluble rFc γ RIIIA, which was obtained as described above, was analyzed for direct binding against human monomeric or aggregated IgG using an ELISA assay. The plate is coated with 10ng of soluble rFc γ RIIIA overnight in 1X PBS. Subsequent to coating, the plate is washed three times in 1X PBS/0.1% Tween 20. Human IgG, either biotinylated monomeric IgG or biotinylated aggregated IgG, is added to the wells at a concentration ranging from 0.03 mg/mL to 2 mg/mL, and allowed to bind to the soluble rFc γ RIIIA. The reaction is carried out for one hour at 37°C. The plate is washed again three times with 1X PBS/0.1% Tween 20. The binding of human IgG to soluble rFc γ RIIIA is detected with streptavidin horseradish peroxidase conjugate by monitoring the absorbance at 650nm. The absorbance at 650nm is proportional to the bound aggregated IgG.

[0482] In a blocking ELISA experiment, the ability of an Fc γ RIIIA monoclonal antibody, 3G8, a mouse anti-Fc γ RIIIA antibody (Pharming), to block the binding of the receptor to aggregated IgG is monitored. The washing and incubation conditions were the same as described above, except that prior to IgG addition, a 5-fold molar excess of 3G8 was added and allowed to incubate for 30 minutes at 37°C.

RESULTS

[0483] Purified, recombinant soluble Fc γ RIIIA binds aggregated IgG specifically

[0484] The direct binding of purified recombinant soluble Fc γ RIIIA to aggregated and monomeric IgG was tested using an ELISA assay (FIG. 4). At an IgG concentration of 2 μ g/ml, strong binding to the aggregated IgG was observed. However, at a similar concentration, no binding was detected to the monomeric IgG. The binding to aggregated IgG was blocked by 3G8, a mouse anti-Fc γ RIIIA monoclonal antibody that blocks the ligand binding site, indicating that the aggregated IgG binding is via that of the normal Fc γ RIIIA ligand binding site (FIG. 4). Soluble rFc γ RIIB was also characterized and shown to bind to IgG with similar characteristics as the soluble rFc γ RIIIA (data not shown).

6.2 FORMATION OF SOLUBLE Fc γ R TETRAMERIC COMPLEXES

MATERIALS AND METHODS

Constriction of plasmids for expression of soluble FcR γ IIIA and FcR γ IIB fused to the AVITAG peptide.

[0485] To generate soluble Fc γ R tetrameric complexes, the soluble region of the human FcR γ IIIA gene (amino acids 7-203) was amplified by PCR (Table 12), digested with BamHI/HindIII and ligated into the pET25b(+) (Novagen). This vector was digested with Sall/NotI, and a 370 bp fragment was isolated by agarose gel electrophoresis. The vector hu3A, (gift from J. Ravetch) was digested with BamHI/Sall, and a 270 bp fragment containing the N-terminus of FcR γ IIIA was isolated. Both fragments were coligated into pcDNA3.1 (Invitrogen), which had been digested with BamHI/NotI to create pcDNA3-FcR γ IIIA (amino acids 1- 203).

[0486] The soluble region of FcR γ IIB (amino acids 33 - 180) was amplified by PCR (Table I), digested with BglIII/HindIII

EP 2 573 114 B1

and ligated into pET25b(+) (Novagen). This vector was digested with BamHI/NotI, and a 140 bp fragment was isolated by agarose gel electrophoresis. The vector huRIIb₄ (gift from J. Ravetch) was digested with BamHI/EcoRI, and a 440 bp FcR γ IIB N-terminal fragment was isolated. Both of these fragments were co-ligated into pcDNA3.1, which had been digested with BamHI/NotI to create pcDNA3-FcR γ IIB (amino acids 1-180). Subsequently, the linker-AVITAG sequence was fused to the C-terminus of both FcR γ RIIIA and FcR γ RIIB. To generate the FcR γ RIIIA-linker-avitag and FcR γ RIIB-linker-avitag constructs, the pcDNA3.1 FcR γ RIIIA and FcR γ RIIB constructs were digested with NotI and XbaI (both cut in the vector sequence) and a 86 base pair double stranded oligonucleotide consisting of NotI site at the 5' end and XbaI at the 3' end was ligated into the vector. This 86 bp fragment was generated by annealing two 5' phosphorylated reverse complement oligonucleotides (shown in Table 12 as 5' and 3' linker.avitag primers) with the restrictions sites for NotI and XbaI already pre-designed. Equal volumes of each primer at 100 ng per μ l were mixed and the DNA heated to 90 °C for 15 minutes and cooled at room temperature for an hour to anneal. This created a doublestranded DNA fragment ready to be ligated to the pcDNA3.1-FcR γ RIIIA and FcR γ RIIB constructs digested with the respective enzymes. Therefore, the pcDNA3.1-FcR γ RIIIA-linker-AVITAG and pcDNA3.1-FcR γ RIIB-linker-AVITAG, were constructed.

TABLE 12: PRIMERS USED FOR CONSTRUCTION OF Fc γ R AND IgG VECTORS

Oligomer	Sequence
5' linker.avitag (SEQ. ID NO. 1)	GGCCGCAGGTGGTGGTGGTTCTGGTGGTGGTGGTTCTGGTCTGAACGACATCTT CGAGGCTCAGAAAA TCGAATGGCACGAATGAT
3' linker.avitag (SEQ. ID NO. 2)	CTAGATCATTTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTACAGACCAG AACCACCACCACCAGAACCACCACCACCTGC
FcRIIIA left (SEQ. ID NO. 3)	G T T G G A T C C T C C A A C T G C T C T G C T A C T T C T A G T T
FcRIIIAright(SEQ. ID NO. 4)	G A A A A G C T T A A A G A A T G A T G A G A T G G T T G A C A C T
FcRIIBright (SEQ. ID NO. 5)	G A A G T C G A C A A T G A T C C C C A T T G G T G A A G A G
FcRIIBleft (SEQ. ID NO. 6)	G T T A G A T C T T G C T G T G C T A T T C C T G G C T C C
IgG1 right(SEQ. ID NO. 7)	A T A G T C G A C C A C T G A T T T A C C C G G A G A
IgG1left (SEQ. ID NO. 8)	G G A A T T C A A C A C C A A G G T G G A C A A G A A A G T T
mcr025;chl (f) (SEQ. ID NO. 9)	A A A G G A T C C G C G A G C T C A G C C T C C A C C A A G G
H021 (SEQ. ID NO.)	G T C T G C T C G A A G C A T T A A C C

Biotinylation by BirA

[0487] Soluble Fc receptors (Fc γ R) fused to the 15 amino acid AVITAG sequence (Avidity, CO) (Schatz P.J., 1993, Biotechnology, 11:1138-1143) at the C-terminus of the protein cloned into pcDNA3.1 were generated by transiently transfecting 293H cells using Lipofectamine 2000 reagent (Invitrogen, CA). Supernatants were collected from the cultures and soluble FcR proteins were purified by passing the supernatants over an IgG sepharose column. Concentration of the soluble FcR-AVITAG fusion protein was quantitated by absorbance at 280 nm. The AVITAG present on the soluble FcR proteins was biotinylated according to the manufacturer's protocol (Avidity, CO) with the *E. coli* BirA enzyme, a biotin ligase. A 1:100 final dilution of a cocktail of protease inhibitors (Sigma catalog #P8849) and 1 mg/ml final concentration of Leupeptin (Sigma L-8511) were added to the mixture to prevent degradation of the proteins. The BirA reaction was incubated at room temperature overnight, following which the solution was concentrated using a Biomax 10K-ultrafiltration device (Millipore) by centrifugation at 3500 rpm at 4°C. The protein was loaded onto an FPLC Superdex 200 HR 10/30 column (Pharmacia Biotech) in Tris-HCl (20 mM, pH 8.0), 50 mM NaCl to separate the labeled soluble Fc γ R from free biotin.

Determination of the extent of biotinylation by streptavidin shift assay

[0488] Approximately 80-85% of the protein was biotinylated by the BirA enzyme (Avidity, CO). The streptavidin-shift assay was used to determine the extent of biotinylation of the protein. Biotinylated protein was incubated with streptavidin (MW 60,000 Daltons) in different ratios. Unbiotinylated protein alone and streptavidin alone are included as controls to determine the extent of biotinylation. The incubation is carried out either on ice for 2 hours or overnight at 4°C. Samples are analyzed on a 4-12% SDS-PAGE Bis-Tris (Invitrogen, CA) with reducing agent and without boiling of the samples. Streptavidin bound biotinylated protein migrates as a high molecular weight band. The extent of biotinylation is estimated by the amount of monomeric protein left in the sample. Absence of monomeric low molecular weight species and presence of a complex with molecular weight greater than streptavidin alone indicates a high degree of biotinylation.

Formation of Fc γ R tetrameric complexes

[0489] Formation of Fc γ R tetrameric complexes was performed according to previously established methodologies for MHC class I tetramers (See Busch, D. H. et al., 1998 Immunity 8:353-362; Altman, J. D. et al., 1996, Science 274: 94-96). The concentration of the biotinylated monomeric Fc γ R was calculated based on absorbance at 280 nm. One molecule of streptavidin-phycoerythrin (SA-PE) (Molecular Probes, OR) has the capacity to bind 4 molecules of biotin. A 5:1 molar ratio of monomeric biotinylated Fc γ R to SA-PE (5X monomeric biotinylated Fc γ R: 1X SA-PE) was used to ensure an excess of biotinylated protein. The calculated molecular weight of SA-PE is 300,000 Daltons, therefore 303 mL of a 1 mg/mL solution of streptavidin-PE has 1 nmole of SA-PE, which was added to 5 nmole of protein. Efficient formation of tetrameric protein requires SA-PE to be added in step-wise increments. Half the amount of SA-PE was added upfront, and the remaining SA-PE was added in small aliquots every 20-30 minutes at 4°C in the dark. The intervals for the addition of the remaining SA-PE is flexible. After the addition of SA-PE was complete, the solution was concentrated and loaded over an FPLC size exclusion column as above in phosphate buffered saline, at pH 7.4. The fraction that eluted in the void volume with a molecular weight greater than SA-PE alone was collected. Protease inhibitors were replenished to prevent protein degradation. The solution was concentrated and additional protease inhibitors were added to the final complex for storage. The final concentration of the soluble Fc γ R tetrameric complex was calculated based on the starting concentration of the biotinylated monomeric protein. For example, if 500 μ g of biotinylated protein was used to make the tetrameric complex and the final concentrated tetramers were in a volume of 500 μ L, the concentration is estimated to be approximately 1 mg/mL (The losses incurred during concentration are not taken into account as it is difficult to accurately determine how much is lost during each step of the formation of the tetramers. It is also not possible to take an absorbance at 280 nm to measure the concentration due to interference from the PE). Soluble Fc γ R tetrameric complexes were dispensed in small aliquots at -80°C for long term storage with protease inhibitors. Sodium azide was not added to these preparations as the tetramers were used for screening a yeast display library. On thawing an aliquot, the tetramers were stored at 4°C for up to 1 week.

ELISA assay for Characterizing the Tetrameric Fc γ R Complexes

[0490] An ELISA was used to characterize the tetrameric Fc γ R complexes. Maxisorb F96 well plate (Nunc) was coated with 25 ng of human IgG in PBS buffer, and incubated overnight at 4 °C. The plates were washed with PBS/0.5% BSA/0.1% Tween 20

[0491] (wash and diluent buffer) before adding the combination of Fc γ R1IIIA tetramers and test antibodies to determine blocking with 3G8, a mouse anti-human Fc γ R1IIIA antibody as described below: The blocking step was performed as follows: soluble Fc γ R1IIIA tetramers at a fixed 0.5 mg/ml final concentration were pre-incubated with antibodies for 1 h at room temperature in buffer, PBS/0.5% BSA/0.1% Tween 20. The final concentrations of the antibodies ranged from 60 mg/mL to 0.25 mg/mL. 3G8 is a mouse anti-human Fc γ R1IIIA antibody, and for the purpose of this experiment, a chimeric version was used, *i.e.*, the variable region of the antibody is a mouse anti-human Fc γ R1IIIA and the constant region of the heavy and light chains is from the IgG1 human region. A chimeric 4.4.20. D265A was also used in this experiment, which is an anti-fluorescein antibody, such that the Fc region contains a mutation at position 265, where an aspartic acid is substituted with alanine in the human IgG1, which results in a reduced binding to Fc γ R. This antibody has been characterized previously (See Clynes et al., 2000, Nat. Med. 6: 443-446; Shields et al., 2001, J. Biol. Chem., 276: 6591-6604). This antibody was used as negative isotype control.

[0492] The antibodies were allowed to bind to Fc γ R1IIIA tetramers, by preincubation for 1 hour at room temperature. The mixture was then added to the IgG on the washed plate and incubated for an additional hour at room temperature. The plate was washed with buffer and DJ130c (a mouse anti-human Fc γ R1IIIA antibody available from DAKO, Denmark; its epitope is distinct from that of the 3G8 antibody) at 1:5000 dilution was added and allowed to incubate for 1 hr. at room temperature in order to detect the bound Fc γ R1IIIA tetramers. Unbound antibodies were washed out with buffer and the bound DJ130c was detected with goat anti-mouse peroxidase (Jackson laboratories). This reagent will not detect

the human Fc. After washing out the unbound peroxidase-conjugated antibody, the substrate, TMB reagent (BioF_x), was added to detect the extent of blocking with 3G8 versus the isotype control and the developed color was read at 650 nm.

[0493] For direct binding of soluble tetrameric Fc_γR1IIIA to IgG by ELISA, maxisorb plates were coated with 25 ng IgG as described above. The soluble tetrameric Fc_γR1IIIA were added from 20 mg/mL to 0.1 mg/mL and the biotinylated monomeric soluble tetrameric Fc_γR1IIIA were added at concentrations ranging from 20 mg/mL to 0.16 mg/mL. Detection was the same as above with DJ130c, followed by goat anti-mouse-peroxidase antibody. Color developed with the TMB reagent and the plate was read at 650 nm.

RESULTS

Soluble Fc_γR1IIIA tetrameric complex binds monomeric human IgG via its normal ligand binding site

[0494] Soluble Fc_γR1IIIA-AVITAG fusion proteins were generated, isolated, and analyzed as described in the Material and Methods section using an ELISA assay and were shown to have similar properties as the non-AVITAG soluble Fc_γR1IIIA protein (data not shown). The fusion proteins were biotinylated, and the tetrameric complexes were generated as described above.

[0495] The soluble Fc_γR tetrameric complex was then assessed for binding its ligand, monomeric human IgG, using an ELISA assay. Analysis by ELISA showed the soluble tetrameric Fc_γR complexes bind monomeric human IgG specifically. As shown in FIG. 5A, binding of soluble tetrameric Fc_γR1IIIA to monomeric human IgG is blocked by 3G8, a mouse anti-human Fc_γIIIa monoclonal antibody, as monitored by the absorbance at 650nm. On the other hand, the 4-4-20 monoclonal antibody harboring the D265A mutation was not able to block the binding of soluble tetrameric Fc_γR1IIIA to monomeric human IgG (FIG. 5A). This experiment thus confirms that binding of the soluble tetrameric Fc_γR1IIIA complex occurs through the native ligand binding site.

Soluble Fc_γR1IIIA tetrameric complex binds monomeric human IgG with a greater avidity than monomeric soluble Fc_γR1IIIA

[0496] The direct binding of soluble tetrameric Fc_γR1IIIA to aggregated human IgG was assessed using an ELISA assay and compared to the direct binding of soluble monomeric Fc_γR1IIIA to monomeric human IgG. As shown in FIG. 5B, soluble tetrameric Fc_γR1IIIA binds human IgG with a higher avidity (8-10 fold) than the soluble monomeric receptor, as monitored by the absorbance at 450 nm.

[0497] The binding of soluble Fc_γR1IIIA tetrameric complex was also assayed using magnetic beads coated with Fc Fragment purified from IgG1 (FIG. 5). Soluble Fc_γR1IIIA tetrameric complex binds to the IgG1 Fc-coated beads, under conditions in which monomer binding is not detected. Specificity of binding was shown by pre-incubating the receptor complex, with an anti-Fc_γR1IIIA monoclonal antibody, LNK16, which blocks Fc binding. This assay further confirms that soluble Fc_γR1IIIA tetrameric complex binds monomeric IgG through its normal ligand binding site, and the avidity of the receptor is increased due to multiple binding sites within the complex.

6.3 CONSTRUCTION OF YEAST STRAIN FOR DISPLAY OF MUTANT IgG1 Fc DOMAINS

MATERIALS AND METHODS

[0498] The pYD1 vector (Invitrogen) is derived directly from a yeast replicating vector, pCT302 (Shusta, et al., 2000 Nat. Biotechnol. 18: 754-759, that has been successfully used to display T-cell receptors and a number of scFVs. This plasmid is centromeric and harbors the TRP1 gene enabling a relatively constant copy number of 1-2 plasmids per cell in a *trp1* yeast strain. Directional cloning into the polylinker places the gene of interest under the control of the *GAL1* promoter and in-frame with *AGA2*. Fusion of the IgG Fc domain to the yeast Aga2p results in the extracellular secretion of the Aga2-Fc fusion protein and subsequent display of the Fc protein on the cell wall via disulfide bonding to the yeast Aga lp protein, which is an integral cell wall protein.

[0499] In order to optimize the display levels, different fragments from the IgG1 heavy chain were amplified by PCR and cloned into pYD1. Specifically, the Fc region of the IgG1 heavy chain (allotype IG1m(a); amino acids 206- 447) was amplified by PCR (Table 1) from the IMAGE clone 182740, digested with EcoRI/Sall and ligated into the pYD1 vector (Invitrogen). The initial clone from IMAGE contained a deletion of a single nucleotide at position 319 which was corrected by *in vitro* site directed mutagenesis to construct pYD-GIF206 (Quickchange, Stratagene).

[0500] The CH1-CH3 fragment (amino acids 118-447) was amplified from the heavy chain clone of the MAb B6.2 in the pCINEO vector using a 5' oligo (mcr025;chl(f)) and a 3' oligo (H021) (See Table 8). The fragment was digested with BamHI/NotI and ligated into the pYD1 vector to construct pYD-CH1.

[0501] FIG. 7, shows a schematic presentation of the constructs. The CH1-CH3 construct contains the CH1 domain in addition to the hinge-CH2-CH3 domains of the heavy chain, GIF206 contains 6 amino acid residues upstream of the

hinge and GIF227 starts within the hinge region at an endogenous proteolytic cleavage site (Jendeborg et al., 1997 J. Immunol Meth. 201: 25-34).

6.4 IMMUNOLocalIZATION AND CHARACTERIZATION OF Fc DOMAINS ON THE YEAST CELL WALL

MATERIALS AND METHODS

[0502] Constructs containing the Aga2p-Fc fusion proteins and a control vector, pYDI, lacking any insert, were transformed into the yeast strain EBY100 (Invitrogen), *MATa ura3-52 trp1 leu2Δ1 his3A200 pep4::HIS3 prb1Δ1.6R can1 GAL::GAL-AGA1*, using a standard lithium acetate yeast transformation protocol (Gietz et al., 1992 Nucleic Acids Res. 20: 1425) Subsequently, tryptophan prototrophs were selected on defined media. Amplification of independent cell populations and induction of Agalp and the Aga2p-Fc fusion proteins were accomplished by growth in glucose, followed by growth in media containing galactose as the primary carbon source for 24-48 hrs at 20°C. Growth in galactose induces expression of the Aga2-Fc fusion proteins via the GAL1 promoter, which subsequently leads to the display of the Fc fusion proteins on the yeast cell surface.

RESULTS

FACS Analysis of Fc Fusion Proteins

[0503] Expression of Fc fusion proteins on the yeast cell surface was analyzed by immunostaining using a PE-conjugated polyclonal F(ab)₂ goat anti-human Fc γ R and HP6017 (Sigma) antibody (Jackson Immunoresearch Laboratories, Inc.). Fluorescence microscopy shows peripheral staining for the three Fc fusion proteins. The control strain, harboring vector alone, shows little or no staining (data not shown). FACS analysis was used to quantitate the staining (FIG. 8). The yeast strain containing the CH1-CH3 fusion demonstrated the highest percentage of cells stained with both antibodies (FIG. 8B and F). The GIF227 construct showed the greatest mean fluorescence intensity (FIG. 8, panels C and G).

Characterization of the Binding of Fc Fusion Proteins Expressed on the Yeast cell Surface

[0504] The natural context of the Fc and Fc γ R proteins places the receptor on the cell surface and the Fc as the soluble ligand; however, the yeast Fc surface display reverses the geometry of the natural interaction. Detection of the IgG1 Fc proteins on the surface of the yeast cell wall is complicated by both the low affinity of the Fc γ R for its ligand and the reverse geometry inherent in the display system. Although the latter point cannot be altered, the avidity of the ligand was improved as explained above by forming soluble Fc γ R tetrameric complexes, which allows detection of Fc γ R binding to the Fc fusion proteins expressed on the surface yeast cell wall.

[0505] To characterize the binding of soluble tetrameric Fc γ R complexes to the surface displayed Fc fusion proteins, yeast cells expressing different Fc constructs were incubated with the soluble rFc γ R111A tetrameric complex and analyzed by FACS. Yeast cells harboring pYD-CH1, displaying the wild type CH1-CH3 construct were bound by the soluble rFc γ R111A tetrameric complex as shown by FACS analysis. The GIF206 and GIF227 strains, however, showed little or no binding to the soluble rFc γ R111A tetrameric complex as shown by FACS analysis (data not shown).

[0506] Mutations in the Fc region that block binding to the Fc γ Rs have been identified (Shields et al., 2001; J Biol.Chem. 276: 6591-6604). One of these mutations, D265A, was incorporated into pYD-CH1 and this mutant was expressed on the yeast cell surface. These cells were incubated with the soluble Fc γ R111A tetrameric complex using a high concentration of ligand (0.15 mM of Fc; 7.5 mM of D265A) FACS analysis indicated that soluble Fc γ R111A tetrameric complex bound to wild type Fc (FIG. 9A) but soluble Fc γ R111A tetrameric complex did not bind to the D265A-Fc mutant indicating that Fc γ R is interacting with the normal FcR binding site in the lower hinge-CH2 region (FIG. 9B).

[0507] Antibodies against the Fc γ R111A ligand binding site blocked binding of the soluble Fc γ R111A tetrameric complex to the wild type Fc protein displayed on the yeast cell surface wall, as analyzed by FACS (FIG. 10). The binding of soluble Fc γ R111A tetrameric complex was blocked by the 3G8 antibody, as well as the LNK16 antibody, another anti-Fc γ R111A monoclonal antibody (Advanced Immunological) (Tam et al., 1996 J. Immunol. 157:, 1576-1581) and was not blocked by an irrelevant isotype control. Therefore, binding of soluble Fc γ R111A tetrameric complex to the Fc proteins displayed on the yeast cell surface occurs through the normal ligand binding site. The limited binding of the Fc γ R111A tetrameric complex indicates that a subpopulation of cells have a correctly folded Fc that is accessible to Fc γ R. There are numerous reasons why only a subpopulation of cells may be able to bind the ligand, for example, they may be at different stages of cell cycle or the fusion proteins may not have been exported.

[0508] In order to determine the dissociation constant of the Fc γ R111A-tetramer binding to the Fc fusion proteins on the yeast cell surface, the binding of a range of Fc γ R111A tetrameric complex was analyzed using FACS. Fc γ R111A tetrameric complex was titrated at concentrations of 1.4 μ M to 0.0006 μ M. Using the mean fluorescence intensity as a

EP 2 573 114 B1

measure of binding affinity and nonlinear regression analysis, the K_D was determined to be 0.006 μM (+/- 0.001) (data not shown).

6.5 CONSTRUCTION OF Fc MUTANT LIBRARY

[0509] A mutant Fc library was constructed using primers flanking the Fc fragment in the Fc-CH1 construct and error-prone PCR (Genomorph, Stratagene). The CH1-CH3 insert in vector pYD-CHI was amplified using a mutagenic PCR (Genomorph, Stratagene). Five reactions were carried out using the pYD-upstream and pYD-downstream primers (Invitrogen). The resultant amplified fragment was digested with XhoI/BamHI and ligated into pYD1. The ligation reaction was then transformed into XL 10 ultracompetent cells (Stratagene), which resulted in $\sim 1 \times 10^6$ transformants, with 80% of the transformants containing inserts.

[0510] Sequence analysis of 28 random plasmids from the library indicated a mutation frequency ~ 2 -3 mutations/kb with a breakdown of 40% conserved nucleotide changes and 60% of the mutations resulting in amino acid changes.

[0511] The library was transformed into the yeast strain EBY100, MAT α *ura3-52 trp1 leu2 Δ 1 his3 Δ 200 pep4::HIS3 prb1 Δ 1.6R can1 GAL GAL-AGA 1::URA3* to a high efficiency, $\sim 3.3 \times 10^5$ transformants/ μg , in 30 independent transformation reactions to create a total of $\sim 10^7$ yeast transformants (Gietz, et al., 1992, Nucleic Acids Res. 20: 1425). The library was pooled and amplified by growth in glucose.

6.6 SELECTION AND ANALYSIS OF Fc MUTANTS

MATERIALS AND METHODS

ELISA assay for screening Fc mutants

[0512] ELISA plates (Nunc F96 MaxiSorp Immunoplate) were coated with 50 μl /well of 0.5 mg/ml BSA-FITC in carbonate buffer at 4°C, and allowed to incubate overnight. Plates were washed with 1X PBS/0.1% Tween 20 (PBST) 3 times. 200 μl /well of PBST/0.5% BSA was added and the plates were incubated for 30 mins at room temperature. Plates were washed three additional times with PBST. 50 μl /well of 1:4 diluted 4-4-20 antibody (approximately 3 mg/mL which would lead to a final concentration of 0.7-0.8 mg/well) either wild type or containing an Fc mutant, was added from conditional medium in PBST/0.5% BSA and allowed to incubate for 2 hrs at room temperature. Plates were washed with PBST three times. Purified, biotinylated monomeric Fc γ RIIIA at 3 mg/ml (in PBST/0.5% BSA) was added (50 μl /well) to the plates and allowed to incubate for 1.5 hours at room temperature. Plates were washed with PBST three times. 50 μl /well of a 1:5000 dilution of Streptavidin-HRP (Pharmacia, RPN 123v) in PBST/0.5% BSA was added and the plates were incubated for 30 minutes at room temperature. Plates were washed with PBST three times. 80 μl /well of TMB reagent (BioFX) was then added to the plates, and allowed to incubate for 10-15 minutes at room temperature in a dark place. The reactions were finally stopped by adding 40 μl /well of stop solution (0.18 M sulfuric acid). Plates were then monitored for absorbance at 450 nm. After the first screen, the interesting candidates were further confirmed by serial titration of 4-4-20-Fc mutants in the immuno-complex based binding ELISA. A few modifications were made in this ELISA. For coating the plates, 2 mg/ml BSA-FITC was used. Based on IgG quantitation results, diluted 4-4-20Fc (wild type or mutants) from conditional medium was added to a final concentration of 1, 0.5, 0.25, 0.125, 0.063, and 0 mg/ml in PBST/0.5% BSA.

FACS Screen for the Cell Surface displayed Fc proteins

[0513] Cells were grown in at least 10 mls of HSM-Trp-Ura pH 5.5 with glucose for 16-24 hrs or until OD₆₀₀ was greater than 2.0. Cells were spun down at ~ 2000 rpm for 5 minutes. Cells were resuspended in an equal volume of HSM-Trp-Ura, pH 7.0 with galactose. In a 125 ml flask, 36 mls of galactose media was added, and inoculated with 9 mls of culture, which was incubated at 20°C with shaking for 24-48 hrs. Growth was monitored by measuring OD₆₀₀ at 8-16 hr intervals. Cells were harvested at 2K rpm for 5 minutes, and resuspended in an equal volume of 1XPBS, pH 7.4.

[0514] *Equilibrium screen:* An appropriate amount of cells was incubated while maintaining an excess of ligand. For example, it is preferred to start with a number of cells needed to ensure 10-fold coverage of the library. For the first sort with a library containing 10^7 transformants, 10^8 cells should be used. In fact it is best to start with 10^9 cells to compensate for loss during the staining protocol.

[0515] Incubation was typically done in a 1.5 mL tube in volumes of 20-100 μl for 1 hour at 4°C in the dark on a rotator (incubation buffer: 1XPBS H7.4; 1 mg/ml BSA). Cells were washed once in 500 μl of incubation buffer and spun down at 4K rpm for 2.5 minutes. Cells were resuspended in 100 μl incubation buffer and incubated with the second staining reagent. For Fc-CH1, a F(ab)₂ goat anti-hFc F(ab)₂-FITC antibody (Jackson ImmunoResearch Laboratories, Inc.) can be used to stain for CH1 expression. Staining was done with 1 μl for 30 minutes. Cells were washed additionally

EP 2 573 114 B1

in 500 mL of incubation buffer and spun down at 4K rpm for 2.5 minutes, resuspended in 1 mL IX PBS 1 mg/mL BSA and analyzed by FACS.

[0516] Typical equilibrium screen sort gates and number of cells collected are shown in Table 13.

TABLE 13. SORT GATES AND NUMBER OF CELLS SORTED

Sort	Gate	total cells screened	cells collected
1 st	5%	10^8	5×10^6
2 nd	1%	10^7	1×10^5
3 rd	0.2%	10^7	2×10^4
4 th	0.2%	10^7	2×10^4

[0517] After the 3rd and 4th sorts, cells were plated directly on -trp-ura plates to identify individual mutants. This typically recovered ~200-400 colonies per plate. After collection the cells were placed in 10 mLs of glucose media in a 50 mL conical tube and grown at 30°C. The whole procedure was repeated iteratively.

RESULTS

FACS analysis of Fc Mutants

[0518] After induction in galactose media, cells were harvested and co-stained with soluble Fc γ R1IIA tetrameric complex-PE labeled and F(ab₂) of mouse anti-human Fc-FITC labeled (Jackson ImmunoResearch Laboratories, Inc.). Cells were analyzed by FACS and sort gates were used to select the cells that showed the highest affinity for the soluble Fc γ R1IIA tetrameric complex relative to the amount of Fc expression on the cell surface (FIG. 11). For example, a cell containing a mutant Fc that binds better to the soluble Fc γ R1IIA tetrameric complex may express fewer Fc fusion proteins on the yeast cell surface, and this cell will be in the lower left hand corner of the sort gate.

[0519] Four consecutive sorts were done to enrich for those mutants that showed the highest affinity for the soluble Fc γ R1IIA tetrameric complex. The gates for each successive sort were 5.5%, 1%, 0.2% and 0.1%. After the last sort, cells were plated onto selective media and individual colonies were isolated. Each individual colony represented a clonal population of cells harboring a single Fc mutant within the Aga2-Fc fusion protein. Initially 32 independent colonies were picked and tested by FACS for binding to soluble Fc γ R1IIA tetrameric complex (FIG. 12). Eighteen mutants showed an increase in binding intensity as measured by the percentage of cells bound by soluble Fc γ R1IIA tetrameric complex and the mean fluorescence intensity of the bound cells.

[0520] Mutations showing an increase in binding to Fc γ R1IIA were also tested for binding to soluble Fc γ R1IIB tetrameric complex (FIG. 12). Most mutations that lead to an increase in binding to the soluble Fc γ R1IIA tetrameric complex also resulted in detection of Fc γ R1IIB tetrameric complex staining (FIG. 12). Based on both previous physical and genetic data, some mutations that increase binding to Fc γ R1IIA, are expected to also increase binding to Fc γ R1IIB (Shields et al., 2001, J Biol. Chem. 276: 6591-6604; Sondermann et al., 2000, Nature 406: 267-273).

Analysis of mutants in a 4-4-20 MAb produced in a human cell line.

[0521] Isolation and analysis of mutations in the yeast system allows for fast identification of novel mutant alleles. The use of a heterologous system to isolate mutations could result in the identification of mutations that enhance binding through an alteration that results in misfolding or alteration in glycosylation that is specific to yeast. To analyze the Fc mutations in an immunoglobulin molecule that is produced in human cells, the mutants were subcloned into a mammalian expression vector, containing the heavy chain of the anti-fluorescein monoclonal antibody, 4-4-20 (Kranz et al., 1982 J.Biol.Chem, 257(12): 6987-6995). The mutant 4-4-20 heavy chains were transiently coexpressed with the light chain clones in the human kidney cell line (293H). Supernatants were collected and analyzed by ELISA (FIG. 13).

[0522] According to the ELISA assay, the majority of the mutants that were identified as having an enhanced affinity for the soluble monomeric Fc γ R1IIA complex, in the secondary FACS analysis, also showed an increase in binding to the soluble Fc γ R1IIA tetrameric complex when present in the Fc region of the 4-4-20 monoclonal antibody produced in the human cell line (FIG. 13A). Two mutants, number 16 and number 19, however, showed a decrease in binding to the soluble Fc γ R1IIA monomeric complex.

[0523] Table 14, summarizes the mutations that have been identified and their corresponding binding characteristics to Fc γ R1IIA and Fc γ R1IIB, as determined by both yeast display based assays and ELISA. In Table 14, the symbols represent the following: ● corresponds to a 1-fold increase in affinity; + corresponds to a 50% increase in affinity; -cor-

EP 2 573 114 B1

responds to a 1-fold decrease in affinity; → corresponds to no change in affinity compared to a comparable molecule comprising a wild-type Fc region.

TABLE 14: MUTATIONS IDENTIFIED AND BINDING CHARACTERISTICS

Clone #	Mutation sites	Domain	IIIA binding	IIB binding
4	A339V, Q347H	CH2, CH3	+	+
5	L251P, S415I	CH2, CH3	+	+
7	Aga2p-T43I	Note: This is a mutation in Aga2P that enhances display.		Aga2p-T43I
8	V185M, K218N, R292L, D399E	CH1,hinge,CH2, CH3	no change	-
12	K290E, L142P	CH1,CH2	+	not tested
16	A141V, H268L, K288E, P291S	CH1,CH2	-	not tested
19	L133M, P150Y, K205E, S383N, N384K	CH1,CH2,CH3	-	not tested
21	P396L	CH3	●	●+
25	P396H	CH3	●●●	●●
6	K392R	CH3	no change	no change
15	R301C, M252L, S192T	CH1,CH2	-	not tested
17	N315I	CH2	no change	not tested
18	S132I	CH1	no change	not tested
26	A162V	CH1	no change	not tested
27	V348M, K334N, F275I, Y202M, K147T	CH1,Ch2	+	+
29	H310Y, T289A, G337E	CH2	-	not tested
30	S119F, G371S, Y407N, E258D	CH1,CH2,CH3	+	no change
31	K409R, S166N	CH1,CH3	no change	not tested
20	S408I, V215I, V125I	CH1,hinge,CH3	+	no change
24	G385E,P247H	CH2, CH3	●●●	+
16	V379M	CH3	●●	no change
17	S219Y	Hinge	●	-
18	V282M	CH2	●	-
31	F275I, K334N, V348M	CH2	+	no change
35	D401V	CH3	+	no change
37	V280L, P395S	CH2	+	-
40	K222N	Hinge	●	no change
41	K246T, Y319F	CH2	●	no change
42	F243I, V379L	CH2,CH3	●+	-
43	K334E	CH2	●+	-
44	K246T,P396H	CH2,CH3	●	●●+
45	H268D, E318D	CH2	●+	●●●●●

EP 2 573 114 B1

(continued)

Clone #	Mutation sites	Domain	IIIA binding	IIB binding	
5	49	K288N, A330S, P396L	CH2,CH3	●●●●●●	●●●●
	50	F243L, R255L, E318K	CH2	●	-
	53	K334E, T359N, T366S	CH2,CH3	●	no change
	54	I377F	CH3	●+	+
10	57	K334I	CH2	●	no change
	58	P244H, L358M, V379M, N384K, V397M	CH2,CH3	●+	●+
	59	K334E, T359N, T366S (independent isolate)	CH2,CH3	●+	no change
15	61	I377F (independent isolate)	CH3	●●●	●●+
	62	P247L	CH2	●●	●●+
20	64	P217S, A378V, S408R	Hinge, CH3	●●	●●●●+
	65	P247L, I253N, K334N	CH2	●●●	●●+
	66	K288M, K334E	CH2	●●●	-
	67	K334E, E380D	CH2,CH3	●+	-
25	68	P247L (independent isolate)	CH2	+	●●●●
	69	T256S, V305I, K334E, N390S	CH2,CH3	●+	no change
	70	K326E	CH2	●+	●●+
30	71	F372Y	CH3	+	●●●●●+
	72	K326E (independent isolate)	CH2	+	●●
	74	K334E, T359N, T366S (independent isolate)	CH2,CH3	●●	no change
35	75	K334E (independent isolate)	CH2	●●+	no change
	76	P396L (independent isolate)	CH3	●+	no change
	78	K326E (independent isolate)	CH2	●●	●●●+
40	79	K246I, K334N	CH2	●	●●●●
	80	K334E (independent isolate)	CH2	●	no change
	81	T335N, K370E, A378, T394M, S424L	CH2,CH3	●	no change
45	82	K320E, K326E	CH2	●	●
	84	H224L	Hinge	●	●●●●●
	87	S375C,P396L	CH3	●+	●●●●+
	89	E233D, K334E	CH2	●+	no change
50	91	K334E (independent isolate)	CH2	●	no change
	92	K334E (independent isolate)	CH2	●	no change
55	94	K334E, T359N, T366S, Q386R	CH2	●	no change

[0524] Analysis of soluble Fc γ R1IB tetrameric complex binding shows that 7 out of the 8 mutants that showed an increase in binding to the soluble Fc γ R1IIA tetrameric complex also had an increased binding to the soluble Fc γ R1IB

tetrameric complex (FIG. 13B). One mutant, number 8, showed a decrease in binding to the soluble Fc γ R1IB tetrameric complex. Three of the mutants show no difference in binding to either the soluble Fc γ R1IIIA tetrameric complex or the soluble Fc γ R1IB tetrameric complex, possibly due to mutations that result in yeast specific alterations.

5 6.7 ADCC ASSAY OF Fc MUTANTS

[0525] *Effectors cell preparation:* Peripheral blood mononuclear cells (PBMC) were purified by Ficoll-Paque (Pharmacia, 17-1440-02) Ficoll-Paque density gradient centrifugation from normal peripheral human blood (Biowhittaker/Poietics, 1W-406). Blood was shipped the same day at ambient temperature, and diluted 1:1 in PBS and glucose (1g/1L) and layered onto Ficoll in 15 mL conical tubes (3 mL Ficoll; 4 mL PBS/blood) or 50mL conical tubes (15mL: Ficoll; 20mL PBS/blood). Centrifugation was done at 1500 rpm (400 rcf) for 40 minutes at room temperature. The PBMC layer was removed (approximately 4-6 mL from 50 mL conical tube) and diluted 1:10 in PBS (which contains no Ca²⁺ or Mg²⁺) in a 50 mL conical tube, and spun for an additional ten minutes at 1200 rpm (250 rcf) at room temperature. The supernatant was removed and the pellets were resuspended in 10-12 mL PBS (which contains no Ca²⁺ or Mg²⁺), transferred to 15 mL conical tubes, and spun for another 10 minutes at 1200 rpm at room temperature. The supernatant was removed and the pellets were resuspended in a minimum volume (1-2 mL) of media (Isocove's media (IMDM) + 10% fetal bovine serum (FBS), 4 mM Gln, Penicillin/Streptomycin (P/S)). The resuspended PBMC were diluted to the appropriate volume for the ADCC assay; two fold dilutions were done in an ELISA 96 well plate (Nunc F96 MaxiSorp Immunoplate). The yield of PBMC was approximately 3-5x10⁷ cells per 40-50 mL of whole blood.

[0526] *Target cell preparation:* Target cells used in the assay were SK-BR-3 (ATCC Accession number HTB-30; Trempe et al., 1976, Cancer Res. 33-41), Raji (ATCC Accession number CCL-86; Epstein et al., 1965, J. Natl. Cancer Inst. 34: 231-40), or Daudi cells (ATCC Accession number CCL-213; Klein et al., 1968, Cancer Res. 28: 1300-10) (resuspended in 0.5 mL IMDM media) and they were labeled with europium chelate bis(acetoxymethyl) 2,2',6',2" terpyridine 6,6' dicarboxylate (BATDA reagent; Perkin Elmer DELFIA reagent; C136-100). K562 cells (ATCC Accession number CCL-243) were used as control cells for NK activity. The Daudi and Raji cells were spun down; the SK-BR-3 cells were trypsinized for 2-5 minutes at 37°C, 5% CO₂ and the media was neutralized prior to being spun down at 200-350 G. The number of target cells used in the assays was about 4-5x10⁶ cells and it did not exceed 5x10⁶ since labeling efficiency was best with as few as 2x10⁶ cells. Once the cells were spun down, the media was aspirated to 0.5 mL in 15 mL Falcon tubes. 2.5 μ l of BATDA reagent was added and the mixture was incubated at 37°C, 5% CO₂ for 30 minutes. Cells were washed twice in 10mL PBS and 0.125 mM sulfinpyrazole ("SP"; SIGMA S-9509); and twice in 10 mL assay media (cell media + 0.125 mM sulfinpyrazole). Cells were resuspended in 1 mL assay media, counted and diluted.

[0527] When SK-BR-3 cells were used as target cells after the first PBS/SP wash, the PBS/SP was aspirated and 500 μ g/mL of FITC was added (PIERCE 461110) in IMDM media containing SP, Gln, and P/S and incubated for 30 minutes at 37°C, 5% CO₂. Cells were washed twice with assay media; resuspended in 1 mL assay media, counted and diluted.

[0528] *Antibody Opsonization:* Once target cells were prepared as described *supra*, they were opsonized with the appropriate antibodies. In the case of Fc variants, 50 μ L of 1x10⁵ cells/mL were added to 2x concentration of the antibody harboring the Fc variant. Final concentrations were as follows: Ch-4-4-20 final concentration was 0.5-1 μ g/mL; and Ch4D5 final concentration was 30 ng/mL-1 ng/mL.

[0529] Opsonized target cells were added to effector cells to produce an effector:target ratio of 75:1 in the case of the 4-4-20 antibodies with Fc variants. In the case of the Ch4D5 antibodies with Fc variants, effector: target ratio of 50:1 or 75:1 were achieved. Effective PBMC gradient for the assay ranges from 100:1 to 1:1. Spontaneous release (SR) was measured by adding 100 μ L of assay media to the cells; maximal release (MR) was measured by adding 4% TX-100. Cells were spun down at 200 rpm in a Beckman centrifuge for 1 minute at room temperature at 57 G. Cells were incubated for 3-3.5 hours at 37°C, 5%CO₂. After incubation, the cells were spun at 1000 rpm in a Beckman centrifuge (about 220xg) for five minutes at 10°C. 20 μ l of supernatant was collected; 200 μ L of Eu solution was added and the mixture was shaken for 15 minutes at room temperature at 120 rpm on a rotary shaker. The fluorescence was quantitated in a time resolved fluorometer (Victor 1420, Perkin Elmer)

50 RESULTS

[0530] As described above, the variant Fc regions were subcloned into a mammalian expression vector, containing the heavy chain of the anti-fluoresceine monoclonal antibody, 4-4-20 (Kranz et al., 1982 J.Biol.Chem, 257(12): 6987-6995). The variant 4-4-20 heavy chains were transiently coexpressed with the light chain clones in the human kidney cell line (293H). Supernatants were collected and analyzed using the ADCC assay. FIG. 14 shows that ADCC activity of the mutants is concentration-dependent. As summarized in Table 8, five immunoglobulins with variant Fc regions had an enhanced ADCC activity relative to wild type ch 4-4-20. The five mutants were as follows: MGFc-27 (G316D, A378V, D399E); MGFc-31 (P247L, N421K); MGFc-10 (K288N, A330S, P396L); MGFc-28 (N315I, V379M,

EP 2 573 114 B1

T394M); MGFc-29 (F243I, V379L, G420V).

[0531] Additional 4-4-20 immunoglobulins with variant Fc regions were assayed for their ADCC activity relative to a 4-4-20 immunoglobulin with a wild-type Fc region. These results are summarized in Table 15.

[0532] ADCC assays were also carried out using the same protocol as previously described for the 4-4-20 antibody, however, the variant Fc regions were cloned into a humanized antibody (Ab4D5) which is specific for the human epidermal growth factor receptor 2 (HER2/neu). In this case, SK-BR-3 cells were used as the target cells that were opsonized with a HER2/neu antibody carrying a variant Fc region. HER2/neu is endogenously expressed by the SK-BR-3 cells and therefore present on the surface these cells. FIG. 15 shows the ADCC activity of HER2/neu antibodies carrying variant Fc regions. Table 16 summarizes the results of ADCC activity of the mutants in the context of the HER2/neu antibody. Normalization was carried out by comparing the concentration of the mutant to the wildtype antibody required for a specific value of percent cell lysis.

[0533] As shown in FIG. 15A, MGFc-5 (V379M), MGFc-9 (P243I, V379L), MGFc-10 (K288N, A330S, P396L), MGFc-13 (K334E, T359N, T366S), and MGFc-27 (G316D, A378V, D399E) mutants that were cloned in to the humanized anti-HER2/neu antibody exhibited a higher % specific lysis of SK-BR-3 cells relative to the wild antibody.

Table 15. SUMMARY OF ADCC ACTIVITY OF MUTANTS

Label	Ref	Fc Variant Amino Acid Variation	ADCC			
			1ug/ml		0.5ug/ml	
			% specific lysis	Normalized	% specific lysis	Normalized
MGFc-27	2C4	G316D, A378V, D399E	33%	2.24	22%	3.60
MGFc-31	3B9	P247L, N421K	30%	2.05	17%	2.90
MGFc-10	1E1	K288N, A330S, P396L	24%	1.66	10%	1.67
MGFc-28	2C5	N315I, V379M, T394M	20%	1.37	10%	1.69
MGFc-29	3D11	F243I, V379L, G420V	20%	1.35	7%	1.17
ch4-4-20 (P54008)			15%	1.00	6%	1.00
MGFc-35	3D2	R255Q, K326E	11%	0.79	3%	0.53
MGFc-36	3D3	K218R, G281D, G385R	10%	0.67	5%	0.78
MGFc-30	3A8	F275Y	9%	0.64	2%	0.37
MGFc-32	3C8	D280E, S354F, A431D, L441I	9%	0.62	4%	0.75
MGFc-33	3C9	K317N, F423deleted	3%	0.18	-1%	-0.22
MGFc-34	3B10	F241L, E258G	-1%	-0.08	-4%	-0.71
MGFc-26		D265A	1%	0.08	-3%	-0.45

Table 16: SUMMARY OF MUTANTS

Fc Variant	Amino Acid changes	FcR3A, K_D/K_{off}	FcR2B, K_D/K_{off}	ELISA IIIA binding	ELISA IIB binding	Phagocytosis (mutant/WT)	4-4-20 ADCC (mutant/wt)	Anti-HER2 ADCC (mutant/wt)
Wt	none	198/0.170	94-.094	1	1	1	1	1
MGFc 5	V379M	160/0.167	70/0.10	2X	N/C	0.86	2.09	1.77
MGFc 9	P243I, V379L	99.7/0.105	120/0.113	1.5X	reduced	?	2.25	2.04
MGFc 10	K288N, A330S, P396L	128/0.115	33.4/0.050	5X	3X	1.2	2.96	2.50
MGFc 11	F243L, R255L	90/0.075	74.7/0.09	1x	reduced	0.8	2.38	1.00
MGFc 13	K334E, T359N, T366S	55.20.128	72/0.11	1.5X	N/C	[1.57	3.67
MGFc 14	K288M, K334E	75.4/0.1	95.6/0.089	3X	reduced	[1.74	
MOFc 23	K334E, R292L	70.2/0.105	108/0.167			[2.09	1.6
MGFc 27	G316D, A378V, D399E	72/0.117	46/0.06	1.5X	14X	1.4	3.60	6.88
MGFc 28	N315I, A379M, D399E			1X	9X	1.37	1.69	1.00
MGFc 29	P243I, V379L, G420V	108/0.082	93.4/.101	2.5X	7X	0.93	1.17	1.00
MGFc 31	P247L, N421K	62/0.108	66/0.065	3X	N/C	1.35	2.90	1.00
MGFc 37	K248M	154/0.175	100/0.091	1.4X	reduced	0.98	3.83	0.67
MGFc 38	K392T, P396L	84/0.104	150/0.041	4.5X	2.5X	1.4	3.07	2.50
MGFc 39	E293V, Q295E, A327T	195/0.198	86/0.074	1.4X	reduced	1.5	4.29	0.50
MGFc 40	K248M	180/0.186	110/0.09	1.4X	reduced	1-14	4.03	
MGFc 41	H268N, P396L	1178/0.159	46.6/0.036	2.2X	4.5X	1.96	2.24	0.67
MGFc 43	Y319F, P352L, P396L	125/0.139	55.7/0.041	3.5X	2X	1.58	1.09	

6.8 ANALYSIS OF KINETIC PARAMETERS OF Fc MUTANTS

[0534] Kinetic parameters of the binding of ch4-4-20 antibodies harboring Fc mutants to Fc γ R1IIIA and Fc γ R1IIB were analyzed using a BIAcore assay (BIAcore instrument 1000, BIAcore Inc., Piscataway, N.J.). The Fc γ R1IIIA used in this assay was a soluble monomeric protein, the extracellular region of Fc γ R1IIIA joined to the linker-AVITAG sequence as described in Section 6.2 *supra*. The Fc γ R1IIB used in this assay was a soluble dimeric protein prepared in accordance with the methodology described in U.S. Provisional Application No. 60/439,709 filed on January 13, 2003, which is incorporated herein by reference. Briefly, the Fc γ R1IIB used was the extracellular domain of Fc γ R1IIB fused to the hinge-CH2-CH3 domain of human IgG2.

[0535] BSA-FITC (36 μ g/mL in 10mM Acetate Buffer at pH 5.0) was immobilized on one of the four flow cells (flow cell 2) of a sensor chip surface through amine coupling chemistry (by modification of carboxymethyl groups with mixture of NHS/EDC) such that about 5000 response units (RU) of BSA-FITC was immobilized on the surface. Following this, the unreacted active esters were "capped off" with an injection of 1M Et-NH₂. Once a suitable surface was prepared, ch 4-4-20 antibodies carrying the Fc mutations were passed over the surface by one minute injections of a 20 μ g/mL solution at a 5 μ L/mL flow rate. The level of ch-4-4-20 antibodies bound to the surface ranged between 400 and 700 RU. Next, dilution series of the receptor (Fc γ R1IIIA and Fc γ R1IIB-Fc fusion protein) in HBS-P buffer (10mM HEPES, 150 mM NaCl, .005% Surfactant P20, 3mMEDTA, pH 7.4) were injected onto the surface at 100 μ L/min. Antibody regeneration between different receptor dilutions was carried out by single 5 second injections of 100mM NaHCO₃ pH 9.4; 3M NaCl.

[0536] The same dilutions of the receptor were also injected over a BSA-FITC surface without any ch-4-4-20 antibody at the beginning and at the end of the assay as reference injections.

[0537] Once an entire data set was collected, the resulting binding curves were globally fitted using computer algorithms supplied by the manufacturer, BIAcore, Inc. (Piscataway, NJ). These algorithms calculate both the K_{on} and K_{off} , from which the apparent equilibrium binding constant, K_D is deduced as the ratio of the two rate constants (*i.e.*, K_{off}/K_{on}). More detailed treatments of how the individual rate constants are derived can be found in the BIAevaluation Software Handbook (BIAcore, Inc., Piscataway, NJ).

[0538] Binding curves for two different concentrations (200 nM and 800 nM for Fc γ R1IIIA and 200 nM and 400nM for Fc γ R1IIB fusion protein) were aligned and responses adjusted to the same level of captured antibodies, and the reference curves were subtracted from the experimental curves. Association and dissociation phases were fitted separately. Dissociation rate constant was obtained for interval 32-34 sec of the dissociation phase; association phase fit was obtained by a 1:1 Langmuir model and base fit was selected on the basis R_{max} and χ^2 criteria.

RESULTS

[0539] FIG. 16 shows the capture of ch 4-4-20 antibodies with mutant Fc regions on the BSA-FITC-immobilized sensor chip. 6 μ L of antibodies at a concentration of about 20 μ g/mL were injected at 5 μ L/min over the BSA-FITC surface. FIG. 17 is a sensogram of real time binding of Fc γ R1IIIA to ch-4-4-20 antibodies carrying variant Fc regions. Binding of Fc γ R1IIIA was analyzed at 200 nM concentration and resonance signal responses were normalized at the level of the response obtained for the wild type ch-4-4-20 antibody. Kinetic parameters for the binding of Fc γ R1IIIA to ch-4-4-20 antibodies were obtained by fitting the data obtained at two different Fc γ R1IIIA concentrations, 200 and 800 nM (FIG. 18). The solid line represents the association fit which was obtained based on the K_{off} values calculated for the dissociation curves in interval 32-34 seconds. K_D and K_{off} represent the average calculated from the two different Fc γ R1IIIA concentrations used. FIG. 19 is a sensogram of real time binding of Fc γ R1IIB-Fc fusion protein to ch-4-4-20 antibodies carrying variant Fc regions. Binding of Fc γ R1IIB-Fc fusion protein was analyzed at 200 nM concentration and resonance signal responses were normalized at the level of the response obtained for the wild type ch-4-4-20 antibody. Kinetic parameters for the binding of Fc γ R1IIB-Fc fusion protein to ch-4-4-20 antibodies were obtained by fitting the data obtained at two different Fc γ R1IIB-Fc fusion protein concentrations, 200 and 800 nM (FIG. 20). The solid line represents the association fit which was obtained based on the K_{off} calculated for the dissociation curves in interval 32-34 seconds. K_D and K_{off} represent the average from the two different Fc γ R1IIB-Fc fusion protein concentrations used.

[0540] The kinetic parameters (K_{on} and K_{off}) that were determined from the BIAcore analysis correlated with the binding characteristic of the mutants as determined by an ELISA assay and the functional activity of the mutants as determined in an ADCC assay. Specifically, as seen in Table 17, mutants that had an enhanced ADCC activity relative to the wild-type protein, and had an enhanced binding to Fc γ R1IIIA as determined by an ELISA assay had an improved K_{off} for Fc γ R1IIIA (*i.e.*, a lower K_{off}). Therefore, a lower K_{off} value for Fc γ R1IIIA for a mutant Fc protein relative to a wild type protein may be likely to have an enhanced ADCC function. On the other hand, as seen in Table 18, mutants that had an enhanced ADCC activity relative to the wild-type protein, and had a reduced binding for Fc γ R1IIB-Fc fusion protein as determined by an ELISA assay had a higher K_{off} for Fc γ R1IIB - Fc fusion protein.

[0541] Thus, the K_{off} values for Fc γ R1IIIA and Fc γ R1IIB can be used as predictive measures of how a mutant will behave in a functional assay such as an ADCC assay. In fact, ratios of K_{off} values for Fc γ R1IIIA and Fc γ R1IIB-Fc fusion protein of

EP 2 573 114 B1

the mutants to the wild type protein were plotted against ADCC data (FIG 21). Specifically, in the case of K_{off} values for $Fc\gamma RIIIA$, the ratio of K_{off} (wt)/ K_{off} (mutant) was plotted against the ADCC data; and in the case of K_{off} values for $Fc\gamma RIIIB$, the ratio of K_{off} (mut)/ K_{off} (wt) was plotted against the ADCC data. Numbers higher than one (1) show a decreased dissociation rate for $Fc\gamma RIIIA$ and an increased dissociation rate for $Fc\gamma RIIIB$ -Fc relative to wild type. Mutants that fall within the indicated box have a lower off rate for $Fc\gamma RIIIA$ binding and a higher off-rate for $Fc\gamma RIIIB$ -Fc binding, and possess an enhanced ADCC function.

Table 17. Kinetic parameters of FcRIIIa binding to ch4-4-20Ab obtained by “separate fit” of 200nM and 800nM binding curves

Ch4-4-20Ab	BIACore Kd,nM	K_{on} 1/Ms	K_{off} , 1/s	ELISA,OD	ADCC, %
Wt(0225)	319	6.0×10^5	0.170	0.5	17.5
Mut11(0225)	190	8.22×10^5	0.1075	0.37	32
Mut5(0225)	214	8.2×10^5	0.172	0.75	26
Mut6(0225)	264	6.67×10^5	0.175	0.6	23
Mut8(0225)	234	8.3×10^5	0.196	0.5	22
Mut10(0225)	128	9.04×10^5	0.115	1.0	41
Mut12(0225)	111	1.04×10^6	0.115	1.0	37
Mut15(0225)	167.9	1.97×10^6	0.133	1.0	15
Mut16(0225)	184.8	1.60×10^6	0.133	1.0	15
Mut18(0225)	92	1.23×10^6	0.112	1.0	28
Mut25(0225)	48.6	2.05×10^6	0.1	1.0	41
Mut14(0225)	75.4	1.37×10^6	0.1	1.1	28
Mut17(0225)	70.5	1.42×10^6	0.1	1.25	30
Mut19(0225)	100	1.20×10^6	0.120	0.75	14
Mut20(0225)	71.5	1.75×10^6	0.126	0.5	10
Mut23(0225)	70.2	1.43×10^6	0.105	1.25	25

[0542] Highlighted mutants do not fit to the group by ELISA or ADCC data.

Table 18. Kinetic parameters of FcRIIB-Fc binding to wild type and mutant ch4-4-20Ab obtained by “separate fit” of 200 nM and 800 nM binding curves.

Ch4-4-20Ab	BIAcore Kd,nM	K _{on} 1/Ms	K _{off} , 1/s	ELISA,OD	ADCC, %
Wt(0225)	61.4		0.085	0.4	17.5
Mut1(0225)	82.3		0.08	0.08	32
Mut5(0225)	50		0.057	0.6	26
Mut6(0225)	66.5		0.060	0.35	23
Mut8(0225)	44.2		0.068	0.25	22
Mut10(0225)	41.3		0.05	1.2	41
Mut12(0225)	40.1		0.051	0.4	37
Mut15(0225)	37.8		0.040	1.55	15
Mut16(0225)	40		0.043	1.55	15
Mut18(0225)	51.7		0.043	1.25	28
Mut25(0225)			0.042	0.08	41
Mut14(0225)	95.6		0.089	0.13	28
Mut17(0225)	55.3		0.056	0.38	30
Mut19(0225)	45.3		0.046	1.0	11
Mut20(0225)	24.1		0.028	0.8	10
Mut23(0225)	108		0.107	0.1	25

6.9 SCREENING FOR Fc MUTANTS USING MULTIPLE ROUNDS OF ENRICHMENT USING A SOLID PHASE ASSAY

[0543] The following mutant screens were aimed at identifying additional sets of mutants that show improved binding to Fc γ RIIIA and reduced binding to Fc γ RIIB. Secondary screening of selected Fc variants was performed by ELISA followed by testing for ADCC in the 4-4-20 system. Mutants were then selected primarily based on their ability to mediate ADCC via 4-4-20 using Fluorescein coated SK-BR3 cells as targets and isolated PBMC from human donors as the effector cell population. Fc mutants that showed a relative increase in ADCC, e.g., an enhancement by a factor of 2 were then cloned into anti-HER2/neu or anti-CD20 chAbs and tested in an ADCC assay using the appropriate tumor cells as targets. The mutants were also analyzed by BIAcore and their relative K_{off} were determined.

[0544] *Screen 1: Sequential solid phase depletion and selection using Magnetic beads coated with Fc γ RIIB followed by selection with magnetic beads coated with Fc γ RIIIA.* The aim of this screen was identification of Fc mutants that either no longer bind Fc γ RIIB or show reduced binding to Fc γ RIIB. A 10-fold excess of the naive library (~10⁷ cells) was incubated with magnetic beads ("My One", Dynal) coated with Fc γ RIIB. Yeast bound to beads were separated from the non-bound fraction by placing the tube containing the mixture in a magnetic field. Those yeast cells that were not bound to the beads were removed and placed in fresh media. They were next bound to beads that were coated with Fc γ RIIIA. Yeast bound to beads were separated from the nonbound fraction by placing the tube containing the mixture in a magnetic field. Nonbound yeast were removed and the bound cells were removed by vigorous vortexing. The recovered cells were regrown in glucose containing media and reinduced in selective media containing galactose. The selection process was repeated. The final culture was then used to harvest DNA. Inserts containing the Fc domain were amplified by PCR and cloned into 4-4-20. Approximately 90 Fc mutants were screened by 4-4-20 ELISA and ADCC assays and the resultant positive mutants are shown in Table 19.

Table 19: Mutants selected by sequential solid phase depletion and selection using Magnetic beads coated with Fc γ R1IB followed by selection with magnetic beads coated with Fc γ R1IIIA.

	Mutant	Amino Acid changes
5	MgFc37	K248M
	MgFc38	K392T, P396L
	MgFc39	E293V, Q295E, A327T
	MgFc41	H268N, P396LN
10	MgFc43	Y319F, P352L, P396L
	MgFc42	D221E, D270E, V308A, Q311 H, P396L, G402D

[0545] Screens 2&3: *Mutants Selected by FACS, Equilibrium and Kinetic Screening:* The first library screen identified a mutation at position 396, changing the amino acid from Proline to Leucine (P396L). This Fc variant showed increased binding to both Fc γ R1IIIA and Fc γ R1IB. A second library was constructed using P396L as a base line. PCR mutagenesis was used to generate $\sim 10^7$ mutants each of which contained the P396L mutation and contained additional nucleotide changes. The P396L library was screened using two sets of conditions.

[0546] An equilibrium screen was performed using biotinylated Fc γ R1IIIA -linker-avitag as a monomer, using methods already described. Approximately 10-fold excess of library (10^8 cells) was incubated in a 0.5 mL of approximately 7 nM Fc γ R1IIIA for 1 hr. The mixture was sorted by FACS, selecting top 1.2% of binders. Selected yeast cells were grown in selective media containing glucose and reinduced in selective media containing galactose. The equilibrium screen was repeated a second time and the sort gate was set to collect the top 0.2% of binders. The selected yeast cells were then grown under selective conditions in glucose. This culture was then used to harvest DNA. Inserts containing the Fc domain were amplified by PCR and cloned into the nucleotide sequence encoding 4-4-20 variable domain using methods already described. Approximately 90 Fc mutants were screened by 4-4-20 ELISA and ADCC and the resultant positive mutants are shown in Table 20.

Table 20: Mutants selected by FACS using an Equilibrium screen with concentrations of FcR1IIIA of approximately 7 nM.

	Mutant	Amino Acid changes
	MgFc43b	K288R, T307A, K344E, P396L
	MgFc44	K334N, P396L
35	MgFc46	P217S, P396L
	MgFc47	K210M, P396L
	MgFc48	V379M, P396L
	MgFc49	K261N, K210M, P396L
40	MgFc60	P217S, P396L

[0547] A kinetic screen was also implemented to identify mutants with improved K_{off} in binding Fc γ R1IIIA. Conditions were established for screening the P396L library using a strain with the P396L Fc variant displayed on the yeast surface. Briefly cells grown under inducing conditions were incubated with 0.1 μ M biotinylated Fc γ R1IIIA -linker-avitag monomer for 1 hr. The cells were washed to remove the labeled ligand. Labeled cells were then incubated for different times with 0.1 μ M unlabeled Fc γ R1IIIA-linker-avitag monomer, washed and then stained with SA:PE for FACS analysis (FIG. 22). Cells were also stained with goat anti-human Fc to show that the Fc display was maintained during the experiment.

[0548] Based on the competition study it was determined that a 1 minute incubation resulted in approximately 50% loss of cell staining. This time point was chosen for the kinetic screen using the P396L library. Approximately 10-fold excess of library (10^8 cells) was incubated with 0.1 μ M biotinylated Fc γ R1IIIA-linker-avitag monomer in a 0.5 mL volume. Cells were washed and then incubated for 1 minute with unlabeled ligand. Subsequently the cells were washed and labeled with SA:PE. The mixture was sorted by FACS, selecting the top 0.3% of binders. Selected yeast cells were grown in selective media containing glucose and reinduced in selective media containing galactose. The kinetic screen was repeated a second time and the sort gate was set to collect the top 0.2% of binders. The nonselected P396L library was compared to the yeast cells selected for improved binding by FACS (FIG. 23). The histograms show the percentage of cells that are costained with both Fc γ R1IIIA /PE and goat anti-human Fc/FITC (upper right).

[0549] The selected yeast cells from the second sort were then grown under selective conditions in glucose. This culture was then used to harvest DNA. Inserts containing the Fc domain were amplified by PCR and cloned into the

EP 2 573 114 B1

nucleotide sequence encoding 4-4-20 variable domain using methods described above. Approximately 90 Fc mutants were screened by 4-4-20 ELISA and ADCC and the resultant positive mutants are shown in Table 21.

Table 21: Mutants selected by FACS using a Kinetic screen using equimolar amounts of unlabeled CD16A for 1 minute.

Mutants	Amino Acid changes
MgFc50	P247S, P396L
MgFc51	Q419H, P396L
MgFc52	V240A, P396L
MgFc53	L410H, P396L
MgFc54	F243L, V305I, A378D, F404S, P396L
MgFc55	R2551, P396L
MgFc57	L242F, P396L
MgFc59	K370E, P396L

Screens 4 and 5: Combining the Solid Phase Fc γ R1IB Depletion Step with Fc γ R1IIIA Selection by FACS Sort, using the Fc γ R1IIIA 158V allele

[0550] Analysis of Fc variants from Screen 1 showed that the mutations that were selected from the secondary screen had improved binding to both Fc γ R1IIIA and Fc γ R1IB. Therefore, the data suggested that sequential depletion and selection using magnetic beads (solid phase) under the established conditions did not efficiently select for differential binding of Fc γ R1IIIA and Fc γ R1IB. Therefore, in order to screen more effectively for mutants that bind Fc γ R1IIIA, while having reduced or no binding to Fc γ R1IB, the solid phase Fc γ R1IB depletion step was combined with Fc γ R1IIIA selection by FACS sort. This combination identified Fc variants that bind Fc γ R1IIIA with greater or equal affinity than wild-type Fc.

[0551] A 10-fold excess of the naive library ($\sim 10^7$) was incubated with magnetic beads coated with Fc γ R1IB. Yeast bound to beads were separated from the non-bound fraction by placing the tube containing the mixture in a magnetic field. Those yeast cells that were not bound to the beads were removed and placed in fresh media and subsequently reinduced in media containing galactose. The Fc γ R1IB depletion by magnetic beads was repeated 5 times. The resulting yeast population was analyzed and found to show greater than 50% cell staining with goat anti-human Fc and a very small percentage of cells were stained with Fc γ R1IIIA. These cells were then selected twice by a FACS sort using 0.1 μ M biotinylated Fc γ R1IIIA linker-avitag (data not shown). The Fc γ R1IIIA was the 158V allotype. Yeast cells were analyzed for both Fc γ R1IIIA and Fc γ R1IB binding after each sort and compared to binding by wild-type Fc domain (FIGs. 24A-B).

[0552] The selected yeast cells from the second sort were then grown under selective conditions in glucose. This culture was then used to harvest DNA. Inserts containing the Fc domain were amplified by PCR and cloned into the nucleotide sequence encoding 4-4-20 variable domain. Approximately 90 Fc mutants were screened by 4-4-20 ELISA and ADCC and the resultant positive mutants are shown in Table 22 (mutants 61-66).

Table 22: Mutants selected by magnetic bead depletion using beads coated with CD32B and final selection by FACS using Fc γ R1IIIA 158Valine or 158Phenylalanine

Mutants	Amino Acid Changes
MgFc61	A330V
MgFc62	R292G
MgFc63	S298N, K360R, N361D
MgFc64	E233G
MgFc65	N276Y
MgFc66	A330V, V427M
MgFc67	V284M, S298N, K334E, R355W, R416T

[0553] *Screening of Fc mutants using the 158F allele of Fc γ R1IIIA:* Two different alleles of Fc γ R1IIIA receptor exist that have different binding affinities for the IgG1 Fc domain (Koene et al., 1997, Blood 90: 1109-1114; Wu et al., 1997, J. Clin. Invest. 100: 1059-70). The 158F allele binds to the Fc domain with a binding constant 5-10 fold lower than the 158V allele. Previously all of the Fc screens using yeast display were done using the high binding 158V allele as a ligand. In this experiment, Fc mutants were selected from the Fc γ R1IB depleted yeast population using biotinylated Fc γ R1IIIA 158F-linker-avitag monomer as a ligand. The sort gate was set to select the top 0.25 percent Fc γ R1IIIA 158F binders. The

EP 2 573 114 B1

resulting enriched population was analyzed by FACS (FIG. 24B). Individual clones were then isolated and their binding to different Fc γ Rs were analyzed by FACS (FIG. 24B). Analysis of individual clones from the population resulted in the identification of a single mutant harboring 5 mutations MgFc67 (V284M, S298N, K334E, R355W, R416S), which had an enhanced binding to Fc γ R11A and a reduced binding to Fc γ R11B.

5

Secondary Screen of Mutants by an ADCC assay For Screens 1, 2, and 3:

[0554] Mutants that were selected in the above screens were then analyzed using a standard ADCC assay to determine the relative rates of lysis mediated by ch4-4-20 harboring the Fc mutants. ch4-4-20 antibodies carrying the Fc variants were constructed using methods already described above. SK-BR3 cells were used as targets and effector cells were PBMC that were isolated from donors using a Ficoll gradient, as described supra (Section 6.7). The ADCC activity results for the mutants are summarized in Table 23.

10

[0555] As seen in Table 23, mutants isolated using the above primary and secondary screens based on Fc γ R11B depletion and Fc γ R11A selection showed enhanced ADCC activity relative to wild-type.

15

Table 23: Analysis of ADCC mediated by 4-4-20 anti-Fluorescein antibody on SKBR3 cells coated with fluorescein.

Mutant	Amino Acid Change	Relative rate of lysis
MgFc37	K248M	3.83
MgFc38	K392T, P396L	3.07
MgFc39	E293V, Q295E, A327T	4.29
MgFc41	H268N, P396LN	2.24
MgFc43	Y319F, P352L, P396L	1.09
MgFc42	D221E, D270E, V308A, Q311H, P396L, G402D	3.17
MgFc43b	K288R, T307A, K344E, P396L	3.3
MgFc44	K334N, P396L	2.43
MgFc46	P217S, P396L	2.04
MgFc47	K210M, P396L	2.02
MgFc48	V379M, P396L	2.01
MgFc49	K261N, K210M, P396L	2.06
MgFc50	P247S, P396L	2.1
MgFc51	Q419H, P396L	2.24
MgFc52	V240A, P396L	2.35
MgFc53	L410H, P396L	2
MgFc54	F243L, V305I, A378D, F404S, P396L	3.59
MgFc55	R255I, P396L	2.79
MgFc57	L242F, P396L	2.4
MgFc59	K370E, P396L	2.47
MgFc60	P217S, P396L	1.44

45

[0556] Mutants 37, 38, 39, 41, 43 were analyzed using 0.5 μ g/mL ch4-4-20. All other antibodies were tested at 1 μ g/mL. All rates were normalized to wild type ch4-4-20 (IgG1).

[0557] Mutants were additionally cloned into the heavy chain of antitumor monoclonal antibody 4D5 (anti-HER2/neu) and anti-CD20 monoclonal antibody 2H7 by replacing the Fc domain of these monoclonal antibodies. These chimeric monoclonal antibodies were expressed and purified and tested in an ADCC assay using standard methods by transient transfection into 293H cells and purification over protein G column. The chimeric 4D5 antibodies were tested in an ADCC assay using SK-BR3 cells as targets (FIG. 25), whereas the chimeric 2H7 antibodies were tested in an ADCC assay using Daudi cells as targets (FIG. 26).

50

[0558] *Secondary Screen of Mutants via BIAcore:* Mutants that were selected in the above screens were then analyzed by BIAcore to determine the kinetic parameters for binding Fc γ R11A(158V) and Fc γ R11B. The method used was similar to that disclosed in Section 6.8, supra.

55

[0559] The data displayed are K_{off} values relative to wild type off rates as determined from experiments using the Fc mutants in the ch4-4-20 monoclonal antibody. Relative numbers greater than one indicate a decrease in K_{off} rate.

EP 2 573 114 B1

Numbers less than one indicate an increase in off rate.

[0560] Mutants that showed a decrease in off rates for Fc γ RIIIA were MgFc38 (K392, P396L), MgFc43(Y319F, P352L, P396L), MgFc42(D221E, D270E, V308A, Q311H, P396L, G402D), MgFc43b (K288R, T307A, K344E, P396L), MgFc44 (K334N, P396L), MgFc46 (P217S, P396L), MgFc49 (K261N, K210M, P396L). Mutants that showed a decrease in off rate for Fc γ RIIB were, MgFc38(K392, P396L), MgFc39 (E293V, Q295E, A327T), MgFc43 (K288R, T307A, K344E, P396L), MgFc44 (K334N, P396L). The Biacore data is summarized in Table 24.

Table 24: Biacore data.

	Fc mutant	AA residues	Fc γ RIIIA158V (Koff WT/ Mut)	Fc γ RIIB (Koff WT/ Mut)
	MgFc37	K248M	0.977	1.03
	MgFc38	K392T, P396L	1.64	2.3
	MgFc39	E293V, Q295E, A327T	0.86	1.3
15	MgFc41	H268N, P396LN	0.92	1.04
	MgFc43	Y319F, P352L, P396L	1.23	2.29
	MgFc42	D221E, D270E, V308A, Q311H, P396L, G402D	1.38	
20	MgFc43b	K288R, T307A, K344E, P396L	1.27	0.89
	MgFc44	K334N, P396L	1.27	1.33
	MgFc46	P217S, P396L	1.17	0.95
	MgFc47	K210M, P396L		
	MgFc48	V379M, P396L		
25	MgFc49	K261N, K210M, P396L	1.29	0.85
	MgFc50	P247S, P396L		
	MgFc51	Q419H, P396L		
	MgFc52	V240A, P396L		
30	MgFc53	L410H, P396L		
	MgFc54	F243L, V305I, A378D, F404S, P396L		
	MgFc55	R255I, P396L		
	MgFc57	L242F, P396L		
	MgFc59	K370E, P396L		
35	MgFc60	P217S, P396L		
	MgFc61	A330V	1	0.61
	MgFc62	R292G	1	0.67
	MgFc63	S298N, K360R, N361D	1	0.67
	MgFc64	E233G	1	0.54
40	MgFc65	N276Y	1	0.64
	MgFc66	A330V, G427M,	1	0.62
	MgFc67	V284M, S298N, K334E, R355W, R416T		

6.10 PBMC MEDIATED ADCC ASSAYS

MATERIALS AND METHODS

[0561] Fc variants that show improved binding to Fc γ RIIIA were tested by PBMC based ADCC using 60:1 effector:target ratio. Two different tumor model systems were used as targets, SK-BR3 (anti-HER2/neu) and Daudi (anti-CD20). Percent specific Lysis was quantitated for each mutant. Linear regression analysis was used to plot the data setting the maximal percent lysis at 100%.

[0562] ADCC is activated on immune system effector cells via a signal transduction pathway that is triggered by an interaction between low affinity Fc γ R and an immune complex. Effector cell populations were derived from either primary blood or activated monocyte derived macrophages (MDM). Target cells were loaded with europium and incubated with chimeric MAb and subsequently incubated with effector cell populations. Europium works the same way as ⁵¹Cr, but it is non-radioactive and the released europium is detected in a fluorescent plate reader. Lymphocytes harvested from

peripheral blood of donors (PBM) using a Ficoll-Paque gradient (Pharmacia) contain primarily natural killer cells (NK). The majority of the ADCC activity will occur via the NK containing Fc γ R1IIIA but not Fc γ R1IIB on their surface.

[0563] Experiments were performed using two different target cell populations, SK-BR- 3 and Daudi, expressing HER2/neu and CD20, respectively. ADCC assays were set up using Ch4-4-20/ FITC coated SK-BR-3, Ch4D5/SKBR3, and Rituxan/Daudi (data not shown). Chimeric MAbs were modified using Fc mutations identified. Fc mutants were cloned into Ch4D5. Purified Ab was used to opsonize SK-BR-3 cells or Daudi cells. Fc mutants were cloned into Ch4D5.

[0564] **RESULTS.** Fc mutants showed improved PBMC mediated ADCC activity in SK BR3 cells (FIG. 29). The plot shows linear regression analysis of a standard ADCC assay. Antibody was titrated over 3 logs using an effector to target ratio of 75:1. % lysis = (Experimental release - SR)/(MR-SR) * 100.

[0565] Fc mutants showed improved PBMC mediated ADCC activity in Daudi cells (FIG. 30).

6.11 MONOCYTE DERIVED MACROPHAGE (MDM) BASED ADCC

ASSAYS

[0566] Fc γ R dependent tumor cell killing is mediated by macrophage and NK cells in mouse tumor models (Clynes et al., 1998, PNAS USA, 95: 652-6). Elutriated monocytes from donors were used as effector cells to analyze the efficiency Fc mutants to trigger cell cytotoxicity of target cells in ADCC assays. Expression patterns of Fc γ R1, Fc γ R3A, and Fc γ R2B are affected by different growth conditions. Fc γ R expression from frozen monocytes cultured in media containing different combinations of cytokines and human serum were examined by FACS using FcR specific MAbs. (FIG. 31). Cultured cells were stained with Fc γ R specific antibodies and analyzed by FACS to determine MDM Fc γ R profiles. Conditions that best mimic macrophage *in vivo* Fc γ R expression, *i.e.*, showed the greatest fraction of cells expressing CD 16 and CD32B were used in a monocyte derived macrophage (MDM) based ADCC assay. For the experiment in FIG. 31, frozen elutriated monocytes were grown for 8 days in DMEM and 20% FBS containing either M-CSF (condition 1) or GM-CSF (condition 2). For the experiment in FIG. 32, frozen elutriated monocytes were cultured for 2 days in DMEM and 20% FBS containing GM-CSF, IL-2 and

[0567] IFN γ prior to ADCC assay. Serum free conditions have also been developed which allow for high levels of CD16 and CD32B expression (data not shown). Briefly, purified monocytes were grown for 6-8 days in Macrophage-SFM (Invitrogen) containing GM-CSF, M-CSF, IL-6, IL-10, and IL-1 β . While the incidence of CD32B+/CD16+ cells in these cultures is highest using a mixture of cytokines, combinations of two or more cytokines will also enhance Fc γ R expression (M-CSF/IL-6, M-CSF/IL-10; or M-CSF/IL-1 β). For ADCC assays, IFN γ is added for the final 24-48 hours.

[0568] MDM based ADCC required incubation times of >16 hrs to observe target cell killing. Target cells were loaded with Indium-111 which is retained for long incubations within the target cells. Indium release was quantitated using a gamma counter. All other reagents, Abs and target cells, were similar to the PBMC based ADCC assay. ADCC activity due to Fc γ R1 can be efficiently blocked using the anti-FcR1 blocking antibody (M21, Ancell). The assay conditions differ slightly from the PBMC based assay. 20:1 target to effector; 18-14 hr incubation at 37C.

[0569] Fc mutants that show improved PBMC ADCC, increased binding to Fc γ R1IIIA, or decreased binding to Fc γ R1IIB were tested (FIG. 32).

6.12 EFFECT OF Fc MUTANTS ON COMPLEMENT ACTIVITY

[0570] Fc mutants were originally identified based on their increased binding to Fc γ R1IIIA. These mutants were subsequently validated for their improved affinity for all low affinity receptors and in many cases improved activity in ADCC mediated by PBMC. *In vivo* antibody mediated cytotoxicity can occur through multiple mechanisms. In addition to ADCC other possible mechanisms include complement dependent cytotoxicity (CDC) and apoptosis. The binding of C1q to the Fc region of an immunoglobulin initiates a cascade resulting in cell lysis by CDC. The interaction between C1q and the Fc has been studied in a series of Fc mutants. The results of these experiments indicate that C1q and the low affinity FcR bind to overlapping regions of the Fc, however the exact contact residues within the Fc vary.

[0571] Mutants that showed improved ADCC in the PBMC based assay were examined for their effect in CDC. Antibodies were analyzed in the anti CD20 Ch-mAb, 2H7. We detected improved CDC for each mutant ch-mAb tested. Interestingly even though these mutants were selected for their improved ADCC they also show enhanced CDC

[0572] **MATERIALS AND METHODS.** CDC assay was used to test the Fc mutants using anti-CD20 and Daudi cells as targets. Guinea Pig Serum was used as the source for complement (US Biological). The CDC assay was similar to PBMC based ADCC. Target cells were loaded with europium and opsonized with ChMab. However complement, guinea pig serum, was added instead of effector cells. FIG. 33 shows a flow chart of the assay. Anti-CD20 ChMab over 3 orders of magnitude was titrated. % lysis was calculated. Daudi cells, (3×10^6) were labeled with BADTA reagent. 1×10^4 cells were aliquoted into wells in a 96 well plate. Antibodies were titrated into the wells using 3 fold dilutions. The opsonization reaction was allowed to proceed for 30-40 minutes at 37° C in 5% CO $_2$. Guinea pig serum was added to a final conc.

of 20%. The reaction was allowed to proceed for 3.5 hrs at 37° C in 5% CO₂. Subsequently, 100 uls of cell media was added to the reaction and cells were spun down. For detection 20 uls of the supernatant was added to 200 uls of the Europium solution and the plates were read in the Victor2(Wallac).

[0573] RESULTS: All mutants that show improved binding for either activating FcR or C1q were placed in the CDC assay (FIG. 34). Fc mutants that showed enhanced binding to FcγRIIIA also showed improved complement activity Each of the mutants show enhanced complement activity compared to wild type. The mutants tested are double mutants. In each case one of the mutations present is P396L.

[0574] To determine whether the increase in CDC correlated with increased binding of C1q to IgG 1 Fc binding between the two proteins was measured in realtime using surface plasmon resonance: In order to examine the binding between C1q and an IgG 1 Fc the Fc variants were cloned into an anti-CD32B ch-mAb, 2B6. This allowed us to capture the wt and mutant antibodies to the glass slide via soluble CD32B protein (FIG. 36A). Three of the four mutants tested in CDC were also examined in the Biacore. All 3 showed greatly enhanced K_{off} compare to wild type Fc (FIG. 36B). Biacore format for C1q binding to 2B6 mutants demonstrate enhanced binding of mutants with P396L mutation (FIG. 37). Mutation D270E can reduce C1q binding at different extent. A summary of the kinetic analysis of FcγR and C1q binding is depicted in the table 25 below.

TABLE 25 KINETIC ANALYSIS OF FcγR and C1q binding to mutant 2B6

2B6Mutants	3aV158	3aF158	2bfcagl	2aR131Fcagl	2aH131Fcagl	C1q
WT	0.192	0.434	0.056	0.070	0.053	0.124
MgFc38 (K392T,P396L)	0.114	0.243	0.024	0.028	0.024	0.096
MgFc51 (Q419H,P396L)	0.142	0.310	0.030	0.036	0.028	0.074
MgFc55 (R255I,P396L)	0.146	0.330	0.030	0.034	0.028	0.080
MgFc59 (K370E,P396L)	0.149	0.338	0.028	0.033	0.028	0.078
MgFc31/60	0.084	0.238	0.094	0.127	0.034	0.210
MgFc51/60	0.112	0.293	0.077	0.089	0.028	0.079
MgFc55/60	0.113	0.288	0.078	0.099	0.025	0.108
MgFc59/60	0.105	0.296	0.078	0.095	0.024	0.107

6.13 DESIGNING Fc VARIANTS WITH DECREASED BINDING TO FcγRIIB

[0575] Based on a selection for Fc mutants that reduce binding to FcγRIIB and increase binding to FcγRIIA 131H a number of mutations including D270E were identified. Each mutation was tested individually for binding to the low affinity Fc receptors and their allelic variants.

[0576] D270E had the binding characteristics that suggested it would specifically reduce FcγRIIB binding. D270E was tested in combination with mutations that were previously identified based on their improved binding to all FcR.

[0577] RESULTS. As shown in Tables 26 and 27 and FIGs. 38 and 39 addition of D270E mutation enhances FcγRIIA and FcγRIIA H131 binding and reduces binding to FcγRIIB. FIG. 40 shows the plot of MDM ADCC data against the K_{off} as determined for CD32A H131H binding for select mutants.

TABLE 26. OFF RATE (1/s) of FcγR BINDING TO WILD TYPE AND MUTANT CHIMERIC 4D5 Ab OBTAINED BY BIA CORE ANALYSIS

4D5Mutants	3aV158	3aF158	2bfcagl	2aR131Fcagl	2aH131Fcagl
Wt pure	0.175	0.408	0.078	10.067	0.046
MgFc55	0.148	0.381	0.036	0.033	0.029
MgFc55/60	0.120	0.320	0.092	0.087	0.013

EP 2 573 114 B1

(continued)

4D5Mutants	3aV158	3aF158	2bfcagl	2aR131Fcagl	2aH131Fcagl
MgFc55/60+R292G	0.116	0.405	0.124	0.112	0.037
MgFc55160+Y300L	0.106	0.304	0.092	0.087	0.015
MgFc52	0.140	0.359	0.038	0.040	0.026
MgFc52/60	0.122	0.315	0.094	0.087	0.013
MgFc59	0.145	0.378	0.039	0.047	0.033
MgFc59/60	0.117	0.273	0.088	0.082	0.012
MgFc31	0.125	0.305	0.040	0.043	0.030
MgFc31/60	0.085	0.215	0.139	0.132	0.020
MgFc51	0.135	0.442	0.060	0.047	0.062
MgFc51/60	0.098	0.264	0.118	0.106	0.023
MgFc38	0.108	0.292	0.034	0.025	0.032
MgFc38/60	0.089	0.232	0.101	0.093	0.021

TABLE 27 KINETIC CHARACTERISTICS OF 4D5 MUTANTS

4D5Mutants	3aV158	3aF158	2bfcagl	2aR131Fcagl	2aH131Fcagl
MgFc70	0.101	0.250	0.030	0.025	0.025
MgFc71	0.074	0.212	0.102	0.094	0.020
MgFc73	0.132	0.306	0.190	-----	0.024
MgFc74	0.063	0.370	n.b.	0.311	0.166
WT023stable	0.150	0.419	0.071	0.068	0.043

6.14 ANALYSIS OF KINETIC PARAMETERS OF Fc MUTANTS

[0578] Kinetic parameters of binding of chimeric 4D5 antibodies harboring Fc mutants to the two allotypes of Fc γ R11A, Fc γ R11A 131H and Fc γ R11B were analyzed by BIAcore using a method similar to that disclosed in Section 6.8 *supra*. The two allotypes of Fc γ R11A, Fc γ R11A 158V and Fc γ R11A 158F, are described in further detail in Section 6.9 *supra*.

Materials and Methods

[0579] Both allotypes of Fc γ R11A used in this assay were soluble monomeric proteins, the extracellular region of Fc γ R11A joined to the linker-AVITAG sequence as described in Section 6.2. The Fc γ R11B and Fc γ R11A used in this assay were soluble dimeric proteins, *i.e.* the extracellular domain of Fc γ R11B or Fc γ R11A fused to the hinge-CH2-CH3 domain of human IgG2 as described in Section 6.8 *supra*.

[0580] Details of BIAcore methodology and analysis are found in Section 6.8. In this assay, variant Fc regions were cloned into a chimeric 4D5 antibody, which is specific for human epidermal growth factor receptor 2 (HER2/neu). The antigen, HER2/neu, was immobilized on one of the flow cells of the sensor chip. The chimeric 4D5 antibodies carrying the Fc mutations were then passed over the surface by 3 minute injections of a 300 nM solution at 5 μ l/min flow rate. Next, dilution series of the receptor in HBS-P buffer (10 mM HEPES, 150 mM NaCl, .005% Surfactant P20, 3 mM EDTA,

EP 2 573 114 B1

pH7.4) were injected onto the surface at 100 μ l/min.

[0581] Binding curves for two different concentrations of receptor(400 nM and 800 nM for both Fc γ R1IIIA V158 and Fc γ R1IIIA 158F; 100 nM and 200 nM for both Fc γ R1IIA and Fc γ R1IIB) were aligned and responses adjusted to the same levels of captured antibodies, and reference curves subtracted from experimental curves. Association and dissociation phases were separately fitted.

Results

[0582] Binding of Fc γ R1IIIA, allotype 158 V and 158F, Fc γ R1IIB and Fc γ R1IIA 131H were analyzed and resonance responses were normalized at the level of response obtained for a wild type chimeric 4D5 antibody. Kinetic parameters for the binding of the Fc γ Rs to the chimeric 4D5 antibody were obtained by fitting the data at two different Fc γ R concentrations: 400 nM and 800 nM for both Fc γ R1IIIA V158 and Fc γ R1IIIA 158F; 100 nM and 200 nM for both Fc γ R1IIA and Fc γ R1IIB.

[0583] Table 28 presents the off rate for each of the four receptors analyzed in association with the indicated variant Fc regions.

Table 28. Off rate (1/s) of Fc γ R binding to wild type and mutant chimeric 4D5 Ab obtained by BIAcore analysis

Chimeric 4D5 Fc Region	Amino Acid at Position					Fc γ R Receptor			
	243	292	300	305	396	3A 158V	3A 158F	2B	2A 131H
Wild Type	F	R	Y	V	P	0.186	0.294	0.096	0.073
MgFc0088	L	P	L	I	L	0.016	0.064	0.058	0.035
MGFc0143	I	P	L	I	L	0.017	0.094	0.091	0.049
Quadruple									
MGFc0088A	L	P	L		L	0.016	0.094	0.075	0.044
MGFc0084	L	P		I	L	0.048	0.133	0.278	0.083
MGFc0142	L		L	I	L				
Triple									
MGFc0155	L	P	L			0.029	0.135	0.155	0.057
MGFc0074	L	P		I		0.063	0.37	NB	0.166
MGFc0093		P		I	L	0.080	0.197	0.125	0.190
Double									
MGFc0162	L	P				0.041	0.515	0.900	0.18
MGFc0091	L				L	0.108	0.330	0.036	0.026
MGFc0070		P		I		0.101	0.250	0.030	0.025
Single									
SV12/F243L	L					0.048	0.255	0.112	0.100
MGFc0161		P				0.067	0.485	0.421	0.117
		G				0.124	NT	0.384	NT
MGFc0092			L			0.211	NT	0.058	0.02
MGFc0089					L	0.127	0.306	0.031	0.039

[0584] Table 29 presents the results of an duplicate study wherein the K_{off} values of the chimeric 4D5 antibodies were computed relative to wild type off rates. Relative numbers greater than one indicate a decrease in K_{off} rate. Numbers less than one indicate an increase in K_{off} rate.

Table 29. Relative Off-Rate of ch4D5 antibodies obtained by BIAcore analysis

Chimeric 4D5 Fc Region	Fc γ R Receptor Relative Off Rate (K_{off} WT/ K_{off} MUT)			
	3A 158V	3A 158 F	2B	2A 131H
F243L, R292P, Y300L, V305I, P396L	10.06	8.25	1.38	1.11
F243L, R292P, Y300L	6.69	2.3	0.32	0.65
F243L, R292P, P396L	5.37	3.52	0.32	0.65
F243L, R292P, Y300L, P396L	10.06	5.62	1.07	0.89
F243L, R292P, V305I	2.56	1.43	nb*	0.23
F243L	4.79	3.44	0.84	0.57
*nb, no binding				

6.15 ADCC ASSAY OF Fc MUTANTS

[0585] Fc mutations identified in Example 6.14 as comprising increased affinity for Fc γ IIIA and/or Fc γ IIA were analyzed for their relative ADCC activity.

Materials and Methods

[0586] Details regarding ADCC assays are found in Section 6.7. In this assay, HT29 colon carcinoma cells (ATCC Accession No. HTB-38) loaded with Indium-111 were used as targets and effector cells were PBMC that were isolated from donors using a Ficoll gradient. Target cells were opsonized with chimeric 4D5 antibodies comprising the variant Fc regions at final concentrations of 2-5000 ng/ml. Opsonized target cells were then added to effector cells to produce an effector:target ratio of 50:1 and incubated for 18 hours at 37°C, 5% CO₂. After incubation, cells were centrifuged at ~220xg for five minutes at 10°C. The level of Indium-111 in the supernatant was recorded by a gamma counter.

Results

[0587] Chimeric 4D5 antibodies comprising variant Fc regions MGFc88 (F243L,R292P,Y300L,V305I,P396L), MGFc88A (F243L,R292P,Y300L, P396L) and MGFc155 (F243L,R292P,Y300L) were selected based on enhanced affinity for Fc γ RIIIA and/or Fc γ IIA and tested for their ADCC activity. FIGS. 41A & B show that the Fc variants tested exhibit enhanced ADCC activity relative to wild type antibody at opsonization concentrations above 20 ng/ml in a concentration dependent manner. The data indicate that Fc mutants identified as comprising increased affinity for Fc γ RIIIA are also likely to exhibit enhanced ADCC activity.

6.16 Fc MUTANT MEDIATED TUMOR GROWTH CONTROL IN AN IN VIVO TUMOR MODEL

[0588] Fc mutations identified as comprising enhanced affinity for Fc γ IIIA and/or Fc γ IIA were further analyzed for relative efficacy of tumor control using an *in vivo* tumor model system.

Materials and Methods

[0589] Antibodies harboring Fc mutants were tested for anti-tumor activity in a murine xenograft system. Balbc/nude mice are subcutaneously injected with 5x10⁶ Daudi cells and subsequently monitored for general signs of illness, e.g., weight gain/loss and grooming activity. Without treatment, this model system results in 100 % mortality with an average survival time of approximately 2 weeks post tumor cell inoculation. Treatment consists of doses of wild-type antibody or antibody comprising a variant Fc region administered at weekly intervals. Animals administered buffer alone at the same intervals serve as a control. Tumor weight is calculated based on the estimated volume of the subcutaneous tumor according to the formula (width² X length)/2.

Results

[0590] At weekly intervals, mice inoculated with Daudi cells received wild-type humanized 2B6 ("h2B6"), humanized

EP 2 573 114 B1

2B6 comprising mutant FcMG0088 (F243L, R292P, Y300L, V305I P396L) ("h2B6 0088") or buffer alone. Wild-type and Fc mutant h2B6 antibody showed similar levels of tumor suppression at the highest dose schedule tested, weekly doses of 25 µg (FIGs. 42A and B). However, significant differences in antibody efficacy were observed when dosages were reduced. 100 and 10 fold reduction in wild-type h2B6 dosages provided no greater tumor control than administration of buffer alone (FIG. 42 A). In contrast, h2B6 0088 provided significant protection at weekly doses of 2.5 µg and at least limited protection at weekly doses of .25 µg (FIG. 42 B).

[0591] The protection conferred by even the lowest dose of Fc mutant antibody was confirmed in survival comparisons. At 11 weeks, 4 out of 7 mice remained alive in the group treated with 0.25 µg doses of h2B6 0088 compared to only 1 out of 7 in the group treated with the same dose of wild-type h2B6 (FIGs. 43A & B)

SEQUENCE LISTING

[0592]

<110> Macrogenics, Inc.

<120> Identification and Engineering of Antibodies with Variant Fc Regions and Methods of using same

<130> 11183-055-228

<140> 60/707,419

<141> 2005-08-10

<160> 30

<170> FastSEQ for windows version 4.0

<210> 1

<211> 121

<212> PRT

<213> Artificial sequence

<220>

<223> Humanized heavy chain variable region

<400> 1

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1      5      10      15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20
Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35      40      45
Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
 50      55      60
Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65      70      75      80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85      90      95
Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
100      105      110
Gln Gly Thr Thr Val Thr Val Ser Ser
115      120

```

<210> 2

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

EP 2 573 114 B1

<223> H2B6VH-A

<400> 2

5 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30
 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 10 Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Met Thr Val Val Val Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 15 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
 100 105 110

<110> Macrogenics, Inc.

20 <120> Identification and Engineering of Antibodies with variant Fc Regions and Methods of using Same

<130> 11183-055-228

25 <140> 60/707,419

<141> 2005-08-10

<160> 30

30 <170> FastSEQ for Windows version 4.0

<210> 1

<211> 121

<212> PRT

35 <213> Artificial sequence

<220>

<223> Humanized heavy chain variable region

40 <400> 1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30
 45 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
 50 55 60
 50 Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
 100 105 110
 55 Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 2

<211> 121

EP 2 573 114 B1

<212> PRT
 <213> Artificial sequence

<220>
 <223> H2B6VH-A

<400> 2

10 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30
 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 15 Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Met Thr Val Val Val Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 20 Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
 100 105 110
 25 Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> H2B6VH-3

<400> 3

40 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30
 Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 45 Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
 50 55 60
 Lys Gly Arg Val Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 50 Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
 100 105 110
 55 Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 4
 <211> 107
 <212> PRT
 <213> Artificial sequence

<220>

EP 2 573 114 B1

<223> Humanized 2B6 light chain variable region - Hu2B6VL-1

<400> 4

```

5      Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
      1      5      10      15
      Glu Lys Val Thr Ile Thr Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
      20      25      30
10     Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
      35      40      45
      Lys Asn Val Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
      50      55      60
      Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
      65      70      75      80
15     Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
      85      90      95
      Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
      100      105
  
```

<210> 5

20 <211> 107

<212> PRT

<213> Artificial sequence

<220>

25 <223> Humanized 2B6 light chain variable region - Hu2B6VL-2

<400> 5

```

30     Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
      1      5      10      15
      Glu Lys Val Thr Ile Thr Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
      20      25      30
35     Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
      35      40      45
      Lys Tyr Val Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
      50      55      60
40     ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
      65      70      75      80
      Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
      85      90      95
      Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
      100      105
  
```

45 <210> 6

<211> 107

<212> PRT

<213> Artificial sequence

<220>

50 <223> Humanized 2B6 light chain variable region - Hu2B6VL-3

<400> 6

55

EP 2 573 114 B1

1 Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 5 1 5 10 15
 20 Glu Lys Val Thr Ile Thr Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
 25 30
 35 Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
 40 45
 50 Lys Tyr Ala Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
 55 60
 65 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
 70 75 80
 10 85 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
 90 95
 100 Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
 105

15 <210> 7
 <211> 107
 <212> PRT
 <213> mus sp.

20 <220>
 <223> mouse 3H7 Light chain Variable Region

<400> 7

25 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 20 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr
 25 30
 35 Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Arg Arg Leu Ile
 40 45
 50 Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
 55 60
 65 Ser Trp Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
 70 75 80
 85 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Val Ser Tyr Pro Tyr
 90 95
 35 100 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 105

40 <210> 8
 <211> 107
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> H2B6VL-5

<400> 8

50

55

EP 2 573 114 B1

1 Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 5 Glu Lys Val Thr Phe Thr Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
 10 Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
 15 Lys Glu Val Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
 20 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
 25 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
 30 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105

<210> 9
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 8B5.3.4 VH

<400> 9

25 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 30 Ser Met Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asp Ala
 35 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 40 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Tyr Tyr Ala Glu
 45 Ser Val Ile Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
 50 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr
 55 Tyr Cys Gly Ala Leu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
 60 Thr Val Ser Ser
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110
 115

<210> 10
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> 8B5.3.4 VL

<400> 10

50 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Leu Ala Ala Leu Gly
 55 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr
 60 Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile
 65 Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
 70 Ser Glu Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
 75 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Phe Ser Tyr Pro Leu

EP 2 573 114 B1

85 90 95
 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105

5 <210> 11
 <211> 321
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> 8B5.3.4 VL
 <400> 11

15 gacattcaga tgacacagtc tccatcctcc ctacttgagg cgctgggaga aagagtcagt 60
 ctcacttgtc gggcaagtca ggaaattagt ggttacttaa gctggcttca gcagaaacca 120
 gatggaacta ttaaacgcct gatctacgcc gcatccactt tagattctgg tgtcccaaaa 180
 aggttcagtg gcagtgagtc tgggtcagat tattctctca ccatcagcag tcttgagtct 240
 gaagattttg cagactatta ctgtctacaa tatttttagtt atccgctcac gttcgggtgct 300
 20 gggaccaagc tggagctgaa a 321

<210> 12
 <211> 348
 <212> DNA
 25 <213> Artificial Sequence

<220>
 <223> 8B5.3.4 VH
 30 <400> 12

gaagtgaagc ttgaggagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc 60
 tcttgtgaag cctctggatt cacttttagt gacgcctgga tggactgggt ccgtcagtct 120
 ccagagaagg ggcttgagtg ggttgctgaa attagaaaca aagctaaaaa tcatgcaaca 180
 35 tactatgctg agtctgtgat agggaggttc accatctcaa gagatgattc caaaagtagt 240
 gtctacctgc aaatgaacag cttaaagagct gaagacactg gcatttatta ctgtggggct 300
 ctgggccttg actactgggg ccaaggcacc actctcacag tctcctcg 348

<210> 13
 40 <211> 121
 <212> PRT
 <213> mus sp.

<220>
 45 <223> Mouse 2B6 heavy chain variable region
 <400> 13

50

55

EP 2 573 114 B1

1 Gln Val Gln Leu Gln 5 Gln Pro Val Thr Glu 10 Leu Val Arg Pro Gly Ala
 Ser Val Met Leu Ser Cys Lys Ala Ser 25 Asp Tyr Pro Phe Thr 30 Asn Tyr
 5 Trp Ile His 35 Trp Val Lys Gln Arg 40 Pro Gly Gln Gly Leu 45 Glu Trp Ile
 Gly Val Ile Asp Pro Ser Asp 55 Thr Tyr Pro Asn Tyr 60 Asn Lys Lys Phe
 Lys Gly Lys Ala Thr Leu Thr Val Val Val Ser Ser Ser Thr Ala Tyr
 65 Met Gln Leu Ser Ser 85 Leu Thr Ser Asp 90 Ser Ser Ala Val Tyr Tyr Cys
 10 Ala Arg Asn Gly Asp Ser Asp Tyr Tyr 105 Ser Gly Met Asp Tyr 110 Trp Gly
 Gln Gly Thr 115 Ser Val Thr Val Ser Ser 120

15

<210> 14
 <211> 107
 <212> PRT
 <213> mus sp.

20

<220>
 <223> Mouse 2B6 light chain variable region

25

<400> 14

30

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly
 1 Glu Arg Val Ser Phe Ser Cys Arg Thr 10 Ser Gln Ser Ile Gly Thr Asn
 20 Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Phe Pro Arg Leu Leu Ile
 35 Lys Asn Val Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 Ser Gly Ser Gly Thr Asp Phe Ile Leu Ser Ile Asn Ser Val Glu Ser
 65 Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
 80 Thr Phe Gly Gly 85 Gly Thr Lys Leu Glu 90 Ile Lys 95

40

<210> 15
 <211> 5
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> 2B6 Heavy chain variable region - CDR1

<400> 15

50

Asn Tyr Trp Ile His
1 5

55

<210> 16
 <211> 5
 <212> PRT
 <213> Artificial Sequence

EP 2 573 114 B1

<220>

<223> 3H7 Heavy chain Variable region - CDR1

<400> 16

5

Asp Ala Trp Met Asp
1 5

<210> 17

10

<211> 17

<212> PRT

<213> Artificial sequence

<220>

15

<223> 2B6 Heavy chain variable region - CDR2

<400> 17

20

Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe Lys
1 5 10 15
Gly

<210> 18

25

<211> 19

<212> PRT

<213> Artificial sequence

<220>

30

<223> 3H7 Heavy chain variable region - CDR2

<400> 18

35

Glu Ile Arg Asn Lys Ala Asn Asn Leu Ala Thr Tyr Tyr Ala Glu Ser
1 5 10 15
Val Lys Gly

<210> 19

40

<211> 12

<212> PRT

<213> Artificial sequence

<220>

45

<223> 2B6 Heavy chain variable region - CDR3

<400> 19

50

Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr
1 5 10

<210> 20

55

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

EP 2 573 114 B1

<223> 3H7 Heavy Chian variable region - CDR3

<400> 20

5

Tyr Ser Pro Phe Ala Tyr
1 5

<210> 21

10

<211> 11

<212> PRT

<213> Artificial sequence

<220>

15

<223> 2B6 Light chain variable region - CDR1

<400> 21

20

Arg Thr ser Gln ser Ile Gly Thr Asn Ile His
1 5 10

<210> 22

<211> 11

25

<212> PRT

<213> Artificial sequence

<220>

30

<223> 3H7 Light Chian variable region - CDR1

<400> 22

Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser
1 5 10

35

<210> 23

<211> 7

<212> PRT

<213> Artificial sequence

40

<220>

<223> 2B6 Light chain variable region - CDR2

<400> 23

45

Asn Val Ser Glu Ser Ile Ser
1 5

50

<210> 24

<211> 7

<212> PRT

<213> Artificial sequence

55

<220>

<223> 2B6 Light chain variable region - CDR2

<400> 24

EP 2 573 114 B1

Tyr Val Ser Glu Ser Ile Ser
1 5

5 <210> 25
<211> 7
<212> PRT
<213> Artificial sequence

10 <220>
<223> 2B6 Light chain variable region - CDR2

<400> 25

15 Tyr Ala Ser Glu Ser Ile Ser
1 5

<210> 26
<211> 7
<212> PRT
<213> Artificial sequence

<220>
25 <223> 3H7 Light Chain variable region - CDR2

<400> 26

30 Ala Ala Ser Thr Leu Asp Ser
1 5

<210> 27
<211> 9
<212> PRT
35 <213> Artificial sequence

<220>
<223> 286 Light chain variable region - CDR3

40 <400> 27

Gln Gln Ser Asn Thr Trp Pro Phe Thr
1 5

45 <210> 28
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
50 <223> 3H7 Light Chain Variable region - CDR3

<400> 28

55 Leu Gln Tyr Val Ser Tyr Pro Tyr Thr
1 5

EP 2 573 114 B1

<210> 29
 <211> 451
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> H2B6Hc-3Fc0088 (Heavy chain)

10

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
	1				5					10					15	
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asn	Tyr
				20					25					30		
15	Trp	Ile	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
			35					40					45			
	Gly	Val	Ile	Asp	Pro	Ser	Asp	Thr	Tyr	Pro	Asn	Tyr	Asn	Lys	Lys	Phe
		50					55					60				
	Lys	Gly	Arg	Val	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr
		65				70					75					80
20	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
	Ala	Arg	Asn	Gly	Asp	Ser	Asp	Tyr	Tyr	Ser	Gly	Met	Asp	Tyr	Trp	Gly
				100					105					110		
	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser
			115					120					125			
25	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala
		130					135					140				
	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val
		145				150					155					160
	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala
					165					170					175	
30	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val
				180					185					190		
	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His
			195					200					205			
	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys
		210					215					220				
35	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly
						230					235					240
	Gly	Pro	Ser	Val	Phe	Leu	Leu	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met
					245					250					255	
	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His
				260					265					270		
40	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
			275					280					285			
	His	Asn	Ala	Lys	Thr	Lys	Pro	Pro	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Leu
		290					295					300				
	Arg	Val	Val	Ser	Ile	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
						310					315					320
45	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
					325					330					335	
	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
				340					345					350		
	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser
			355					360					365			
50	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu
							375					380				
	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Leu
						390					395					400
	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val
					405					410					415	
55	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met
				420					425					430		

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445
 Pro Gly Lys
 450

5
 10
 15
 20
 25
 30
 35
 40

<210> 30
 <211> 214
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> H2B6 Lc-5 (Light chain)
 <400> 30

Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 1 5 10 15
 Glu Lys Val Thr Phe Thr Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
 20 25 30
 Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
 35 40 45
 Lys Glu Val Ser Glu Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
 65 70 75 80
 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

Claims

1. A polypeptide comprising a variant IgG1 Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type IgG1 Fc region, such that:
 - (I) said variant Fc region of said polypeptide binds:
 - (A) FcγRIIIA with a greater affinity, and
 - (B) FcγRIIB with altered binding affinity;
 wherein said greater and altered binding affinities are relative to the binding affinities exhibited by such polypeptide to said FcγRs if comprising a wild-type Fc region; and
 - (II) wherein said at least one amino acid modification comprises a set of substitutions selected from the group consisting of:
 - (1) a substitution at position 243 with leucine and at position 292 with proline;
 - (2) a substitution at position 243 with leucine, at position 292 with proline, and at position 305 with isoleucine;

EP 2 573 114 B1

(3) a substitution at position 243 with leucine, at position 292 with proline, and at position 396 with leucine;
(4) a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine; and
(5) a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and
at position 396 with leucine;

5 wherein the positions are numbered according to the EU index as in Kabat.

2. The polypeptide of claim 1, wherein said polypeptide is an antibody, or a fragment of an antibody, that contains said variant Fc region.
- 10 3. The antibody or fragment thereof of claim 2, wherein said antibody is a monoclonal antibody, a humanized antibody, or a human antibody.
4. The antibody or fragment thereof of claim 2, wherein said antibody comprises a variable domain which binds to CD16A or CD32B.
- 15 5. The antibody or fragment thereof of claim 2, wherein said antibody is antibody 2B6 produced by the hybridoma having ATCC Accession No. PTA-4591.
6. The antibody or fragment thereof of claim 3, wherein said antibody is a humanized version of antibody 2B6 produced by the hybridoma having ATCC Accession No. PTA-4591.
- 20 7. The antibody or fragment thereof of claim 2, wherein said antibody competitively inhibits the binding of antibody 2B6 produced by the hybridoma having ATCC Accession No. PTA-4591 to CD32B.
- 25 8. A nucleic acid comprising a nucleotide sequence encoding the polypeptide of claim 1.
9. A vector comprising the nucleic acid of claim 8.
10. An isolated host cell comprising the nucleic acid of claim 9.
- 30 11. A method for recombinantly producing the polypeptide of claim 1, said method comprising: (i) culturing in a medium a host cell comprising a nucleic acid encoding said polypeptide under conditions suitable for the expression of said polypeptide; and (ii) recovering said polypeptide from said medium.
- 35 12. The antibody or fragment thereof of claim 2, wherein said antibody or said fragment additionally specifically binds a cancer antigen or an antigen of an infectious agent.
13. The antibody, or fragment thereof, of claim 12, wherein said antibody mediates enhanced antibody dependent cell mediated cytotoxicity relative to a comparable antibody comprising a wild-type Fc region.
- 40 14. The use of the antibody, or fragment thereof of claim 12 in the preparation of a medicament for the treatment of cancer in a patient having a cancer **characterized by** said cancer antigen.
15. The antibody, or fragment thereof, of claim 12 or the use of claim 14, wherein said cancer antigen is MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, p15, beta-catenin, MUM-1, CDK4, HER-2/neu, human papillomavirus-E6, human papillomavirus-E7, or MUC-1.
- 45 16. The antibody, or fragment thereof, of claim 12 or the use of claim 14, wherein said cancer antigen is a breast, ovarian, prostate, cervical, or pancreatic carcinoma antigen.
- 50 17. The use of the polypeptide of claim 1 in the preparation of a medicament for the treatment of an inflammatory disease.
18. A composition comprising a therapeutically effective amount of the polypeptide of claim 1, or of the antibody or fragment thereof of any of claims 2-7, 12-13 or 15-16, and a pharmaceutically acceptable carrier.
- 55 19. A nucleic acid comprising a nucleotide sequence encoding a heavy chain of an antibody of claim 2.
20. A vector comprising the nucleic acid of claim 19.

21. An isolated host cell comprising the nucleic acid of claim 19.
22. The antibody of claim 2, wherein said antibody has an enhanced ADCC activity relative to the ADCC activity of said antibody if comprising a wild type Fc region.
23. The polypeptide of claim 1, wherein said variant Fc region further comprises one or more of the amino acid modifications listed in Table 5, 6, 7, or 8.

5

10

Patentansprüche

1. Polypeptid, umfassend eine Variante einer IgG1-Fc-Region, wobei die Variante der Fc-Region wenigstens eine Aminosäuremodifikation in Bezug auf eine Wildtyp-IgG1-Fc-Region umfasst, sodass:

15

(I) die Variante der Fc-Region des Polypeptids an Folgendes bindet:

- (A) Fc γ RIIIA mit einer höheren Affinität und
(B) Fc γ RIIIB mit veränderter Bindungsaffinität;

20

wobei die höhere und die veränderte Bindungsaffinität im Verhältnis zu den Bindungsaffinitäten stehen, die von einem derartigen Polypeptid zu den Fc γ R gezeigt werden, wenn es eine Wildtyp-Fc-Region umfasst; und

(II) wobei die wenigstens eine Aminosäuremodifikation eine Reihe von Substitutionen umfasst, ausgewählt aus der Gruppe bestehend aus:

25

- (1) einer Substitution an Position 243 mit Leucin und an Position 292 mit Prolin;
(2) einer Substitution an Position 243 mit Leucin, an Position 292 mit Prolin und an Position 305 mit Isoleucin;
(3) einer Substitution an Position 243 mit Leucin, an Position 292 mit Prolin und an Position 396 mit Leucin;
(4) einer Substitution an Position 243 mit Leucin, an Position 292 mit Prolin und an Position 300 mit Leucin;
und
(5) einer Substitution an Position 243 mit Leucin, an Position 292 mit Prolin, an Position 300 mit Leucin und an Position 396 mit Leucin;
wobei die Positionen gemäß dem EU-Index nach Kabat nummeriert sind.

30

35

2. Polypeptid nach Anspruch 1, wobei das Polypeptid ein Antikörper oder ein Fragment eines Antikörpers ist, das die Variante der Fc-Region enthält.

3. Antikörper oder Fragment davon nach Anspruch 2, wobei der Antikörper ein monoklonaler Antikörper, ein humanisierter Antikörper oder ein humaner Antikörper ist.

40

4. Antikörper oder Fragment davon nach Anspruch 2, wobei der Antikörper eine variable Domäne umfasst, die an CD16A oder CD32B bindet.

45

5. Antikörper oder Fragment davon nach Anspruch 2, wobei der Antikörper ein Antikörper 2B6 ist, der von dem Hybridom mit der ATCC-Zugangsnr. PTA-4591 erzeugt wird.

6. Antikörper oder Fragment davon nach Anspruch 3, wobei der Antikörper eine humanisierte Version von Antikörper 2B6 ist, der von dem Hybridom mit der ATCC-Zugangsnr. PTA-4591 erzeugt wird.

50

7. Antikörper oder Fragment davon nach Anspruch 2, wobei der Antikörper kompetitiv das Binden des Antikörpers 2B6, der von dem Hybridom mit der ATCC-Zugangsnr. PTA-4591 erzeugt wird, an CD32B hemmt.

8. Nukleinsäure, umfassend eine Nukleotidsequenz, die für das Polypeptid nach Anspruch 1 codiert.

55

9. Vektor, umfassend die Nukleinsäure nach Anspruch 8.

10. Isolierte Wirtszelle, umfassend die Nukleinsäure nach Anspruch 9.

EP 2 573 114 B1

- 5
11. Verfahren zum rekombinanten Erzeugen des Polypeptids nach Anspruch 1, wobei das Verfahren Folgendes umfasst:
(i) Kultivieren, in einem Medium, einer Wirtszelle, umfassend eine Nukleinsäure, die für das Polypeptid unter Bedingungen codiert, die für das Expressieren des Polypeptids geeignet sind; und (ii) Rückgewinnen des Polypeptids aus dem Medium.
12. Antikörper oder Fragment davon nach Anspruch 2, wobei der Antikörper oder das Fragment zusätzlich spezifisch ein Krebsantigen oder ein Antigen eines Infektionserregers bindet.
- 10 13. Antikörper oder Fragment davon nach Anspruch 12, wobei der Antikörper verbesserte antikörperabhängige zellvermittelte Zytotoxizität bezogen auf einen vergleichbaren Antikörper vermittelt, der eine Wildtyp-Fc-Region umfasst.
14. Verwendung des Antikörpers oder des Fragments davon nach Anspruch 12 beim Herstellen eines Medikaments für die Behandlung von Krebs in einem Patienten mit einem Krebs, der durch das Krebsantigen gekennzeichnet ist.
- 15 15. Antikörper oder Fragment davon nach Anspruch 12 oder die Verwendung nach Anspruch 14, wobei das Krebsantigen MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-Acetylglucosaminyltransferase, p15, Beta-Catenin, MUM-1, CDK4, HER-2/neu, humanes Papillomvirus-E6, humanes Papillomvirus-E7 oder MUC-1 ist.
- 20 16. Antikörper oder Fragment davon nach Anspruch 12 oder Verwendung nach Anspruch 14, wobei das Krebsantigen ein Brust-, Eierstock-, Prostata-, Gebärmutterhals- oder Pankreaskarzinom-Antigen ist.
17. Verwendung des Polypeptids nach Anspruch 1 beim Herstellen eines Medikaments für die Behandlung einer Entzündungserkrankung.
- 25 18. Zusammensetzung, umfassend eine therapeutisch wirksame Menge des Polypeptids nach Anspruch 1 oder den Antikörper oder das Fragment davon nach einem der Ansprüche 2-7, 12-13 oder 15-16 und einen pharmazeutisch unbedenklichen Träger.
- 30 19. Nukleinsäure, umfassend eine Nukleotidsequenz, die für eine schwere Kette eines Antikörpers aus Anspruch 2 codiert.
20. Vektor, umfassend die Nukleinsäure nach Anspruch 19.
21. Isolierte Wirtszelle, umfassend die Nukleinsäure nach Anspruch 19.
- 35 22. Antikörper nach Anspruch 2, wobei der Antikörper eine erhöhte ADCC-Aktivität bezogen auf die ADCC-Aktivität des Antikörpers aufweist, wenn es eine Wildtyp-Fc-Region umfasst.
- 40 23. Polypeptid nach Anspruch 1, wobei die Variante der Fc-Region ferner eine oder mehrere der in Tabelle 5, 6, 7 oder 8 aufgelisteten Aminosäuremodifikationen umfasst.

Revendications

- 45 1. Polypeptide comprenant une région Fc variante d'IgG1, dans lequel ladite région Fc variante comprend au moins une modification d'acide aminé par rapport à la région Fc d'IgG1 de type sauvage, de sorte que :
- (I) ladite région Fc variante dudit polypeptide se lie à :
- 50 (A) Fc γ R111A avec une affinité supérieure, et
(B) Fc γ R111B avec une affinité de liaison modifiée ;
lesdites affinités de liaison supérieure et modifiée étant par rapport aux affinités de liaison présentées par ce polypeptide auxdits Fc γ R s'il comprend une région Fc de type sauvage ; et
- 55 (II) ladite au moins une modification d'acide aminé comprenant un jeu de substitutions choisies dans le groupe constitué par :
- (1) une substitution en position 243 par la leucine et en position 292 par la proline ;

EP 2 573 114 B1

(2) une substitution en position 243 par la leucine, en position 292 par la proline et en position 305 par l'isoleucine ;

(3) une substitution en position 243 par la leucine, en position 292 par la proline et en position 396 par la leucine ;

5 (4) une substitution en position 243 par la leucine, en position 292 par la proline et en position 300 par la leucine ; et

(5) une substitution en position 243 par la leucine, en position 292 par la proline, en position 300 par la leucine et en position 396 par la leucine ;

les positions étant numérotées conformément à l'indice EU comme dans Kabat.

10

2. Polypeptide selon la revendication 1, ledit polypeptide étant un anticorps ou un fragment d'un anticorps, qui contient ladite région Fc variante.

15

3. Anticorps ou fragment de celui-ci selon la revendication 2, ledit anticorps étant un anticorps monoclonal, un anticorps humanisé ou un anticorps humain.

4. Anticorps ou fragment de celui-ci selon la revendication 2, ledit anticorps comprenant un domaine variable qui se lie à CD16A ou CD32B.

20

5. Anticorps ou fragment de celui-ci selon la revendication 2, ledit anticorps étant un anticorps 2B6 produit par l'hybridome ayant le numéro d'ordre ATCC PTA-4591.

25

6. Anticorps ou fragment de celui-ci selon la revendication 3, ledit anticorps étant une version humanisée de l'anticorps 2B6 produit par l'hybridome ayant le numéro d'ordre ATCC PTA-4591.

7. Anticorps ou fragment de celui-ci selon la revendication 2, ledit anticorps inhibant de façon compétitive la liaison de l'anticorps 2B6 produit par l'hybridome ayant le numéro d'ordre ATCC PTA-4591 à CD32B.

30

8. Acide nucléique comprenant une séquence nucléotidique codant pour le polypeptide selon la revendication 1.

9. Vecteur comprenant l'acide nucléique selon la revendication 8.

10. Cellule hôte isolée comprenant l'acide nucléique selon la revendication 9.

35

11. Procédé de production recombinante du polypeptide selon la revendication 1, ledit procédé comprenant les étapes consistant à : (i) cultiver dans un milieu une cellule hôte comprenant un acide nucléique codant pour ledit polypeptide dans des conditions appropriées pour l'expression dudit polypeptide ; et (ii) récupérer ledit polypeptide dans ledit milieu.

40

12. Anticorps ou fragment de celui-ci selon la revendication 2, ledit anticorps ou ledit fragment se liant en outre de façon spécifique à un antigène de cancer ou un antigène d'un agent infectieux.

13. Anticorps, ou fragment de celui-ci, selon la revendication 12, ledit anticorps induisant une cytotoxicité à médiation cellulaire dépendant des anticorps accrue par rapport à un anticorps comparable comprenant une région Fc de type sauvage.

45

14. Utilisation de l'anticorps, ou d'un fragment de celui-ci, selon la revendication 12 dans la préparation d'un médicament pour le traitement du cancer chez un patient ayant un cancer **caractérisé par** ledit antigène de cancer.

50

15. Anticorps, ou fragment de celui-ci, selon la revendication 12 ou utilisation selon la revendication 14, ledit antigène de cancer étant MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, la N-acétylglucosaminyltransférase, p15, la bêta-caténine, MUM-1, CDK4, HER-2/neu, le papillomavirus humain E6, le papillomavirus humain E7 ou MUC-1.

55

16. Anticorps, ou fragment de celui-ci, selon la revendication 12 ou utilisation selon la revendication 14, ledit antigène de cancer étant un antigène du carcinome du sein, de l'ovaire, de la prostate, du col de l'utérus ou du pancréas.

17. Utilisation du polypeptide selon la revendication 1 dans la préparation d'un médicament pour le traitement d'une maladie inflammatoire.

EP 2 573 114 B1

18. Composition comprenant une quantité thérapeutiquement efficace du polypeptide selon la revendication 1, ou de l'anticorps ou d'un fragment de celui-ci selon l'une quelconque des revendications 2 à 7, 12 à 13 ou 15 à 16, et un support pharmaceutiquement acceptable.
- 5 19. Acide nucléique comprenant une séquence nucléotidique codant pour une chaîne lourde d'un anticorps selon la revendication 2.
20. Vecteur comprenant l'acide nucléique selon la revendication 19.
- 10 21. Cellule hôte isolée comprenant l'acide nucléique selon la revendication 19.
22. Anticorps selon la revendication 2, ledit anticorps ayant une activité ADCC accrue par rapport à l'activité ADCC dudit anticorps s'il comprend une région Fc de type sauvage.
- 15 23. Polypeptide selon la revendication 1, dans lequel ladite région Fc variante comprend en outre une ou plusieurs des modifications d'acides aminés énumérées dans le Tableau 5, 6, 7 ou 8.

20

25

30

35

40

45

50

55

8B5.3.4 VL nucleotide/amino acid sequence

```

gac att cag atg aca cag tet cca tcc tcc cta ctt gcg gcg ctg gga 48
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Leu Ala Ala Leu Gly
 1           5           10           15

                                CDR1
gaa aga gtc agt ctc act tgt cgg gca agt cag gaa att agt ggt tac 96
Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr
          20           25           30

tta agc tgg ctt cag cag aaa cca gat gga act att aaa cgc ctg atc 144
Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile
          35           40           45

                                CDR2
tac gcc gca tcc act tta gat tct ggt gtc cca aaa agg ttc agt ggc 192
Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
          50           55           60

agt gag tct ggg tca gat tat tct ctc acc atc agc agt ctt gag tct 240
Ser Glu Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
 65           70           75           80

                                CDR3
gaa gat ctt gca gac tat tac tgt cta caa tat ttt agt tat ccg ctc 288
Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Phe Ser Tyr Pro Leu
          85           90           95

acg ttc ggt gct ggg acc aag ctg gag ctg aaa 321
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
          100           105

```

FIG. 1

8B5.3.4 VH nucleotide/amino acid sequence

```

gaa gtg aag ctt gag gag tct gga gga ggc ttg gtg caa cct gga gga 48
Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15

tcc atg aaa ctc tct tgt gaa gcc tct gga ttc act ttt agt gac gcc 96
Ser Met Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asp Ala
 20           25           30

CDR1
tgg atg gac tgg gtc cgt cag tct cca gag aag ggg ctt gag tgg gtt 144
Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 35           40           45

CDR2
gct gaa att aga aac aaa gct aaa aat cat gca aca tac tat gct gag 192
Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Tyr Tyr Ala Glu
 50           55           60

tot gtg ata ggg agg ttc acc atc tca aga gat gat tcc aaa agt agt 240
Ser Val Ile Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
 65           70           75           80

gtc tac ctg caa atg aac agc tta aga gct gaa gac act ggc att tat 288
Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr
 85           90           95

CDR3
tac tgt ggg gct ctg ggc ctt gac tac tgg ggc caa ggc acc act ctc 336
Tyr Cys Gly Ala Leu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
 100           105           110

aca gtc tcc tcg 348
Thr Val Ser Ser
 115

```

FIG. 2



FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B-A




FIG. 6B-B




FIG. 6B-C




FIG. 6B-D




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F




FIG. 8G




FIG. 8H




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 12H




FIG. 12I




FIG. 12J




FIG. 12K




FIG. 12L




FIG. 12M




FIG. 12N




FIG. 13A




FIG. 13B




FIG. 14

ADCC_ch4D5 Fc Variants
E:T ratio 50:1




FIG. 15A

ADCC_ch4D5 Fc Variants
E:I ratio 50:1




FIG. 15B




FIG. 16




FIG. 17

0225wt/FeR11a, $\sigma K_d=319nM$, $k_{off}=0.170$ 1/s




FIG. 18A




FIG. 18B

0225mut10/FcR1IIa,avKd=128nM,koff=0.115 1/s




FIG. 18C

0225mut11FcRIIIa, $avKd=91.8nM$, $koff=0.073$ 1/s




FIG. 18D




FIG. 18E

0225mut14/FcR11a,avKd=75.4nM,koff=0.1 1/s




FIG. 18F

0225mut16/FcR1IIa,avKd=84.8nM,koff=0.133 1/s




FIG. 18G

0225mut19/FcRIIIa,qvKd=100nM,koff=0.120 1/s




FIG. 18H




FIG. 19

0.225wt/FcRIIb, avKd=61.4nM, koff=0.0847 1/s




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 21




FIG. 22




FIG. 23A

FIG. 23B

FIG. 23C

3aLAVI(V158) P051




FIG. 24A-1

3aLAVI(V158) P051




FIG. 24A-2

3aLAVI(V158) P051




FIG. 24A-3




FIG. 24A-4




FIG. 24A-5




FIG. 24A-6




FIG. 24B-1




FIG. 24B-2




FIG. 24B-3




FIG. 24B-4




FIG. 24B-5




FIG. 24B-6




FIG. 25

Summary of ADCC mediated by 2H7 on Daudi Cells




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36A




FIG. 36B

FIG. 37A




FIG. 37B

RU




FIG. 37C

RU




FIG. 37D

RU




FIG. 38A




FIG. 38B




FIG. 38C




FIG. 38D




FIG. 39A




FIG. 39B




FIG. 39C





FIG. 39D






FIG. 40




FIG. 41A




FIG. 41B




FIG. 42A




FIG. 42B

Tumor-free survival of h2B6 3.5: Survival proportions




FIG. 43A

Tumor-free survival of h2B6 3.5 0088: Survival proportions




FIG. 43B

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 04063351 A2 [0010]
- WO 0042072 A2 [0010]
- WO 04099249 A2 [0010]
- US 5624821 A [0034] [0167] [0268]
- US 5885573 A [0034] [0167] [0268]
- US 6194551 B [0034] [0167] [0268]
- WO 0042072 A [0034] [0167] [0268]
- WO 9958572 A [0034] [0167] [0268]
- US 27114005 A [0059]
- US 20060134709 A [0059]
- US 40326602 P [0060] [0223] [0255]
- US 64385703 A [0060] [0223] [0255]
- US 20040185045 A [0060] [0223]
- US 20050260213 A [0060]
- US 20060013810 A [0060] [0223]
- US 75492204 A [0136]
- US 43949803 P [0136] [0338]
- US 45604103 P [0136] [0338]
- US 51454903 P [0136]
- US 58725104 P [0136]
- US 6218149 B [0159]
- EP 0359096 B1 [0159]
- US 20020028486 A [0159]
- WO 03035835 A [0159]
- US 20030115614 A [0159] [0168]
- US 6472511 B [0159]
- US 6602684 B [0168]
- US 10277370 A [0168]
- US 10113929 A [0168]
- WO 0061739 A1 [0168]
- WO 01292246A1 A [0168]
- WO 02311140A1 A [0168]
- WO 0230954 A1 [0168]
- WO 00061739 A [0168]
- EA 01229125 [0168]
- WO 9823289 A [0173] [0174]
- WO 9734631 A [0173] [0174]
- US 6277375 B [0173] [0174]
- WO 9315199 A [0174]
- WO 9315200 A [0174]
- WO 0177137 A [0174]
- EP 413622 A [0174]
- US 5939598 A, Kucherlapati [0206] [0217]
- WO 9317715 A [0207]
- WO 9208802 A [0207]
- WO 9100360 A [0207] [0212]
- WO 9205793 A [0207]
- US 4474893 A [0207]
- US 4714681 A [0207]
- US 4925648 A [0207]
- US 5573920 A [0207]
- US 5601819 A [0207]
- WO 9308829 A [0209]
- WO 9404690 A [0211]
- WO 9627011 A [0211]
- US 4676980 A [0212] [0250]
- WO 92200373 A [0212]
- EP 03089 A [0212]
- US 5807715 A [0215] [0349]
- US 4816567 A [0215]
- US 4816397 A [0215]
- US 5585089 A, Queen [0215]
- EP 239400 A [0215]
- WO 9109967 A [0215]
- US 5225539 A [0215]
- US 5530101 A [0215]
- EP 592106 A [0215]
- EP 519596 A [0215]
- US 5565332 A [0215]
- US 5693762 A [0215]
- WO 5693761 A [0215]
- WO 5585089 A [0215]
- WO 6180370 A [0215]
- US 20040049014 A [0215]
- US 200300229208 A [0215]
- US 4444887 A [0216]
- US 4716111 A [0216]
- WO 9846645 A [0216]
- WO 9850433 A [0216]
- WO 9824893 A [0216] [0217]
- WO 9816654 A [0216]
- WO 9634096 A [0216] [0217]
- WO 9633735 A [0216] [0217]
- WO 9110741 A [0216]
- WO 9201047 A [0217]
- EP 0598877 A [0217]
- US 5413923 A [0217]
- US 5625126 A [0217]
- US 5633425 A [0217]
- US 5569825 A [0217]
- US 5661016 A [0217]
- US 5545806 A [0217]
- US 5814318 A [0217]
- US 5885793 A [0217]
- US 5916771 A [0217]
- US 56280404 P [0223] [0255]
- US 58204404 P [0223] [0255]
- US 58204504 P [0223] [0255]

- US 63666304 P [0223] [0255]
- US 52413405 A [0223] [0255]
- US 20050215767 A [0223]
- US 56988204 P [0223] [0255]
- US 58204304 P [0223] [0255]
- US 12697805 A [0223] [0255]
- WO 9733899 A [0242]
- WO 9734911 A [0242]
- WO 9923105 A [0242]
- US 5605793 A [0244]
- US 5811238 A [0244]
- US 5830721 A [0244]
- US 5834252 A [0244]
- US 5837458 A [0244]
- US 4741900 A [0245]
- US 43970903 P [0252] [0272] [0338] [0534]
- US 5877397 A [0260]
- US 6676927 B [0260]
- US 6423538 B [0294]
- US 6114147 A [0294]
- US 6300065 B [0294]
- US 4347935 A [0303]
- US 5464581 A [0303]
- US 5483469 A [0303]
- US 5602039 A [0303]
- US 5643796 A [0303]
- US 6211477 B [0303]
- US 5223409 A [0310]
- US 5571698 A [0310]
- US 5403484 A [0310]
- WO 9416101 A [0314]
- US 6373577 B [0336]
- US 6289286 B [0336]
- US 5322798 A [0336]
- US 5341215 A [0336]
- US 6268125 B [0336]
- US 5166057 A [0409]
- US 6019968 A [0417]
- US 5985320 A [0417]
- US 5985309 A [0417]
- US 5934272 A [0417]
- US 5874064 A [0417]
- US 5855913 A [0417]
- US 5290540 A [0417]
- US 4880078 A [0417]
- WO 9219244 A [0417]
- WO 9732572 A [0417]
- WO 9744013 A [0417]
- WO 9831346 A [0417]
- WO 9966903 A [0417]
- US 4526938 A [0424] [0426]
- WO 9105548 A [0424] [0426]
- WO 9620698 A [0424] [0426]
- US 5679377 A [0425]
- US 5916597 A [0425]
- US 5912015 A [0425]
- US 5989463 A [0425]
- US 5128326 A [0425]
- WO 9915154 A [0425]
- WO 9920253 A [0425]
- US 5945155 A, Dunn [0425]
- US 5888533 A [0425]
- US 4980286 A [0427] [0443]
- WO 9206180 A [0443]
- WO 9222635 A [0443]
- WO 9220316 A [0443]
- WO 9314188 A [0443]
- WO 9320221 A [0443]
- WO 9412649 A [0445]
- US 5436146 A [0446]
- WO 9408598 A [0452]
- US 5877396 A [0458]

Non-patent literature cited in the description

- **RAVETCH J.V et al.** *Annu Rev Immunol.*, vol. 9, 457-92 [0003]
- **GERBER J.S. et al.** *Microbes and Infection*, 2001, vol. 3, 131-139 [0003]
- **BILLADEAU D.D. et al.** *The Journal of Clinical Investigation*, 2002, vol. 2 (109), 161-1681 [0003]
- **RAVETCH J.V. et al.** *Science*, 2000, vol. 290, 84-89 [0003]
- **RAVETCH J.V. et al.** *Annu. Rev. Immunol.*, 2001, vol. 19, 275-90 [0003]
- **RAVETCH J.V.** *Cell*, 1994, vol. 78 (4), 553-60 [0003]
- Immunobiology: The Immune System in Health and Disease. Elsevier Science Ltd/Garland Publishing, 1999 [0003]
- **SHIELDS et al.** *J. Biol. Chem.*, 2001, vol. 276 (9), 6591-6604 [0010]
- **STAVENHAGEN et al.** *Cancer Res.*, 2007, vol. 67 (18), 8882-8890 [0010]
- **ROBBINS ; ANGELL.** Basic Pathology. W.B. Saunders Co, 1976, 68-122 [0011]
- Principles of Cancer Patient Management. **STOCKDALE.** Scientific American: Medicine. 1998, vol. 3 [0014]
- **GOODMAN ; GILMAN'S.** The Pharmacological Basis of Therapeutics. Pergamom Press, 1990 [0015]
- **STOCKDALE.** Principles Of Cancer Patient Management. *Scientific American Medicine*, 1998, vol. 3 [0016]
- **GREEN M.C. et al.** *Cancer Treat Rev.*, 2000, vol. 26, 269-286 [0017]
- **WEINER LM.** *Semin Oncol.*, 1999, vol. 26 (14), 43-51 [0017]
- **SUZANNE A. ECCLES.** *Breast Cancer Res.*, 2001, vol. 3, 86-90 [0017]
- Textbook of Human Virology. PSG Publishing, 1984 [0028]

- **WYNGAARDEN ; SMITH.** Cecil Textbook of Medicine. W.B. Saunders Co, 1988, 1750-1753 [0029]
- **MITSUYA et al.** *FASEB J.*, 1991, vol. 5, 2369-2381 [0029]
- **DUNCAN et al.** *Nature*, 1988, vol. 332, 563-564 [0034] [0167] [0268]
- **LUND et al.** *J. Immunol.*, 1991, vol. 147, 2657-2662 [0034] [0167] [0268]
- **LUND et al.** *Mol Immunol.*, 1992, vol. 29, 53-59 [0034] [0167] [0268]
- **ALEGRE et al.** *Transplantation*, 1994, vol. 57, 1537-1543 [0034] [0167] [0268]
- **HUTCHINS et al.** *Proc Natl. Acad Sci USA*, 1995, vol. 92, 11980-11984 [0034]
- **JEFFERIS et al.** *Immunol Lett.*, 1995, vol. 44, 111-117 [0034] [0167] [0268] [0480]
- **LUND et al.** *Faseb J.*, 1995, vol. 9, 115-119 [0034] [0167] [0268]
- **JEFFERIS et al.** *Immunol Lett.*, 1996, vol. 54, 101-104 [0034] [0167] [0268]
- **LUND et al.** *J Immunol.*, 1996, vol. 157, 4963-4969 [0034] [0167] [0268]
- **ARMOUR et al.** *Eur J Immunol.*, 1999, vol. 29, 2613-2624 [0034] [0167] [0268]
- **IDUSOGIE et al.** *J Immunol.*, 2000, vol. 164, 4178-4184 [0034] [0167] [0268]
- **REDDY et al.** *J Immunol.*, 2000, vol. 164, 1925-1933 [0034] [0167] [0268]
- **XU et al.** *Cell Immunol.*, 2000, vol. 200, 16-26 [0034] [0167] [0268]
- **IDUSOGIE et al.** *J Immunol.*, 2001, vol. 166, 2571-2575 [0034] [0167] [0268]
- **SHIELDS et al.** *J Biol Chem.*, 2001, vol. 276, 6591-6604 [0034] [0167] [0268]
- **JEFFERIS et al.** *Immunol Lett.*, 2002, vol. 82, 57-65 [0034] [0167] [0268]
- **PRESTA et al.** *Biochem Soc Trans.*, 2002, vol. 30, 487-490 [0034] [0167] [0268]
- **SONDERMANN et al.** *Nature*, 2000, vol. 406, 267-273 [0040] [0146] [0147] [0262] [0520]
- **BODER ; WITTRUP.** *Methods in Enzymology*, 2000, vol. 328, 430-444 [0049] [0294]
- **CARTER et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285-9 [0058] [0220] [0254] [0328]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. Public Health Service, 1991 [0073]
- **DIESENHOFER et al.** *Biochemistry*, 1981, vol. 20, 2361-2370 [0147]
- **SHIELDS et al.** *J. Biol. Chem.*, 2001, vol. 276, 6591-6604 [0147] [0148] [0491]
- **JEFFERIS et al.** *Immunol. Lett.*, 1995, vol. 44, 111-7 [0148]
- **HINTON et al.** *J. Biol. Chem.*, 2004, vol. 279 (8), 6213-6 [0148]
- **IDUSOGIE et al.** *J. Immunol.*, 2000, vol. 164, 4178-4184 [0148]
- **JEFFERIS et al.** *Immunology Letters*, 1995, vol. 44, 111-7 [0157]
- **J. D. WATSON et al.** In Vitro Mutagenesis," Recombinant DNA: A Short Course. W.H. Freeman and Company, 1983, 106-116 [0158]
- **WANG et al.** *Chem. Comm.*, 2002, vol. 1, 1-11 [0163]
- **WANG et al.** *Science*, 2001, vol. 292, 498-500 [0163]
- **VAN HEST et al.** *Chem. Comm.*, 2001, vol. 19, 1897-1904 [0163]
- **TANG et al.** *J. Am. Chem.*, 2001, vol. 123 (44), 11089-11090 [0163]
- **KIICK et al.** *FEBS Lett.*, 2001, vol. 505 (3), 465 [0163]
- **HUTCHINS et al.** *Proc Natl. Acad Sci U S A*, 1995, vol. 92, 11980-11984 [0167] [0268]
- **UMANA et al.** *Nat. Biotechnol.*, 1999, vol. 17, 176-180 [0168]
- **DAVIES et al.** *Biotechnol Bioeng.*, vol. 74, 288-294 [0168]
- **SHIELDS et al.** *J Biol Chem.*, 2002, vol. 277, 26733-26740 [0168] [0265]
- **SHINKAWA et al.** *J Biol Chem.*, 2003, vol. 278, 3466-3473 [0168] [0265]
- **OKAZAKI et al.** *JMB*, 2004, vol. 336, 1239-49 [0168]
- **IDUSOGIE et al.** *J. Immunol.*, 2001, vol. 166 (4), 2571-5 [0177]
- **IDUSOGIE et al.** *J. Immunol.*, 2000, vol. 164 (8), 4178-4184 [0177]
- **TUTT et al.** *J. Immunol.*, 1991, vol. 147, 60-69 [0207]
- **KOSTELNY et al.** *J. Immunol.*, 1992, vol. 148, 1547-1553 [0207]
- **MILLSTEIN et al.** *Nature*, 1983, vol. 305, 537-539 [0209]
- **TRAUNECKER et al.** *EMBO J.*, 1991, vol. 10, 3655-3659 [0209]
- **SURESH et al.** *Methods in Enzymology*, 1986, vol. 121, 210 [0211]
- **TUTT et al.** *J. Immunol.*, 1991, vol. 147, 60 [0213]
- **MORRISON.** *Science*, 1985, vol. 229, 1202 [0215]
- **Ol et al.** *BioTechniques*, 1986, vol. 4, 214 [0215]
- **GILLIES et al.** *J. Immunol. Methods*, 1989, vol. 125, 191-202 [0215]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323 [0215]
- **PADLAN.** *Molecular Immunology*, 1991, vol. 28 (4/5), 489-498 [0215]
- **STUDNICKA et al.** *Protein Engineering*, 1994, vol. 7 (6), 805-814 [0215]
- **ROGUSKA et al.** *Proc Natl. Acad. Sci. USA*, 1994, vol. 91, 969-973 [0215]
- **LONBERG ; HUSZAR.** *Int. Rev. Immunol.*, 1995, vol. 13, 65-93 [0217]
- **JESPERS et al.** *Biolotechnology*, 1988, vol. 12, 899-903 [0218]
- *Current Protocols in Molecular Biology.* Green Publishing Associates, Inc. and John Wiley and Sons, Inc, 1989, vol. 1, 6.3.1-6.3.6, 2.10.3 [0226]
- **MATSUDA et al.** *J. Exp. Med.*, 1998, vol. 188, 2151062 [0231]
- **RAVETCH et al.** *Cell*, 1981, vol. 27 (3), 583-91 [0231]

- LAUTNER-RIESKE et al. *Eur. J. Immunol.*, 1992, vol. 22, 1023-1029 [0231]
- HIETER et al. *J. Biol. Chem.*, 1982, vol. 257, 1516-22 [0231]
- TAKAHASHI et al. *J. Immunol.*, 1994, vol. 6, 1567-1574 [0242]
- GENTZ et al. *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 821-824 [0243]
- WILSON et al. *Cell*, 1984, vol. 37, 767 [0243]
- KNAPPIK et al. *Biotechniques*, 1994, vol. 17 (4), 754-761 [0243]
- PATTEN et al. *Curr. Opinion Biotechnol.*, 1997, vol. 8, 724-33 [0244]
- HARAYAMA. *Trends Biotechnol.*, 1998, vol. 16, 76 [0244]
- HANSSON et al. *J. Mol. Biol.*, 1999, vol. 287, 265 [0244]
- LORENZO ; BLASCO. *BioTechniques*, 1998, vol. 24, 308 [0244]
- DENARDO et al. *Clin Cancer Res.*, 1998, vol. 4, 2483-90 [0248]
- PETERSON et al. *Bioconjug. Chem.*, 1999, vol. 10, 553 [0248]
- ZIMMERMAN et al. *Nucl. Med. Biol.*, 1999, vol. 26, 943-50 [0248]
- Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy. ARNON et al. Monoclonal Antibodies And Cancer Therapy. Alan R. Liss, Inc, 1985, 243-56 [0249]
- Antibodies For Drug Delivery. HELLSTROM et al. Controlled Drug Delivery. Marcel Dekker, Inc, 1987, 623-53 [0249]
- Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review. THORPE et al. Monoclonal Antibodies '84: Biological And Clinical Applications. 1985, 475-506 [0249]
- Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy. Monoclonal Antibodies For Cancer Detection And Therapy. Academic Press, 1985, 303-16 [0249]
- THORPE et al. *Immunol. Rev.*, 1982, vol. 62, 119-58 [0249]
- PEREZ ; WALKER. *J. Immunol.*, 1990, vol. 142, 3662-3667 [0253]
- BUMAL. *Hybridoma*, 1988, vol. 7 (4), 407-415 [0253] [0372]
- YU et al. *Cancer Res.*, 1991, vol. 51 (2), 468-475 [0253]
- TAILOR et al. *Nucl. Acids Res.*, 1990, vol. 18 (16), 4928 [0253]
- HENTTU ; VIHKO. *Biochem. Biophys. Res. Comm.*, 1989, vol. 160 (2), 903-910 [0253]
- ISRAELI et al. *Cancer Res.*, 1993, vol. 53, 227-230 [0253] [0372]
- ESTIN et al. *J. Natl. Cancer Instit.*, 1989, vol. 81 (6), 445-446 [0253]
- VIJAYASARDAHL et al. *J. Exp. Med.*, 1990, vol. 171 (4), 1375-1380 [0253] [0372]
- NATALI et al. *Cancer*, 1987, vol. 59, 55-63 [0253]
- MITTELMAN et al. *J. Clin. Invest.*, 1990, vol. 86, 2136-2144 [0253] [0372]
- FOON et al. *Proc. Am. Soc. Clin. Oncol.*, 1994, vol. 13, 294 [0253] [0372]
- YOKATA et al. *Cancer Res.*, 1992, vol. 52, 3402-3408 [0253] [0372]
- RAGNHAMMAR et al. *Int. J. Cancer*, 1993, vol. 53, 751-758 [0253] [0372]
- HERLYN et al. *J. Clin. Immunol.*, 1982, vol. 2, 135 [0253] [0372]
- GHETIE et al. *Blood*, 1994, vol. 83, 1329-1336 [0253] [0372]
- REFF et al. *Blood*, 1994, vol. 83, 435-445 [0253] [0372]
- SGOUROS et al. *J. Nucl. Med.*, 1993, vol. 34, 422-430 [0253] [0372]
- SALEH et al. *J. Immunol.*, 1993, vol. 151, 3390-3398 [0253]
- SHITARA et al. *Cancer Immunol. Immunother.*, 1993, vol. 36, 373-380 [0253] [0372]
- LIVINGSTON et al. *J. Clin. Oncol.*, 1994, vol. 12, 1036-1044 [0253] [0372]
- HOON et al. *Cancer Res.*, 1993, vol. 53, 5244-5250 [0253] [0372]
- HELLSTROM et al. *Cancer. Res.*, 1985, vol. 45, 2210-2188 [0253] [0372]
- HELLSTROM et al. *Cancer Res.*, 1986, vol. 46, 3917-3923 [0253] [0372]
- BHATTACHARYA-CHATTERJEE et al. *J. of Immun.*, 1988, vol. 141, 1398-1403 [0253] [0372]
- HILKENS et al. *Trends in Bio. Chem. Sci.*, 1992, vol. 17, 359 [0253] [0372]
- BERNHARD et al. *Science*, 1989, vol. 245, 301-304 [0253] [0372]
- FEIZI. *Nature*, 1985, vol. 314, 53-57 [0253] [0372]
- KRANZ et al. *J. Biol. Chem.*, 1982, vol. 257 (12), 6987-6995 [0254] [0328]
- LIU et al. *Journal of Immunology*, 1987, vol. 139, 3521-6 [0254] [0328]
- SHA et al. *Cancer Biother.*, 1994, vol. 9 (4), 341-9 [0254]
- UMAHA et al. *Nat Biotechnol*, 1999, vol. 17, 176-180 [0265]
- DAVIES et al. *Biotechnol Bioeng*, 2001, vol. 74, 288-294 [0265]
- MIMURA et al. *J Biol Chem*, 2001, vol. 276, 45539 [0265]
- RADAEV et al. *J Biol Chem*, 2001, vol. 276, 16478-16483 [0265]
- FELDHHAUS et al. *Nat. Biotech.*, 2003, vol. 21 (2), 163-170 [0282]
- STEMMER et al. *Proc. Natl. Acad. Sci. U.S.A.*, 1994, vol. 91, 10747-51 [0284]
- LEUNG et al. *Technique*, 1989, vol. 1, 11 [0286]

- KUNKEL et al. *Methods Enzymol.*, 1987, vol. 154, 367-82 [0288]
- TOMIC et al. *Nucleic Acids Res.*, 1987, vol. 18 (6), 1656 [0289]
- UPENDER et al. *Biotechniques*, 1995, vol. 18 (1), 29-30, 32 [0289]
- MICHAEL. *Biotechniques*, 1994, vol. 16 (3), 410-2 [0289]
- WELLS et al. *Gene*, 1985, vol. 34, 315 [0290]
- BODER et al. *Nat. Biotechnol.*, 1997, vol. 15, 553-7 [0294]
- BODER et al. *Biotechnol. Prog.*, 1998, vol. 14, 55-62 [0294] [0298]
- BODER et al. *Methods Enzymol.*, 2000, vol. 328, 430-44 [0294]
- BODER et al. *Proc. Natl. Acad. Sci. U.S.A.*, 2000, vol. 97, 10701-5 [0294]
- SHUSTA et al. *Nat. Biotechnol.*, 1998, vol. 16, 773-7 [0294]
- SHUSTA et al. *J. Mol. Biol.*, 1999, vol. 292, 949-56 [0294]
- SHUSTA et al. *Curr. Opin. Biotechnol.*, 1999, vol. 10, 117-22 [0294]
- SHUSTA et al. *Nat. Biotechnol.*, 2000, vol. 18, 754-9 [0294]
- WITTRUP et al. *Ann. N.Y. Acad. Sci.*, 1994, vol. 745, 321-30 [0294]
- WITTRUP et al. *Cytometry*, 1994, vol. 16, 206-13 [0294]
- WITTRUP. *Curr. Opin. Biotechnol.*, 1995, vol. 6, 203-8 [0294]
- WITTRUP. *Trends Biotechnol.*, 1999, vol. 17, 423-4 [0294]
- WITTRUP. *Nat. Biotechnol.*, 2000, vol. 18, 1039-40 [0294]
- WITTRUP. *Curr. Opin. Biotechnol.*, 2001, vol. 12, 395-9 [0294]
- PARTRIDGE et al. *Molecular Immunology*, 1986, vol. 23 (12), 1365-72 [0296]
- HAWKINS et al. *J. Mol. Biol.*, 1992, vol. 226, 889-896 [0298]
- STEMMER et al. *Nature*, 1994, vol. 370, 389-91 [0298]
- STEMMER et al. *Proc. Natl. Acad. Sci. USA*, 1994, vol. 91, 10747-51 [0298]
- KOENE et al. *Blood*, 1997, vol. 90, 1109-14 [0299]
- WU et al. *J. Clin. Invest.*, 1997, vol. 100, 1059-70 [0299] [0553]
- SONDERMAN et al. *Nature*, 2000, vol. 100, 1059-70 [0299]
- CARTRON et al. *Blood*, 2002, vol. 99 (3), 754-8 [0299]
- SHAPIRO et al. *Practical Flow Cytometry*, 1995 [0303]
- HOUGHTEN. *BiolTechniques*, 1992, vol. 13, 412-421 [0310]
- LAM. *Nature*, 1991, vol. 354, 82-84 [0310]
- FODOR. *Nature*, 1993, vol. 364, 555-556 [0310]
- CULL et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 1865-1869 [0310]
- SCOTT ; SMITH. *Science*, 1990, vol. 249, 386-390 [0310]
- DEVLIN. *Science*, 1990, vol. 249, 404-406 [0310]
- CWIRLA et al. *Proc. Natl. Acad. Sci. USA*, 1990, vol. 87, 6378-6382 [0310]
- FELICI. *J. Mol. Biol.*, 1991, vol. 222, 301-310 [0310]
- Current Protocols in Molecular Biology. John Wiley & Sons, Inc, 1994, vol. 1 [0311]
- MAXIM ; GILBERT. *Proc. Natl. Acad. Sci. USA*, 1977, vol. 74, 560 [0314]
- SANGER. *Proc. Natl. Acad. Sci. USA*, 1977, vol. 74, 5463 [0314]
- *BiolTechniques*, 1995, vol. 19, 448 [0314]
- COHEN et al. *Adv. Chromatogr.*, 1996, vol. 36, 127-162 [0314]
- GRIFFIN et al. *Appl. Biochem. Biotechnol.*, 1993, vol. 38, 147-159 [0314]
- PERUSSIA et al. *Methods Mol. Biol.*, 2000, vol. 121, 179-92 [0315] [0318]
- BAGGIOLINI et al. *Experientia*, 1998, vol. 44 (10), 841-8 [0315]
- LEHMANN et al. *J. Immunol.. Methods*, 2000, vol. 243 (1-2), 229-42 [0315]
- BROWN EJ. *Methods Cell Biol.*, 1994, vol. 45, 147-64 [0315]
- MUNN et al. *J. Exp. Med.*, 1990, vol. 172, 231-237 [0315]
- ABDUL-MAJID et al. *Scand. J. Immunol.*, 2002, vol. 55, 70-81 [0315]
- DING et al. *Immunity*, 1998, vol. 8, 403-411 [0315]
- BROWN EJ. *Methods Cell Biol.*, 1994, vol. 45, 147-164 [0316]
- TRIDANDAPANI et al. *J. Biol. Chem.*, 2000, vol. 275, 20480-7 [0316]
- BEDZYK et al. *J. Biol. Chem.*, 1989, vol. 264 (3), 1565-1569 [0317]
- DING et al. *Immunity*, 1998, vol. 8, 403-11 [0319]
- FLEIT et al. *J. Leuk. Biol.*, 1991, vol. 49, 556 [0321]
- PRICOP et al. *J. Immunol.*, 2000, vol. 166, 531-7 [0321]
- TRIDANDAPANI et al. *J. Biol Chem.*, 2002, vol. 277, 5082-9 [0321]
- PEARSE et al. *PNAS USA*, 1993, vol. 90, 4314-8 [0321]
- KOREN et al. *Nature*, 1979, vol. 279, 328-331 [0321]
- CLYNES et al. *PNAS USA*, 1998, vol. 95, 652-656 [0322]
- RALPH et al. *J. Immunol.*, vol. 119, 950-4 [0323]
- TREMP et al. *Cancer Res.*, 1976, 33-41 [0325]
- EPSTEIN et al. *J. Natl. Cancer Inst.*, 1965, vol. 34, 231-240 [0325]
- KLEIN et al. *Cancer Res.*, 1968, vol. 28, 1300-10 [0325] [0526]
- BLOMBERG et al. *Journal of Immunological Methods*, 1996, vol. 193, 199-206 [0327]

- **GAZZANO-SANTORO et al.** *J. Immunol. Methods*, 1996, vol. 202, 163 [0334]
- **KORZENIEWSKI et al.** *Immunol. Methods*, 1983, vol. 64 (3), 313-20 [0335]
- **DECKER et al.** *J. Immunol. Methods*, 1988, vol. 115 (1), 61-9 [0335]
- **MULLET et al.** *Methods*, 2000, vol. 22, 77-91 [0336]
- **DONG et al.** *Review in Mol. Biotech.*, 2002, vol. 82, 303-23 [0336]
- **FIVASH et al.** *Current Opinion in Biotechnology*, 1998, vol. 9, 97-101 [0336]
- **RICH et al.** *Current Opinion in Biotechnology*, 2000, vol. 11, 54-61 [0336]
- **MYSZKA.** *Current Opinion in Biotechnology*, 1997, vol. 8, 50-7 [0340]
- **FISHER et al.** *Current Opinion in Biotechnology*, 1994, vol. 5, 389-95 [0340]
- **O'SHANNESSY.** *Current Opinion in Biotechnology*, 1994, vol. 5, 65-71 [0340]
- **CHAIKEN et al.** *Analytical Biochemistry*, 1992, vol. 201, 197-210 [0340]
- **MORTON et al.** *Analytical Biochemistry*, 1995, vol. 227, 176-85 [0340]
- **O'SHANNESSY et al.** *Analytical Biochemistry*, 1996, vol. 236, 275-83 [0340]
- **SAMBROOK et al.** *Molecular Cloning, A Laboratory Manual.* Cold Spring Harbor Laboratory, 2001 [0343]
- *Current Protocols in Molecular Biology.* John Wiley & Sons, 1998 [0343] [0346]
- **CHOTHIA et al.** *J. Mol. Biol.*, 1998, vol. 278, 457-479 [0344]
- **SAMBROOK et al.** *Molecular Cloning, A Laboratory Manual.* Cold Spring Harbor Laboratory, 1990 [0346]
- **FOECKING et al.** *Gene*, 1998, vol. 45, 101 [0348]
- **COCKETT et al.** *Biol/Technology*, 1990, vol. 8, 2 [0348]
- **RUTHER et al.** *EMBO J.*, 1983, vol. 2, 1791 [0350]
- **INOUYE ; INOUYE.** *Nucleic Acids Res.*, 1985, vol. 13, 3101-3109 [0350]
- **VAN HEEKE ; SCHUSTER.** *J. Biol. Chem.*, 1989, vol. 24, 5503-5509 [0350]
- **LOGAN ; SHENK.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 355-359 [0352]
- **BITTNER et al.** *Methods in Enzymol.*, 1987, vol. 153, 51-544 [0352]
- **WIGLER et al.** *Cell*, 1977, vol. 11, 223 [0355]
- **SZYBALSKA ; SZYBALSKI.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 48, 202 [0355]
- **LOWY et al.** *Cell*, 1980, vol. 22, 817 [0355]
- **WIGLER et al.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 357 [0355]
- **O'HARE et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 1527 [0355]
- **MULLIGAN ; BERG.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 2072 [0355]
- *Clinical Pharmacy*, vol. 12, 488-505 [0355]
- **TOLSTOSHEV.** *Ann. Rev. Pharmacol. Toxicol.*, 1993, vol. 32, 573-596 [0355] [0439]
- **MULLIGAN.** *Science*, 1993, vol. 260, 926-932 [0355] [0439]
- **MORGAN ; ANDERSON.** *Ann. Rev. Biochem.*, 1993, vol. 62, 191-217 [0355] [0439]
- *TIB TECH*, May 1993, vol. 11 (5), 155-215 [0355]
- *Current Protocols in Molecular Biology.* John Wiley & Sons, 1993 [0355] [0439]
- **KRIEGLER.** *Gene Transfer and Expression, A Laboratory Manual.* Stockton Press, 1990 [0355] [0439]
- *Current Protocols in Human Genetics.* John Wiley & Sons, 1994 [0355]
- **COLBERRE-GARAPIN et al.** *J. Mol. Biol.*, 1981, vol. 150, 1 [0355]
- **SANTERRE et al.** *Gene*, 1984, vol. 30, 147 [0355]
- **BEBBINGTON ; HENTSCHEL.** *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning.* Academic Press, 1987, vol. 3 [0356]
- **CROUSE et al.** *Mol. Cell. Biol.*, 1983, vol. 3, 257 [0356]
- **PROUDFOOT.** *Nature*, 1986, vol. 322, 52 [0357]
- **KOHLER.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 2197 [0357]
- **CARTON et al.** *Blood*, 2002, vol. 99, 754-8 [0364]
- **WENG et al.** *J Clin Oncol.*, 2003, vol. 21 (21), 3940-7 [0364]
- **SUN et al.** *Infection and Immunity*, 1999, vol. 67 (3), 1172-9 [0368]
- **PEREZ ; WALKER.** *J. Immunol.*, 1990, vol. 142, 32-37 [0372]
- **YU et al.** *Cancer Res.*, 1991, vol. 51 (2), 48-475 [0372]
- **TAILOR et al.** *Nucl. Acids Res.*, 1990, vol. 18 (1), 4928 [0372]
- **HENTTU ; VIHKO.** *Biochem. Biophys. Res. Comm.*, 1989, vol. 10 (2), 903-910 [0372]
- **ESTIN et al.** *J. Natl. Cancer Instit.*, 1989, vol. 81 (6), 445-44 [0372]
- **NATALI et al.** *Cancer*, 1987, vol. 59, 55-3 [0372]
- **SALEH et al.** *J.Immunol.*, 1993, vol. 151, 3390-3398 [0372]
- **EDELSON.** *The Cancer Journal*, 1998, vol. 4, 62 [0372]
- **FISHMAN et al.** *Medicine.* J.B. Lippincott Co, 1985 [0373]
- **MURPHY et al.** *Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery.* Penguin Books U.S.A., Inc, 1997 [0373]
- *Physician's Desk Reference.* 2002 [0384]
- **WU.** *J. Biol. Chem.*, 1987, vol. 262, 4429-4432 [0417]
- **LANGER.** *Science*, 1990, vol. 249, 1527-1533 [0423] [0426]
- **TREAT et al.** *Liposomes in the Therapy of Infectious Disease and Cancer.* Liss, 1989, 353-365 [0423]
- **LOPEZ-BERESTEIN.** *LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE AND CANCER.* vol. 3, 17-327 [0423]

- **NING et al.** Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel. *Radiotherapy & Oncology*, 1996, vol. 39, 179-189 [0424]
- **SONG et al.** Antibody Mediated Lung Targeting of Long-Circulating Emulsions. *PDA Journal of Pharmaceutical Science & Technology*, 1995, vol. 50, 372-397 [0424]
- **CLEEK et al.** Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application. *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.*, 1997, vol. 24, 853-854 [0424]
- **LAM et al.** Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery. *Proc. Int'l. Symp. Control Rel. Bioact. Mater.*, 1997, vol. 24, 759-760 [0424]
- **SEFTON.** *CRC Crit. Ref. Biomed. Eng.*, 1987, vol. 14, 20 [0425]
- **BUCHWALD et al.** *Surgery*, 1980, vol. 88, 507 [0425]
- **SAUDEK et al.** *N. Engl. J. Med.*, 1989, vol. 321, 574 [0425]
- Medical Applications of Controlled Release. CRC Pres, 1974 [0425]
- Controlled Drug Bioavailability, Drug Product Design and Performance. Wiley, 1984 [0425]
- **RANGER ; PEPPAS. J.**, *Macromol. Sci. Rev. Macromol. Chem.*, 1983, vol. 23, 61 [0425]
- **LEVY et al.** *Science*, 1985, vol. 228, 190 [0425]
- **DURING et al.** *25. Ann. Neurol.*, 1989, 351 [0425]
- **HOWARD et al.** *J. Neurosurg.*, 1989, vol. 7 1, 105 [0425]
- **GOODSON.** *Medical Applications of Controlled Release*, 1984, vol. 2, 115-138 [0425]
- **NING et al.** *Radiotherapy & Oncology*, 1996, vol. 39, 179-189 [0426]
- **SONG et al.** *PDA Journal of Pharmaceutical Science & Technology*, 1995, vol. 50, 372-397 [0426]
- **CLEEK et al.** *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.*, 1997, vol. 24, 853-854 [0426]
- **LAM et al.** *Proc. Int'l. Symp. Control Rel. Bioact. Mater.*, 1997, vol. 24, 759-760 [0426]
- **JOLIOT et al.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 1864-1868 [0427]
- **GOLDSPIEL et al.** *Clinical Pharmacy*, 1993, vol. 12, 488-505 [0439]
- **WU ; WU.** *Biotherapy*, 1991, vol. 3, 87-95 [0439]
- **TIBTECH**, May 1993, vol. 11 (5), 155-215 [0439]
- **KOLLER ; SMITHIES.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 8932-8935 [0440] [0443]
- **ZIJLSTRA et al.** *Nature*, 1989, vol. 342, 435-438 [0440] [0443]
- **WU ; WU.** *J. Biol. Chem.*, 1987, vol. 262, 4429-4432 [0443]
- **MILLER et al.** *Meth. Enzymol.*, 1993, vol. 217, 581-599 [0444]
- **BOESEN et al.** *Biotherapy*, 1994, vol. 6, 291-302 [0444]
- **CLOWES et al.** *J. Clin. Invest.*, 1994, vol. 93, 644-651 [0444]
- **KLEIN et al.** *Blood*, 1994, vol. 83, 1467-1473 [0444]
- **SALMONS ; GUNZBERG.** *Human Gene Therapy*, 1993, vol. 4, 129-141 [0444]
- **GROSSMAN ; WILSON.** *Curr. Opin. in Genetics and Devel.*, 1993, vol. 3, 110-114 [0444]
- **KOZARSKY ; WILSON.** *Current Opinion in Genetics and Development*, 1993, vol. 3, 499-503 [0445]
- **BOUT et al.** *Human Gene Therapy*, 1994, vol. 5, 3-10 [0445]
- **ROSENFELD et al.** *Science*, 1991, vol. 252, 431-434 [0445]
- **ROSENFELD et al.** *Cell*, 1992, vol. 68, 143-155 [0445]
- **MASTRANGELI et al.** *J. Clin. Invest.*, 1993, vol. 91, 225-234 [0445]
- **WANG et al.** *Gene Therapy*, 1995, vol. 2, 775-783 [0445]
- **WALSH et al.** *Proc. Soc. Exp. Biol. Med.*, 1993, vol. 204, 289-300 [0446]
- **LOEFFLER ; BEHR.** *Meth. Enzymol.*, 1993, vol. 217, 599-618 [0448]
- **COHEN et al.** *Meth. Enzymol.*, 1993, vol. 217, 618-644 [0448]
- *Clin. Pharma. Ther.*, 1985, vol. 29, 69-92 [0448]
- **STEMPLE ; ANDERSON.** *Cell*, 1992, vol. 7 (1), 973-985 [0452]
- **RHEINWALD.** *Meth. Cell Bio.*, 1980, vol. 21A, 229 [0452]
- **PITTELKOW ; SCOTT.** *Mayo Clinic Proc.*, 1986, vol. 61, 771 [0452]
- **HUDSIK et al.** *Mol. Cell Biol.*, 1989, vol. 9, 1165-72 [0459]
- **LEWIS et al.** *Cancer Immunol, Immunother.*, 1993, vol. 37, 255-63 [0459]
- **BERGMAN et al.** *Clin. Cancer Res.*, 2001, vol. 7, 2050-6 [0459]
- **JOHNSON et al.** *Anticancer Res.*, 1995, 1387-93 [0459]
- **WU et al.** *Trends Cell Biol.*, 2001, vol. 11, 2-9 [0460]
- **CLYNES et al.** *Nat. Med.*, 2000, vol. 6, 443-6 [0461]
- Arthritis and Autoimmunity in Animals. **CROFFORD L.J. ; WILDER R.L. et al.** Arthritis and Allied Conditions: A Textbook of Rheumatology. Lee and Febiger, 1993 [0462] [0463]
- **HANSRA P. et al.** Carrageenan-Induced Arthritis in the Rat. *Inflammation*, 2000, vol. 24 (2), 141-155 [0464]
- **WINTER C. A. et al.** Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs. *Proc. Soc. Exp. Biol Med.*, 1962, vol. 111, 544-547 [0465]
- **KIM et al.** *Scand. J. Gastroentrol.*, 1992, vol. 27, 529-537 [0466]
- **STROBER.** *Dig. Dis. Sci.*, 1985, vol. 30 (12), 3S-10S [0466]

EP 2 573 114 B1

- **FLANDERS et al.** *Autoimmunity*, 1999, vol. 29, 235-246 [0467]
- **KROGH et al.** *Biochimie*, 1999, vol. 81, 511-515 [0467]
- **FOSTER.** *Semin. Nephrol.*, 1999, vol. 19, 12-24 [0467]
- Relevance of Tumor Models for Anticancer Drug Development. 1999 [0471]
- **KARGER.** *Contributions to Oncology*, 1999 [0471]
- The Nude Mouse in Oncology Research. 1991 [0471]
- Anticancer Drug Development Guide. 1997 [0471]
- **SCHATZ P.J.** *Biotechnology*, 1993, vol. 11, 1138-1143 [0487]
- **BUSCH, D. H. et al.** *Immunity*, 1998, vol. 8, 353-362 [0489]
- **ALTMAN, J. D. et al.** *Science*, 1996, vol. 274, 94-96 [0489]
- **CLYNES et al.** *Nat. Med.*, 2000, vol. 6, 443-446 [0491]
- **SHUSTA et al.** *Nat. Biotechnol.*, 2000, vol. 18, 754-759 [0498]
- **JENDEBERG et al.** *J. Immunol Meth.*, 1997, vol. 201, 25-34 [0501]
- **GIETZ et al.** *Nucleic Acids Res.*, 1992, vol. 20, 1425 [0502] [0511]
- **SHIELDS et al.** *J Biol.Chem.*, 2001, vol. 276, 6591-6604 [0506]
- **TAM et al.** *J. Immunol.*, 1996, vol. 157, 1576-1581 [0507]
- **SHIELDS et al.** *J Biol. Chem.*, 2001, vol. 276, 6591-6604 [0520]
- **KRANZ et al.** *J.Biol.Chem*, 1982, vol. 257 (12), 6987-6995 [0521] [0530]
- **TREMPE et al.** *Cancer Res.*, 1976, 33-41 [0526]
- **EPSTEIN et al.** *J. Natl. Cancer Inst.*, 1965, vol. 34, 231-40 [0526]
- **KOENE et al.** *Blood*, 1997, vol. 90, 1109-1114 [0553]
- **CLYNES et al.** *PNAS USA*, 1998, vol. 95, 652-6 [0566]

Variáns fc-régiókkal rendelkező antitestek azonosítása és előállítása valamint eljárások azok alkalmazására

Szabadalmi igénypontok

1. Egy polipeptid, amely tartalmaz egy variáns IgG1-Fc-régiót, ahol a nevezett variáns Fc-régió tartalmaz legalább egy aminosav-módosítást egy vad típusú IgG1-Fc-régióhoz viszonyítva oly módon, hogy:

(I) a nevezett polipeptidnek a nevezett variáns Fc-régiója megköt:

(A) egy nagyobb affinitású FcγRIIIA-t, és

(B) megváltoztatott kötési affinitású FcγRIIB-t;

ahol a nevezett nagyobb és megváltoztatott kötési affinitások kapcsolatban vannak a kötési affinitásokkal, amelyek ilyen polipeptid által vannak mutatva a nevezett FcγR-ekhez képest, ha az tartalmaz egy vad típusú Fc-régiót; és

(II) ahol a nevezett legalább egy aminosav-módosítás tartalmaz egy készlet szubsztitúciót a következőket tartalmazó csoportból választva:

(1) szubsztitúció a 243-as pozícióban leucinra és a 292-es pozícióban prolinra;

(2) szubsztitúció a 243-as pozícióban leucinra, a 292-es pozícióban prolinra, és a 305-ös pozícióban izoleucinra;

(3) szubsztitúció a 243-as pozícióban leucinra, a 292-es pozícióban prolinra, és a 396-os pozícióban leucinra;

(4) szubsztitúció a 243-as pozícióban leucinra, a 292-es pozícióban prolinra, és a 300-as pozícióban leucinra;

(5) szubsztitúció a 243-as pozícióban leucinra, a 292-es pozícióban prolinra, a 300-as pozícióban leucinra, és a 396-os pozícióban leucinra;

ahol a pozíciók az EU indexnek megfelelően vannak számozva, mint a Kabat-nál.

2. A polipeptid az 1. igénypont szerint, ahol a nevezett polipeptid egy antitest vagy egy antitest egy fragmentuma, amely tartalmazza a nevezett variáns Fc-régiót.

3. Az antitest vagy annak fragmentuma a 2. igénypont szerint, ahol a nevezett antitest egy monoklonális antitest, egy humanizált antitest vagy egy humán antitest.

4. Az antitest vagy annak fragmentuma a 2. igénypont szerint, ahol a nevezett antitest tartalmaz egy variábilis domént, amely CD16A-hoz vagy CD32B-hez kötődik.

5. Az antitest vagy annak fragmentuma a 2. igénypont szerint, ahol a nevezett antitest a 2B6 antitest, amely a hibridóma által van előállítva, amelynek ATCC letéti száma PTA-4591.

6. Az antitest vagy annak fragmentuma a 3. igénypont szerint, ahol a nevezett antitest a 2B6 antitest egy humanizált verziója, amely a hibridóma által van előállítva, amelynek ATCC letéti száma PTA-4591.

7. Az antitest vagy annak fragmentuma a 2. igénypont szerint, ahol a nevezett antitest kompetitíve gátolja a 2B6 antitestnek a kötődését, amely a hibridóma által van előállítva, amelynek ATCC letéti száma PTA-4591, a CD32B-hez.

8. Egy nukleinsav, amely tartalmaz egy nukleotid szekvenciát, amely kódolja az 1. igénypont szerinti polipeptidet.

9. Egy vektor, amely tartalmazza a 8. igénypont szerinti nukleinsavat.

10. Egy izolált gazdasejt, amely tartalmazza a 9. igénypont szerinti nukleinsavat.

11. Eljárás az 1. igénypont szerinti polipeptid rekombináns módon történő előállítására, ahol a nevezett eljárás magában foglalja a következőket: (i) egy gazdasejt tenyésztése egy médiumban, amely tartalmaz egy nukleinsavat, amely kódolja a nevezett polipeptidet a nevezett polipeptidnek az expresszáására alkalmas feltételek alatt; és (ii) a nevezett polipeptid visszanyerése a nevezett médiumból.

12. Az antitest vagy annak fragmentuma a 2. igénypont szerint, ahol a nevezett antitest vagy a nevezett fragmentum továbbá specifikusan megköt egy rák antigént vagy egy fertőző ágens egy antigénjét.

13. Az antitest vagy annak fragmentuma a 12. igénypont szerint, ahol a nevezett antitest javított antitest-függő, sejt által mediált citotoxícitást közvetít egy hasonló antitesthez viszonyítva, amely tartalmaz egy vad típusú Fc-régiót.

14. A 12. igénypont szerinti antitest vagy annak fragmentumának alkalmazása gyógyszer előállítására, amely rák kezelésére szolgál egy betegben, aki nevezett rák antigénnel jellemezhető rákbeteg.

15. Az antitest vagy annak fragmentuma a 12. igénypont szerint, vagy a 14. igénypont szerinti alkalmazás, ahol a nevezett rák antigén a MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetil-glükózaminil-transzferáz, p15, béta-catenin, MUM-1, CDK4, HER-2/neu, humán papillomavírus E6, humán papillomavírus E7 vagy MUC-1.

16. A 12. igénypont szerinti antitest vagy annak fragmentuma, vagy a 14. igénypont szerinti alkalmazás, ahol nevezett rák antigén egy emlő-, petefészek-, prosztata-, méhnyak- vagy hasnyálmirigy-karcinóma antigén.

17. Az 1. igénypont szerinti polipeptid alkalmazása gyógyszer előállítására gyulladáscsökkentő megbetegedés kezelésére.

18. Kompozíció, amely tartalmazza az 1. igénypont szerinti polipeptid terápiásan hatékony mennyiségét, vagy a 2. - 7., 12. - 13., vagy 15. - 16. igénypontok bármelyike szerinti antitestet vagy annak fragmentumát és gyógyszerészetileg elfogadható hordozót.

19. Nukleinsav, amely a 2. igénypont szerinti valamely antitest nehézláncát kódoló nukleinsav szekvenciát tartalmazza.

20. Vektor, amely a 19. igénypont szerinti nukleinsavat tartalmazza.

21. Izolált gazdasejt, amely a 19. igénypont szerinti nukleinsavat tartalmazza.

22. A 2. igénypont szerinti antitest, ahol nevezett antitest javított ADCC aktivitással rendelkezik ahhoz az ADCC aktivitáshoz képest, ha a nevezett antitest a vad típusú Fc régiót tartalmazza.

23. Az 1. igénypont szerinti polipeptid, ahol nevezett variáns Fc régió tartalmaz továbbá az 5., 6., 7. vagy 8. táblázatban felsorolt aminosavmódosítások közül egyet vagy többet.